



US008202969B2

(12) **United States Patent**
Heinrich et al.(10) **Patent No.:** **US 8,202,969 B2**
(45) **Date of Patent:** **Jun. 19, 2012**(54) **PLATELET DERIVED GROWTH FACTOR
RECEPTOR ALPHA (PDGFRA)
POLYPEPTIDES COMPRISING ACTIVATING
MUTATION(S)**(75) Inventors: **Michael C. Heinrich**, Lake Oswego, OR
(US); **Christopher C. Corless**, Portland,
OR (US); **Jonathan A. Fletcher**,
Brookline, MA (US); **George D.
Demetri**, Brookline, MA (US)(73) Assignees: **Oregon Health & Science University**,
Portland, OR (US); **U.S. Department of
Veteran Affairs**, Washington, DC (US);
Dana-Farber Cancer Institute, Boston,
MA (US); **Brigham and Women's
Hospital**, Boston, MA (US)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.(21) Appl. No.: **12/959,588**(22) Filed: **Dec. 3, 2010**(65) **Prior Publication Data**

US 2011/0081730 A1 Apr. 7, 2011

Related U.S. Application Data(62) Division of application No. 12/466,218, filed on May
14, 2009, now Pat. No. 7,875,710, which is a division
of application No. 10/517,905, filed as application No.
PCT/US03/18901 on Jun. 13, 2003, now Pat. No.
7,595,154.(60) Provisional application No. 60/389,107, filed on Jun.
13, 2002, provisional application No. 60/438,899,
filed on Jan. 8, 2003.(51) **Int. Cl.****C07K 14/71** (2006.01)**C07K 16/30** (2006.01)**C07K 7/00** (2006.01)**A61K 39/395** (2006.01)**G01N 33/574** (2006.01)(52) **U.S. Cl.** **530/350**; 435/7.23; 424/138.1;
424/139.1; 424/143.1; 530/300; 530/387.7;
530/387.9; 530/388.22; 514/7.5(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**5,376,531 A * 12/1994 Anderson et al. 435/7.23
5,686,572 A 11/1997 Wolf et al.
5,795,975 A 8/1998 Wallach et al.
5,795,976 A 8/1998 Oefner et al.
5,833,986 A 11/1998 LaRochelle et al.
6,187,536 B1 2/2001 Weinberg et al.
6,194,158 B1 2/2001 Kroes et al.
6,291,661 B1 9/2001 Graddis et al.
7,595,154 B2 * 9/2009 Heinrich et al. 435/6
7,875,710 B2 * 1/2011 Heinrich et al. 536/23.5**OTHER PUBLICATIONS**Benjamini et al., 1991. Immunology: A Short Course, 2nd edition, p.
40 only.*Houghten et al., 1991. Nature. 354: 84-86.*
"Gleevec™ Shows Promise for Type of Gastrointestinal Tumor,"
National Cancer Institute—Clinical Trial Results <http://www.cancer.gov/clinicaltrials/results/gleevec-shows-promise0202>, posted Jul.
20, 2001; printed Feb. 26, 2005.Abu-Duhier et al., "FLT3 internal tandem duplication mutations in
adult acute myeloid leukaemia define a high-risk group," *J.
Haematol.*, 111(1):190, 2000.Abu-Duhier et al., "Identification of novel FLT-3 Asp835 mutations
in adult acute myeloid leukaemia," *J. Haematol.*, 113(4):983-988,
2001.Al-Ali et al., "High incidence of BCR-ABL kinase domain mutations
and absence of mutations of the PDGFR and KIT activation loops in
CML patients with secondary resistance to imatinib," *Haematol. J.*
5(1):55-60, 2004.Bai et al., "The SH2-containing Adapter Protein GRB10 interacts
with BCR-ABL" *Oncogene*, 17:941-948, 1998.Baxter et al., "The t(4:22)(q12;q11) in Atypical Chronic Myeloid
Leukaemia fuses BCR to PDGFRA" *Human Molecular Genetics*,
11(12):1391-1397, 2002.Blanke et al., "Evaluation of the Safety and Efficacy of an Oral
Molecularly-Targeted Therapy, STI571, in Patients (Pts) with
Unresectable or Metastatic Gastrointestinal Stromal Tumors
(GISTs) Expressing C-KIT (CD117)," *ASCO*, May 12-15, 2001
(*Meeting Abstract*).Borg et al., "Novel mode of action of c-kit tyrosine kinase inhibitors
leading to NK cell-dependent antitumor effects," *J. Clinical. Inves-
tigation*, 114(3):379-388, 2004.Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,"
Genome Research, 10:398-400, 2000.Brenner, "Errors in genome annotation," *Trends in Genetics*,
15(4):132-133, 1999.Chen et al., "Imatinib inhibits various types of activating mutant kit
found in gastrointestinal stromal tumors," *J. Cancer*, 105(1):130-
135, 2003.Corless et al., "Biology of gastrointestinal stromal tumors," *J. Clin.
Oncol.*, 22(18):3813-3825, 2004.Debiec-Rychter et al., "Use of c-KIT/PDGFRα mutational analysis
to predict the clinical response to imatinib in patients with advanced
gastrointestinal stromal tumours entered in phase I and II studies of
the EORTC Soft Tissue and Bone Sarcoma Group," *Eur J Cancer*,
40(5):689-95, 2004.Demetri et al., "Phase III dose-randomized study of imatinib
mesylate (Gleevec, STI571) for GIST: intergroup S0033 early
results," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).Demetri, "Targeting c-kit Mutations in Solid Tumors: Scientific
Rationale and Novel Therapeutic Options," *Semin Oncol.*, 5 Suppl
17:19-26, 2001.Doerks et al., "Protein annotation: detective work for function pre-
diction," *Trends in Genetics*, 14(6):248-250, 1998.

(Continued)

Primary Examiner — Bridget E Bunner*Assistant Examiner* — Zachary Howard(74) *Attorney, Agent, or Firm* — Klarquist Sparkman, LLP(57) **ABSTRACT**This disclosure provides tyrosine kinase protein and nucleic
acid variants, particularly PDGFRA variants, which are acti-
vating forms of these molecules and are linked to neoplasms
and/or the development or progression of cancer. The disclo-
sure further provides methods of diagnosis and prognosis,
and development of new therapeutic agents using these mol-
ecules and fragments thereof, and kits for employing these
methods and compositions.**15 Claims, 7 Drawing Sheets**

OTHER PUBLICATIONS

- Duensing et al., "Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)," *Cancer Res.*, 64(15):5127-5131, 2004.
- Fenski et al., "Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells," *J. Haematol.*, 108(2):322-330, 2000.
- Gari et al., "c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia," *J. Haematol.*, 105(4):894-900, 1999.
- Griswold et al., "Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis," *Blood*, 104(9):2912-2918, 2004.
- Heinrich et al., "Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alternations," *Hum. Pathol.*, 33(5):484-95, 2002.
- Heinrich et al., "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor," *Blood*, 96(3):925-932, 2000.
- Heinrich et al., "Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies," *J. Clinical Oncology*, 20(6):1692-1703, 2002.
- Heinrich et al., "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor," *J. Clin. Oncol.*, 21(23):4342-4349, 2003.
- Heinrich et al., "KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs)," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Heinrich et al., "PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors," *Science*, 299:708-710, 2003.
- Heinrich et al., "Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas," *Cancer Treatment Res.*, 120:129-150, 2004.
- Hirota et al., "Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours," *J. Pathol.*, 193(4):505-510, 2001.
- Hirota et al., "Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor α Gene in Gastrointestinal Stromal Tumors," *Gastroenterology*, 125:660-667, 2003.
- Hochhaus et al., "Interim analysis of imatinib treatment in 300 patients with chronic myelogenous leukemia (CML): evaluation of response and resistance," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Homo sapiens* platelet-derived growth factor receptor, alpha polypeptide (PDGFRA), mRNA, Locus ID: XM_011186, PRI Feb. 7, 2002, *NCBI*, printed Apr. 18, 2002.
- Human DNA for alpha-platelet-derived growth factor receptor, exon 1, Locus ID: D50001S01, PRI Apr. 14, 2000, *NCBI*, printed Jun. 5, 2002.
- Joensuu et al., "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor," *N Engl J Med*, 344(14):1052-1056, 2001.
- Joensuu et al., "Gastrointestinal stromal tumor (GIST) patients who respond to imatinib (STI571, Gleevec) show marked decline of circulating levels of VEGF, KIT, and bFGF in serum, but not stem cell factor (SCF) levels," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Johnson et al., "Phase II study of STI571 (Gleevec™) for patients with small cell lung cancer," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Kaufman et al., "Transgenic Analysis of a 100-kb Human β -Globin Cluster—Containing DNA Fragment Propagated as a Bacterial Artificial Chromosome," *Blood*, 94:3178-3184, 1999.
- Kubota et al., "Chemosensitivity of gastric cancer detected by cDNA microarray," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Madani et al., "Expression of KIT and epidermal growth factor receptor (EGFR) in chemotherapy refractory non-seminomatous germ cell tumors (GCT)," *ASCO*, May 28-21, 2002 (*Meeting Abstract*).
- Medeiros et al., "KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications," *Am J. Surg. Pathol.*, 28(7):889-894, 2004.
- Nakamura et al., "Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes," *J. Nippon Med Sch*, 68(2):143-148 (Apr. 2001) (*English Abstract Only*).
- Ngo et al., "The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox," pp. 433-440 and 492-495 only, 1994.
- O'Farrell et al., "Analysis of mechanism of action and biomarkers for kinase inhibitor SU5416 in AML patients," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- O'Farrell et al., "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo," *Blood*, 101(9):3597-3605, 2003.
- Omura et al., "Immunoglobulin-like Domain 4-mediated Receptor-Receptor Interactions contribute to Platelet-derived Growth Factor-induced Receptor Dimerization" *JBC*, 272(19):12676-12682, 1997.
- PDGFRA: platelet-derived growth factor receptor, alpha polypeptide, Locus ID: 5156, *NCBI*, printed Jun. 5, 2002.
- Phillips, A., "The challenge of gene therapy and DNA delivery," *J. Pharm Pharmacology*, 53:1169-1174, 2001.
- Rubin et al., "KIT Activation is a Ubiquitous Feature of Gastrointestinal Stromal Tumors," *Cancer Research*, 61:8118-8121, 2001.
- Singer et al., "Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors," *J. Clinical Oncology*, 20(18):3898-3905, 2002.
- Skolnick et al., "From genes to protein structure and function: novel application of computational approaches in the genomic era," *Trends in Biotech.*, 18(1):34, 2000.
- Subramanian et al., "Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles," *Oncogene*, 23(47):7780-7790, 2004.
- van Oosterom et al., "Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study," *Lancet*, 358(9291):1421-1423, 2001.
- van Oosterom et al., "STI571, an Active Drug in Metastatic Gastrointestinal Stromal Tumors (GIST), an EORTC Phase I Study," *ASCO*, May 12-15, 2001 (*Meeting Abstract*).
- von Mehren et al., "High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs)," *ASCO*, May 18-21, 2002 (*Meeting Abstract*).
- Wang et al., "Rapid analysis of gene expression (RAGE) facilitates universal expression profiling," *Nuc. Acids Res.*, 27:4609-4618, 1999.
- Wells, "Additivity of Mutational Effects in Proteins," *Biochemistry*, 29(37):8509-8517, 1990.
- Corless et al., "PDGFRA Mutation in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib," *J. Clin. Oncol.*, 23(23):5357-5364, 2005.
- Guida et al., "Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants," *Clin Cancer Res.*, 13:3363-3369, 2007.
- Heinrich et al., "Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases," *Clin Cancer Res.*, 14:2717-2725, 2008.
- Lierman et al., "FIPIL1-PDGFR α D842V, a novel panresistant mutant, emerging after treatment of FIPIL1-PDGFR α T674I eosinophilic leukemia with a single agent sorafenib," *Leukemia*, 23(5):845-851, 2009.

* cited by examiner


FIGURE 1




FIGURE 2A**FIGURE 2B****FIGURE 2C**



FIGURE 3**FIGURE 4**



FIGURE 5**FIGURE 6**

FIGURE 7A

181551 GCTTTCTCTC TGTTGGGAGT GGGTGGAGTG AGAACCTGGG AGAAGGCCAG
CGAAAGAGAG ACAACCCTCA CCCACCTCAC TCTTGGACCC TCTTCCGGTC

181601 CCCTTTATAT CCAGGCAGAC AGCTCCAAGT GCCACCATGG ATCAGCCAGT
GGGAAATATA GGTCCGTCTG TCGAGGTTCA CGGTGGTACC TAGTCGGTCA

PDGFrA 181640F PDGFrA 181671F
181651 CTTGCAGGGG TGATGCTATT CAGCTACAGA TGGCTTGATC CTGAGTCATT
GAACGTCCCC ACTACGATAA GTCGATGTCT ACCGAACTAG GACTCAGTAA

181701 TCTTCCTTTT CCATGCAGTG TGTCCACCGT GATCTGGCTG CTCGCAACGT Exon 18
AGAAGGAAAA GGTACGTCAC ACAGGTGGCA CTAGACCGAC GAGCGTTGCA
C V H R D L A A R N V Frame 3

PDGFrA 181752F (SNP Exclusion)
181751 CCTCCTGGCA CAAGGAAAAA TTGTGAAGAT CTGTGACTTT GGCCTGGCCA
GGAGGACCGT GTTCCTTTTT AACACTTCTA GACACTGAAA CCGGACCGGT
L L A Q G K I V K I C D F G L A R Frame 3

181801 GAGACATCAT GCATGATTCG AACTATGTGT CGAAAGGCAG TGTACGTCCT
CTCTGTAGTA CGTACTAAGC TTGATACACA GCTTTCCGTC ACATGCAGGA
D I M H D S N Y V S K G S

PDGFrA 181862R PDGFrA 181874R
181851 CACTTCCCTC ACTGGTCAGG CTCATCCTCC TTCACTTTAA TCTCTAAAGT
GTGAAGGGAG TGACCAGTCC GAGTAGGAGG AAGTGAAATT AGAGATTTC

181901 CAGGTGTTGC TTCTAGAGAT TCGGTGCCTG TTTTTTAAAA CATCAATAGA
GTCCACAACG AAGATCTCTA AGCCACGGAC AAAAAATTTT GTAGTTATCT

FIGURE 7B

170551 AAGCATAGCA ACCTAGTTCA GTGCTTGGCA CAGAGAAGGA GCTCAGCAAT
TTCGTATCGT TGGATCAAGT CACGAACCGT GTCTCTTCCT CGAGTCGTTA

PDGFrA 170636F

170601 TACATGTGGA GTGAACGTTG TTGGACTCTA CTGTGTCCAG TCACTGTGCT
ATGTACACCT CACTTGCAAC AACCTGAGAT GACACAGGTC AGTGACACGA

PDGFrA 170658F

170651 GCTTCAGTGA AGCTCTGGTG CACTGGGACT TTGGTAATTC ACCAGTTACC
CGAAGTCACT TCGAGACCAC GTGACCCTGA AACCATTAAG TGGTCAATGG

170701 TGTCCTGGTC ATTTATAGAA ACCGAGGTAT GAAATTCGCT GGAGGGTCAT Exon 12
ACAGGACCAG TAAATATCTT TGGCTCCATA CTTTAAGCGA CCTCCCAGTA
K P R Y E I R W R V I Frame 1

170751 TGAATCAATC AGCCCAGATG GACATGAATA TATTTATGTG GACCCGATGC
ACTTAGTTAG TCGGGTCTAC CTGTACTTAT ATAAATACAC CTGGGCTACG
E S I S P D G H E Y I Y V D P M Q Frame 1

170801 AGCTGCCTTA TGA CTCAAGA TGGGAGTTTC CAAGAGATGG ACTAGTGCTT
TCGACGGAAT ACTGAGTTCT ACCCTCAAAG GTTCTCTACC TGATCACGAA
L P Y D S R W E F P R D G L V L Frame 1

PDGFrA 170866R PDGFrA 170894R

170851 GGTAAGTTCC ATGGGGTAAC CTCCCAAGAC TCCCTTTTCC CTTGCACACA
CCATTCAAGG TACCCCATTG GAGGGTTCTG AGGGAAAAGG GAACGTGTGT

170901 ACTTTACAAT TTATAGGCCT TGGCAGAATA GAGATCTGAG CTTGTGCTTA
TGAAATGTTA AATATCCGGA ACCGTCTTAT CTCTAGACTC GAACACGAAT

FIGURE 8





FIGURE 9



1

**PLATELET DERIVED GROWTH FACTOR
RECEPTOR ALPHA (PDGFRA)
POLYPEPTIDES COMPRISING ACTIVATING
MUTATION(S)**

**CROSS REFERENCE TO RELATED
APPLICATION**

This is a division of co-pending application Ser. No. 12/466,218, filed May 14, 2009, issued as U.S. Pat. No. 7,875,710 on Jan. 25, 2011, which is a division of U.S. application Ser. No. 10/517,905, filed Dec. 10, 2004, issued as U.S. Pat. No. 7,595,154 on Sep. 29, 2009, which is the U.S. National Stage of International Application No. PCT/US03/18901, filed Jun. 13, 2003, which was published in English under PCT Article 21(2), and which in turn claims the benefit of U.S. Provisional Applications No. 60/389,107, filed Jun. 13, 2002 and No. 60/438,899, filed Jan. 8, 2003. Each of these applications is incorporated herein in its entirety.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with United States government support pursuant to employment of one of the inventors as a Federal employee, as well as grant funding from a Veterans Affairs Merit Review Grant; the United States government has certain rights in the invention.

FIELD

This disclosure relates to tyrosine kinases, particularly receptor tyrosine kinases with one or more activation mutations. Further, it relates to methods of using these molecules in screens and analyses, including diagnoses, prognoses, and systems for identification and/or selection of pharmaceutical compounds.

BACKGROUND OF THE DISCLOSURE

Tyrosine kinases are expressed by many human cancers. These enzymes are attractive targets for the development of anticancer drugs, as it has been possible to optimize compounds with excellent inhibitory potency and selectivity to individual target tyrosine kinases. The utility of this approach has been highlighted by the success of imatinib mesylate (Gleevec™) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs).

Expression of tyrosine kinases is ubiquitous in both cancers and normal tissues. Therefore, the efficacy of a kinase inhibitor is dependent on two factors: 1) the degree to which the target kinase is activated in a particular cancer, and 2) the degree to which the growth and survival of the cancer cells is dependent on the activated target kinase.

Gastrointestinal stromal tumors provide an excellent example of this principle. KIT tyrosine kinase is detectable by immunohistochemistry in a wide variety of cancers and normal tissues, but mutations of the KIT gene that yield constitutively active KIT kinase are found in only a small subset of tumors (Heinrich et al., *J. Clin. Oncol.*, 20: 1692-1703, 2002). More than 85% of GISTs harbor such activating mutations (Blanke et al., *Proceedings of ASCO* 20, 1a-1a, 2001; Heinrich et al., *J. Clin. Oncol.*, 20: 1692-1703, 2002; Hirota et al., *J. Pathol.*, 193: 505-510, 2001; Rubin et al., *Cancer Res.*, 61: 8118-8121, 2001) and, correspondingly, phosphorylation of KIT kinase (a marker of activation) was recently demonstrated in most fresh-frozen GIST specimens (Rubin et al., *Cancer Res.*, 61: 8118-8121, 2001). Such phosphorylation of

2

KIT is rarely observed in other cancer specimens. Recent success in the treatment of advanced malignant GISTs with imatinib mesylate is thought to reflect an important role of KIT activation in the growth and/or survival of GIST tumor cells (Blanke et al., *Proceedings of ASCO* 20, 1a-1a, 2001; Joensuu et al., *N Engl J Med.*, 344: 1052-1056, 2001; Van Oosterom et al., *Lancet*, 358:1421-1423, 2001). The observation that treatment results with imatinib mesylate are significantly better for tumors with evidence of mutational activation of KIT than for tumors with no KIT mutation further supports this view (Heinrich et al., *J. Clin. Oncol.*, 20: 1692-1703, 2002). Thus, in the case of GISTs, testing of clinical specimens for genomic mutations resulting in tyrosine kinase activation will be useful in determining which patients are most likely to respond to a tyrosine kinase inhibitor.

The PDGFRA (or PDGFR- α) protein is a type III receptor tyrosine kinase with homology to KIT, FLT3, CSF1-R and PDGFR- β (PDGFRB). Although PDGFRA activation has been hypothesized to be involved in certain cancers, most notably gliomas, evidence of genomic activation in human cancer has only recently been reported in two cases of myeloproliferative disease associated with translocation of the BCR and PDGFRA genes.

SUMMARY OF THE DISCLOSURE

Disclosed herein are novel mutations of PDGFRA that result in constitutive activation of this tyrosine kinase. These mutations were initially discovered in GISTs. Also disclosed are consensus PDGFRA nucleic acid and amino acid sequences, which summarize certain groups of activating mutations and regions of relatively active mutation.

Thus, this disclosure provides several novel PDGFRA variant proteins, and nucleic acids encoding these variants. Also disclosed are methods of using these molecules in detecting biological conditions associated with an activating PDGFRA mutation in a subject, methods of treating such conditions, methods of selecting treatments (e.g., specific tyrosine kinase inhibitors), and methods of screening for inhibitors of PDGFRA activity, particularly activated PDGFRA variant activity. Oligonucleotides for use in examples of such methods are also provided.

Also disclosed herein are protein specific binding agents, such as antibodies, that bind specifically to at least one epitope of a PDGFRA variant protein preferentially compared to wildtype PDGFRA, and methods of using such antibodies in diagnosis, treatment, and screening.

Kits are also provided for carrying out the methods described herein.

The foregoing and other features and advantages will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 (including FIG. 1A and FIG. 1B): Immunostaining for phosphotyrosine (A) and PDGFRA (B) in GIST478. A) A strongly tyrosine phosphorylated doublet at 150/170 kD is seen in the RTK immunoprecipitate (lane 2). This phosphorylated doublet corresponds to two of the stronger phosphoproteins in the total cell lysate (lane 1), and comigrates with the strongly phosphorylated PDGFRA doublet (lane 4). KIT is not demonstrably phosphorylated (lane 3). B) The strongly phosphorylated RTK (lane 2) was confirmed as PDGFRA, by stripping and restaining the blot with a specific antibody to PDGFRA.

3

FIG. 2 (including FIGS. 2A, 2B, and 2C): Sequential staining of GIST immunoblot for KIT (A), phosphoPDGFRA Y754 (B), and total PDGFRA (C). A) The four GISTs analyzed here include two cases with a low (lane 1) or absent (lane 2) level of KIT expression and two cases with strong KIT expression (lanes 3 and 4). B) Strongly phosphorylated PDGFRA (doublet at 150/170 kD) is seen in the GISTs with low-to-absent KIT expression. C) Total PDGFRA is also expressed strongly in the two GISTs with low-to-absent KIT expression. The two GISTs with phosphoPDGFRA have D842V oncogenic mutations.

FIG. 3: Detection of PDGFRA activation loop deletion mutations by D-HPLC. DNA was isolated from GISTs and amplified using primer pair PDGFRA 181634F and PDGFRA 181874R as described herein. Amplicons were analyzed at 50° C. using a Transgenomics WAVE™ D-HPLC system. Sample 1 has the DIMH deletion described herein. The deletion mutant is readily detected due to the appearance of novel peaks representing species homozygous for the deletion and heteroduplexes of wild-type and deletion mutation.

FIG. 4: Detection of PDGFRA activation loop V824V SNP and D842V point mutation by D-HPLC. Amplicons were prepared from GISTs using the PDGFRA 181634F and PDGFRA 181874R primer pair as described above and analyzed at 61° C. using a Transgenomics WAVE™ D-HPLC system. Under partially denaturing conditions, amplicons with the V824V SNP and the D842V point mutation (two examples) elute in a complex pattern. The V824V and D842V amplicons have unique elution profiles. Direct DNA sequencing was performed to confirm that the V824V and D842V amplicons contained the equivalent stretch of PDGFRA nucleotide sequence.

FIG. 5: Detection of D842V point mutation using a primer pair that excludes the V824V SNP. Amplicons were prepared from GISTs using the PDGFRA 181752F (SNP exclusion) and PDGFRA 181874R primer pair as described above and analyzed at 61° C. using a Transgenomics WAVE™ D-HPLC system. Under partially denaturing conditions, amplicons with the D842V point mutation elute in a complex pattern. Note that this amplicon does not contain the V824V SNP and therefore these amplicons have the same elution profile as for wild-type PDGFRA. Direct DNA sequencing was performed to confirm that the amplicons from GISTs with V824V (two examples) versus D842V contained the equivalent stretch of PDGFRA nucleotide sequence.

FIG. 6: Detection of PDGFRA Exon 12 Deletion and Insertion Variants. Amplicons were prepared from GISTs using the PDGFRA 170636F and PDGFRA 170894R primer pair as described above and analyzed at 50° C. using a Transgenomics WAVE™ D-HPLC system. The amplicons prepared from the two samples with wild-type PDGFRA exon 12 elute as a single peak. In contrast, amplicons from tumors with either a deletion mutation or an insertion are easily detected due to the appearance of novel peaks representing species homozygous for the deletion and heteroduplexes of wild-type and deletion mutation. In tumors homozygous for these mutations, only a single unique elution peak would be detected. These mutations would be identifiable based on the unique peak elution profile compared with wild type amplicons.

FIG. 7 (including FIGS. 7A and 7B): Differential sensitivity of various KIT activation loop mutants to imatinib mesylate. FIG. 7 shows the genomic sequences of PDGFRA around exon 18 (FIG. 7A) (SEQ ID NO: 28 and its reverse complement) and exon 12 (FIG. 7B) (SEQ ID NO: 30 and its reverse complement). PDGFRA primers are indicated; PDGFRA exon sequences and amino acid translations (SEQ ID NOs: 29 and 31, respectively) are also shown.

4

FIG. 8: DGFRA mutations in GISTs result in constitutive activation of PDGFRA kinase. FIG. 8 shows a series of immunoblots, probed with antibodies to phospho-tyrosine and PDGFRA. CHO cells were transiently transfected with expression vectors encoding cDNAs for wild-type or mutant PDGFRA. Transfected cells were serum starved overnight and treated with vehicle or ligand (recombinant human PDGF-AA) for 10 minutes. Whole cell lysates were immunostained sequentially for phospho-tyrosine and PDGFRA. Wild type PDGFRA displays low-level phosphorylation that is upregulated by ligand stimulation with PDGF-AA. In contrast, the mutant PDGFRA proteins display ligand-independent phosphorylation.

FIG. 9: Cell signaling profiles in PDGFRA-mutant (2686, 478, and 1015) and KIT-mutant GISTs (174 and 208). FIG. 9 shows a series of immunoblots, illustrating the cell signaling profiles of the indicated mutants. Whole cell lysates were prepared from snap-frozen GISTs, and immunoblots were detected with antibodies to phosphorylated and total forms of AKT, MAPK, and STATs. All GISTs express phosphorylated AKT, MAPK, STAT1, and STAT3, whereas STAT5 is not tyrosine phosphorylated.

SEQUENCE LISTING

The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. Unless specifically noted otherwise herein, the position numbering associated with the name of a variant PDGFRA molecule is based on numbering in the corresponding wildtype molecule. Where a reference is made to positions in a variant, the numbering is based on the actual position in the specified variant. The Sequence Listing is submitted as an ASCII text file in the form of the file of ~578,000 bytes created on Dec. 30, 2011, which is incorporated by reference herein.

In the accompanying sequence listing:

SEQ ID NO: 1 shows the nucleic acid sequence of the human PDGFRA cDNA (GenBank Accession No. XM_011186); the sequence list also shows the encoded protein.

SEQ ID NO: 2 shows the amino acid sequence of human PDGFRA protein.

SEQ ID NO: 3 shows the nucleic acid sequence of the human PDGFRA D842V variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 4 shows the amino acid sequence of human PDGFRA D842V variant protein.

SEQ ID NO: 5 shows the nucleic acid sequence of the human PDGFRA DIMH842-845 variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 6 shows the amino acid sequence of human PDGFRA DIMH842-845 variant protein.

SEQ ID NO: 7 shows the nucleic acid sequence of the human PDGFRA HDSN845-848P variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 8 shows the amino acid sequence of human PDGFRA HDSN845-848P variant protein.

SEQ ID NO: 9 shows the nucleic acid sequence of the human PDGFRA ER561-562 variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 10 shows the amino acid sequence of human PDGFRA ER561-562 variant protein.

SEQ ID NO: 11 shows the nucleic acid sequence of the human PDGFRA SPDGHE566-571R variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 12 shows the amino acid sequence of human PDGFRA SPDGHE566-571R variant protein.

SEQ ID NOS: 13-18 are amino acid sequences of the RTK catalytic domain sequences of different families of human RTK proteins.

SEQ ID NO: 19 is the genomic sequence of PDGFRA, with introns and exons indicated. Regions where the sequence is unknown or unconfirmed have been indicated with "n" designations using standard conventions. This sequence is available in the April 2002 release of the human genome project, as provided by University of California, Santa Cruz, on their Internet website.

SEQ ID NO: 20 shows the nucleic acid sequence of the human PDGFRA V561D variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 21 shows the amino acid sequence of human PDGFRA V561D variant protein.

SEQ ID NO: 22 shows the nucleic acid sequence of the human PDGFRA RVIES560-564 variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 23 shows the amino acid sequence of human PDGFRA RVIES560-564 variant protein.

SEQ ID NO: 24 shows the nucleic acid sequence of the human PDGFRA Substitution RD841-842KI variant cDNA; the sequence list also shows the encoded protein.

SEQ ID NO: 25 shows the amino acid sequence of human PDGFRA Substitution RD841-842KI variant protein.

SEQ ID NO: 26 shows the consensus sequence produced by aligning the nucleic acid sequences of each of the identified activating PDGFRA mutants (SEQ ID NOS: 3, 5, 7, 9, 11, 20, 22, and 24), and the consensus protein encoded thereby.

SEQ ID NO: 27 shows a PDGFRA consensus sequence.

SEQ ID NO: 28 shows the genomic sequence of PDGFRA around exon 18.

SEQ ID NO: 29 shows the amino acid sequence encoded by PDGFRA exon 18.

SEQ ID NO: 30 shows the genomic sequence of PDGFRA around exon 12.

SEQ ID NO: 31 shows the amino acid sequence encoded by PDGFRA exon 12.

DETAILED DESCRIPTION

I. Abbreviations

2D-PAGE two-dimensional polyacrylamide gel electrophoresis

ASO allele-specific oligonucleotide

ASOH allele-specific oligonucleotide hybridization

DASH dynamic allele-specific hybridization

ELISA enzyme-linked immunosorbant assay

HPLC high pressure liquid chromatography

MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight

PCR polymerase chain reaction

PDGFRA platelet derived growth factor receptor alpha

PDGFRB platelet derived growth factor receptor beta

RT-PCR reverse-transcription polymerase chain reaction

SSCP single-strand conformation polymorphism

TKI tyrosine kinase inhibitor

II. Terms

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in

molecular biology may be found in Benjamin Lewin, *Genes V*, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

In order to facilitate review of the various embodiments of the invention, the following explanations of specific terms are provided:

Antisense, Sense, and Antigene: Double-stranded DNA (dsDNA) has two strands, a 5'→3' strand, referred to as the plus strand, and a 3'→5' strand (the reverse complement), referred to as the minus strand. Because RNA polymerase adds nucleic acids in a 5'→3' direction, the minus strand of the DNA serves as the template for the RNA during transcription. Thus, the RNA formed will have a sequence complementary to the minus strand and identical to the plus strand (except that U is substituted for T).

Antisense molecules are molecules that are specifically hybridizable or specifically complementary to either RNA or the plus strand of DNA. Sense molecules are molecules that are specifically hybridizable or specifically complementary to the minus strand of DNA. Antigene molecules are either antisense or sense molecules directed to a dsDNA target.

cDNA (complementary DNA): A piece of DNA lacking internal, non-coding segments (introns) and transcriptional regulatory sequences. cDNA may also contain untranslated regions (UTRs) that are responsible for translational control in the corresponding RNA molecule. cDNA is usually synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.

DNA (deoxyribonucleic acid): DNA is a long chain polymer which comprises the genetic material of most living organisms (some viruses have genes comprising ribonucleic acid (RNA)). The repeating units in DNA polymers are four different nucleotides, each of which comprises one of the four bases, adenine (A), guanine (G), cytosine (C), and thymine (T) bound to a deoxyribose sugar to which a phosphate group is attached. Triplets of nucleotides (referred to as codons) code for each amino acid in a polypeptide, or for a stop signal. The term codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the DNA sequence is transcribed.

Unless otherwise specified, any reference to a DNA molecule is intended to include the reverse complement of that DNA molecule. Except where single-strandedness is required by the text herein, DNA molecules, though written to depict only a single strand, encompass both strands of a double-stranded DNA molecule. Thus, a reference to the nucleic acid molecule that encodes a specific protein, or a fragment thereof, encompasses both the sense strand and its reverse complement. For instance, it is appropriate to generate probes or primers from the reverse complement sequence of the disclosed nucleic acid molecules.

Hybridization: Oligonucleotides and their analogs hybridize by hydrogen bonding, which includes Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary bases. Generally, nucleic acid consists of nitrogenous bases that are either pyrimidines (cytosine (C), uracil (U), and thymine (T)) or purines (adenine (A) and guanine (G)). These nitrogenous bases form hydrogen bonds between a pyrimidine and a purine, and the bonding of the pyrimidine to the purine is referred to as "base pairing." More specifically, A will hydrogen bond to T or U, and G will bond to C. "Complementary" refers to the base

pairing that occurs between two distinct nucleic acid sequences or two distinct regions of the same nucleic acid sequence.

“Specifically hybridizable” and “specifically complementary” are terms that indicate a sufficient degree of complementarity such that stable and specific binding occurs between the oligonucleotide (or its analog) and the DNA or RNA target. The oligonucleotide or oligonucleotide analog need not be 100% complementary to its target sequence to be specifically hybridizable. An oligonucleotide or analog is specifically hybridizable when binding of the oligonucleotide or analog to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide or analog to non-target sequences under conditions where specific binding is desired, for example under physiological conditions in the case of in vivo assays or systems. Such binding is referred to as specific hybridization.

Hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially the Na⁺ concentration) of the hybridization buffer will determine the stringency of hybridization, though waste times also influence stringency. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (ed.), *Molecular Cloning: A Laboratory Manual*, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, chapters 9 and 11, herein incorporated by reference.

For present purposes, “stringent conditions” encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence. “Stringent conditions” may be broken down into particular levels of stringency for more precise definition. Thus, as used herein, “moderate stringency” conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of “medium stringency” are those under which molecules with more than 15% mismatch will not hybridize, and conditions of “high stringency” are those under which sequences with more than 10% mismatch will not hybridize. Conditions of “very high stringency” are those under which sequences with more than 6% mismatch will not hybridize.

Injectable composition: A pharmaceutically acceptable fluid composition including at least one active ingredient. The active ingredient is usually dissolved or suspended in a physiologically acceptable carrier, and the composition can additionally include amounts of one or more non-toxic auxiliary substances, such as emulsifying agents, preservatives, and pH buffering agents and the like. Such injectable compositions that are useful for use with the provided nucleotides and proteins are conventional; appropriate formulations are well known in the art.

In vitro amplification: Techniques that increase the number of copies of a nucleic acid molecule in a sample or specimen. An example of in vitro amplification is the polymerase chain reaction, in which a biological sample collected from a subject is contacted with a pair of oligonucleotide primers, under conditions that allow for the hybridization of the primers to nucleic acid template in the sample. The primers are extended under suitable conditions, dissociated from the template, and then re-annealed, extended, and dissociated to amplify the number of copies of the nucleic acid.

The product of in vitro amplification may be characterized by electrophoresis, restriction endonuclease cleavage patterns, oligonucleotide hybridization or ligation, and/or nucleic acid sequencing, using standard techniques.

Other examples of in vitro amplification techniques include strand displacement amplification (see U.S. Pat. No. 5,744,311); transcription-free isothermal amplification (see U.S. Pat. No. 6,033,881); repair chain reaction amplification (see WO 90/01069); ligase chain reaction amplification (see EP-A-320 308); gap filling ligase chain reaction amplification (see U.S. Pat. No. 5,427,930); coupled ligase detection and PCR (see U.S. Pat. No. 6,027,889); and NASBA™ RNA transcription-free amplification (see U.S. Pat. No. 6,025,134).

Isolated: An “isolated” biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.

Mutation: Any change of the DNA sequence within a gene or chromosome. In some instances, a mutation will alter a characteristic or trait (phenotype), but this is not always the case. Types of mutations include base substitution point mutations (e.g., transitions or transversions), deletions, and insertions. Missense mutations are those that introduce a different amino acid into the sequence of the encoded protein; nonsense mutations are those that introduce a new stop codon. In the case of insertions or deletions, mutations can be in-frame (not changing the frame of the overall sequence) or frame shift mutations, which may result in the misreading of a large number of codons (and often leads to abnormal termination of the encoded product due to the presence of a stop codon in the alternative frame).

This term specifically encompasses variations that arise through somatic mutation, for instance those that are found only in disease cells, but not constitutionally, in a given individual. Examples of such somatically-acquired variations include the point mutations that frequently result in altered function of various genes that are involved in development of cancers. This term also encompasses DNA alterations that are present constitutionally, that alter the function of the encoded protein in a readily demonstrable manner, and that can be inherited by the children of an affected individual. In this respect, the term overlaps with “polymorphism,” as defined below, but generally refers to the subset of constitutional alterations that have arisen within the past few generations in a kindred and that are not widely disseminated in a population group. In particular embodiments, the term is directed to those constitutional alterations that have major impact on the health of affected individuals.

Nucleotide: “Nucleotide” includes, but is not limited to, a monomer that includes a base linked to a sugar, such as a pyrimidine, purine or synthetic analogs thereof, or a base linked to an amino acid, as in a peptide nucleic acid (PNA). A nucleotide is one monomer in a polynucleotide. A nucleotide sequence refers to the sequence of bases in a polynucleotide.

Oligonucleotide: An oligonucleotide is a plurality of joined nucleotides joined by native phosphodiester bonds, between about 6 and about 500 nucleotides in length. An oligonucleotide analog refers to moieties that function similarly to oligonucleotides but have non-naturally occurring portions. For

example, oligonucleotide analogs can contain non-naturally occurring portions, such as altered sugar moieties or inter-sugar linkages, such as a phosphorothioate oligodeoxynucleotide. Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include PNA molecules.

Particular oligonucleotides and oligonucleotide analogs can include linear sequences up to about 300 nucleotides in length, for example a sequence (such as DNA or RNA) that is at least 6 bases, for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200 or more bases long, or from about 6 to about 50 bases, for example about 10-25 bases, such as 12, 15, 20, or 25 bases.

Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.

Open reading frame (ORF): A series of nucleotide triplets (codons) coding for amino acids without any internal termination codons. These sequences are usually translatable into a peptide.

Ortholog: Two nucleic acid or amino acid sequences are orthologs of each other if they share a common ancestral sequence and diverged when a species carrying that ancestral sequence split into two species. Orthologous sequences are also homologous sequences.

Parenteral: Administered outside of the intestine, e.g., not via the alimentary tract. Generally, parenteral formulations are those that will be administered through any possible mode except ingestion. This term especially refers to injections, whether administered intravenously, intrathecally, intramuscularly, intraperitoneally, or subcutaneously, and various surface applications including intranasal, intradermal, and topical application, for instance.

Peptide Nucleic Acid (PNA): An oligonucleotide analog with a backbone comprised of monomers coupled by amide (peptide) bonds, such as amino acid monomers joined by peptide bonds.

Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers useful with the compositions provided herein are conventional. By way of example, Martin, in *Remington's Pharmaceutical Sciences*, published by Mack Publishing Co., Easton, Pa., 19th Edition, 1995, describes compositions and formulations suitable for pharmaceutical delivery of the nucleotides and proteins herein disclosed.

In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

Polymorphism: Variant in a sequence of a gene, usually carried from one generation to another in a population. Polymorphisms can be those variations (nucleotide sequence dif-

ferences) that, while having a different nucleotide sequence, produce functionally equivalent gene products, such as those variations generally found between individuals, different ethnic groups, or geographic locations. The term polymorphism also encompasses variations that produce gene products with altered function, i.e., variants in the gene sequence that lead to gene products that are not functionally equivalent. This term also encompasses variations that produce no gene product, an inactive gene product, or increased or decreased activity gene product.

Polymorphisms can be referred to, for instance, by the nucleotide position at which the variation exists, by the change in amino acid sequence caused by the nucleotide variation, or by a change in some other characteristic of the nucleic acid molecule or protein that is linked to the variation (e.g., an alteration of a secondary structure such as a stem-loop, or an alteration of the binding affinity of the nucleic acid for associated molecules, such as polymerases, RNases, and so forth).

Probes and primers: Nucleic acid probes and primers can be readily prepared based on the nucleic acid molecules provided as indicators of disease or disease progression. It is also appropriate to generate probes and primers based on fragments or portions of these nucleic acid molecules. Also appropriate are probes and primers specific for the reverse complement of these sequences, as well as probes and primers to 5' or 3' regions.

A probe comprises an isolated nucleic acid attached to a detectable label or other reporter molecule. Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, e.g., in Sambrook et al. (*In Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989) and Ausubel et al. (*In Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1998).

Primers are short nucleic acid molecules, for instance DNA oligonucleotides 10 nucleotides or more in length. Longer DNA oligonucleotides may be about 15, 20, 25, 30 or 50 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other in vitro nucleic-acid amplification methods known in the art.

Methods for preparing and using nucleic acid probes and primers are described, for example, in Sambrook et al. (*In Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989), Ausubel et al. (ed.) (*In Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1998), and Innis et al. (*PCR Protocols, A Guide to Methods and Applications*, Academic Press, Inc., San Diego, Calif., 1990). Amplification primer pairs (for instance, for use with polymerase chain reaction amplification) can be derived from a known sequence such as the PDGFRA or other tyrosine kinase sequences described herein, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, © 1991, Whitehead Institute for Biomedical Research, Cambridge, Mass.).

One of ordinary skill in the art will appreciate that the specificity of a particular probe or primer increases with its length. Thus, for example, a primer comprising 30 consecutive nucleotides of a tyrosine kinase protein encoding nucleotide will anneal to a target sequence, such as another

homolog of the designated tyrosine kinase protein, with a higher specificity than a corresponding primer of only 15 nucleotides. Thus, in order to obtain greater specificity, probes and primers can be selected that comprise at least 20, 23, 25, 30, 35, 40, 45, 50 or more consecutive nucleotides of a tyrosine kinase-encoding nucleotide sequence.

Also provided are isolated nucleic acid molecules that comprise specified lengths of tyrosine kinase-encoding nucleotide sequences. Such molecules may comprise at least 10, 15, 20, 23, 25, 30, 35, 40, 45 or 50 or more (e.g., at least 100, 150, 200, 250, 300 and so forth) consecutive nucleotides of these sequences or more. These molecules may be obtained from any region of the disclosed sequences (e.g., a PDGFRA nucleic acid may be apportioned into halves or quarters based on sequence length, and isolated nucleic acid molecules may be derived from the first or second halves of the molecules, or any of the four quarters, etc.). A cDNA or other encoding sequence also can be divided into smaller regions, e.g. about eighths, sixteenths, twentieths, fiftieths, and so forth, with similar effect.

Another mode of division, provided by way of example, is to divide a tyrosine kinase-encoding sequence based on the regions of the sequence that are relatively more or less homologous to other tyrosine kinase sequences.

Another mode of division is to select the 5' (upstream) and/or 3' (downstream) region associated with a tyrosine kinase gene (e.g., PDGFRA).

Nucleic acid molecules may be selected that comprise at least 10, 15, 20, 25, 30, 35, 40, 50, 100, 150, 200, 250, 300 or more consecutive nucleotides of any of these or other portions of a PDGFRA nucleic acid molecule, such as those disclosed herein, and associated flanking regions. Thus, representative nucleic acid molecules might comprise at least 10 consecutive nucleotides of the PDGFRA cDNA shown in SEQ ID NO: 1.

Protein: A biological molecule expressed by a gene or recombinant or synthetic coding sequence and comprised of amino acids.

Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell or within a production reaction chamber (as appropriate).

Recombinant: A recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

Sequence identity: The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or orthologs of human PDGFRA protein, and the corresponding cDNA or gene sequence(s), will possess a relatively high degree of sequence identity when aligned using standard methods. This homology will be more significant when the orthologous proteins or genes or cDNAs are derived from species that are more closely related (e.g., human and chimpanzee sequences), compared to species more distantly related (e.g., human and *C. elegans* sequences).

Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman *Adv. Appl. Math.* 2: 482, 1981; Needleman & Wunsch *J. Mol. Biol.* 48: 443, 1970; Pearson & Lipman *Proc. Natl. Acad. Sci. USA* 85: 2444, 1988; Higgins & Sharp *Gene*, 73: 237-244, 1988; Higgins & Sharp *CABIOS* 5: 151-153, 1989; Corpet et al. *Nuc. Acids Res.* 16, 10881-90, 1988; Huang et al. *Computer Appls. in the Biosciences* 8, 155-65, 1992; and Pearson et al. *Meth. Mol. Bio.* 24, 307-31, 1994. Altschul et al. (*J. Mol. Biol.* 215:403-410, 1990), presents a detailed consideration of sequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al. *J. Mol. Biol.* 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. By way of example, for comparisons of amino acid sequences of greater than about 30 amino acids, the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1). When aligning short peptides (fewer than around 30 amino acids), the alignment is performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties).

An alternative indication that two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions. Stringent conditions are sequence-dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5° C. to 20° C. lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence remains hybridized to a perfectly matched probe or complementary strand. Conditions for nucleic acid hybridization and calculation of stringencies can be found in Sambrook et al. (In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989) and Tijssen (*Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes* Part I, Chapter 2, Elsevier, New York, 1993). Nucleic acid molecules that hybridize under stringent conditions to a human tyrosine kinase protein-encoding sequence will typically hybridize to a probe based on either an entire human tyrosine kinase protein-encoding sequence or selected portions of the encoding sequence under wash conditions of 2xSSC at 50° C.

Nucleic acid sequences that do not show a high degree of sequence identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein.

Specific binding agent: An agent that binds substantially only to a defined target. Thus a protein-specific binding agent binds substantially only the specified protein. By way of example, as used herein, the term "PDGFRA-protein specific binding agent" includes anti-PDGFRA protein antibodies (and functional fragments thereof) and other agents (such as soluble receptors) that bind substantially only to the PDGFRA protein.

Anti-PDGFRA protein antibodies (or antibodies to another tyrosine kinase) may be produced using standard procedures described in a number of texts, including Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988). The determination that a particular agent binds substantially

only to the specified protein may readily be made by using or adapting routine procedures. One suitable in vitro assay makes use of the Western blotting procedure (described in many standard texts, including Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988)). Western blotting may be used to determine that a given protein binding agent, such as an anti-PDGFR α protein monoclonal antibody, binds substantially only to the PDGFR α protein.

Shorter fragments of antibodies can also serve as specific binding agents. For instance, Fabs, Fvs, and single-chain Fvs (SCFvs) that bind to a specified protein would be specific binding agents. These antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')₂, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab')₂, a dimer of two Fab' fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (6) single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Methods of making these fragments are routine.

Subject: Living multi-cellular vertebrate organisms, a category that includes both human and non-human mammals.

Target sequence: "Target sequence" is a portion of ssDNA, dsDNA or RNA that, upon hybridization to a therapeutically effective oligonucleotide or oligonucleotide analog, results in the inhibition of expression. For example, hybridization of therapeutically effective oligonucleotide(s) to a PDGFR α target sequence results in inhibition of PDGFR α expression. Either an antisense or a sense molecule can be used to target a portion of dsDNA, since both will interfere with the expression of that portion of the dsDNA. The antisense molecule can bind to the plus strand, and the sense molecule can bind to the minus strand. Thus, target sequences can be ssDNA, dsDNA, and RNA.

Transformed: A transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques. As used herein, the term transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.

Vector: A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell. A vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector may also include one or more selectable marker genes and other genetic elements known in the art.

Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Hence "com-

prising A or B" means including A, or B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

III. Overview of Several Embodiments

One embodiment is an isolated variant PDGFR α polypeptide. Specific examples of such polypeptides comprise an amino acid sequence as set forth in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25 or a fragment thereof comprising at least 10 contiguous amino acids including the variant site as set forth in position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25. Also encompassed herein are the PDGFR α polypeptides defined by the consensus sequence shown in SEQ ID NO: 27, and fragments thereof, particularly fragments that overlap one or more of the noted variable regions.

Also provided are isolated nucleic acid molecules encoding such polypeptides, recombinant nucleic acid molecules comprising a promoter sequence operably linked to these nucleic acid molecules, and cells transformed with such recombinant nucleic acid molecules. Specific examples of nucleic acid molecules comprise a nucleotide sequence as set forth in SEQ ID NO: 3, 5, 7, 9, 11, 20, 22, or 24; or a fragment thereof including the variant nucleic sequence shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2071 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24. Also encompassed herein are the PDGFR α nucleic acid molecules defined by the consensus sequence shown in SEQ ID NO: 26, and fragments thereof, particularly fragments that overlap one or more of the noted variable regions.

A further embodiment is a method of detecting a biological condition (e.g., neoplasia) associated with an activating PDGFR α mutation in a subject, comprising determining whether the subject has an activating mutation in PDGFR α , and wherein the activating mutation comprises the variant nucleic sequence shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2071 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24, or in any one or more of the variable positions indicated in SEQ ID NO: 26. Specific examples of biological conditions contemplated herein are neoplasias that comprise a GIST.

In specific examples of these methods, the method involves reacting at least one PDGFR α molecule contained in a clinical sample from the subject with a reagent comprising a PDGFR α -specific binding agent to form a PDGFR α :agent complex. For instance, the PDGFR α molecule in some instances is a PDGFR α encoding nucleic acid or a PDGFR α protein, and the PDGFR α specific binding agent is a PDGFR α oligonucleotide or a PDGFR α protein specific binding

agent. In some embodiments, the sample from the subject includes a neoplastic cell, or is prepared from a neoplastic cell or a sample comprising a neoplastic cell.

In some of the provided methods of detecting a biological condition, the PDGFRA molecule is a PDGFRA encoding nucleic acid sequence. Specific examples of such methods involve using an agent that comprises a labeled nucleotide probe. For instance, the nucleotide probe will in some instances have a sequence as shown in SEQ ID NO: 3, 5, 7, 9, 11, 20, 22, or 24, or a fragment of one of these sequences that is at least 15 nucleotides in length, and that includes the sequence shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2071 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24.

Specific method embodiments involve in vitro amplifying a PDGFRA nucleic acid prior to detecting the activating PDGFRA mutation. By way of example, the PDGFRA nucleic acid is in some cases in vitro amplified using at least one oligonucleotide primer derived from a PDGFRA-protein encoding sequence, such as the specific oligonucleotide primers listed herein. Other specific oligonucleotide primers comprise at least 15 contiguous nucleotides from SEQ ID NO: 3, 5, 7, 9, 11, 20, 22, or 24. For instance, representative examples of such primers include a sequence as represented by at least 15 contiguous nucleotides shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2071 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24. Also included are primers that would be situated across a region including one or more of these variant positions, or any variant position indicated in SEQ ID NO: 26, so that the primers could be used to prime the amplification of a nucleic acid sequence encompassing one or more of the variants.

In other method of detection embodiments, the PDGFRA molecule is a PDGFRA protein, for instance a variant PDGFRA protein comprising a sequence as shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25. In examples of such methods, the complexes are detected by western blot assay, or by ELISA.

Specific examples of PDGFRA-specific binding agents are PDGFRA-specific antibody or a functional fragment thereof, for instance monoclonal antibodies or fragments of monoclonal antibodies. Optionally, such monoclonal antibodies recognize an epitope of a variant PDGFRA (such as an epitope of a variant PDGFRA having an amino acid sequence as shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25) and not (or to a lesser extent) an epitope of wildtype PDGFRA. In particular methods, the antibody is reactive to an epitope including the amino acid sequence shown in position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25.

Also provided in the disclosure are kits for detecting an activating PDGFRA mutation in a subject using methods described herein. Examples of such kits are used with protein-detection methods, and include at least one PDGFRA protein specific binding agent. For instance, in specific kits the agent (e.g., an antibody) is capable of specifically binding to an epitope within a PDGFRA variant protein but not to an epitope of wildtype PDGFRA. Thus, some such agents are capable of specifically binding to an epitope within the amino acid sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25, or more particularly antigenic fragments of (a) that com-

prise the sequence shown in position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25. Examples of the protein-detection kits further include a means for detecting binding of the PDGFRA protein binding agent to a PDGFRA polypeptide.

A further embodiment is a kit for determining whether or not a subject (e.g., an animal, or more particularly a mammal) has a biological condition (e.g., neoplasia, such as that comprising a GIST) associated with an activating PDGFRA mutation by detecting a mutant PDGFRA sequence in the subject, which kit includes a container comprising at least one oligonucleotide specific for a PDGFRA mutation sequence; and instructions for using the kit, the instructions indicating steps for performing a method to detect the presence of mutant PDGFRA nucleic acid in the sample; and analyzing data generated by the method, wherein the instructions indicate that presence of the mutant nucleic acid in the sample indicates that the individual has or is predisposed to the biological condition. Optionally, such kits further include at least one container that comprises a detectable oligonucleotide. Specific examples of oligonucleotides (labeled or not) that may be included in these kits will be specific for a PDGFRA mutation sequence. For instance, particular example oligonucleotides comprise a sequence specific for a PDGFRA encoding sequence and containing the specific sequence shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2071 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24.

Another specific embodiment is a kit for determining whether or not a subject (e.g., an animal, or more particularly a mammal) has a biological condition (e.g., neoplasia, such as that comprising a GIST) associated with an activating PDGFRA mutation, the kit including a container comprising a PDGFRA mutant specific antibody; a container comprising a negative control sample; and instructions for using the kit, the instructions indicating steps for: performing a test assay to detect a quantity of PDGFRA mutant protein in a test sample of tissue and/or bodily fluid from the subject, performing a negative control assay to detect a quantity of PDGFRA mutant protein in the negative control sample; and comparing data generated by the test assay and negative control assay, wherein the instructions indicate that a quantity of PDGFRA mutant protein in the test sample more than the quantity of PDGFRA mutant protein in the negative control sample indicates that the subject has the biological condition. Specific examples of such kits further include one or more detectable antibodies that bind to the antibody specific for PDGFRA mutant protein (e.g., to be used in detection of the primary antibody).

Yet another embodiment is a method of screening for a compound useful in influencing (for instance, inhibiting or treating) PDGFRA-mediated neoplasia in a mammal, comprising determining if a test compound binds to or interacts with the polypeptide or fragment according to claim 1, and selecting a compound that so binds. In specific examples of this method, binding of the compound inhibits a PDGFRA protein biological activity (e.g., kinase activity). In certain examples, the test compound is applied to a test cell. Compounds identified or selected by such methods, whether or not formulated for use as therapeutic agents, are also contemplated.

Also provided are compositions that include at least one antigenic fragment of a provided PDGFRA variant protein, where the antigenic fragment includes the variant sequence as shown at position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25.

IV. Identification of Activating Mutations of PDGFRA

The inventors have determined that mutations in the platelet derived growth factor receptor alpha (PDGFRA) gene, particularly mutations that produce activated PDGFRA protein, are linked to neoplastic disease such as cancer, and thereby can be used to assess whether a subject suffers from or is susceptible to such a condition. The following examples illustrate this by showing particular examples of mutations that are associated with specific cancers in human subjects. Moreover, guidance is provided about finding other mutations associated with other specific cancers, both in PDGFRA and in other tyrosine kinases. Hence, in its broadest aspect, the disclosure is not limited to particular mutations, but is instead premised on the finding that activating PDGFRA mutations are associated with neoplastic disease.

The PDGFRA protein is a type III receptor tyrosine kinase with homology to KIT, FLT3, CSF1-R, and PDGFR beta (PDGFRB). Although PDGFRA activation has been hypothesized to be involved in certain cancers, most notably gliomas, evidence of genomic activation in human cancer has only recently been reported in two cases of myeloproliferative disease associated with translocation of the BCR and PDGFR genes. We report herein several novel mutations of PDGFRA resulting in constitutive activation. These mutations were initially discovered in GISTs. Based on experience with KIT and FLT3, it is likely that mutations in other regions of the PDGFRA gene may result in constitutive activation of tyrosine kinase activity. At least in the case of KIT, the site of mutation varies between different diseases (e.g., mastocytosis vs. GIST). Finally, findings reported herein strongly suggest that similar mutations can activate related family members PDGFRB and CSF1-R, and that these mutant proteins are likely to be therapeutic targets in human cancer.

The discovery that mutations in the sequence of PDGFRA predisposes a subject to developing neoplasms also enables a variety of diagnostic, prognostic, and therapeutic methods that are further embodiments. The new appreciation of the role of activated PDGFRA in neoplastic diseases, such as cancers, enables detection of predisposition to or diagnosis of these conditions in a subject. This disclosure also enables early detection of subjects at high risk of these conditions, identification of subjects with particularly severe disease and/or tendency to progress, and in some embodiments detection of resistance or susceptibility of a subject to drug(s). Identification of the activating mutations described herein provides opportunities for prevention and/or early treatment as well as particular treatment selection.

V. Diagnostic and Therapeutic Applications

The presence of PDGFRA gene mutations in GIST strongly suggests that other human cancers will have similar mutations. When present in a cancer, mutant isoforms of PDGFRA represent a therapeutic target for tyrosine kinase inhibitors (TKIs), immunotherapy and other novel targeted approaches. Because PDGFRA gene mutations are not found

in all tumors, the selection of patients for therapy targeting mutant PDGFRA isoforms would be optimized by pre-therapy analysis of cancer cells for the presence of PDGFRA gene mutations.

Such analysis can be based on PCR-based assays for these mutations, using for instance one or more of the following approaches: size fractionation by gel electrophoresis, direct sequencing, single-strand conformation polymorphism (SSCP), high pressure liquid chromatography (including partially denaturing HPLC), allele-specific hybridization, amplification refractory mutation screening, PDGFRA mutation screening by oligonucleotide microarray, restriction fragment polymorphism, MALDI-TOF mass spectrometry, or various related technologies (Abu-Duhier et al., *Br. J. Haematol.*, 113: 983-988, 2001; Kottaridis et al., *Blood*, 98: 1752-1759, 2001; Choy et al., *Ann. Hum. Gen.*, 63: 383-391, 1999; Grompe, *Nature Genetics*, 5: 111-117, 1993; Perlin & Szabady, *Hum. Mutat.*, 19: 361-373, 2002; Amos & Patnaik, *Hum. Mutat.*, 19: 324-333, 2002; Cotton, *Hum. Mutat.*, 19: 313-314, 2002; Stirewalt et al., *Blood*, 97: 3589-3595, 2001; Hung et al., *Blood Coagul. Fibrinolysis*, 13: 117-122, 2002; Larsen et al., *Pharmacogenomics*, 2: 387-399, 2001; Shechinov et al., *Nucleic Acids Res.*, 29: 3864-3872, 2001).

In addition, mutant PDGFRA proteins may be detected through novel epitopes recognized by polyclonal and/or monoclonal antibodies used in ELISA, immunoblotting, flow cytometric, immunohistochemical and other mutant protein detection strategies (Wong et al., *Cancer Res.*, 46: 6029-6033, 1986; Luwor et al., *Cancer Res.*, 61: 5355-5361, 2001; Mishima et al., *Cancer Res.*, 61: 5349-5354, 2001; Ijaz et al., *J. Med. Virol.*, 63: 210-216, 2001). Additionally mutant PDGFRA proteins could be detected by mass spectrometry assays coupled to immunoaffinity assays, the use of matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass mapping and liquid chromatography/quadrupole time-of-flight electro spray ionization tandem mass spectrometry (LC/Q-TOF-ESI-MS/MS) sequence tag of tumor derived proteins separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) (Kiernan et al., *Anal. Biochem.*, 301: 49-56, 2002; Poutanen et al., *Mass Spectrom.*, 15: 1685-1692, 2001). All of these approaches may be used to detect a sequence anomaly or variant of the PDGFRA protein, a relative increase in the phosphorylation of the protein, or an increase in the inherent kinase activity of the protein.

In addition to direct detection of mutant PDGFRA proteins, it is expected that various PDGFRA mutants will result in distinctive signal transduction profiles that could be detected by global gene expression profile or analysis of the activation of various signaling intermediates (e.g., STAT5) (Hofmann et al., *Lancet*, 359: 481-486, 2002).

Utility of this disclosure is highlighted by the correlative studies of response to imatinib mesylate and tumor KIT genotype in patients treated in a phase II trial of imatinib mesylate. In this trial, response to treatment was vastly superior in patients with an imatinib mesylate-sensitive KIT mutation compared with patients with no detectable KIT mutation (Heinrich et al., *Proc. of ASCO*, 21:2A, 2002).

It is believed that the nature and location of PDGFRA mutations affects the sensitivity of the resultant mutant protein to various TKIs. For example, imatinib mesylate is highly active against the kinase activity of wild-type KIT and against activating mutations involving the extracellular, juxtamembrane and TK1 domain (Tuveson et al., *Oncogene*, 20: 5054-5058, 2001; Heinrich et al., *Blood*, 96: 925-932, 2000). In contrast, imatinib mesylate has no clinically useful activity against mutations of the aspartic acid residue at position 816 (e.g., D816V, D816Y, D816F, or D816H) (Ma et al., *Blood*,

99: 1741-1744, 2002). The KIT D816V mutation is homologous to the D842V PDGFRA mutation described in this application. In addition, indolinone and tyrphostin compounds have little or no activity against KIT D816 mutations (or the equivalent D814 residue in murine KIT) but are potent inhibitors of the kinase activity of wild-type and juxtamembrane mutant KIT polypeptides (Ma et al., *Blood*, 99: 1741-1744, 2002; Ikeda et al., *Blood* 96, 99a-99a. Nov. 16, 2000; Ma et al., *J. Invest. Derma.*, 114: 392-394, 2000). However, imatinib mesylate has some activity against other KIT activation loop mutations that involve residues other than aspartic acid 816.

Based on homology to KIT, it is predicted that imatinib mesylate and indolinone compounds would have minimal activity against the D842V PDGFRA mutation but might have clinically useful activity against PDGFRA deletion and/or insertion mutations. In the absence of structural biology information concerning the structure of both wild type and mutant PDGFRA proteins and the site of binding of imatinib mesylate or other TKIs to these proteins, it will be necessary to empirically determine the activity of TKIs against the kinase activity of various mutant PDGFRA proteins. This could be accomplished by cloning cDNAs of the various PDGFRA mutant isoforms and the recombinant protein in prokaryotic or eukaryotic cells (Ma et al., *Blood*, 99: 1741-1744, 2002; Wood et al., *Cancer Res*, 60: 2178-2189, 2000). Protein expressed in such a manner could be used to determine biochemical activity of existing TKIs and could also be used in high throughput screening of chemical libraries to help identify and optimize pre-clinical development of new compounds against these or other PDGFRA mutant isoforms (Chroeder et al., *J. Med. Chem.*, 44: 1915-1926, 2001; Hamby et al., *J. Med. Chem.*, 40: 2296-2303, 1997; Druker et al., *Nature Medicine*, 2: 561-566, 1996). Prior determination of biochemical potency of specific compounds to different PDGFRA mutations would allow clinical testing of patient specimens for PDGFRA mutations and selection of the appropriate TKI based on the specific mutation and sensitivity associated with that patient's tumor.

Since the novel PDGFRA activating protein variants are only expressed by neoplastic cells, they have the potential to serve as tumor-specific antigens for cytotoxic T-lymphocytes (CTL). Indeed, it has been shown that the unique peptide sequence generated by the BCR-ABL fusion protein characteristic of chronic myelogenous leukemia can serve as the basis of an in vivo immune therapy that utilizes BCR-ABL peptide loaded dendritic cells to generate CTL with BCR-ABL specificity (He et al., *Cancer Immunol. Immunother.*, 50: 31-40, 2001).

VI. Prediction of Additional Types of PDGFRA Mutations

Based on experience with KIT and FLT3, it is likely that mutations in other regions of the PDGFRA gene may result in constitutive activation of tyrosine kinase activity. Other likely sites of PDGFRA activating mutations include the proximal extra-cellular, juxtamembrane, and TK1 domains of PDGFRA (Rubin et al., *Cancer Res*, 61: 8118-8121, 2001; Lux et al., *Am. J. Pathol.*, 156: 791-795, 2000; Abu-Duhier et al., *Br. J. Haematol.*, 111: 190-195, 2000). Indeed, it should be noted that there is one solitary case report of an astrocytoma with a large in-frame deletion of 81 amino acids involving portions of the fourth and fifth immunoglobulin domains of PDGFRA. The tumor in that report had genomic amplification of this PDGFRA mutant allele. The activity of PDGFRA kinase of this mutant isoform was not reported (Kumabe et al., *Oncogene*, 7: 627-633, 1992). Recently Baxter et al. reported a translocation having the structure t(4; 22) (q12; q11) in two cases of atypical chronic myeloid leukemia. Molecular cloning of the translocation revealed fusion of a portion of the BCR gene with part of exon 12 of PDGFRA (Baxter et al., *Hum. Mol. Genet.* 11:1391-1397, 2002). The fusion gene from these translocations is predicted to encode a constitutively activated tyrosine kinase, however no formal biochemical characterization of these proteins was performed (Baxter et al., 2002). Without meaning to be limited to a single interpretation, it is believed that fusion mechanisms of oncogenesis involving PDGFRA (e.g., the BCR-PDGFRA fusions reported by Baxter et al.) likely are a rare occurrence, while point mutation and deletion activations are expected to be more common, and that these two mechanisms are independent of each other.

In KIT, FLT3, and CSF-1R, kinase activation results from a variety of amino acid substitutions at the conserved aspartic acid in the activation loop (D816 KIT, D835 FLT3, and D802 of CSF-1R) (Morley et al., *Oncogene*, 18: 3076-3084, 1999; Moriyama et al., *J. Biol. Chem.*, 271: 3347-3350, 1996). In the case of KIT and FLT3, a number of these substitutions have been found in association with certain malignancies (Ma et al., *Blood*, 99: 1741-1744, 2002; Abu-Duhier et al., *Br. J. Haematol.*, 113: 983-988, 2001; Yamamoto et al., *Blood*, 97: 2434-2439, 2001; Longley et al., *Leuk. Res.*, 25: 571-576, 2001; Ning et al., *Leuk. Lymphoma*, 41: 513-522, 2001). To date, no mutations of D802 of CSF-1R have been found in any human cancer. Thus far, we have found only a valine substitution at D842 of PDGFRA, but it can be predicted that a variety of amino acid substitutions at this position of PDGFRA would be activating. Assuming a single nucleotide change in codon 842, the most likely possible mutations of PDGFRA would be substitution of Asparagine, Tyrosine, Histidine, Valine, Alanine, Glycine, or Glutamic acid for the normal Aspartic acid. We predict that these additional PDGFRA mutations would also be oncogenic and will be found in one or more human neoplasms.

VII. Prediction of Similar Activating Mutations in PDGFRB

The amino acid sequence of the members of the Type III receptor tyrosine kinase family are highly conserved in the activation loop:

DFGLARDIMHDSN	Human PDGFRA
DFGLARDIMRDSN	Human PDGFRB
DFGLARDIKNDSN	Human KIT
DFGLARDIMNDSN	Human CSF-1R
DFGLARDIMSDSN	Human FLT3

As noted above, amino acid substitutions at the conserved aspartic acid (shown in bold) result in constitutive activation of the tyrosine kinase activity of KIT, PDGFRA or FLT3 in different human malignancies (Rosnet et al., *Blood*, 82: 1110-1119, 1993; Claesson-Welsh et al., *Proc. Natl. Acad. Sci. U.S.A.*, 86: 4917-4921, 1989; Gronwald et al., *Proc. Natl. Acad. Sci. U.S.A.*, 85: 3435-3439, 1988; Yarden et al., *Nature*, 323: 226-232, 1986). Amino acid substitution at the same aspartic acid of CSF-1R is also activating, but has not yet been found in association with human disease. Based on our findings, we predict that amino acid substitution at the same

aspartic acid of PDGFRB would also be activating and that this mutation will be found in some human malignances.

VIII. Identification of Compounds that Inhibit PDGFRA Variants

This disclosure further relates in some embodiments to novel methods for screening test compounds for their ability to treat, detect, analyze, ameliorate, reverse, and/or prevent neoplasia, especially pre-cancerous lesions. In particular, the present disclosure provides methods for identifying test compounds that can be used to treat, ameliorate, reverse, and/or prevent neoplasia, including precancerous lesions. The compounds of interest can be tested by exposing the novel activating PDGFRA variants described herein to the compounds, and if a compound inhibits one of the PDGFRA variants, the compound is then further evaluated for its anti-neoplastic properties.

One aspect involves a screening method to identify a compound effective for treating, preventing, or ameliorating neoplasia, which method includes ascertaining the compound's inhibition of a provided novel activating PDGFRA variant or another activating PDGFRA variant. In some embodiments, the screening method further includes determining whether the compound inhibits the growth of tumor cells in a cell culture.

By screening compounds in this fashion, potentially beneficial and improved compounds for treating neoplasia can be identified more rapidly and with greater precision than possible in the past.

A. In General

Activating tyrosine kinase mutants, for instance the novel activating PDGFRA variants described herein, are useful to identify compounds that can be used to treat, ameliorate, or prevent neoplasms.

The screening or creation, identification and selection of appropriate high affinity inhibitors of activating PDGFRA mutants can be accomplished by a variety of methods. Broadly speaking these may include, but are not limited to, two general approaches. One approach is to use structural knowledge about the target enzyme to design a candidate molecule with which it will precisely interact. An example would be computer assisted molecular design. A second approach is to use combinatorial or other libraries of molecules, whereby a large library of molecules is screened for affinity with regard to the target enzyme.

Cancer and precancer may be thought of as diseases that involve unregulated cell growth. Cell growth involves a number of different factors. One factor is how rapidly cells proliferate, and another involves how rapidly cells die. Cells can die either by necrosis or apoptosis depending on the type of environmental stimuli. Cell differentiation is yet another factor that influences tumor growth kinetics. Resolving which of the many aspects of cell growth a test compound affects can be important to the discovery of a relevant target for pharmaceutical therapy. Screening assays based on this technology can be combined with other tests to determine which compounds have growth inhibiting and pro-apoptotic activity.

B. Inhibitor Screening

Some embodiments provided herein involve determining the ability of a given compound to inhibit activating PDGFRA mutants, for instance the ability to specifically inhibit constitutive kinase and/or transforming activities in the PDGFRA D842V, PDGFRA V561D, PDGFRA DIMH842-845, PDGFRA HDSN845-848P, insertion ER561-562, or SPDGHE566-571R, RD841-842KI, or RVIES560-564 deletion mutants described herein. Test compounds can be

assessed for their probable ability to treat neoplastic lesions either directly, or indirectly by comparing their activities against compounds known to be useful for treating neoplasia. In particular, the compounds are tested for their ability to inhibit a neoplasia that is found to contain an activating PDGFRA mutation.

C. Determining Tyrosine Kinase Influencing Activity

Compounds can be screened for inhibitory or other effects on the activity of the novel activating PDGFRA mutants described herein using an expressed recombinant version of the enzyme, or a homolog or ortholog isolated from another species. Alternatively, cells expressing one of these tyrosine kinases can be treated with a test compound and the effect of the test compound on phosphorylation of a specific target can be determined, for instance using one of the techniques described herein. Additional detail regarding methods for determining tyrosine kinase phosphorylation influencing activity (e.g., inhibition) is provided herein.

D. Determining Whether a Compound Reduces the Number of Tumor Cells

In an alternate embodiment, provided screening methods involve further determining whether the compound reduces the growth of tumor cells, for instance tumor cells known to express an activated tyrosine kinase mutation such as a mutation in PDGFRA.

Various cell lines can be used, which may be selected based on the tissue to be tested. For example, these cell lines include: SW-480—colonic adenocarcinoma; HT-29—colonic adenocarcinoma, A-427—lung adenocarcinoma carcinoma; MCF-7—breast adenocarcinoma; and UACC-375—melanoma line; and DU145—prostate carcinoma. Cell lines can also be used that are known to express activated, mutant, tyrosine kinase proteins, for example: GIST882—gastrointestinal stromal tumor cell line expressing KIT tyrosine kinase point mutant; SKBR3—breast carcinoma cell line expressing ERBB2 amplification mutant; and K562—leukemia cell line expressing BCR-ABL tyrosine kinase fusion mutant. Cytotoxicity data obtained using these cell lines are indicative of an inhibitory effect on neoplastic lesions. Certain cell lines are well characterized, and are used for instance by the United States National Cancer Institute (NCI) in their screening program for new anti-cancer drugs. Though a compound may be identified by its ability to inhibit a specific tyrosine kinase activating mutant, its activity likely will not be limited to inhibition of only that mutant protein, thus testing in different cell lines and samples is beneficial to determine the scope of its activity.

By way of example, a test compound's ability to inhibit tumor cell growth in vitro can be measured using the HT-29 human colon carcinoma cell line obtained from ATCC (Bethesda, Md.). HT-29 cells have previously been characterized as a relevant colon tumor cell culture model (Fogh & Trempe, In: *Human Tumor Cells in Vitro*, Fogh (ed.), Plenum Press, N.Y., pp. 115-159, 1975). HT-29 cells are maintained in RPMI media supplemented with 5% fetal bovine calf serum (Gemini Bioproducts, Inc., Carlsbad, Calif.) and 2 mM glutamine, and 1% antibiotic-antimycotic, in a humidified atmosphere of 95% air and 5% CO₂ at 37° C. Briefly, HT-29 cells are plated at a density of 500 cells/well in 96 well microtiter plates and incubated for 24 hours at 37° C. prior to the addition of test compound. Each determination of cell number involved six replicates. After six days in culture, the cells are fixed by the addition of cold trichloroacetic acid (TCA) to a final concentration of 10% and protein levels are measured, for instance using the sulforhodamine B (SRB) colorimetric protein stain assay as previously described by Skehan et al. (*J. Natl. Cancer Inst.* 82: 1107-112, 1990). In

addition to the SRB assay, a number of other methods are available to measure growth inhibition and could be substituted for the SRB assay. These methods include counting viable cells following trypan blue staining, labeling cells capable of DNA synthesis with BrdU or radiolabeled thymidine, neutral red staining of viable cells, or MTT staining of viable cells.

Significant tumor cell growth inhibition greater than about 30% at a dose of 100 μ M or below is further indicative that the compound is useful for treating neoplastic lesions. An IC_{50} value may be determined and used for comparative purposes. This value is the concentration of drug needed to inhibit tumor cell growth by 50% relative to the control. In some embodiments, the IC_{50} value is less than 100 μ M in order for the compound to be considered further for potential use for treating, ameliorating, or preventing neoplastic lesions.

E. Determining Whether a Test Compound Induces Apoptosis

In other embodiments, screening methods provided herein further involve determining whether the test compound induces apoptosis in cultures of tumor cells.

Two distinct forms of cell death may be described by morphological and biochemical criteria: necrosis and apoptosis. Necrosis is accompanied by increased permeability of the plasma membrane, whereby the cells swell and the plasma membrane ruptures within minutes. Apoptosis is characterized by membrane blebbing, condensation of cytoplasm, and the activation of endogenous endonucleases.

Apoptosis occurs naturally during normal tissue turnover and during embryonic development of organs and limbs. Apoptosis also can be induced by various stimuli, including cytotoxic T-lymphocytes and natural killer cells, by ionizing radiation and by certain chemotherapeutic drugs. Inappropriate regulation of apoptosis is thought to play an important role in many pathological conditions including cancer, AIDS, or Alzheimer's disease, etc.

Test compounds can be screened for induction of apoptosis using cultures of tumor cells maintained under conditions as described above. In some examples of such screening methods, treatment of cells with test compounds involves either pre- or post-confluent cultures and treatment for two to seven days at various concentrations of the test compounds. Apoptotic cells can be measured in both the attached and "floating" portions of the cultures. Both are collected by removing the supernatant, trypsinizing the attached cells, and combining both preparations following a centrifugation wash step (10 minutes, 2000 rpm). The protocol for treating tumor cell cultures with sulindac and related compounds to obtain a significant amount of apoptosis has been described in the literature (e.g., Piazza et al., *Cancer Res.*, 55:3110-16, 1995). Particular features include collecting both floating and attached cells, identification of the optimal treatment times and dose range for observing apoptosis, and identification of optimal cell culture conditions.

Following treatment with a test compound, cultures can be assayed for apoptosis and necrosis, for instance by fluorescent microscopy following labeling with acridine orange and ethidium bromide. Many methods for measuring apoptotic cells are known to those of ordinary skill in the art; for instance, one method for measuring apoptotic cell number has been described by Duke & Cohen (*Curr. Prot. Immunol.*, Coligan et al., eds., 3.17.1-3.17.1, 1992).

For example, floating and attached cells are collected by trypsinization and washed three times in PBS. Aliquots of cells are then centrifuged. The pellet is resuspended in media and a dye mixture containing acridine orange and ethidium bromide prepared in PBS and mixed gently. The mixture then

can be placed on a microscope slide and examined for morphological features of apoptosis.

Apoptosis also can be quantified by measuring an increase in DNA fragmentation in cells that have been treated with test compounds. Commercial photometric EIA for the quantitative in vitro determination of cytoplasmic histone-associated-DNA-fragments (mono- and oligo-nucleosomes) are available (e.g., Cell Death Detection ELISA, Boehringer Mannheim). The Boehringer Mannheim assay is based on a sandwich-enzyme-immunoassay principle, using mouse monoclonal antibodies directed against DNA and histones, respectively. This allows the specific determination of mono- and oligo-nucleosomes in the cytoplasmic fraction of cell lysates. According to the vendor, apoptosis is measured as follows: The sample (cell-lysate) is placed into a streptavidin-coated microtiter plate ("MTP"). Subsequently, a mixture of anti-histone-biotin and anti-DNA peroxidase conjugates is added and incubated for two hours. During the incubation period, the anti-histone antibody binds to the histone-component of the nucleosomes and simultaneously fixes the immunocomplex to the streptavidin-coated MTP via its biotinylation. Additionally, the anti-DNA peroxidase antibody reacts with the DNA component of the nucleosomes. After removal of unbound antibodies by a washing step, the amount of nucleosomes is quantified by the peroxidase retained in the immunocomplex. Peroxidase is determined photometrically with ABTS7 (2,2'-Azido-[3-ethylbenzthiazolin-sulfonate]) as substrate.

By way of example, SW-480 colon adenocarcinoma cells are plated in a 96-well MTP at a density of 10,000 cells per well. Cells are then treated with test compound, and allowed to incubate for 48 hours at 37° C. After the incubation, the MTP is centrifuged and the supernatant is removed. The cell pellet in each well is then resuspended in lysis buffer for 30 minutes. The lysates are then centrifuged and aliquots of the supernatant (i.e., cytoplasmic fraction) are transferred into a streptavidin-coated MTP. Care is taken not to shake the lysed pellets (i.e., cell nuclei containing high molecular weight, un-fragmented DNA) in the MTP. Samples are then analyzed. Fold stimulation ($FS = OD_{max}/OD_{veh}$), an indicator of apoptotic response, is determined for each compound tested at a given concentration. EC_{50} values may also be determined by evaluating a series of concentrations of the test compound.

Statistically significant increases of apoptosis (i.e., greater than 2 fold stimulation at a test compound concentration of 100 μ M) are further indicative that the compound is useful for treating neoplastic lesions. Preferably, the EC_{50} value for apoptotic activity should be less than 100 μ M for the compound to be further considered for potential use for treating neoplastic lesions. EC_{50} is understood herein to be the concentration that causes 50% induction of apoptosis relative to vehicle treatment.

F. Organ Culture Model Tests

Test compounds identified by the methods described herein can be tested for antineoplastic activity by their ability to inhibit the incidence of preneoplastic lesions in an organ culture system, such as a mammary gland organ culture system. The mouse mammary gland organ culture technique has been successfully used by other investigators to study the effects of known antineoplastic agents such as NSAIDs, retinoids, tamoxifen, selenium, and certain natural products, and is useful for validation of the screening methods provided herein.

By way of example, female BALB/c mice can be treated with a combination of estradiol and progesterone daily, in order to prime the glands to be responsive to hormones in vitro. The animals are sacrificed, and thoracic mammary

glands are excised aseptically and incubated for ten days in growth media supplemented with insulin, prolactin, hydrocortisone, and aldosterone. DMBA (7,12-dimethylbenz(a)anthracene) is added to medium to induce the formation of premalignant lesions. Fully developed glands are then deprived of prolactin, hydrocortisone, and aldosterone, resulting in the regression of the glands but not the premalignant lesions.

The test compound is dissolved in, for instance, DMSO and added to the culture media for the duration of the culture period. At the end of the culture period, the glands are fixed in 10% formalin, stained with alum carmine, and mounted on glass slides. The incidence of forming mammary lesions is the ratio of the glands with mammary lesions to glands without lesions. The incidence of mammary lesions in test compound treated glands is compared with that of the untreated glands.

The extent of the area occupied by the mammary lesions can be quantitated by projecting an image of the gland onto a digitization pad. The area covered by the gland is traced on the pad and considered as 100% of the area. The space covered by each of the unregressed structures is also outlined on the digitization pad and quantitated by the computer.

The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the invention to the particular features or embodiments described.

EXAMPLES

The PDGFRA protein is a type III receptor tyrosine kinase with homology to KIT, FLT3, CSF1-R and PDGFR beta (PDGFRB). Although PDGFRA activation has been suspected to be involved in certain cancers, most notably gliomas, evidence of genomic activation in human cancer has not been previously reported. Provided herein are novel mutations of PDGFRA resulting in constitutive activation. These mutations were initially discovered in GISTs. It is expected that other human cancers will have identical or similar mutations. Based on experience with KIT and FLT3, it is likely that mutations in other regions of the PDGFRA gene may result in constitutive activation of tyrosine kinase activity. At least in the case of KIT, the site of mutation varies between different diseases (e.g., mastocytosis vs. GIST). Finally, these findings strongly suggest that similar mutations can activate related family members PDGFRB and CSF-1R, and that these mutant proteins are likely to be therapeutic targets in human cancer.

Example 1

Activating Mutations in PDGFRA in GISTs

Methods

Three to five mm³ pieces of frozen gastrointestinal stromal tumors were homogenized by 5 to 10 strokes of a Tissue Tearor™ homogenizer in ice-cold lysis buffer (1% Nonidet P-40, 50 mmol/L Tris, pH 8.0, 100 mmol/L sodium fluoride, 30 mmol/L sodium pyrophosphate, 2 mmol/L sodium molybdate, 5 mmol/L ethylenediaminetetracetic acid, 2 mmol/L sodium vanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 100 µg/ml phenylmethylsulfonyl fluoride) and rocked overnight at 4° C. Residual cell debris was removed by centrifugation (14,000 g) for 20 minutes at 4° C., and the supernatant protein concentrations were determined using the BioRad™ MMT assay. Five hundred microliters (µl) of protein cell lysates (2 mg/ml) were pre-cleared with 20 µl of normal rabbit

serum (Zymed Laboratories) and 20 µl of protein A sepharose 4B (Zymed Laboratories) for one hour at 4° C., followed by sequential additions of 20 µl of panRTK antibodies and 20 µl of protein A sepharose 4B with end-to-end rotation for two hours after each addition.

Antibodies used for immunoprecipitation were to KIT (Santa Cruz sc-168), PDGFRA (Santa Cruz sc-338), and panRTK. The panRTK antibodies were raised against combinations of epitopes, each epitope representing one variation of the conserved RTK catalytic domain sequence (#1 YVHRDLAARNIL (SEQ ID NO: 13); #2 CIHRDLAARNVL (SEQ ID NO: 14); #3 FVHRDLAARNCM (SEQ ID NO: 15); #4 LVHRDLAARNVL (SEQ ID NO: 16); #5 FIHRDLAARNCL (SEQ ID NO: 17); and #6 FVHRDLA-TRNCL (SEQ ID NO: 18)). Each rabbit was injected with three panRTK epitopes, either combination #1 (YVHRDLAARNIL, CIHRDLAARNVL and FVHRDLAARNCM) or combination #2 (LVHRDLAARNVL, FIHRDLAARNCL, and FVHRDLAARNCL). The panRTK antisera were then affinity purified using the same combinations of epitopes against which they had been raised. These panRTK antisera are expected to react with all human and murine RTKs, and with a subset of nonreceptor tyrosine kinase proteins (e.g., JAK family members, SRC family members, FAK/PTK2, ABL, and ARG) that contain the conserved epitope. The panRTK antisera immunoprecipitate individual RTK proteins with lower efficiency than specific kinase antibodies, inasmuch as they react with the entire class of RTK proteins, rather than targeting a specific kinase protein. Typically, 10-20 µg of panRTK antisera are required per immunoprecipitation, in order to purify the same amount of each RTK protein that would typically be immunoprecipitated with 2-4 µg of an optimized, specific antibody.

The immunoprecipitates were then washed three times in lysis buffer, 10 minutes each wash, and once in 10 mM Tris for one hour. After discharging the supernatant, 20 µl of sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis loading buffer was added to the immunoprecipitates, and heated for six minutes at 95° C. The supernatants were then collected and loaded into 4-12% sodium dodecyl sulfate-polyacrylamide gel gradient gels (NuPAGE™, Invitrogen, Carlsbad, Calif.), followed by electrophoretic transfer to nitrocellulose membranes (PROTRAN™, Schleicher & Schuell, Keene, N.H.). Ponceau S solution was used to confirm adequate protein transfer (Sigma Chemical Co., St Louis, Mo.).

The membranes were then blocked overnight using a 1% solution of bovine serum albumin (BSA; Sigma Chemical Co., St Louis, Mo.) in 0.01% phosphate-buffered saline (PBS)-Tris at pH 7.4. Protein tyrosine phosphorylation was detected by staining the membranes with anti-phosphotyrosine monoclonal mouse antibody (PY99; Santa Cruz Biotechnology, Santa Cruz, Calif.; 1:4000) in 1% BSA/0.01% PBS-Tris solution for 2 hours at room temperature (RT) and with anti-mouse immunoglobulin-horseradish peroxidase goat polyclonal antibody (Amersham Pharmacia Biotech, Piscataway, N.J.; 1:5000). The membranes were then stripped, blocked with 5% non-fat milk/0.01% PBS-Tris solution for one hour at room temperature, and restained with specific antibodies to PDGFRA (Santa Cruz) or KIT (Dako). All antibody reactions were detected by chemiluminescence (ECL; Pierce, Rockford, Ill.).

Tumor tissue was identified on unstained, 5 µm sections by comparison with H&E (Hematoxylin and Eosin) stained slides and was carefully collected using a clean, sterile scalpel blade into a microfuge tube. Dissection by this approach was straightforward and there was minimal contamination from

adjacent normal tissue. Dissected tissue was deparaffinized by serial extraction with xylene and ethanol and allowed to air-dry. DNA was extracted using the Qiagen mini-kit (Qiagen, 51304) in accordance with the manufacturer's recommendations.

0.5 µg of purified tumor DNA was subjected to 45 cycles of in vitro amplification by polymerase chain reaction (PCR) using the High Fidelity PCR System (Roche #1732078). Primer pairs for each exon analyzed are listed in Table 1. Negative controls were included in every set of amplifications. In a minority of cases there was insufficient amplified DNA for screening by HPLC after single step amplification and therefore a second round of amplification was performed using nested primers (Table 1).

For the analysis of mutations in PDGFRA exon 18, the following primer pairs used were 1) PDGFRA 181634F (residues 181634 through 181653 of SEQ ID NO: 19) and PDGFRA 181874R (residues 181844 through 181874 of SEQ ID NO: 19) or 2) PDGFRA 181752F (SNP exclusion) (residues 181752 through 181772 of SEQ ID NO: 19) and PDGFRA 181874R. The locations of these primers are indicated in FIG. 7A, along with PDGFRA 181671F (residues 181671 through 181690 of SEQ ID NO: 19) and PDGFRA 181862R (residues 181842 through 181862 of SEQ ID NO: 19).

For the analysis of mutations in PDGFRA exon 12, the following primer pairs were used: 1) PDGFRA 170636F (residues 170636 through 170655 of SEQ ID NO: 19) and PDGFRA 170894R (residues 170876 through 170894 of SEQ ID NO: 19), and 2) PDGFRA 170658F (residues 170658 through 170677 of SEQ ID NO: 19) and PDGFRA 170866R (residues 170847 through 170866 of SEQ ID NO: 19).

Five to 20 µl aliquots of the final PCR reaction were screened for mutations on a Transgenomic WAVE HPLC system (D-HPLC; Transgenomic, Inc., Omaha, Nebr.) by running at non-denaturing (50° C.) or partially denaturing temperature (61° C.). D-HPLC-detected mutations were confirmed by two methods: 1) re-amplification of the exon and repeat D-HPLC analysis on a different day; 2) bi-directional sequence analysis on an ABI 377 sequencer using the BigDye terminator kit (Applied Biosciences, Inc.). D-HPLC-detected mutations were confirmed by two methods: 1) re-amplification of the exon and repeat D-HPLC analysis on a different day; 2) bi-directional sequence analysis on an ABI 377 sequencer using the BigDye terminator kit (Applied Biosciences, Inc.) (Corless et al., *Am. J. Pathol.* 160, 1567, 2002).

Using primer pair 1, it was possible to reliably detect the D842V point mutation as well as the deletion and insertion mutations (FIGS. 3 and 4). However, there is a fairly common single nucleotide polymorphism (SNP) in the PDGFRA gene that is detected using these primer pairs and D-HPLC analysis. This SNP is C2472T (V824V) in PDGFRA cDNA (using numbering system of GenBank Accession No. XM_011186). To exclude this SNP, the mutation detection assay was further optimized by using primer pair 2. The forward primer of this set begins immediately 3' of the SNP and thus the resultant amplicon from this primer set does not contain the SNP. Using this primer pair, the D842V activating mutation can be reliably detected and differentiated from the C2472T (V824V) SNP (FIG. 5).

To further verify the sequence of the PDGFRA exon 18 deletion mutations we cloned the amplification products into pCR®4-TOPO using the TOPO TA cloning kit (Invitrogen, version H) and the ligated plasmids were used to transform competent *E. coli* (OneShot TOP10, Invitrogen). Isolated plasmids were screened for the mutant exon insert by PCR

and D-HPLC. Direct sequence analysis of cloned mutant DNA confirmed the presence of an in-frame exon 18 deletion in these cases.

Results

Activation of PDGFRA in GISTs

Using methods described above, RTK activation was assessed in three GISTs lacking apparent KIT oncoproteins. This was accomplished by immunoprecipitating with pan-RTK antibodies, and then immunoblotting with an antibody against phosphotyrosine (FIG. 1). Normally, KIT is heavily phosphorylated in GISTs and is one of the dominant tyrosine phosphorylated protein (FIG. 1).

By sequentially stripping and reprobing the membrane with additional antibodies, the predominant RTK phosphoprotein appeared to be PDGFRA. The possibility of a highly activated PDGFRA protein was then confirmed by immunoprecipitating PDGFRA, using a specific antibody to this protein. These studies revealed that the highly activated phosphoRTK comigrated with equally strongly phosphorylated PDGFRA (FIG. 1). Further, these studies showed that KIT was inactive (non-phosphorylated) in the GISTs with strongly phosphorylated PDGFRA. Therefore, the studies revealed that PDGFRA is highly activated in a subset of GISTs that lack KIT activation, and—furthermore—PDGFRA is the predominant activated RTK, and indeed one of the predominant tyrosine phosphorylated proteins (FIG. 1) in those GISTs.

Additional studies indicated that KIT and PDGFRA oncoproteins are typically alternative, rather than synergistic, mechanisms of transformation in GISTs. Therefore, PDGFRA activation and high-level PDGFRA expression can be found in GISTs that have reduced levels of KIT expression (FIG. 2) and that lack KIT genomic oncogenic mutations. Analysis of Genomic Mechanisms of PDGFRA activation in GISTs

The large amount of phosphorylated PDGFRA in these GISTs suggested the possibility of activating mutations in the PDGFRA gene. Clues to a possible location for such mutations came from comparisons with other related kinases. As mentioned above, mutation of KIT is common in GISTs (approximately 80-90% of cases); mutations also occur in seminoma (25% of cases), mastocytosis (95%+) and rarely in cases of acute myeloid leukemia (AML) (Heinrich et al., *J. Clin. Oncol.*, 20: 1692-1703, 2002; Rubin et al., *Cancer Res.* 61: 8118-8121, 2001; Lux et al., *Am. J. Pathol.*, 156: 791-795, 2000). KIT mutations in GIST are found most commonly in the juxtamembrane and extracellular domains, as well as the first portion of the tyrosine kinase domain, whereas mutations in mastocytosis and seminoma are found in the activation loop located in the second portion of the tyrosine kinase domain (Hirota et al., *J. Pathol.*, 193: 505-510, 2001; Lasota et al., *Am. J. Pathol.*, 157: 1091-1095, 2000; Lux et al., *Am. J. Pathol.*, 156: 791-795, 2000; Ma et al., *Blood*, 99: 1741-1744, 2002; Beghini et al., *Blood*, 95: 726-727, 2000; Tian et al., *Am. J. Pathol.*, 154: 1643-1647, 1999; Longley et al., *Nature Genetics*, 12: 312-314, 1996). Somatic mutation of FLT3 has also been associated with certain human malignancies. Mutation of FLT3 has been reported in approximately 20-40% of cases of AML and rarely in Acute Lymphoblastic Leukemia. In AML, mutations of FLT3 are most commonly found in the juxtamembrane domain and less commonly in the activation loop (Abu-Duhier et al., *Br. J. Haematol.*, 113: 983-988, 2001; Kottaridis et al., *Blood*, 98: 1752-1759, 2001; Meshinchi et al., *Blood*, 97: 89-94, 2001; Yamamoto et al., *Blood*, 97: 2434-2439, 2001).

Based on the homology of PDGFRA to KIT and FLT3, we hypothesized that mutation of the PDGFRA activation loop in a subset of GISTs might result in activation of tyrosine kinase activity. Thus, we developed a polymerase chain reaction (PCR) based assay to test for mutations of the PDGFRA activation loop (exon 18) (see FIG. 7). Genomic DNA was purified from formalin fixed, paraffin embedded archival pathology specimens or fresh frozen tumor specimens that were obtained in accordance with the rules and regulations of both OHSU and the Portland VA Medical Center. Amplification of PDGFRA exon 18 was performed using primer sets described in the methods section below. Amplicons were analyzed using a Transgenomic WAVE HPLC instrument using both non-denaturing (50° C.) and partially denaturing temperatures (58° C.). Amplicons with abnormal HPLC elution profiles were directly sequenced.

Two different classes of PDGFRA activation loop mutations were identified in GISTs using this technique—point mutation and small in-frame deletions (FIG. 3). These ampli-

result in constitutive activation of the tyrosine kinase activity of PDGFRA. This is based on prior observations that in-frame deletions or insertion in the activation loop of the related FLT3 RTK are known to result in constitutive activation of tyrosine kinase activity (Abu-Duhier et al., *Br. J. Haematol.*, 113: 983-988, 2001); and our observations that PDGFRA is strongly activated in protein lysates from GIST tumors that harbor these PDGFRA mutations, but not in GISTs expressing wild-type PDGFRA (see FIGS. 1 and 2).

We have also found one GIST with an acquired mutation of exon 12 of PDGFRA, specifically insertion of GAGAGG at nucleotide position 1681 of PDGFRA. This mutation results in insertion of novel amino acid residues ER between amino acids 560 and 561. Based on analogy with similar length mutations in FLT3 and KIT, this inframe insertion would be predicted to result in constitutive activation of PDGFRA kinase activity. We have also found a second example of an insertion/deletion mutation in exon 12 in a GIST: SPDGHE566-571R.

TABLE 1

Genotype	DNA sequence (top line) Translation (bottom line)
PDGFRA Wild type (Ac. No. XM_011186; SEQ ID NOs: 1 and 2)	2906* GGCCTGGCCAGAGACATCATGCATTCGAACTATGTG 838 G L A R D I M H D S N Y V
D842V (SEQ ID NOs: 3 and 4)	2906 GGCCTGGCCAGAGTCATCATGCATTCGAACTATGTG 838 G L A R V I M H D S N Y V
Deletion of DIMH842-845 (SEQ ID NOs: 5 and 6)	2906 GGCCTGGCCAGA-----GATTCGAACTATGTG 838 G L A R - - - - D S N Y V
Deletion of HDSN845-848P (SEQ ID NOs: 7 and 8)	2906 GGCCTGGCCAGAGACATCATGC-----CCTATGTG 838 G L A R D I M P Y V
PDGFRA Wild type	2060 GAAATTCGCTGGAGGGTCATTGAATCA 556 E I R W R V I E S
PDGFRA Insertion ER561-562 (SEQ ID NOs: 9 and 10)	2060 GAAATTCGCTGGAGGGAGAGGGTCATTGAATCA 556 E I R W R E R V I E S
PDGFRA Wild type	2081 GAATCAATCAGCCCGGATGGACATGAATATATT 563 E S I S P D G H E Y I
PDGFRA Deletion SPDGHE566-571R (SEQ ID NOs: 11 and 12)	2081 GAATCAATC-----CGCTATATT 563 E S I - - - - R Y I

*Numbering as in SEQ ID NO: 1 and SEQ ID NO: 2.

cons have been directly sequenced and/or cloned into plasmids and the resultant clones sequenced. The most common mutation is a change of the conserved aspartic acid at position 842 of PDGFRA to valine (D842V). This aspartic acid is highly conserved in kinases related to PDGFRA. The homologous mutation D816V of KIT is observed in mastocytosis and seminoma, while the homologous D835V mutation of FLT3 is found in some cases of AML.

Two different in-frame deletions of PDGFRA exon 18 were identified in GISTs. The first is deletion of genomic nucleotides 53264-53275, which encode PDGFRA amino residues 842-845 (DIMH). In this mutation the conserved aspartic residue at position 842 is substituted by the aspartic acid at position 846 that is immediately 3' of the deletion. The second deletion found to date is a deletion with insertion of a single cytosine at the 3' end of the deletion—the result is deletion of residues 845-848 (HDSN) with generation of a novel proline residue that follows the normal methionine residue at position 844. Thus, these two deletions are partially overlapping. These deletions are novel; it is believed that they

TABLE 2

Mutation	Cases (% total)
D842V	10 (24.4%)
Exon 18 Deletion	2 (4.9%)
Exon 12 Insertion/Deletion	2 (4.9%)
No mutation	27 (65.9%)
Total	41 (100.0%)

In our analysis of GISTs to date, we have found KIT mutation and PDGFRA mutation to be mutually exclusive. That is, PDGFRA mutations have only been found in GISTs without any detectable KIT mutation. Based on our studies to date, we believe that mutations of PDGFRA are found in approximately 34-35% of KIT wild-type GISTs or 3-6% of all GISTs.

31

Example 2

Other Activating PDGFRA Mutations

With the provision herein of the correlation between activating PDGFRA mutations and neoplastic disease, the isolation and identification of additional activating PDGFRA mutations is enabled. Any conventional method for the identification of genetic mutations in a population can be used to identify such additional mutations.

For instance, existing populations (e.g., human populations) are assessed for the presence of neoplastic or tumorous cells, and individuals within the population are genotyped as relates to a PDGFRA sequence. These PDGFRA sequences are then compared to a reference PDGFRA sequence, such as the alleles described herein, to determine the presence of one or more variant nucleotide positions. Once variant nucleotides are identified, statistical analysis of the population is used to determine whether these variants are correlated with neoplasm or tumorous growth or development.

By way of example, it is predicted that additional mutations will be identified at least in positions similar to those identified herein. SEQ ID NO: 26 shows a nucleic acid consensus sequence for the PDGFRA activating mutations discussed herein; the consensus polypeptide encoded by SEQ ID NO: 26 is shown in SEQ ID NO: 27. Explicitly contemplated herein are additional PDGFRA mutations and variant molecules that occur in the variable positions indicated in these consensus sequences, alone or in combination with one or more of the mutations described herein. Included are insertion and deletion mutations, such as examples provided herein, as well as point mutations.

Example 3

Clinical Uses of PDGFRA Variants

To perform a diagnostic test for the presence or absence of a mutation in a PDGFRA sequence of an individual, a suitable genomic DNA-containing sample from a subject is obtained and the DNA extracted using conventional techniques. For instance, a blood sample, a buccal swab, a hair follicle preparation, or a nasal aspirate is used as a source of cells to provide the DNA sample; similarly, a surgical specimen, biopsy, or other biological sample containing genomic DNA could be used. It is particularly contemplated that tumor biopsies or tumor DNA found in plasma or other blood products can serve as a source. The extracted DNA is then subjected to amplification, for example according to standard procedures. The allele of the single base-pair mutation is determined by conventional methods including manual and automated fluorescent DNA sequencing, primer extension methods (Nikiforov, et al., *Nucl Acids Res.* 22:4167-4175, 1994), oligonucleotide ligation assay (OLA) (Nickerson et al., *Proc. Natl. Acad. Sci. USA* 87:8923-8927, 1990), allele-specific PCR methods (Rust et al., *Nucl. Acids Res.* 6:3623-3629, 1993), RNase mismatch cleavage, single strand conformation polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), Taq-Man™, oligonucleotide hybridization, and the like. Also, see the following U.S. patents for descriptions of methods or applications of polymorphism analysis to disease prediction and/or diagnosis: U.S. Pat. No. 4,666,828 (RFLP for Huntington's); U.S. Pat. No. 4,801,531 (prediction of atherosclerosis); U.S. Pat. No. 5,110,920 (HLA typing); U.S. Pat. No. 5,268,267 (prediction of small cell carcinoma); and U.S. Pat. No. 5,387,506 (prediction of dysautonomia).

32

Examples of activating tyrosine kinase mutations are the PDGFRA D842V and V561D point mutations, the ER561-562 in frame insertion, and the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, and SPDGHE566-571R in-frame deletions. In addition to these particular mutations, other mutations can be detected that may be associated with variable predisposition to development of a neoplastic disease or likelihood of having a tumor, and used in combination with the disclosed PDGFRA mutations, to predict the probability that a subject will develop neoplasia, or have a tumor with drug responsive tyrosine kinase activity.

The activating mutations of the present disclosure can be utilized for the detection of, and differentiation of, individuals who are homozygous and heterozygous for activating and/or drug responsive variants. The value of identifying individuals who carry an activating allele of PDGFRA (i.e., individuals who are heterozygous or homozygous for an allele that contains the D842V or V561D point mutation, the ER561-562 in frame insertion, or one of the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletions, or any combination thereof, or another mutation in one or proximal to one of the variable regions indicated in SEQ ID NOs: 26 or 27) is that these individuals could then initiate customized therapies (such as specific drug therapies that inhibit the mutant, activated, PDGFRA), or undergo more aggressive treatment of the condition, and thereby beneficially alter its course.

Example 4

Mutation Gene Probes and Markers

Sequences surrounding and overlapping single base-pair mutations and deletions and insertions in the PDGFRA gene can be useful for a number of gene mapping, targeting, and detection procedures. For example, genetic probes can be readily prepared for hybridization and detection of the D842V or the V561D point mutation, the ER561-562 in frame insertion, or one of the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletion mutations. As will be appreciated, probe sequences may be greater than about 12 or more oligonucleotides in length and possess sufficient complementarity to distinguish between the variant sequence and the wildtype, for instance, between the Valine (at amino acid residue 842 in the D842V activating allele) and Aspartic acid (in the wild-type allele). Similarly, sequences surrounding and overlapping any of the specifically disclosed mutations (or other mutations found in accordance with the present teachings, including those encompassed in or proximal to the variable regions indicated in SEQ ID NOs: 26 or 27), or longer sequences encompassing for instance the entire length of exon 18 of PDGFRA, or portions thereof, can be utilized in allele specific hybridization procedures. A similar approach can be adopted to detect other PDGFRA mutations.

Sequences surrounding and overlapping a PDGFRA mutation, or any portion or subset thereof that allows one to identify the mutations, are highly useful. Thus, another embodiment provides a genetic marker predictive of the one or more of the D842V or the V561D point mutation, the ER561-562 in frame insertion, or the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletions of PDGFRA, comprising a partial sequence of the human genome including at least about 10 contiguous

nucleotide residues such as those shown in Table 1 or Table 3, and sequences complementary therewith.

Example 5

Detecting Single Nucleotide Alterations

PDGFRA single nucleotide alterations, whether categorized as SNPs or new mutations (such as that giving rise to the D842V variant) can be detected by a variety of techniques. Clinically relevant PDGFRA single nucleotide alterations include those arising as somatic mutations—i.e., restricted to the neoplastic cells—as well as those that are present constitutionally in both normal and neoplastic cells in a given individual. The constitutional single nucleotide alterations can arise either from new germline mutations, or can be inherited from a parent who possesses a SNP or mutation in their own germline DNA. The techniques used in evaluating either somatic or germline single nucleotide alterations include allele-specific oligonucleotide hybridization (ASOH) (Stoneking et al., *Am. J. Hum. Genet.* 48:370-382, 1991) which involves hybridization of probes to the sequence, stringent washing, and signal detection. Other new methods include techniques that incorporate more robust scoring of hybridization. Examples of these procedures include the ligation chain reaction (ASOH plus selective ligation and amplification), as disclosed in Wu and Wallace (*Genomics* 4:560-569, 1989); mini-sequencing (ASOH plus a single base extension) as discussed in Syvanen (*Meth. Mol. Biol.* 98:291-298, 1998); and the use of DNA chips (miniaturized ASOH with multiple oligonucleotide arrays) as disclosed in Lipshutz et al. (*BioTechniques* 19:442-447, 1995). Alternatively, ASOH with single- or dual-labeled probes can be merged with PCR, as in the 5'-exonuclease assay (Heid et al., *Genome Res.* 6:986-994, 1996), or with molecular beacons (as in Tyagi and Kramer, *Nat. Biotechnol.* 14:303-308, 1996).

Another technique is dynamic allele-specific hybridization (DASH), which involves dynamic heating and coincident monitoring of DNA denaturation, as disclosed by Howell et al. (*Nat. Biotech.* 17:87-88, 1999). A target sequence is amplified by PCR in which one primer is biotinylated. The biotinylated product strand is bound to a streptavidin-coated microtiter plate well, and the non-biotinylated strand is rinsed away with alkali wash solution. An oligonucleotide probe, specific for one allele, is hybridized to the target at low temperature. This probe forms a duplex DNA region that interacts with a double strand-specific intercalating dye. When subsequently excited, the dye emits fluorescence proportional to the amount of double-stranded DNA (probe-target duplex) present. The sample is then steadily heated while fluorescence is continually monitored. A rapid fall in fluorescence indicates the denaturing temperature of the probe-target duplex. Using this technique, a single-base mismatch between the probe and target results in a significant lowering of melting temperature (T_m) that can be readily detected.

A variety of other techniques can be used to detect the mutations in DNA. Merely by way of example, see U.S. Pat. Nos. 4,666,828; 4,801,531; 5,110,920; 5,268,267; 5,387,506; 5,691,153; 5,698,339; 5,736,330; 5,834,200; 5,922,542; and 5,998,137 for such methods.

Example 6

Detection of PDGFRA Nucleic Acid Level(s)

Individuals carrying activating mutations in the PDGFRA gene, or having amplifications or heterozygous or homozy-

gous deletions of the PDGFRA gene, may be detected at the DNA or RNA level with the use of a variety of techniques. The detection of point mutations, or SNPs, was discussed above; in the following example, techniques are provided for detecting the level of PDGFRA nucleic acid molecules in a sample.

For such diagnostic procedures, a biological sample of the subject (an animal, such as a mouse or a human), which biological sample contains either DNA or RNA derived from the subject, is assayed for a mutated, amplified or deleted PDGFRA encoding sequence, such as a genomic amplification of the PDGFRA gene or an over- or under-abundance of a PDGFRA mRNA. Suitable biological samples include samples containing genomic DNA or mRNA obtained from subject body cells, such as those present in peripheral blood, urine, saliva, tissue biopsy, surgical specimen, amniocentesis samples and autopsy material. The detection in the biological sample of a mutant PDGFRA gene, a mutant PDGFRA RNA, or an amplified or homozygously or heterozygously deleted PDGFRA gene, may be performed by a number of methodologies.

Gene dosage (copy number) can be important in disease states, and can influence mRNA and thereby protein level; it is therefore advantageous to determine the number of copies of PDGFRA nucleic acids in samples of tissue. Probes generated from the encoding sequence of PDGFRA (PDGFRA probes or primers) can be used to investigate and measure genomic dosage of the PDGFRA gene.

Appropriate techniques for measuring gene dosage are known in the art; see for instance, U.S. Pat. No. 5,569,753 ("Cancer Detection Probes") and Pinkel et al. (*Nat. Genet.* 20:207-211, 1998) ("High Resolution Analysis of DNA Copy Number Variation using Comparative Genomic Hybridization to Microarrays").

Determination of gene copy number in cells of a patient-derived sample using other techniques is known in the art. For example, PDGFRA amplification in immortalized cell lines as well as uncultured cells taken from a subject can be carried out using bicolor FISH or chromogenic in situ hybridization (CISH) analysis. FISH or CISH evaluations of PDGFRA amplification can be performed in various cell and tissue preparations that include, but are not limited to, venipuncture, biopsy, fine needle aspiration, and cell scraping. Such clinical materials can be analyzed in various forms, which include, but are not limited to, cytogenetic preparations; touch preparations from fresh or frozen biopsies; disaggregated cells from fresh, frozen or paraffin-embedded materials; histological sections from frozen or paraffin-embedded materials; and cytological preparations including cytopins and cell smears (Xiao et al., *Am J Pathol*; Hsi et al. *Pathol.* 147:896-904; 1995; Davison et al., *Am. J. Pathol.* 153:1401-1409; 1998). By way of example, interphase FISH analysis of immortalized cell lines can be carried out as previously described (Barlund et al., *Genes Chromo. Cancer* 20:372-376, 1997). The hybridizations can be evaluated using a Zeiss fluorescence microscope. By way of example, approximately 20 non-overlapping nuclei with intact morphology based on DAPI counterstain are scored to determine the mean number of hybridization signals for each test and reference probe.

Likewise, FISH can be performed on tissue microarrays, as described in Kononen et al., *Nat. Med.* 4:844-847, 1998. Briefly, consecutive sections of the array are deparaffinized, dehydrated in ethanol, denatured at 74° C. for 5 minutes in 70% formamide/2×SSC, and hybridized with test and reference probes. The specimens containing tight clusters of signals or >3-fold increase in the number of test probe as compared to chromosome 17 centromere in at least 10% of the

tumor cells may be considered as amplified. Microarrays using various tissues can be constructed as described in WO 99/44063 and WO 99/44062.

Overexpression of the PDGFRA gene can also be detected by measuring the cellular level of PDGFRA-specific mRNA. mRNA can be measured using techniques well known in the art, including for instance Northern analysis, RT-PCR and mRNA in situ hybridization.

Example 7

Expression of PDGFRA Polypeptides

The expression and purification of proteins, such as the PDGFRA protein, can be performed using standard laboratory techniques. After expression, purified PDGFRA protein may be used for functional analyses, antibody production, diagnostics, and patient therapy. Furthermore, the DNA sequence of the PDGFRA cDNA can be manipulated in studies to understand the expression of the gene and the function of its product. Mutant forms of the human PDGFRA gene may be isolated based upon information contained herein, and may be studied in order to detect alteration in expression patterns in terms of relative quantities, tissue specificity and functional properties of the encoded mutant PDGFRA protein. Partial or full-length cDNA sequences, which encode for the subject protein, may be ligated into bacterial expression vectors. Methods for expressing large amounts of protein from a cloned gene introduced into *Escherichia coli* (*E. coli*) may be utilized for the purification, localization and functional analysis of proteins. For example, fusion proteins consisting of amino terminal peptides encoded by a portion of the *E. coli* lacZ or trpE gene linked to PDGFRA proteins may be used to prepare polyclonal and monoclonal antibodies against these proteins. Thereafter, these antibodies may be used to purify proteins by immunoaffinity chromatography, in diagnostic assays to quantitate the levels of protein and to localize proteins in tissues and individual cells by immunofluorescence.

Intact native protein may also be produced in *E. coli* in large amounts for functional studies. Methods and plasmid vectors for producing fusion proteins and intact native proteins in bacteria are described in Sambrook et al. (In *Molecular Cloning: A Laboratory Manual*, Ch. 17, CSHL, New York, 1989). Such fusion proteins may be made in large amounts, are easy to purify, and can be used to elicit antibody response. Native proteins can be produced in bacteria by placing a strong, regulated promoter and an efficient ribosome-binding site upstream of the cloned gene. If low levels of protein are produced, additional steps may be taken to increase protein production; if high levels of protein are produced, purification is relatively easy. Suitable methods are presented in Sambrook et al. (In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989) and are well known in the art. Often, proteins expressed at high levels are found in insoluble inclusion bodies. Methods for extracting proteins from these aggregates are described by Sambrook et al. (In *Molecular Cloning: A Laboratory Manual*, Ch. 17, CSHL, New York, 1989). Vector systems suitable for the expression of lacZ fusion genes include the pUR series of vectors (Ruther and Muller-Hill, *EMBO J.* 2:1791, 1983), pEX1-3 (Stanley and Luzio, *EMBO J.* 3:1429, 1984) and pMR100 (Gray et al., *Proc. Natl. Acad. Sci. USA* 79:6598, 1982). Vectors suitable for the production of intact native proteins include pKC30 (Shimatake and Rosenberg, *Nature* 292:128, 1981), pKK177-3 (Amann and Brosius, *Gene* 40:183, 1985) and pET-3 (Studier and Moffatt, *J. Mol. Biol.* 189:113, 1986).

Fusion proteins may be isolated from protein gels, lyophilized, ground into a powder and used as an antigen. The DNA sequence can also be transferred from its existing context to other cloning vehicles, such as other plasmids, bacteriophages, cosmids, animal viruses and yeast artificial chromosomes (YACs) (Burke et al., *Science* 236:806-812, 1987). These vectors may then be introduced into a variety of hosts including somatic cells, and simple or complex organisms, such as bacteria, fungi (Timberlake and Marshall, *Science* 244:1313-1317, 1989), invertebrates, plants (Gasser and Fraley, *Science* 244:1293, 1989), and animals (Pursel et al., *Science* 244:1281-1288, 1989), which cell or organisms are rendered transgenic by the introduction of the heterologous PDGFRA cDNA.

For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV) 40 promoter in the pSV2 vector (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981), and introduced into cells, such as monkey COS-1 cells (Gluzman, *Cell* 23:175-182, 1981), to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin (Southern and Berg, *J. Mol. Appl. Genet.* 1:327-341, 1982) and mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981).

DNA sequences can be manipulated with standard procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence-alteration via single-stranded bacteriophage intermediate or with the use of specific oligonucleotides in combination with PCR or other in vitro amplification.

The cDNA sequence (or portions derived from it) or a mini gene (a cDNA with an intron and its own promoter) may be introduced into eukaryotic expression vectors by conventional techniques. These vectors are designed to permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. Vectors containing the promoter and enhancer regions of the SV40 or long terminal repeat (LTR) of the Rous Sarcoma virus and polyadenylation and splicing signal from SV40 are readily available (Mulligan et al., *Proc. Natl. Acad. Sci. USA* 78:1078-2076, 1981; Gorman et al., *Proc. Natl. Acad. Sci. USA* 78:6777-6781, 1982). The level of expression of the cDNA can be manipulated with this type of vector, either by using promoters that have different activities (for example, the baculovirus pAC373 can express cDNAs at high levels in *S. frugiperda* cells (Summers and Smith, In *Genetically Altered Viruses and the Environment*, Fields et al. (Eds.) 22:319-328, CSHL Press, Cold Spring Harbor, New York, 1985) or by using vectors that contain promoters amenable to modulation, for example, the glucocorticoid-responsive promoter from the mouse mammary tumor virus (Lee et al., *Nature* 294:228, 1982). The expression of the cDNA can be monitored in the recipient cells 24 to 72 hours after introduction (transient expression).

In addition, some vectors contain selectable markers such as the gpt (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072-2076, 1981) or neo (Southern and Berg, *J. Mol. Appl. Genet.* 1:327-341, 1982) bacterial genes. These selectable markers permit selection of transfected cells that exhibit stable, long-term expression of the vectors (and therefore the cDNA). The vectors can be maintained in the cells as episomal, freely replicating entities by using regulatory elements of viruses such as papilloma (Sarver et al., *Mol. Cell. Biol.*

37

1:486, 1981) or Epstein-Barr (Sugden et al., *Mol. Cell. Biol.* 5:410, 1985). Alternatively, one can also produce cell lines that have integrated the vector into genomic DNA. Both of these types of cell lines produce the gene product on a continuous basis. One can also produce cell lines that have amplified the number of copies of the vector (and therefore of the cDNA as well) to create cell lines that can produce high levels of the gene product (Alt et al., *J. Biol. Chem.* 253:1357, 1978).

The transfer of DNA into eukaryotic, in particular human or other mammalian cells, is now a conventional technique. The vectors are introduced into the recipient cells as pure DNA (transfection) by, for example, precipitation with calcium phosphate (Graham and vander Eb, *Virology* 52:466, 1973) or strontium phosphate (Brash et al., *Mol. Cell. Biol.* 7:2013, 1987), electroporation (Neumann et al., *EMBO J.* 1:841, 1982), lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413, 1987), DEAE dextran (McCuthan et al., *J. Natl. Cancer Inst.* 41:351, 1968), microinjection (Mueller et al., *Cell* 15:579, 1978), protoplast fusion (Schafner, *Proc. Natl. Acad. Sci. USA* 77:2163-2167, 1980), or pellet guns (Klein et al., *Nature* 327:70, 1987). Alternatively, the cDNA, or fragments thereof, can be introduced by infection with virus vectors. Systems are developed that use, for example, retroviruses (Bernstein et al., *Gen. Engr'g* 7:235, 1985), adenoviruses (Ahmad et al., *J. Virol.* 57:267, 1986), or Herpes virus (Spaete et al., *Cell* 30:295, 1982). Tyrosine kinase encoding sequences can also be delivered to target cells in vitro via non-infectious systems, for instance liposomes.

These eukaryotic expression systems can be used for studies of PDGFRA encoding nucleic acids and mutant forms of these molecules, the PDGFRA protein and mutant forms of this protein. Such uses include, for example, the identification of regulatory elements located in the 5' region of the PDGFRA gene on genomic clones that can be isolated from human genomic DNA libraries using the information contained in the present disclosure. The eukaryotic expression systems may also be used to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring or artificially produced mutant proteins.

Using the above techniques, the expression vectors containing the PDGFRA gene sequence or cDNA, or fragments or variants or mutants thereof, can be introduced into human cells, mammalian cells from other species or non-mammalian cells as desired. The choice of cell is determined by the purpose of the treatment. For example, monkey COS cells (Gluzman, *Cell* 23:175-182, 1981) that produce high levels of the SV40 T antigen and permit the replication of vectors containing the SV40 origin of replication may be used. Similarly, Chinese hamster ovary (CHO), mouse NIH 3T3 fibroblasts or human fibroblasts or lymphoblasts may be used.

The present disclosure thus encompasses recombinant vectors that comprise all or part of the PDGFRA gene or cDNA sequences, for expression in a suitable host. The PDGFRA DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that the PDGFRA polypeptide can be expressed. The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be specifically selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of fd coat protein, the early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus and simian virus, the promoter for 3-phosphoglycerate

38

kinase, the promoters of yeast acid phosphatase, the promoter of the yeast alpha-mating factors and combinations thereof.

The host cell, which may be transfected with the vector of this disclosure, may be selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus subtilis*, *Bacillus stearothermophilus* or other bacilli; other bacteria; yeast; fungi; insect; mouse or other animal; or plant hosts; or human tissue cells.

It is appreciated that for mutant or variant PDGFRA DNA sequences, similar systems are employed to express and produce the mutant product. In addition, fragments of the PDGFRA protein can be expressed essentially as detailed above. Such fragments include individual PDGFRA protein domains or sub-domains, as well as shorter fragments such as peptides. PDGFRA protein fragments having therapeutic properties may be expressed in this manner also.

Example 8

Production of PDGFRA Protein Specific Binding Agents

Monoclonal or polyclonal antibodies may be produced to either the normal PDGFRA protein or mutant forms of this protein, for instance particular portions that contain a mutation and therefore may provide a distinguishing epitope. Optimally, antibodies raised against these proteins or peptides would specifically detect the protein or peptide with which the antibodies are generated. That is, an antibody generated to the PDGFRA protein or a fragment thereof would recognize and bind the PDGFRA protein and would not substantially recognize or bind to other proteins found in human cells. In some embodiments, an antibody is specific for (or measurably preferentially binds to) an epitope in a variant protein versus the wildtype protein, or vice versa, as discussed more fully herein.

The determination that an antibody specifically detects the PDGFRA protein is made by any one of a number of standard immunoassay methods; for instance, the western blotting technique (Sambrook et al., In *Molecular Cloning: A Laboratory Manual*, CSHL, New York, 1989). To determine that a given antibody preparation (such as one produced in a mouse) specifically detects the PDGFRA protein by western blotting, total cellular protein is extracted from human cells (for example, lymphocytes) and electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel. The proteins are then transferred to a membrane (for example, nitrocellulose) by western blotting, and the antibody preparation is incubated with the membrane. After washing the membrane to remove non-specifically bound antibodies, the presence of specifically bound antibodies is detected by the use of an anti-mouse antibody conjugated to an enzyme such as alkaline phosphatase. Application of an alkaline phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium results in the production of a dense blue compound by immunolocalized alkaline phosphatase. Antibodies that specifically detect the PDGFRA protein will, by this technique, be shown to bind to the PDGFRA protein band (which will be localized at a given position on the gel determined by its molecular weight). Non-specific binding of the antibody to other proteins may occur and may be detectable as a weak signal on the Western blot. The non-specific nature of this binding will be recognized by one skilled in the art by the weak signal obtained on the Western blot relative to the strong primary signal arising from the specific antibody-PDGFRA protein binding.

Substantially pure PDGFRA protein or protein fragment (peptide) suitable for use as an immunogen may be isolated

from the transfected or transformed cells as described above. Concentration of protein or peptide in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per milliliter. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of the PDGFRA protein identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (*Nature* 256:495-497, 1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody-producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess un-fused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall (*Meth. Enzymol.* 70:419-439, 1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988).

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein (Example 7), which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with either inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appear to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis et al. (*J. Clin. Endocrinol. Metab.* 33:988-991, 1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al. (In *Handbook of Experimental Immunology*, Wier, D. (ed.) chapter 19. Blackwell, 1973). Plateau concentration of antibody is usually in the range of about 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher (*Manual of Clinical Immunology*, Ch. 42, 1980).

C. Antibodies Raised Against Synthetic Peptides

A third approach to raising antibodies against the PDGFRA protein or peptides is to use one or more synthetic peptides synthesized on a commercially available peptide synthesizer based upon the predicted amino acid sequence of the PDGFRA protein or peptide. Polyclonal antibodies can be generated by injecting these peptides into, for instance, rabbits or mice.

D. Antibodies Raised by Injection of PDGFRA Encoding Sequence

Antibodies may be raised against PDGFRA proteins and peptides by subcutaneous injection of a DNA vector that expresses the desired protein or peptide, or a fragment thereof, into laboratory animals, such as mice. Delivery of the recombinant vector into the animals may be achieved using a hand-held form of the Biolistic system (Sanford et al., *Particulate Sci. Technol.* 5:27-37, 1987) as described by Tang et al. (*Nature* 356:152-154, 1992). Expression vectors suitable for this purpose may include those that express the PDGFRA encoding sequence under the transcriptional control of either the human β -actin promoter or the cytomegalovirus (CMV) promoter.

Antibody preparations prepared according to these protocols are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample; or for immunolocalization of the PDGFRA protein.

In addition, antibodies to PDGFRA are commercially available. See, for instance, rabbit anti-PDGFRA, catalog no. sc-338, from Santa Cruz Biotechnology Inc. (Santa Cruz, Calif.) and rabbit anti-PDGFR, catalog no. 6495, from Upstate Biotechnology (Waltham, Mass.).

For administration to human patients, antibodies, e.g., PDGFRA-specific monoclonal antibodies, can be humanized by methods known in the art. Antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland, UK; Oxford Molecular, Palo Alto, Calif.).

E. Antibodies Specific for Mutant PDGFRA

With the provision of several activating variant PDGFRA proteins, the production of antibodies that specifically recognize these proteins (and peptides derived therefrom) is enabled. In particular, production of antibodies (and fragments and engineered versions thereof) that recognize at least one PDGFRA variant with a higher affinity than they recognize wild type PDGFRA is beneficial, as the resultant antibodies can be used in diagnosis and treatment, as well as in study and examination of the PDGFRA proteins themselves.

In particular embodiments, it is beneficial to generate antibodies from a peptide taken from a mutation or variation-specific region of the PDGFRA protein. By way of example, such regions include a portion or all of exon 18 of PDGFRA, or a portion or all of exon 12. More particularly, it is beneficial to raise antibodies against peptides of four or more contiguous amino acids that overlap the mutations identified in SEQ ID NO: 4, 6, 8, or 25, and particularly which comprise at least four contiguous amino acids including the residue(s) shown in position(s) 842 of SEQ ID NO: 4, positions 841 and 842 of SEQ ID NO: 6, positions 846 and 847 of SEQ ID NO: 8, or positions 841 and 842 of SEQ ID NO: 25.

Similarly, it is beneficial to raise antibodies against peptides of 4 or more contiguous amino acids that overlap the mutations identified in SEQ ID NO: 10, 12, 21, or 23, and particularly which comprise at least four contiguous amino acids including the residue(s) shown in position(s) 561 and 562 of SEQ ID NO: 10 positions 565 and 566 of SEQ ID NO: 12, position 561 of SEQ ID NO: 21, or positions 559 and 560 of SEQ ID NO: 23.

Longer peptides also can be used, and in some instances will produce a stronger or more reliable immunogenic response. Thus, it is contemplated in some embodiments that more than four amino acids are used to elicit the immune response, for instance, at least 5, at least 6, at least 8, at least 10, at least 12, at least 15, at least 18, at least 20, at least 25, or more, such as 30, 40, 50, or even longer peptides. Also, it

will be understood by those of ordinary skill that it is beneficial in some instances to include adjuvants and other immune response enhancers, including passenger peptides or proteins, when using peptides to induce an immune response for production of antibodies.

Embodiments are not limited to antibodies that recognize epitopes containing the actual mutation identified in each variant. Instead, it is contemplated that variant-specific antibodies also may each recognize an epitope located anywhere throughout the PDGFRA variant molecule, which epitopes are changed in conformation and/or availability because of the activating mutation. Antibodies directed to any of these variant-specific epitopes are also encompassed herein.

By way of example, the following references provide descriptions of methods for making antibodies specific to mutant proteins: Hills et al., (*Int. J. Cancer*, 63: 537-543, 1995); Reiter & Maihle (*Nucleic Acids Res.*, 24: 4050-4056, 1996); Okamoto et al. (*Br. J. Cancer*, 73: 1366-1372, 1996); Nakayashiki et al., (*Jpn. J. Cancer Res.*, 91: 1035-1043, 2000); Gannon et al. (*EMBO J.*, 9: 1595-1602, 1990); Wong et al. (*Cancer Res.*, 46: 6029-6033, 1986); and Carney et al. (*J. Cell Biochem.*, 32: 207-214, 1986). Similar methods can be employed to generate antibodies specific to specific PDGFRA variants.

Example 9

Protein-Based Diagnosis

An alternative method of diagnosing PDGFRA mutation, gene amplification, or deletion as well as abnormal PDGFRA expression, is to quantitate the level of PDGFRA protein, and/or to evaluate activation (phosphorylation) of PDGFRA in the cells of an individual. The oncogenic, activating mutations disclosed herein result in constitutive PDGFRA activation as manifested by PDGFRA tyrosine phosphorylation. Therefore, antibodies specific for phosphotyrosine-containing PDGFRA epitopes can be used to routinely detect such mutant, activated, PDGFRA proteins in any mammalian cell type. Such evaluations can be performed, for example, in lysates prepared from cells, in fresh or frozen cells, in cells that have been smeared or touched on glass slides and then either fixed and/or dried, or in cells that have been fixed, embedded (e.g., in paraffin), and then prepared as histological sections on glass slides. This diagnostic tool would also be useful for detecting reduced levels of the PDGFRA protein that result from, for example, mutations in the promoter regions of the PDGFRA gene or mutations within the coding region of the gene that produced truncated, non-functional or unstable polypeptides, as well as from deletions of a portion of or the entire PDGFRA gene. Alternatively, amplification of a PDGFRA-encoding sequence may be detected as an increase in the expression level of PDGFRA protein. Such an increase in protein expression may also be a result of an up-regulating mutation in the promoter region or other regulatory or coding sequence within the PDGFRA gene, or by virtue of a point mutation within the PDGFRA coding sequence, which protects the PDGFRA protein from degradation.

Localization and/or coordination of PDGFRA expression (temporally or spatially) can also be examined using known techniques, such as isolation and comparison of PDGFRA from subcellular fractions, including specific organelles, or from specific cell or tissue types, or at specific time points after an experimental manipulation. Demonstration of reduced or increased PDGFRA protein levels, in comparison to such expression in a control cell (e.g., normal, as in taken

from a subject not suffering from a neoplastic disease, such as cancer), would be an alternative or supplemental approach to the direct determination of PDGFRA gene deletion, amplification or mutation status by the methods outlined above and equivalents.

The availability of antibodies specific to the PDGFRA protein will facilitate the detection and quantitation of cellular PDGFRA by one of a number of immunoassay methods which are well known in the art and are presented in Harlow and Lane (*Antibodies, A Laboratory Manual*, CSHL, New York, 1988). Methods of constructing such antibodies are discussed above, in Example 8.

Any standard immunoassay format (e.g., ELISA, western blot, or RIA assay) can be used to measure PDGFRA polypeptide or protein levels, and to compare these with PDGFRA expression levels in control, reference, cell populations. Altered PDGFRA polypeptide expression may be indicative of an abnormal biological condition related to unregulated cell growth or proliferation, in particular a neoplasm, and/or a predilection to development of neoplastic disease. Immunohistochemical techniques may also be utilized for PDGFRA polypeptide or protein detection. For example, a tissue sample may be obtained from a subject, and a section stained for the presence of PDGFRA using a PDGFRA specific binding agent (e.g., anti-PDGFRA antibody) and any standard detection system (e.g., one which includes a secondary antibody conjugated to horseradish peroxidase). General guidance regarding such techniques can be found in, e.g., Bancroft and Stevens (*Theory and Practice of Histological Techniques*, Churchill Livingstone, 1982) and Ausubel et al. (*Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1998).

For the purposes of quantitating a PDGFRA protein, a biological sample of the subject (which can be any animal, for instance a mouse or a human), which sample includes cellular proteins, is required. Such a biological sample may be obtained from body cells, such as those present in a tissue biopsy, surgical specimens, or autopsy material. In particular embodiments, biological samples may be obtained from peripheral blood sample, urine, saliva, amniocentesis samples, and so forth. Quantitation of PDGFRA protein can be achieved by immunoassay and compared to levels of the protein found in control cells (e.g., healthy, non-neoplastic cells of the same lineage or type as those under evaluation, or from a patient known not to have a neoplastic disease). Detection of tyrosine phosphorylated PDGFRA (using an antibody, i.e. a phospho-specific antibody, that detects such forms and does not detect non-phosphorylated PDGFRA) could be taken as an indication of a PDGFRA protein containing an activating mutation. Detection of phosphorylated PDGFRA could also indicate activation by other mechanisms, such as overexpression of PDGFRA by genomic amplification, or over-expression of PDGFRA ligands, e.g. PDGF-A. A significant (e.g., 10% or greater) reduction in the amount of PDGFRA protein in the cells of a subject compared to the amount of PDGFRA protein found in normal human cells could be taken as an indication that the subject may have deletions or mutations in the PDGFRA gene, whereas a significant (e.g., 10% or greater) increase would indicate that a duplication (amplification), or mutation that increases the stability of the PDGFRA protein or mRNA, may have occurred. Deletion, mutation, and/or amplification within the PDGFRA encoding sequence, and substantial under- or over-expression of PDGFRA protein, may be indicative of neoplastic disease (such as a tumor) and/or a predilection to develop neoplastic disease.

Example 10

Differentiation of Individuals Homozygous Versus Heterozygous for Activating Mutation(s)

Though it is believed that the activating variants described herein are the result of sporadic mutations rather than germline mutations, it may sometimes be beneficial to determine whether a subject is homozygous or heterozygous for the mutation.

By way of example, the oligonucleotide ligation assay (OLA), as described at Nickerson et al. (*Proc. Natl. Acad. Sci. USA* 87:8923-8927, 1990), allows the differentiation between individuals who are homozygous versus heterozygous for the D842V or the V561D point mutation, the ER561-562 in frame insertion, or the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletions. This feature allows one to rapidly and easily determine whether an individual is homozygous for at least one tyrosine kinase activating mutation, which condition is linked to a relatively high predisposition to developing neoplastic disease and/or an increased likelihood of having a tumor. Alternatively, OLA can be used to determine whether a subject is homozygous for either of these mutations.

As an example of the OLA assay, when carried out in microtiter plates, one well is used for the determination of the presence of the PDGFRA allele that contains a T at nucleotide position 2919 (numbering from SEQ ID NO: 1) and a second well is used for the determination of the presence of the PDGFRA allele that contains an A at that nucleotide position in the wildtype sequence. Thus, the results for an individual who is heterozygous for the mutation will show a signal in each of the A and T wells.

Example 11

Suppression of PDGFRA Expression

A reduction of PDGFRA protein expression in a transgenic cell may be obtained by introducing into cells an antisense construct based on the PDGFRA encoding sequence, including the human PDGFRA cDNA or genomic sequence (SEQ ID NOs: 1 and 19, respectively) or flanking regions thereof. For antisense suppression, a nucleotide sequence from a PDGFRA encoding sequence, e.g. all or a portion of the PDGFRA cDNA or gene, is arranged in reverse orientation relative to the promoter sequence in the transformation vector. Other aspects of the vector may be chosen as discussed above (Example 7).

The introduced sequence need not be the full-length human PDGFRA cDNA or gene or reverse complement thereof, and need not be exactly homologous to the equivalent sequence found in the cell type to be transformed. Generally, however, where the introduced sequence is of shorter length, a higher degree of homology to the native PDGFRA sequence will be needed for effective antisense suppression. The introduced antisense sequence in the vector may be at least 30 nucleotides in length, and improved antisense suppression will typically be observed as the length of the antisense sequence increases. The length of the antisense sequence in the vector advantageously may be greater than 100 nucleotides. For suppression of the PDGFRA gene itself, transcription of an antisense construct results in the production of RNA molecules that are the reverse complement of mRNA molecules transcribed from the endogenous PDGFRA gene in the cell.

Although the exact mechanism by which antisense RNA molecules interfere with gene expression has not been eluci-

dated, it is believed that antisense RNA molecules bind to the endogenous mRNA molecules and thereby inhibit translation of the endogenous mRNA.

Suppression of endogenous PDGFRA expression can also be achieved using ribozymes. Ribozymes are synthetic RNA molecules that possess highly specific endoribonuclease activity. The production and use of ribozymes are disclosed in U.S. Pat. No. 4,987,071 to Cech and U.S. Pat. No. 5,543,508 to Haselhoff. The inclusion of ribozyme sequences within antisense RNAs may be used to confer RNA cleaving activity on the antisense RNA, such that endogenous mRNA molecules that bind to the antisense RNA are cleaved, which in turn leads to an enhanced antisense inhibition of endogenous gene expression.

Expression of PDGFRA can also be reduced using small inhibitory RNAs, for instance using techniques similar to those described previously (see, e.g., Tuschl et al., *Genes Dev* 13, 3191-3197, 1999; Caplen et al., *Proc. Natl. Acad. Sci. U.S.A.* 98, 9742-9747, 2001; and Elbashir et al., *Nature* 411, 494-498, 2001).

Finally, dominant negative mutant forms of PDGFRA may be used to block endogenous PDGFRA activity.

Example 12

PDGFRA Gene Therapy

Gene therapy approaches for combating activating mutations in PDGFRA, or reducing the risk of developing neoplastic disease such as cancer, in subjects are now made possible by the present disclosure.

Retroviruses have been considered a preferred vector for experiments in gene therapy, with a high efficiency of infection and stable integration and expression (Orkin et al., *Prog. Med. Genet.* 7:130-142, 1988). The full-length PDGFRA gene or cDNA can be cloned into a retroviral vector and driven from either its endogenous promoter or from the retroviral LTR (long terminal repeat). Other viral transfection systems may also be utilized for this type of approach, including adenovirus, adeno-associated virus (AAV) (McLaughlin et al., *J. Virol.* 62:1963-1973, 1988), Vaccinia virus (Moss et al., *Annu. Rev. Immunol.* 5:305-324, 1987), Bovine Papilloma virus (Rasmussen et al., *Methods Enzymol.* 139:642-654, 1987) or members of the herpesvirus group such as Epstein-Barr virus (Margolskee et al., *Mol. Cell. Biol.* 8:2837-2847, 1988).

Recent developments in gene therapy techniques include the use of RNA-DNA hybrid oligonucleotides, as described by Cole-Strauss et al. (*Science* 273:1386-1389, 1996). This technique may allow for site-specific integration of cloned sequences, thereby permitting accurately targeted gene replacement.

In addition to delivery of a PDGFRA encoding sequence to cells using viral vectors, it is possible to use non-infectious methods of delivery. For instance, lipidic and liposome-mediated gene delivery has recently been used successfully for transfection with various genes (for reviews, see Templeton and Lasic, *Mol. Biotechnol.* 11:175-180, 1999; Lee and Huang, *Crit. Rev. Ther. Drug Carrier Syst.* 14:173-206; and Cooper, *Semin. Oncol.* 23:172-187, 1996). For instance, cationic liposomes have been analyzed for their ability to transfect monocytic leukemia cells, and shown to be a viable alternative to using viral vectors (de Lima et al., *Mol. Membr. Biol.* 16:103-109, 1999). Such cationic liposomes can also be targeted to specific cells through the inclusion of, for instance, monoclonal antibodies or other appropriate targeting ligands (Kao et al., *Cancer Gene Ther.* 3:250-256, 1996).

To reduce the level of PDGFRA expression, gene therapy can be carried out using antisense or other suppressive constructs, the construction of which is discussed above (Example 11).

Example 13

Kits

Kits are provided which contain the necessary reagents for determining the presence or absence of mutation(s) in a PDGFRA-encoding sequence, such as probes or primers specific for the PDGFRA gene or a highly variable region of this gene, such as those regions indicated in SEQ ID NO: 26. Such kits can be used with the methods described herein to determine whether a subject is predisposed to neoplastic disease or tumor development, or whether the subject is expected to respond to one or another therapy, such as a particular tyrosine kinase inhibitory compound.

The provided kits may also include written instructions. The instructions can provide calibration curves or charts to compare with the determined (e.g., experimentally measured) values. Kits are also provided to determine elevated or depressed expression of mRNA (i.e., containing probes) or PDGFRA protein (i.e., containing antibodies or other PDGFRA-protein specific binding agents).

A. Kits for Amplification of PDGFRA Sequences

Oligonucleotide probes and primers, including those disclosed herein, can be supplied in the form of a kit for use in detection of a predisposition to neoplastic disease or tumor formation in a subject. In such a kit, an appropriate amount of one or more of the oligonucleotide primers is provided in one or more containers. The oligonucleotide primers may be provided suspended in an aqueous solution or as a freeze-dried or lyophilized powder, for instance. The container(s) in which the oligonucleotide(s) are supplied can be any conventional container that is capable of holding the supplied form, for instance, microfuge tubes, ampoules, or bottles. In some applications, pairs of primers may be provided in pre-measured single use amounts in individual, typically disposable, tubes or equivalent containers. With such an arrangement, the sample to be tested for the presence of a PDGFRA mutation can be added to the individual tubes and amplification carried out directly.

The amount of each oligonucleotide primer supplied in the kit can be any appropriate amount, depending for instance on the market to which the product is directed. For instance, if the kit is adapted for research or clinical use, the amount of each oligonucleotide primer provided would likely be an amount sufficient to prime several PCR amplification reactions. Those of ordinary skill in the art know the amount of oligonucleotide primer that is appropriate for use in a single amplification reaction. General guidelines may for instance be found in Innis et al. (PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc., San Diego, Calif., 1990), Sambrook et al. (In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y., 1989), and Ausubel et al. (In Current Protocols in Molecular Biology, Greene Publ. Assoc. and Wiley-Intersciences, 1992).

A kit may include more than two primers, in order to facilitate the in vitro amplification of PDGFRA sequences, for instance the PDGFRA gene or the 5' or 3' flanking region thereof.

In some embodiments, kits may also include the reagents necessary to carry out nucleotide amplification reactions, including, for instance, DNA sample preparation reagents,

appropriate buffers (e.g., polymerase buffer), salts (e.g., magnesium chloride), and deoxyribonucleotides (dNTPs).

Kits may in addition include either labeled or unlabeled oligonucleotide probes for use in detection of PDGFRA mutation(s). In certain embodiments, these probes will be specific for a potential mutation that may be present in the target amplified sequences. The appropriate sequences for such a probe will be any sequence that includes one or more of the identified polymorphic sites, particularly nucleotide positions that overlap with the variants shown in Table 1 or Table 3, such that the sequence of the probe is complementary to a polymorphic site and the surrounding PDGFRA sequence.

It may also be advantageous to provide in the kit one or more control sequences for use in the amplification reactions. The design of appropriate positive control sequences is well known to one of ordinary skill in the appropriate art.

B. Kits for Detection of PDGFRA mRNA Expression

Kits similar to those disclosed above for the detection of PDGFRA mutations directly can be used to detect PDGFRA mRNA expression, such as over- or under-expression. Such kits include an appropriate amount of one or more oligonucleotide primers for use in, for instance, reverse transcription PCR reactions, similarly to those provided above with art-obvious modifications for use with RNA amplification.

In some embodiments, kits for detection of altered expression of PDGFRA mRNA may also include some or all of the reagents necessary to carry out RT-PCR in vitro amplification reactions, including, for instance, RNA sample preparation reagents (including e.g., an RNase inhibitor), appropriate buffers (e.g., polymerase buffer), salts (e.g., magnesium chloride), and deoxyribonucleotides (dNTPs). Written instructions may also be included.

Such kits may in addition include either labeled or unlabeled oligonucleotide probes for use in detection of the in vitro amplified target sequences. The appropriate sequences for such a probe will be any sequence that falls between the annealing sites of the two provided oligonucleotide primers, such that the sequence the probe is complementary to is amplified during the PCR reaction. In certain embodiments, these probes will be specific for a potential mutation that may be present in the target amplified sequences, for instance specific for the D842V or V561D point mutation, the ER561-562 in frame insertion, or the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletion, or another mutation identified in PDGFRA.

It may also be advantageous to provide in the kit one or more control sequences for use in the RT-PCR reactions. The design of appropriate positive control sequences is well known to one of ordinary skill in the appropriate art.

Alternatively, kits may be provided with the necessary reagents to carry out quantitative or semi-quantitative Northern analysis of PDGFRA mRNA. Such kits include, for instance, at least one PDGFRA-specific oligonucleotide for use as a probe. This oligonucleotide may be labeled in any conventional way, including with a selected radioactive isotope, enzyme substrate, co-factor, ligand, chemiluminescent or fluorescent agent, hapten, or enzyme. In certain embodiments, such probes will be specific for a potential mutation that may be present in the target amplified sequence, such as the mutations disclosed herein.

C. Kits For Detection of PDGFRA Protein Expression

Kits for the detection of PDGFRA protein expression (such as over- or under-expression) are also encompassed. Such kits may include at least one target protein specific binding agent (e.g., a polyclonal or monoclonal antibody or antibody frag-

ment that specifically recognizes the PDGFRA protein) and may include at least one control (such as a determined amount of PDGFRA protein, or a sample containing a determined amount of PDGFRA protein). The PDGFRA-protein specific binding agent and control may be contained in separate containers. Likewise, kits for detection of activated PDGFRA may include at least one target protein binding agent (e.g., a polyclonal or monoclonal antibody or antibody fragment) that specifically recognizes the PDGFRA protein only when PDGFRA is expressed in activated manner. These kits include, but are not limited to, those in which the PDGFRA binding agent recognizes, and binds specifically with, epitopes in which one or more tyrosine residues are phosphorylated. Kits for detection of activated/phosphorylated PDGFRA might include at least two controls, including a positive control with tyrosine phosphorylated PDGFRA and a negative control lacking tyrosine phosphorylated PDGFRA. The positive controls may include lysates or paraffin sections from cells and tissues expressing mutant (activated) PDGFRA, or expressing native PDGFRA that has been activated by exposure of the cells to PDGF-A. The negative controls may include lysates or paraffin sections from cells and tissues expressing non-activated PDGFRA, e.g. tissues expressing non-mutant PDGFRA, and without exposure to PDGF-A.

The PDGFRA protein expression detection kits may also include a means for detecting PDGFRA:binding agent complexes, for instance the agent may be detectably labeled. If the detectable agent is not labeled, it may be detected by second antibodies or protein A for example, which may also be provided in some kits in one or more separate containers. Such techniques are well known.

Additional components in specific kits may include instructions for carrying out the assay. Instructions will allow the tester to determine whether PDGFRA expression levels are elevated. Reaction vessels and auxiliary reagents such as chromogens, buffers, enzymes, etc. may also be included in the kits.

D. Kits for Detection of Homozygous Versus Heterozygous Allelism

Also provided are kits that allow differentiation between individuals who are homozygous versus heterozygous for the D842V or V561D point mutations, the ER561-562 in frame insertion, or the DIMH842-845, HDSN845-848P, RD841-842KI, RVIES560-564, or SPDGHE566-571R in-frame deletion mutations of PDGFRA. Such kits provide the materials necessary to perform oligonucleotide ligation assays (OLA), as described at Nickerson et al. (*Proc. Natl. Acad. Sci. USA* 87:8923-8927, 1990). In specific embodiments, these kits contain one or more microtiter plate assays, designed to detect mutation(s) in the PDGFRA sequence of a subject, as described herein.

Additional components in some of these kits may include instructions for carrying out the assay. Instructions will allow the tester to determine whether a PDGFRA allele is homozygous or heterozygous. Reaction vessels and auxiliary reagents such as chromogens, buffers, enzymes, etc. may also be included in the kits.

It may also be advantageous to provide in the kit one or more control sequences for use in the OLA reactions. The design of appropriate positive control sequences is well known to one of ordinary skill in the appropriate art.

Example 14

PDGFRA Knockout and Overexpression Transgenic Animals

Mutant organisms that under-express or over-express PDGFRA protein are useful for research. Such mutants allow

insight into the physiological and/or pathological role of PDGFRA in a healthy and/or pathological organism. These mutants are "genetically engineered," meaning that information in the form of nucleotides has been transferred into the mutant's genome at a location, or in a combination, in which it would not normally exist. Nucleotides transferred in this way are said to be "non-native." For example, a non-PDGFRA promoter inserted upstream of a native PDGFRA encoding sequence would be non-native. An extra copy of a PDGFRA gene on a plasmid, transformed into a cell, would be non-native.

Mutants may be, for example, produced from mammals, such as mice, that either over-express PDGFRA or under-express PDGFRA, or that do not express PDGFRA at all. Over-expression mutants are made by increasing the number of PDGFRA genes in the organism, or by introducing a PDGFRA gene into the organism under the control of a constitutive or inducible or viral promoter such as the mouse mammary tumor virus (MMTV) promoter or the whey acidic protein (WAP) promoter or the metallothionein promoter. Mutants that under-express PDGFRA may be made by using an inducible or repressible promoter, or by deleting the PDGFRA gene, or by destroying or limiting the function of the PDGFRA gene, for instance by disrupting the gene by transposon insertion.

Antisense genes may be engineered into the organism, under a constitutive or inducible promoter, to decrease or prevent PDGFRA expression, as discussed above in Example 11.

A gene is "functionally deleted" when genetic engineering has been used to negate or reduce gene expression to negligible levels. When a mutant is referred to in this application as having the PDGFRA gene altered or functionally deleted, this refers to the PDGFRA gene and to any ortholog of this gene. When a mutant is referred to as having "more than the normal copy number" of a gene, this means that it has more than the usual number of genes found in the wild-type organism, e.g., in the diploid mouse or human.

A mutant mouse over-expressing PDGFRA may be made by constructing a plasmid having a PDGFRA encoding sequence driven by a promoter, such as the mouse mammary tumor virus (MMTV) promoter or the whey acidic protein (WAP) promoter. This plasmid may be introduced into mouse oocytes by microinjection. The oocytes are implanted into pseudopregnant females, and the litters are assayed for insertion of the transgene. Multiple strains containing the transgene are then available for study.

WAP is quite specific for mammary gland expression during lactation, and MMTV is expressed in a variety of tissues including mammary gland, salivary gland and lymphoid tissues. Many other promoters might be used to achieve various patterns of expression, e.g., the metallothionein promoter.

An inducible system may be created in which the subject expression construct is driven by a promoter regulated by an agent that can be fed to the mouse, such as tetracycline. Such techniques are well known in the art.

A mutant knockout animal (e.g., mouse) from which a PDGFRA gene is deleted can be made by removing all or some of the coding regions of the PDGFRA gene from embryonic stem cells. The methods of creating deletion mutations by using a targeting vector have been described (Thomas and Capecch, *Cell* 51:503-512, 1987).

Engineered PDGFRA knockout animals are known. See, for instance, Bostrom et al., *Dev. Dyn.*, 223:155-162, 2002; Fruttiger et al., *Development*, 126:457-467, 1999; Hellstrom et al., *J. Cell Biol.*, 153:543-553, 2001; Kaminski et al., *Blood*, 97:1990-1998, 2001; Karlsson et al., *Development*, 127:3457-3466, 2000. In addition, Patch mutant mice have a congenital chromosomal deletion that includes the PDGFR- α gene locus.

Example 15

Knock-in Organisms

In addition to knock-out systems, it is also beneficial to generate “knock-ins” that have lost expression of the wild-type protein but have gained expression of a different, usually mutant form of the same protein. By way of example, the activating mutant PDGFRA mutant proteins provided herein (e.g., as shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, 25, and 27) can be expressed in a knockout background, such as the Patch mutant mice, in order to provide model systems for studying the effects of these mutants. In particular embodiments, the resultant knock-in organisms provide systems for studying neoplasia.

Those of ordinary skill in the relevant art know methods of producing knock-in organisms. See, for instance, Rane et al.

putative PDGFRA fusion gene is not expected to be BCR. Therefore, these leukemias may contain novel forms of PDGFRA fusion oncogenes. FISH analyses will be performed to determine whether any of these translocations targets PDGFRA, in which case the translocation partner gene will be identified by rapid amplification of cDNA ends, and the activating nature of the PDGFRA fusion will be determined by expressing the PDGFRA fusion gene in cell types such as Ba/F3 and CHO.

Example 17

Additional PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

Using methods essentially as described in Example 1, three additional PDGFRA activating mutations were identified in GISTs. These mutations are as shown in Table 3.

TABLE 3

Genotype	DNA sequence (top line) Translation (bottom line)
PDGFRA Wild type (SEQ ID NOs: 1 and 2)	2906* GGCCTGGCCAGAGACATCATGCATGATTCGAACATATGTG 838 G L A R D I M H D S N Y V
PDGFRA Substitution RD841-842KI (SEQ ID NOs: 24 and 25)	2906 GGCCTGGCCAAATCATCATGCATGATTCGAACATATGTG 838 G L A K I I M H D S N Y V
PDGFRA Wild type	2060 GAAATTCGCTGGAGGGTCATTGAATCAATCAGCCCGGAT 556 E I R W R V I E S I S P D
V561D (SEQ ID NOs: 20 and 21)	2060 GAAATTCGCTGGAGGGAACATTGAATCAATCAGCCCGGAT 556 E I R W R D I E S I S P D
PDGFRA Deletion RVIES560-564 (SEQ ID NOs: 22 and 23)	2060 GAAATTCGCTGG-----ATCAGCCCGGAT 556 E I R W - - - - - I S P D

*Numbering as in SEQ ID NO: 1 and SEQ ID NO: 2.

(*Mol. Cell. Biol.*, 22: 644-656, 2002); Sotillo et al. (*EMBO J.*, 20: 6637-6647, 2001); Luo et al. (*Oncogene*, 20: 320-328, 2001); Tomasson et al. (*Blood*, 93: 1707-1714, 1999); Voncken et al. (*Blood*, 86: 4603-4611, 1995); Andrae et al. (*Mech. Dev.*, 107: 181-185, 2001); Reinertsen et al. (*Gene Expr.*, 6: 301-314, 1997); Huang et al. (*Mol. Med.*, 5: 129-137, 1999); Reichert et al. (*Blood*, 97: 1399-1403, 2001); and Huettnner et al. (*Nat. Genet.*, 24: 57-60, 2000), by way of example.

Example 16

Demonstration of PDGFRA Fusion Oncoproteins in Human Leukemias

The PDGFRA activating genomic mutations disclosed herein involve intragenic point mutations or deletions. These models of genomic PDGFRA mutation can readily be extended to different mechanisms of activation, e.g. as might result from chromosomal rearrangement in which the promoter and 5' end of an ectopic gene are fused to the 3' end—including the kinase domain—of PDGFRA. The principle of receptor tyrosine kinase activation, in which cytogenetic rearrangement produces a gene fusion, has been established for several kinase proteins, including FGFR1, FGFR3, NTRK3, and ALK, and have been reported recently for PDGFRA, in two patients with chronic myelogenous leukemia, in which PDGFRA was fused with the BCR gene. In the PDGFRA context, the applicants have identified four leukemias in which cytogenetic banding analyses reveal translocation breakpoints in the PDGFRA gene (chromosome band 4q12) region, and in which—based on cytogenetic correlates—the

After taking into account these three additional mutations, and additional instances of other identified mutations, the total number of each of the identified activating mutations was as shown in Table 4 and Table 5.

TABLE 4

Summary of PDGFRA mutations in KIT-WT GISTs.		
PDGFRA Region	Mutation	#GISTs
Activation Loop (exon 18)	D842V	15
	Del DIMH	4
	Del HDSN845-848P	1
	RD841-842KI	1
Juxtamembrane (exon 12)	V561D	1
	Ins ER561-562	1
	Del RVIES560-564	1
	Del SPDGHE566-571R	1

TABLE 5

Mutation	Cases (% total)
D842V	15 (21.7%)
Exon 18 Deletion	6 (8.7%)
Exon 12 Insertion/Deletion/PM	4 (5.8%)
No mutation	44 (63.7%)
Total	69 (100.0%)

The nucleic acid sequences of all of the identified activating PDGFRA mutations were aligned to produce the consen-

sus sequence shown in SEQ ID NO: 26; the numbering in the consensus sequence aligns with that in the wildtype PDGFRA nucleic acid sequence (SEQ ID NO: 1). In the consensus sequence, the insertion identified in variant PDGFRA Insertion ER561-562 is indicated in a miscellaneous features field in the Sequence Listing. As emphasized and clearly illustrated in the consensus sequence, clusters of activating mutations in the PDGFRA nucleic acid sequence are found in positions 2072 to 2107 and 2916 to 2937, though it is noted that positions 2087, 2088, and 2089 appear to be invariable at least in the current studies.

Example 18

Additional Characterization of PDGFRA Activating Mutations in GISTs

Materials and Methods

Reagents

Antibodies used for immunoblotting were to phosphotyrosine (Santa Cruz PY99), actin (Sigma 1PKCA4), KIT (Dako A4502), PDGFRA (Santa Cruz sc-338), phosphoPDGFRA Y754 (Santa Cruz sc-12911), MAPK (Zymed 61-7400), phosphoMAPK Thr202/Thr204 (Cell Signaling 9106), AKT (Cell Signaling 9272), phosphoAKT S473 (Cell Signaling 9271S), STAT1 (Zymed ST1-3D4), phosphoSTAT1 Y7012 (Zymed ST1P-11A5), STAT3 (Zymed 13-7000), phosphoSTAT3 Y705 (Cell Signaling 9131), STAT5 (Zymed ST5-8F7), and phosphoSTAT5 Y694 (Zymed ST5P-4A9). Antibodies to phosphorylated kinases were validated as phosphospecific by evaluation of phosphatase treated cell lysates, and by evaluation of lysates from GIST cells treated with kinase inhibitors.

Cytogenetic Analyses

Tumor specimens were chopped with scalpel blades, disaggregated enzymatically, and seeded into T25 flasks. The monolayer cultures were expanded for two-to-five days prior to metaphase cell harvesting with Colcemid. Tissue culture, metaphase harvesting, metaphase slide making, and Giemsa-trypsin banding were performed as described previously (Fletcher et al., *N. Engl. J. Med.* 324, 436, 1991).

Cloning, Expression and Characterization of PDGFRA Mutant cDNAs

PDGFRA mutations were cloned by site-directed mutagenesis of the wild type PDGFRA cDNA. CHO cells were transiently transfected with expression vectors encoding for mutant or wild-type PDGFRA cDNA. Transfected cells were serum starved overnight and stimulated with vehicle or 100 ng/ml recombinant human PDGF-AA for 10 minutes before harvesting cells and preparing whole cell lysates for immunoblotting. The membranes were sequentially immunoblotted with antiserum against phosphorylated tyrosines (PY20 Transduction Laboratories) or total PDGFRA (Santa Cruz sc-338).

Results and Discussion

The biochemical consequences of somatic PDGFRA mutations were studied by transient expression of wild-type and mutant PDGFRA cDNA constructs in Chinese hamster ovary (CHO) cells. Baseline tyrosine phosphorylation was weak for non-mutant PDGFRA, and was substantially increased by ligand stimulation (FIG. 8). By contrast, baseline tyrosine phosphorylation was strong in all five of the tested PDGFRA mutants, and was not increased by ligand stimulation (FIG. 8).

Next the signal transduction pathways activated in PDGFRA-mutant versus KIT-mutant GISTs were compared. The PDGFRA-mutant GISTs showed uniform activation of signaling intermediates AKT, MAPK, STAT1, and STAT3, which are also activated in most KIT-mutant GISTs (FIG. 9). The PDGFRA-mutant GISTs lacked expression of phospho-STAT5, despite strong expression of total STAT5, which is also typical of KIT-mutant GISTs. The cytogenetic profiles of four PDGFRA-mutant GISTs and 52 KIT-mutant GISTs were also compared. KIT mutations are early events in GIST tumorigenesis, whereas cytogenetic aberrations occur later in disease progression (Heinrich et al., *Hum. Pathol.* 33, 484, 2002). Most of these GISTs—irrespective of PDGFRA or KIT mutation—featured noncomplex karyotypes with deletions of chromosome 1p, and with monosomies of chromosomes 14 and 22. Hence, these results suggest that the mechanisms of cytogenetic progression and oncoprotein-driven signal transduction are similar in GISTs expressing oncogenic forms of PDGFRA and KIT.

Activating mutations of KIT or PDGFRA appear to be mutually exclusive oncogenic events in GISTs, and these mutations have similar biological consequences. The data presented also highlight a crucial role for PDGFRA in the pathogenesis of a solid tumor. Notably, a translocation involving the BCR and PDGFRA genes has been described in BCR-ABL negative chronic myelogenous leukemia, and is predicted to result in dimerization and kinase activation of the fusion protein (Baxter et al., *Hum. Mol. Genet.* 11, 1391, 2002). PDGFRA is widely expressed in human tissues, so it will be important to determine whether PDGFRA mutations play a role in other human malignancies. Such tumors could be sensitive to Gleevec and other small molecule drugs that inhibit PDGFRA kinase activity (Buchdunger et al., *J. Pharmacol. Exp. Ther.* 295, 139, 2000; Lokker et al., *Cancer Res.* 62, 3729, 2002; Sun et al., *J. Med. Chem.* 43, 2655, 2000).

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, using these molecules and fragments thereof, and kits for employing these methods and compositions. It will be apparent that the precise details of the compositions and methods described may be varied or modified without departing from the spirit of the described invention. We claim all such modifications and variations that fall within the scope and spirit of the claims below.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 31

<210> SEQ ID NO 1

<211> LENGTH: 6633

<212> TYPE: DNA

-continued

<213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395)..(3664)

<400> SEQUENCE: 1

```

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc      60
gtaagagcaa aaagcgaagg cgcaatctgg aactgaggag attcggagcg cagggagttt      120
gagagaaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta      180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa      240
aacgcgggttt ttgagcccat tactgttgga gctacaggga gagaacagg aggagactgc      300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg      360
cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg      415
                Met Gly Thr Ser His Pro Ala
                1                5

ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc      463
Phe Leu Val Leu Gly Cys Leu Leu Thr Gly Leu Ser Leu Ile Leu Cys
                10                15                20

cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg      511
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val
                25                30                35

cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg      559
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val
40                45                50                55

agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc      607
Ser Trp Gln Tyr Pro Met Ser Glu Glu Ser Ser Asp Val Glu Ile
                60                65                70

aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg      655
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val
75                80                85

agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac      703
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn
90                95                100

cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc      751
His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile
105                110                115

tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat      799
Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp
120                125                130                135

tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc      847
Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg
140                145                150

aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg      895
Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val
155                160                165

gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act      943
Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr
170                175                180

gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag      991
Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln
185                190                195

acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat      1039
Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp
200                205                210                215

cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att      1087
Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile
220                225                230

gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg      1135

```


-continued

Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn	Glu	Val	Val	Asp	Leu	Gln	Trp	
			235					240					245			
act	tac	cct	gga	gaa	gtg	aaa	ggc	aaa	ggc	atc	aca	atg	ctg	gaa	gaa	1183
Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys	Gly	Ile	Thr	Met	Leu	Glu	Glu	
		250					255					260				
atc	aaa	gtc	cca	tcc	atc	aaa	ttg	gtg	tac	act	ttg	acg	gtc	ccc	gag	1231
Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val	Tyr	Thr	Leu	Thr	Val	Pro	Glu	
	265						270					275				
gcc	acg	gtg	aaa	gac	agt	gga	gat	tac	gaa	tgt	gct	gcc	cgc	cag	gct	1279
Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr	Glu	Cys	Ala	Ala	Arg	Gln	Ala	
	280					285				290					295	
acc	agg	gag	gtc	aaa	gaa	atg	aag	aaa	gtc	act	att	tct	gtc	cat	gag	1327
Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys	Val	Thr	Ile	Ser	Val	His	Glu	
			300						305					310		
aaa	ggt	ttc	att	gaa	atc	aaa	ccc	acc	ttc	agc	cag	ttg	gaa	gct	gtc	1375
Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr	Phe	Ser	Gln	Leu	Glu	Ala	Val	
		315						320					325			
aac	ctg	cat	gaa	gtc	aaa	cat	ttt	gta	gag	gtg	cgg	gcc	tac	cca		1423
Asn	Leu	His	Glu	Val	Lys	His	Phe	Val	Val	Glu	Val	Arg	Ala	Tyr	Pro	
		330					335					340				
cct	ccc	agg	ata	tcc	tgg	ctg	aaa	aac	aat	ctg	act	ctg	att	gaa	aat	1471
Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn	Asn	Leu	Thr	Leu	Ile	Glu	Asn	
		345					350					355				
ctc	act	gag	atc	acc	act	gat	gtg	gaa	aag	att	cag	gaa	ata	agg	tat	1519
Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu	Lys	Ile	Gln	Glu	Ile	Arg	Tyr	
	360					365				370					375	
cga	agc	aaa	tta	aag	ctg	atc	cgt	gct	aag	gaa	gaa	gac	agt	ggc	cat	1567
Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala	Lys	Glu	Glu	Asp	Ser	Gly	His	
			380						385					390		
tat	act	att	gta	gct	caa	aat	gaa	gat	gct	gtg	aag	agc	tat	act	ttt	1615
Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp	Ala	Val	Lys	Ser	Tyr	Thr	Phe	
		395						400					405			
gaa	ctg	tta	act	caa	ggt	cct	tca	tcc	att	ctg	gac	ttg	gtc	gat	gat	1663
Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser	Ile	Leu	Asp	Leu	Val	Asp	Asp	
		410					415					420				
cac	cat	ggc	tca	act	ggg	gga	cag	acg	gtg	agg	tgc	aca	gct	gaa	ggc	1711
His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr	Val	Arg	Cys	Thr	Ala	Glu	Gly	
		425				430					435					
acg	ccg	ctt	cct	gat	att	gag	tgg	atg	ata	tgc	aaa	gat	att	aag	aaa	1759
Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met	Ile	Cys	Lys	Asp	Ile	Lys	Lys	
		440				445				450					455	
tgt	aat	aat	gaa	act	tcc	tgg	act	att	ttg	gcc	aac	aat	gtc	tca	aac	1807
Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	Leu	Ala	Asn	Asn	Val	Ser	Asn	
			460						465					470		
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg	
		475						480					485			
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala	
		490					495					500				
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro	
		505					510					515				
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Ala	Val	Leu	Val	Leu	Leu	
		520				525				530					535	
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln	
			540						545					550		
aaa	ccg	agg	tat	gaa	att	cgc	tgg	agg	gtc	att	gaa	tca	atc	agc	ccg	2095

-continued

Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	Val	Ile	Glu	Ser	Ile	Ser	Pro	
			555					560					565			
gat	gga	cat	gaa	tat	att	tat	gtg	gac	ccg	atg	cag	ctg	cct	tat	gac	2143
Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	
		570					575					580				
tca	aga	tgg	gag	ttt	cca	aga	gat	gga	cta	gtg	ctt	ggg	cgg	gtc	ttg	2191
Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	
		585					590					595				
ggg	tct	gga	gcg	ttt	ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	gga	tta	2239
Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	
		600				605				610					615	
agc	cgg	tcc	caa	cct	gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	aaa	ccc	2287
Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	
				620						625					630	
acg	gcc	aga	tcc	agt	gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	aag	ata	2335
Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	
				635					640						645	
atg	act	cac	ctg	ggg	cca	cat	ttg	aac	att	gta	aac	ttg	ctg	gga	gcc	2383
Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	
				650				655					660			
tgc	acc	aag	tca	ggc	ccc	att	tac	atc	atc	aca	gag	tat	tgc	ttc	tat	2431
Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	
				665			670					675				
gga	gat	ttg	gtc	aac	tat	ttg	cat	aag	aat	agg	gat	agc	ttc	ctg	agc	2479
Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	
						685				690					695	
cac	cac	cca	gag	aag	cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	ttg	aac	2527
His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	
				700						705					710	
cct	gct	gat	gaa	agc	aca	cgg	agc	tat	gtt	att	tta	tct	ttt	gaa	aac	2575
Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	
				715					720						725	
aat	ggt	gac	tac	atg	gac	atg	aag	cag	gct	gat	act	aca	cag	tat	gtc	2623
Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	
				730				735					740			
ccc	atg	cta	gaa	agg	aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	cag	aga	2671
Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	
				745						750					755	
tca	ctc	tat	gat	cgt	cca	gcc	tca	tat	aag	aag	aaa	tct	atg	tta	gac	2719
Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr	Lys	Lys	Lys	Ser	Met	Leu	Asp	
						765				770					775	
tca	gaa	gtc	aaa	aac	ctc	ctt	tca	gat	gat	aac	tca	gaa	ggc	ctt	act	2767
Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp	Asn	Ser	Glu	Gly	Leu	Thr		
						780				785					790	
tta	ttg	gat	ttg	ttg	agc	ttc	acc	tat	caa	gtt	gcc	cga	gga	atg	gag	2815
Leu	Leu	Asp	Leu	Leu	Ser	Phe	Thr	Tyr	Gln	Val	Ala	Arg	Gly	Met	Glu	
						795				800					805	
ttt	ttg	gct	tca	aaa	aat	tgt	gtc	cac	cgt	gat	ctg	gct	gct	cgc	aac	2863
Phe	Leu	Ala	Ser	Lys	Asn	Cys	Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	
						810									820	
gtc	ctc	ctg	gca	caa	gga	aaa	att	gtg	aag	atc	tgt	gac	ttt	ggc	ctg	2911
Val	Leu	Leu	Ala	Gln	Gly	Lys	Ile	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	
						825						835				
gcc	aga	gac	atc	atg	cat	gat	tcg	aac	tat	gtg	tcg	aaa	ggc	agt	acc	2959
Ala	Arg	Asp	Ile	Met	His	Asp	Ser	Asn	Tyr	Val	Ser	Lys	Gly	Ser	Thr	
						845					850				855	
ttt	ctg	ccc	gtg	aag	tgg	atg	gct	cct	gag	agc	atc	ttt	gac	aac	ctc	3007
Phe	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asp	Asn	Leu	
						860									870	
tac	acc	aca	ctg	agt	gat	gtc	tgg	tct	tat	ggc	att	ctg	ctc	tgg	gag	3055

-continued

Tyr Thr Thr	Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu	
	875 880 885	
atc ttt tcc ctt ggt ggc acc cct tac ccc ggc atg atg gtg gat tct	3103	
Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser		
890 895 900		
act ttc tac aat aag atc aag agt ggg tac cgg atg gcc aag cct gac	3151	
Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp		
905 910 915		
cac gct acc agt gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt	3199	
His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser		
920 925 930 935		
gag ccg gag aag aga ccc tcc ttt tac cac ctg agt gag att gtg gag	3247	
Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu		
940 945 950		
aat ctg ctg cct gga caa tat aaa aag agt tat gaa aaa att cac ctg	3295	
Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu		
955 960 965		
gac ttc ctg aag agt gac cat cct gct gtg gca cgc atg cgt gtg gac	3343	
Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met Arg Val Asp		
970 975 980		
tca gac aat gca tac att ggt gtc acc tac aaa aac gag gaa gac aag	3391	
Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys		
985 990 995		
ctg aag gac tgg gag ggt ggt ctg gat gag cag aga ctg agc gct	3436	
Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala		
1000 1005 1010		
gac agt ggc tac atc att cct ctg cct gac att gac cct gtc cct	3481	
Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val Pro		
1015 1020 1025		
gag gag gag gac ctg ggc aag agg aac aga cac agc tcg cag acc	3526	
Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln Thr		
1030 1035 1040		
tct gaa gag agt gcc att gag acg ggt tcc agc agt tcc acc ttc	3571	
Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Thr Phe		
1045 1050 1055		
atc aag aga gag gac gag acc att gaa gac atc gac atg atg gac	3616	
Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met Asp		
1060 1065 1070		
gac atc ggc ata gac tct tca gac ctg gtg gaa gac agc ttc ctg	3661	
Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe Leu		
1075 1080 1085		
taa ctggcggatt cgaggggttc cttccacttc tggggccacc tctggatccc	3714	
gttcagaaaa ccacttttatt gcaatgcgga ggttgagagg aggacttggt tgatgtttaa	3774	
agagaagtcc ccagccaagg gcctcgggga gcgttctaaa tatgaatgaa tgggatattt	3834	
tgaaatgaac ttgtctagtg ttgcctctcg caatgcctca gtagcatctc agtgggtgtg	3894	
gaagtttgga gatagatgga taagggaata ataggccaca gaaggtgaac ttgtgcttc	3954	
aaggacattg gtgagagtcc aacagacaca atttatactg cgacagaact tcagcattgt	4014	
aattatgtaa ataactctaa ccaaggctgt gtttagattg tattaactat cttctttgga	4074	
cttctgaaga gaccactcaa tccatccatg tacttccctc ttgaaacctg atgtcagctg	4134	
ctgttgaaact ttttaaagaa gtgcatgaaa aaccattttt gaaccttaaa aggtactggt	4194	
actatagcat ttgtctatct tttttagtgt taagagataa agaataataa ttaaccaacc	4254	
ttgtttaata gattttgggtc atttagaagc ctgacaactc attttcatat tgtaactctat	4314	
gtttataata ctactactgt tatcagtaat gctaaatgtg taataatgta acatgatttc	4374	
cctccagaga aagcacaatt taaaacaatc cttactaagt aggtgatgag ttgacagtt	4434	

-continued

```

tttgacattt atattaaata acatgtttct ctataaagta tggtaatagc tttagtgaat 4494
taaathtagt tgagcataga gaacaaagta aaagtagtgt tgtccaggaa gtcagaattt 4554
ttaactgtac tgaatagggt ccccaatcca tcgtattaaa aaacaattaa ctgccctctg 4614
aaataatggg attagaaca aacaaaactc ttaagtccta aaagttctca atgtagaggc 4674
ataaacctgt gctgaacata acttctcatg tatattacc c atggaaaat ataatgatca 4734
gcaaaaagac tggatttgca gaagttttt tttttttct tcatgcctga tgaagcttt 4794
ggcaacccca atatatgtat tttttgaatc tatgaacctg aaaagggta gaaggatgcc 4854
cagacatcag cctccttctt tcaccctta ccccaaagag aaagagtttg aaactcgaga 4914
ccataaagat attctttagt ggaggctgga tgtgcattag cctggatcct cagttctcaa 4974
atgtgtgtgg cagccaggat gactagatcc tgggtttcca tccttgagat tctgaagtat 5034
gaagtctgag ggaaccaga gtctgtattt ttctaaactc cctggctggt ctgatcgcc 5094
agttttcgga aacctgact taggtttcag gaagttgcca tgggaaacaa ataatttgaa 5154
ctttggaaca gggttggaat tcaaccacgc aggaagccta ctatttaaat ccttggtctc 5214
aggtagtga catttaatgc catctagcta gcaattgcga ccttaattta actttccagt 5274
cttagctgag gctgagaaag ctaaagtttg gttttgacag gttttccaaa agtaaagatg 5334
ctacttccca ctgtatggg gagattgaac tttccccgtc tcccgcttc tgcctccac 5394
tccatacccc gccaaagaaa ggcattgtaca aaaattatgc aattcagtgt tccaagtctc 5454
tgtgtaacca gctcagtgtt ttggtgga aaacatttta agttttactg ataatttgag 5514
gttagatggg aggatgaatt gtcacatcta tccacactgt caaacagggt ggtgtgggtt 5574
cattggcatt ctttgcaata ctgcttaatt gctgatacca tatgaatgaa acatgggctg 5634
tgattactgc aatcactgtg ctatcggcag atgatgctt ggaagatgca gaagcaataa 5694
taaaagtact gactacctac tgggtgaatc tcaatgcaag ccccaacttt ctatccaac 5754
ttttcatag taagtgcgaa gactgagcca gattggccaa ttaaaaacga aaacctgact 5814
aggttctgta gagcaatta gacttgaat acgttttgtt ttctagaatc acagctcaag 5874
cattctgttt atcgctcact ctcccttgta cagccttatt ttgttggtgc tttgcatttt 5934
gatattgctg tgagccttgc atgacatcat gaggcggat gaaacttctc agtccagcag 5994
tttccagtc taacaaatgc tcccacctga atttgatat gactgcattt gtgggtgtgt 6054
gtgtgttttc agcaaatcc agatttggtt ccttttggtc tctgcaaag tctccagaag 6114
aaaaattgcc aatctttcct actttctatt tttatgatga caatcaaagc cggcctgaga 6174
aacactatth gtgacttttt aaacgattag tgatgtcctt aaaatgtggt ctgccaatct 6234
gtacaaaatg gtcctatttt tgtgaagagg gacataagat aaaatgatgt tatacatcaa 6294
tatgtatata tgtatttcta tatagacttg gagaatactg ccaaaacatt tatgacaagc 6354
tgtatcactg ccttcgttta tttttttta actgtgataa tccccacagg cacattaact 6414
gttgactttt tgaatgtcca aaatttatat tttagaaata ataaaaagaa agatacttac 6474
atgttcccaa aacaatgggt tgggtgaatgt gtgagaaaaa ctaacttgat aggggtctacc 6534
aatacaaaat gtattacgaa tgcccctgtt catgtttttg ttttaaaacg tgtaaatgaa 6594
gatctttata tttcaataaa tgatatataa tttaaagtt 6633

```

<210> SEQ ID NO 2

<211> LENGTH: 1089

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 2

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
 1 5 10 15
 Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
 20 25 30
 Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
 35 40 45
 Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
 50 55 60
 Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
 65 70 75 80
 Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
 85 90 95
 Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
 100 105 110
 Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
 115 120 125
 Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
 130 135 140
 Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
 145 150 155 160
 Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
 165 170 175
 Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
 180 185 190
 Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
 195 200 205
 Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
 210 215 220
 Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
 225 230 235 240
 Glu Val Val Asp Leu Gln Trp Thr Tyr Pro Gly Glu Val Lys Gly Lys
 245 250 255
 Gly Ile Thr Met Leu Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val
 260 265 270
 Tyr Thr Leu Thr Val Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr
 275 280 285
 Glu Cys Ala Ala Arg Gln Ala Thr Arg Glu Val Lys Glu Met Lys Lys
 290 295 300
 Val Thr Ile Ser Val His Glu Lys Gly Phe Ile Glu Ile Lys Pro Thr
 305 310 315 320
 Phe Ser Gln Leu Glu Ala Val Asn Leu His Glu Val Lys His Phe Val
 325 330 335
 Val Glu Val Arg Ala Tyr Pro Pro Pro Arg Ile Ser Trp Leu Lys Asn
 340 345 350
 Asn Leu Thr Leu Ile Glu Asn Leu Thr Glu Ile Thr Thr Asp Val Glu
 355 360 365
 Lys Ile Gln Glu Ile Arg Tyr Arg Ser Lys Leu Lys Leu Ile Arg Ala
 370 375 380
 Lys Glu Glu Asp Ser Gly His Tyr Thr Ile Val Ala Gln Asn Glu Asp
 385 390 395 400
 Ala Val Lys Ser Tyr Thr Phe Glu Leu Leu Thr Gln Val Pro Ser Ser
 405 410 415

-continued

Ile Leu Asp Leu Val Asp Asp His His Gly Ser Thr Gly Gly Gln Thr
 420 425 430
 Val Arg Cys Thr Ala Glu Gly Thr Pro Leu Pro Asp Ile Glu Trp Met
 435 440 445
 Ile Cys Lys Asp Ile Lys Lys Cys Asn Asn Glu Thr Ser Trp Thr Ile
 450 455 460
 Leu Ala Asn Asn Val Ser Asn Ile Ile Thr Glu Ile His Ser Arg Asp
 465 470 475 480
 Arg Ser Thr Val Glu Gly Arg Val Thr Phe Ala Lys Val Glu Glu Thr
 485 490 495
 Ile Ala Val Arg Cys Leu Ala Lys Asn Leu Leu Gly Ala Glu Asn Arg
 500 505 510
 Glu Leu Lys Leu Val Ala Pro Thr Leu Arg Ser Glu Leu Thr Val Ala
 515 520 525
 Ala Ala Val Leu Val Leu Leu Val Ile Val Ile Ile Ser Leu Ile Val
 530 535 540
 Leu Val Val Ile Trp Lys Gln Lys Pro Arg Tyr Glu Ile Arg Trp Arg
 545 550 555 560
 Val Ile Glu Ser Ile Ser Pro Asp Gly His Glu Tyr Ile Tyr Val Asp
 565 570 575
 Pro Met Gln Leu Pro Tyr Asp Ser Arg Trp Glu Phe Pro Arg Asp Gly
 580 585 590
 Leu Val Leu Gly Arg Val Leu Gly Ser Gly Ala Phe Gly Lys Val Val
 595 600 605
 Glu Gly Thr Ala Tyr Gly Leu Ser Arg Ser Gln Pro Val Met Lys Val
 610 615 620
 Ala Val Lys Met Leu Lys Pro Thr Ala Arg Ser Ser Glu Lys Gln Ala
 625 630 635 640
 Leu Met Ser Glu Leu Lys Ile Met Thr His Leu Gly Pro His Leu Asn
 645 650 655
 Ile Val Asn Leu Leu Gly Ala Cys Thr Lys Ser Gly Pro Ile Tyr Ile
 660 665 670
 Ile Thr Glu Tyr Cys Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys
 675 680 685
 Asn Arg Asp Ser Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu
 690 695 700
 Leu Asp Ile Phe Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr
 705 710 715 720
 Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln
 725 730 735
 Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser
 740 745 750
 Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr
 755 760 765
 Lys Lys Lys Ser Met Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp
 770 775 780
 Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr
 785 790 795 800
 Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His
 805 810 815
 Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val
 820 825 830
 Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met His Asp Ser Asn

-continued

835	840	845
Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro 850 855 860		
Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser 865 870 875 880		
Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr 885 890 895		
Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly 900 905 910		
Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile 915 920 925		
Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr 930 935 940		
His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys 945 950 955 960		
Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala 965 970 975		
Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr 980 985 990		
Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp 995 1000 1005		
Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro 1010 1015 1020		
Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn 1025 1030 1035		
Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly 1040 1045 1050		
Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu 1055 1060 1065		
Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu 1070 1075 1080		
Val Glu Asp Ser Phe Leu 1085		

<210> SEQ ID NO 3
 <211> LENGTH: 6633
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395) .. (3664)

<400> SEQUENCE: 3

ttctccccgc cccccagttg ttgtcgaagt ctggggggtg ggactggacc ccctgattgc	60
gtaagagcaa aaagcgaagg cgcaatctgg aactgggag attcggagcg cagggagttt	120
gagagaaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta	180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa	240
aacgcgggtt ttgagcccat tactgttgga gctacagga gagaacagg aggagactgc	300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg	360
cggaataaca tcggaggaga agtttcccag agct atg ggg act tcc cat ccg gcg	415
Met Gly Thr Ser His Pro Ala	
1 5	
ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc	463
Phe Leu Val Leu Gly Cys Leu Leu Thr Gly Leu Ser Leu Ile Leu Cys	
10 15 20	

-continued

cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val 25 30 35	511
cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val 40 45 50 55	559
agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc Ser Trp Gln Tyr Pro Met Ser Glu Glu Glu Ser Ser Asp Val Glu Ile 60 65 70	607
aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val 75 80 85	655
agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn 90 95 100	703
cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile 105 110 115	751
tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp 120 125 130 135	799
tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg 140 145 150	847
aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val 155 160 165	895
gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr 170 175 180	943
gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln 185 190 195	991
acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp 200 205 210 215	1039
cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile 220 225 230	1087
gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg Val Val Thr Cys Ala Val Phe Asn Asn Glu Val Val Asp Leu Gln Trp 235 240 245	1135
act tac cct gga gaa gtg aaa ggc aaa ggc atc aca atg ctg gaa gaa Thr Tyr Pro Gly Glu Val Lys Gly Lys Gly Ile Thr Met Leu Glu Glu 250 255 260	1183
atc aaa gtc cca tcc atc aaa ttg gtg tac act ttg acg gtc ccc gag Ile Lys Val Pro Ser Ile Lys Leu Val Tyr Thr Leu Thr Val Pro Glu 265 270 275	1231
gcc acg gtg aaa gac agt gga gat tac gaa tgt gct gcc cgc cag gct Ala Thr Val Lys Asp Ser Gly Asp Tyr Glu Cys Ala Ala Arg Gln Ala 280 285 290 295	1279
acc agg gag gtc aaa gaa atg aag aaa gtc act att tct gtc cat gag Thr Arg Glu Val Lys Glu Met Lys Lys Val Thr Ile Ser Val His Glu 300 305 310	1327
aaa ggt ttc att gaa atc aaa ccc acc ttc agc cag ttg gaa gct gtc Lys Gly Phe Ile Glu Ile Lys Pro Thr Phe Ser Gln Leu Glu Ala Val 315 320 325	1375
aac ctg cat gaa gtc aaa cat ttt gtt gta gag gtg cgg gcc tac cca Asn Leu His Glu Val Lys His Phe Val Val Glu Val Arg Ala Tyr Pro 330 335 340	1423

-continued

cct ccc agg ata tcc tgg ctg aaa aac aat ctg act ctg att gaa aat	1471
Pro Pro Arg Ile Ser Trp Leu Lys Asn Asn Leu Thr Leu Ile Glu Asn	
345 350 355	
ctc act gag atc acc act gat gtg gaa aag att cag gaa ata agg tat	1519
Leu Thr Glu Ile Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg Tyr	
360 365 370 375	
cga agc aaa tta aag ctg atc cgt gct aag gaa gaa gac agt ggc cat	1567
Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu Glu Asp Ser Gly His	
380 385 390	
tat act att gta gct caa aat gaa gat gct gtg aag agc tat act ttt	1615
Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val Lys Ser Tyr Thr Phe	
395 400 405	
gaa ctg tta act caa gtt cct tca tcc att ctg gac ttg gtc gat gat	1663
Glu Leu Leu Thr Gln Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp	
410 415 420	
cac cat ggc tca act ggg gga cag acg gtg agg tgc aca gct gaa ggc	1711
His His Gly Ser Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly	
425 430 435	
acg ccg ctt cct gat att gag tgg atg ata tgc aaa gat att aag aaa	1759
Thr Pro Leu Pro Asp Ile Glu Trp Met Ile Cys Lys Asp Ile Lys Lys	
440 445 450 455	
tgt aat aat gaa act tcc tgg act att ttg gcc aac aat gtc tca aac	1807
Cys Asn Asn Glu Thr Ser Trp Thr Ile Leu Ala Asn Asn Val Ser Asn	
460 465 470	
atc atc acg gag atc cac tcc cga gac agg agt acc gtg gag ggc cgt	1855
Ile Ile Thr Glu Ile His Ser Arg Asp Arg Ser Thr Val Glu Gly Arg	
475 480 485	
gtg act ttc gcc aaa gtg gag gag acc atc gcc gtg cga tgc ctg gct	1903
Val Thr Phe Ala Lys Val Glu Glu Thr Ile Ala Val Arg Cys Leu Ala	
490 495 500	
aag aat ctc ctt gga gct gag aac cga gag ctg aag ctg gtg gct ccc	1951
Lys Asn Leu Leu Gly Ala Glu Asn Arg Glu Leu Lys Leu Val Ala Pro	
505 510 515	
acc ctg cgt tct gaa ctc acg gtg gct gct gca gtc ctg gtg ctg ttg	1999
Thr Leu Arg Ser Glu Leu Thr Val Ala Ala Val Leu Val Leu Leu	
520 525 530 535	
gtg att gtg atc atc tca ctt att gtc ctg gtt gtc att tgg aaa cag	2047
Val Ile Val Ile Ile Ser Leu Ile Val Leu Val Val Ile Trp Lys Gln	
540 545 550	
aaa ccg agg tat gaa att cgc tgg agg gtc att gaa tca atc agc ccg	2095
Lys Pro Arg Thr Glu Ile Arg Trp Arg Val Ile Glu Ser Ile Ser Pro	
555 560 565	
gat gga cat gaa tat att tat gtg gac ccg atg cag ctg cct tat gac	2143
Asp Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp	
570 575 580	
tca aga tgg gag ttt cca aga gat gga cta gtg ctt ggt cgg gtc ttg	2191
Ser Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu Gly Arg Val Leu	
585 590 595	
ggg tct gga gcg ttt ggg aag gtg gtt gaa gga aca gcc tat gga tta	2239
Gly Ser Gly Ala Phe Gly Lys Val Val Glu Gly Thr Ala Tyr Gly Leu	
600 605 610 615	
agc ccg tcc caa cct gtc atg aaa gtt gca gtg aag atg cta aaa ccc	2287
Ser Arg Ser Gln Pro Val Met Lys Val Ala Val Lys Met Leu Lys Pro	
620 625 630	
acg gcc aga tcc agt gaa aaa caa gct ctc atg tct gaa ctg aag ata	2335
Thr Ala Arg Ser Ser Glu Lys Gln Ala Leu Met Ser Glu Leu Lys Ile	
635 640 645	
atg act cac ctg ggg cca cat ttg aac att gta aac ttg ctg gga gcc	2383
Met Thr His Leu Gly Pro His Leu Asn Ile Val Asn Leu Leu Gly Ala	
650 655 660	

-continued

tgc acc aag tca ggc ccc att tac atc atc aca gag tat tgc ttc tat	2431
Cys Thr Lys Ser Gly Pro Ile Tyr Ile Ile Thr Glu Tyr Cys Phe Tyr	
665 670 675	
gga gat ttg gtc aac tat ttg cat aag aat agg gat agc ttc ctg agc	2479
Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser Phe Leu Ser	
680 685 690 695	
cac cac cca gag aag cca aag aaa gag ctg gat atc ttt gga ttg aac	2527
His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe Gly Leu Asn	
700 705 710	
cct gct gat gaa agc aca cgg agc tat gtt att tta tct ttt gaa aac	2575
Pro Ala Asp Glu Ser Thr Arg Ser Tyr Val Ile Leu Ser Phe Glu Asn	
715 720 725	
aat ggt gac tac atg gac atg aag cag gct gat act aca cag tat gtc	2623
Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln Tyr Val	
730 735 740	
ccc atg cta gaa agg aaa gag gtt tct aaa tat tcc gac atc cag aga	2671
Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile Gln Arg	
745 750 755	
tca ctc tat gat cgt cca gcc tca tat aag aag aaa tct atg tta gac	2719
Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met Leu Asp	
760 765 770 775	
tca gaa gtc aaa aac ctc ctt tca gat gat aac tca gaa ggc ctt act	2767
Ser Glu Val Lys Asn Leu Leu Ser Asp Asn Ser Glu Gly Leu Thr	
780 785 790	
tta ttg gat ttg ttg agc ttc acc tat caa gtt gcc cga gga atg gag	2815
Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu	
795 800 805	
ttt ttg gct tca aaa aat tgt gtc cac cgt gat ctg gct gct cgc aac	2863
Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn	
810 815 820	
gtc ctc ctg gca caa gga aaa att gtg aag atc tgt gac ttt ggc ctg	2911
Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu	
825 830 835	
gcc aga gtc atc atg cat gat tcg aac tat gtg tcg aaa ggc agt acc	2959
Ala Arg Val Ile Met His Asp Ser Asn Tyr Val Ser Lys Gly Ser Thr	
840 845 850 855	
ttt ctg ccc gtg aag tgg atg gct cct gag agc atc ttt gac aac ctc	3007
Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu	
860 865 870	
tac acc aca ctg agt gat gtc tgg tct tat ggc att ctg ctc tgg gag	3055
Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu	
875 880 885	
atc ttt tcc ctt ggt ggc acc cct tac ccc ggc atg atg gtg gat tct	3103
Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser	
890 895 900	
act ttc tac aat aag atc aag agt ggg tac cgg atg gcc aag cct gac	3151
Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp	
905 910 915	
cac gct acc agt gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt	3199
His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser	
920 925 930 935	
gag ccg gag aag aga ccc tcc ttt tac cac ctg agt gag att gtg gag	3247
Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu	
940 945 950	
aat ctg ctg cct gga caa tat aaa aag agt tat gaa aaa att cac ctg	3295
Asn Leu Leu Pro Gly Gln Tyr Lys Ser Tyr Glu Lys Ile His Leu	
955 960 965	
gac ttc ctg aag agt gac cat cct gct gtg gca cgc atg cgt gtg gac	3343
Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met Arg Val Asp	
970 975 980	

-continued

tca gac aat gca tac att ggt gtc acc tac aaa aac gag gaa gac aag Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys 985 990 995	3391
ctg aag gac tgg gag ggt ggt ctg gat gag cag aga ctg agc gct Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala 1000 1005 1010	3436
gac agt ggc tac atc att cct ctg cct gac att gac cct gtc cct Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val Pro 1015 1020 1025	3481
gag gag gag gac ctg ggc aag agg aac aga cac agc tcg cag acc Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln Thr 1030 1035 1040	3526
tct gaa gag agt gcc att gag acg ggt tcc agc agt tcc acc ttc Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr Phe 1045 1050 1055	3571
atc aag aga gag gac gag acc att gaa gac atc gac atg atg gac Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met Asp 1060 1065 1070	3616
gac atc ggc ata gac tct tca gac ctg gtg gaa gac agc ttc ctg Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe Leu 1075 1080 1085	3661
taa ctggcggatt cgaggggttc cttccaacttc tggggccacc tctggatccc	3714
gttcagaaaa ccacttttatt gcaatgcgga gggtgagagg aggacttggg tgatgtttaa	3774
agagaagttc ccagccaagg gcctcgggga gcgttctaaa tatgaatgaa tgggatattt	3834
tgaaatgaac tttgtcagtg ttgcctctcg caatgcctca gtagcatctc agtgggtgtgt	3894
gaagtttgga gatagatgga taagggaata ataggccaca gaaggtgaac tttgtgcttc	3954
aaggacattg gtgagagtcc aacagacaca atttatactg cgacagaact tcagcattgt	4014
aattatgtaa ataactctaa ccaaggctgt gtttagattg tattaactat cttctttgga	4074
cttctgaaga gaccactcaa tccatccatg tacttccctc ttgaaacctg atgtcagctg	4134
ctgttgaaact ttttaaaaga gtgcatgaaa aaccattttt gaaccttaaa aggtactggt	4194
actatagcat tttgctatct tttttagtgt taagagataa agaataataa ttaaccaacc	4254
ttgtttaata gattttgggtc atttagaagc ctgacaactc attttcatat tgtaacttat	4314
gtttataata ctactactgt tatcagtaat gctaaatgtg taataatgta acatgatctc	4374
cctccagaga aagcacaatt taaaacaatc cttactaagt aggtgatgag tttgacagtt	4434
tttgacattt atattaaata acatgtttct ctataaagta tggtaatagc tttagtgaat	4494
taaatttagt tgagcataga gaacaaagta aaagtagtgt tgtccaggaa gtcagaattt	4554
ttaactgtac tgaatagggt ccccaatcca tcgtattaaa aaacaattaa ctgccctctg	4614
aaataatggg attagaaaca aacaaaactc ttaagtccta aaagttctca atgtagaggc	4674
ataaacctgt gctgaacata acttctcatg tatattaccc aatggaaaat ataatgatca	4734
gcaaaaagac tggatttgca gaagtttttt tttttttctc tcatgcctga tgaagcttt	4794
ggcaacccca atatatgtat tttttgaatc tatgaacctg aaaaggggtc gaaggatgcc	4854
cagacatcag cctccttctt tcacccctta ccccaaagag aaagagtttg aaactcgaga	4914
ccataaagat attcttttagt ggaggtctgga tgtgcattag cctggatcct cagttctcaa	4974
atgtgtgtgg cagccaggat gactagatcc tgggtttcca tccttgagat tctgaagtat	5034
gaagtctgag ggaaccaga gtctgtatct ttctaaactc cctggctggt ctgatcggcc	5094
agttttcgga aacctgact taggtttcag gaagttgcc a tgggaaacaa ataatttgaa	5154
ctttggaaca ggggttgaat tcaaccacgc aggaagccta ctatttaaat ccttggtctc	5214

-continued

```

aggtttagtga catttaatgc catctagcta gcaattgcga ccttaattta actttccagt 5274
cttagctgag gctgagaaag ctaaagttag gttttgacag gttttccaaa agtaaagatg 5334
ctacttccca ctgtatgggg gagattgaac tttccccgtc tcccgctctc tgcctccac 5394
tccatacccc gccaaaggaaa ggcattgtaca aaaattatgc aattcagtgt tccaagtctc 5454
tgtgtaacca gctcagtgtt ttggtggaaa aaacatttta agttttactg ataatttgag 5514
gttagatggg aggatgaatt gtcacatcta tccacactgt caaacagggt ggtgtgggtt 5574
cattggcatt ctttgcaata ctgcttaatt gctgatacca tatgaatgaa acatgggctg 5634
tgattactgc aatcactgtg ctatcggcag atgatgcttt ggaagatgca gaagcaataa 5694
taaagtactt gactacctac tgggtgaatc tcaatgcaag ccccaacttt cttatccaac 5754
tttttcatag taagtgcgaa gactgagcca gattggccaa ttaaaaacga aaacctgact 5814
aggttctgta gagccaatta gacttgaatc acgtttgtgt ttctagaatc acagctcaag 5874
cattctgttt atcgctcact ctcccttgta cagccttatt ttgttgggtc ttgcatttt 5934
gatattgctg tgagccttgc atgacatcat gaggccggat gaaacttctc agtccagcag 5994
tttccagtcc taacaaatgc tcccacctga atttgtatat gactgcattt gtgggtgtgt 6054
gtgtgttttc agcaaattcc agatttgttt ccttttgccc tctgcaaag tctccagaag 6114
aaaaattgccc aatcttttct actttctatt tttatgatga caatcaaagc cggcctgaga 6174
aacactattt gtgacttttt aaacgattag tgatgtcctt aaaatgtggt ctgccaatct 6234
gtacaaaatg gtccatatttt tgtgaagagg gacataagat aaaatgatgt tatacatcaa 6294
tatgtatata tgtattttcta tatagacttg gagaatactg ccaaaacatt tatgacaagc 6354
tgtatcactg ccttcgttta tattttttta actgtgataa tccccacagg cacattaact 6414
gttgcacttt tgaatgtcca aaatttatat tttagaaata ataaaaagaa agatacttac 6474
atgttcccaa aacaatgggt tggatgaatg gtgagaaaaa ctaacttgat aggggtctacc 6534
aatacaaaat gtattacgaa tgcccctgtt catgtttttg ttttaaaacg tgtaaatgaa 6594
gatctttata tttcaataaa tgatatataa tttaaagtt 6633

```

<210> SEQ ID NO 4

<211> LENGTH: 1089

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1           5           10           15
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20          25          30
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35          40          45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50          55          60
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65          70          75          80
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85          90          95
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
100         105         110
Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
115         120         125

```

-continued

Val	Pro	Leu	Gly	Met	Thr	Asp	Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp
130						135					140				
Ser	Ala	Ile	Ile	Pro	Cys	Arg	Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr
145					150					155					160
Leu	His	Asn	Ser	Glu	Gly	Val	Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln
				165					170					175	
Gly	Phe	Asn	Gly	Thr	Phe	Thr	Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr
		180						185					190		
Val	Lys	Gly	Lys	Lys	Phe	Gln	Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu
	195						200					205			
Lys	Ala	Thr	Ser	Glu	Leu	Asp	Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val
	210					215					220				
Tyr	Lys	Ser	Gly	Glu	Thr	Ile	Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn
225					230					235					240
Glu	Val	Val	Asp	Leu	Gln	Trp	Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys
			245						250					255	
Gly	Ile	Thr	Met	Leu	Glu	Glu	Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val
			260					265					270		
Tyr	Thr	Leu	Thr	Val	Pro	Glu	Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr
		275					280					285			
Glu	Cys	Ala	Ala	Arg	Gln	Ala	Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys
	290					295					300				
Val	Thr	Ile	Ser	Val	His	Glu	Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr
305					310					315					320
Phe	Ser	Gln	Leu	Glu	Ala	Val	Asn	Leu	His	Glu	Val	Lys	His	Phe	Val
			325					330						335	
Val	Glu	Val	Arg	Ala	Tyr	Pro	Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn
			340					345					350		
Asn	Leu	Thr	Leu	Ile	Glu	Asn	Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu
		355					360					365			
Lys	Ile	Gln	Glu	Ile	Arg	Tyr	Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala
	370					375					380				
Lys	Glu	Glu	Asp	Ser	Gly	His	Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp
385					390					395					400
Ala	Val	Lys	Ser	Tyr	Thr	Phe	Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser
			405						410					415	
Ile	Leu	Asp	Leu	Val	Asp	Asp	His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr
		420					425						430		
Val	Arg	Cys	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met
		435					440					445			
Ile	Cys	Lys	Asp	Ile	Lys	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile
	450					455					460				
Leu	Ala	Asn	Asn	Val	Ser	Asn	Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp
465					470					475					480
Arg	Ser	Thr	Val	Glu	Gly	Arg	Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr
			485						490					495	
Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg
			500					505					510		
Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala
		515					520					525			
Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val
	530					535					540				
Leu	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg

-continued

545	550	555	560
Val Ile Glu Ser Ile Ser Pro Asp Gly His Glu Tyr Ile Tyr Val Asp	565	570	575
Pro Met Gln Leu Pro Tyr Asp Ser Arg Trp Glu Phe Pro Arg Asp Gly	580	585	590
Leu Val Leu Gly Arg Val Leu Gly Ser Gly Ala Phe Gly Lys Val Val	595	600	605
Glu Gly Thr Ala Tyr Gly Leu Ser Arg Ser Gln Pro Val Met Lys Val	610	615	620
Ala Val Lys Met Leu Lys Pro Thr Ala Arg Ser Ser Glu Lys Gln Ala	625	630	635
Leu Met Ser Glu Leu Lys Ile Met Thr His Leu Gly Pro His Leu Asn	645	650	655
Ile Val Asn Leu Leu Gly Ala Cys Thr Lys Ser Gly Pro Ile Tyr Ile	660	665	670
Ile Thr Glu Tyr Cys Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys	675	680	685
Asn Arg Asp Ser Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu	690	695	700
Leu Asp Ile Phe Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr	705	710	715
Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln	725	730	735
Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser	740	745	750
Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr	755	760	765
Lys Lys Lys Ser Met Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp	770	775	780
Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr	785	790	795
Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His	805	810	815
Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val	820	825	830
Lys Ile Cys Asp Phe Gly Leu Ala Arg Val Ile Met His Asp Ser Asn	835	840	845
Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro	850	855	860
Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser	865	870	875
Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr	885	890	895
Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly	900	905	910
Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile	915	920	925
Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr	930	935	940
His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys	945	950	955
Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala	965	970	975

Val	Ala	Arg	Met	Arg	Val	Asp	Ser	Asp	Asn	Ala	Tyr	Ile	Gly	Val	Thr		
980																985	990
Tyr	Lys	Asn	Glu	Glu	Asp	Lys	Leu	Lys	Asp	Trp	Glu	Gly	Gly	Leu	Asp		
995																1000	1005
Glu	Gln	Arg	Leu	Ser	Ala	Asp	Ser	Gly	Tyr	Ile	Ile	Pro	Leu	Pro			
1010																1015	1020
Asp	Ile	Asp	Pro	Val	Pro	Glu	Glu	Glu	Asp	Leu	Gly	Lys	Arg	Asn			
1025																1030	1035
Arg	His	Ser	Ser	Gln	Thr	Ser	Glu	Glu	Ser	Ala	Ile	Glu	Thr	Gly			
1040																1045	1050
Ser	Ser	Ser	Ser	Thr	Phe	Ile	Lys	Arg	Glu	Asp	Glu	Thr	Ile	Glu			
1055																1060	1065
Asp	Ile	Asp	Met	Met	Asp	Asp	Ile	Gly	Ile	Asp	Ser	Ser	Asp	Leu			
1070																1075	1080
Val	Glu	Asp	Ser	Phe	Leu												
1085																	
<210> SEQ ID NO 5																	
<211> LENGTH: 6621																	
<212> TYPE: DNA																	
<213> ORGANISM: Homo sapiens																	
<220> FEATURE:																	
<221> NAME/KEY: CDS																	
<222> LOCATION: (395)..(3652)																	
<400> SEQUENCE: 5																	
ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc cctgattgc 60																	
gtaagagcaa aaagcgaagg cgcaatctgg aactcgggag attcggagcg cagggagttt 120																	
gagagaaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180																	
tttacttaga gcaaatgatt agttttagaa ggatggacta taacattgaa tcaattacaa 240																	
aacgcggttt ttgagcccat tactgttgga gctacagggg gagaacagg aggagactgc 300																	
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360																	
cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg 415																	
Met Gly Thr Ser His Pro Ala 1 5																	
ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc 463																	
Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys 10 15 20																	
cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg 511																	
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val 25 30 35																	
cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg 559																	
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val 40 45 50 55																	
agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc 607																	
Ser Trp Gln Tyr Pro Met Ser Glu Glu Glu Ser Ser Asp Val Glu Ile 60 65 70																	
aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg 655																	
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val 75 80 85																	
agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac 703																	
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn 90 95 100																	
cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc 751																	
His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile 105 110 115																	
tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat 791																	

-continued

Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp	
120 125 130 135	
tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc	847
Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg	
140 145 150	
aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg	895
Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val	
155 160 165	
gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act	943
Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr	
170 175 180	
gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag	991
Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln	
185 190 195	
acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat	1039
Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp	
200 205 210 215	
cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att	1087
Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile	
220 225 230	
gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg	1135
Val Val Thr Cys Ala Val Phe Asn Asn Glu Val Val Asp Leu Gln Trp	
235 240 245	
act tac cct gga gaa gtg aaa ggc aaa ggc atc aca atg ctg gaa gaa	1183
Thr Tyr Pro Gly Glu Val Lys Gly Lys Gly Ile Thr Met Leu Glu Glu	
250 255 260	
atc aaa gtc cca tcc atc aaa ttg gtg tac act ttg acg gtc ccc gag	1231
Ile Lys Val Pro Ser Ile Lys Leu Val Tyr Thr Leu Thr Val Pro Glu	
265 270 275	
gcc acg gtg aaa gac agt gga gat tac gaa tgt gct gcc cgc cag gct	1279
Ala Thr Val Lys Asp Ser Gly Asp Tyr Glu Cys Ala Ala Arg Gln Ala	
280 285 290 295	
acc agg gag gtc aaa gaa atg aag aaa gtc act att tct gtc cat gag	1327
Thr Arg Glu Val Lys Glu Met Lys Lys Val Thr Ile Ser Val His Glu	
300 305 310	
aaa ggt ttc att gaa atc aaa ccc acc ttc agc cag ttg gaa gct gtc	1375
Lys Gly Phe Ile Glu Ile Lys Pro Thr Phe Ser Gln Leu Glu Ala Val	
315 320 325	
aac ctg cat gaa gtc aaa cat ttt gtt gta gag gtg cgg gcc tac cca	1423
Asn Leu His Glu Val Lys His Phe Val Val Glu Val Arg Ala Tyr Pro	
330 335 340	
cct ccc agg ata tcc tgg ctg aaa aac aat ctg act ctg att gaa aat	1471
Pro Pro Arg Ile Ser Trp Leu Lys Asn Asn Leu Thr Leu Ile Glu Asn	
345 350 355	
ctc act gag atc acc act gat gtg gaa aag att cag gaa ata agg tat	1519
Leu Thr Glu Ile Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg Tyr	
360 365 370 375	
cga agc aaa tta aag ctg atc cgt gct aag gaa gaa gac agt ggc cat	1567
Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu Glu Asp Ser Gly His	
380 385 390	
tat act att gta gct caa aat gaa gat gct gtg aag agc tat act ttt	1615
Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val Lys Ser Tyr Thr Phe	
395 400 405	
gaa ctg tta act caa gtt cct tca tcc att ctg gac ttg gtc gat gat	1663
Glu Leu Leu Thr Gln Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp	
410 415 420	
cac cat ggc tca act ggg gga cag acg gtg agg tgc aca gct gaa ggc	1711
His His Gly Ser Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly	
425 430 435	
acg ccg ctt cct gat att gag tgg atg ata tgc aaa gat att aag aaa	1759

-continued

Thr 440	Pro	Leu	Pro	Asp	Ile 445	Glu	Trp	Met	Ile	Cys 450	Lys	Asp	Ile	Lys	Lys 455	
tgt	aat	aat	gaa	act	tcc	tgg	act	att	ttg	gcc	aac	aat	gtc	tca	aac	1807
Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	Leu	Ala	Asn	Asn	Val	Ser	Asn	
			460					465					470			
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg	
			475					480					485			
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala	
			490					495				500				
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro	
			505					510				515				
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Ala	Val	Leu	Val	Leu	Leu	
					525					530					535	
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln	
					540					545				550		
aaa	ccg	agg	tat	gaa	att	cgc	tgg	agg	gtc	att	gaa	tca	atc	agc	ccg	2095
Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	Val	Ile	Glu	Ser	Ile	Ser	Pro	
			555					560					565			
gat	gga	cat	gaa	tat	att	tat	gtg	gac	ccg	atg	cag	ctg	cct	tat	gac	2143
Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	
			570					575					580			
tca	aga	tgg	gag	ttt	cca	aga	gat	gga	cta	gtg	ctt	ggg	cgg	gtc	ttg	2191
Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	
			585					590					595			
ggg	tct	gga	gcg	ttt	ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	gga	tta	2239
Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	
					605					610					615	
agc	cgg	tcc	caa	cct	gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	aaa	ccc	2287
Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	
					620					625					630	
acg	gcc	aga	tcc	agt	gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	aag	ata	2335
Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	
			635					640					645			
atg	act	cac	ctg	ggg	cca	cat	ttg	aac	att	gta	aac	ttg	ctg	gga	gcc	2383
Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	
			650					655					660			
tgc	acc	aag	tca	ggc	ccc	att	tac	atc	atc	aca	gag	tat	tgc	ttc	tat	2431
Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Gly	Tyr	Cys	Phe	Tyr	
			665					670					675			
gga	gat	ttg	gtc	aac	tat	ttg	cat	aag	aat	agg	gat	agc	ttc	ctg	agc	2479
Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	
					685					690					695	
cac	cac	cca	gag	aag	cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	ttg	aac	2527
His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	
					700					705					710	
cct	gct	gat	gaa	agc	aca	cgg	agc	tat	gtt	att	tta	tct	ttt	gaa	aac	2575
Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	
					715					720				725		
aat	ggg	gac	tac	atg	gac	atg	aag	cag	gct	gat	act	aca	cag	tat	gtc	2623
Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	
			730					735					740			
ccc	atg	cta	gaa	agg	aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	cag	aga	2671
Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	
			745					750					755			
tca	ctc	tat	gat	cgt	cca	gcc	tca	tat	aag	aag	aaa	tct	atg	tta	gac	2719

-continued

Ser Leu Tyr Asp Arg	Pro Ala Ser Tyr Lys	Lys Lys Ser Met Leu Asp	
760	765	770	775
tca gaa gtc aaa aac ctc ctt tca gat gat aac tca gaa ggc ctt act			2767
Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly Leu Thr			
	780	785	790
tta ttg gat ttg ttg agc ttc acc tat caa gtt gcc cga gga atg gag			2815
Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu			
	795	800	805
ttt ttg gct tca aaa aat tgt gtc cac cgt gat ctg gct gct cgc aac			2863
Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn			
	810	815	820
gtc ctc ctg gca caa gga aaa att gtg aag atc tgt gac ttt ggc ctg			2911
Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu			
	825	830	835
gcc aga gat tcg aac tat gtg tcg aaa ggc agt acc ttt ctg ccc gtg			2959
Ala Arg Asp Ser Asn Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val			
	840	845	850
aag tgg atg gct cct gag agc atc ttt gac aac ctc tac acc aca ctg			3007
Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu			
	860	865	870
agt gat gtc tgg tct tat ggc att ctg ctc tgg gag atc ttt tcc ctt			3055
Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu			
	875	880	885
ggg ggc acc cct tac ccc ggc atg atg gtg gat tct act ttc tac aat			3103
Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn			
	890	895	900
aag atc aag agt ggg tac cgg atg gcc aag cct gac cac gct acc agt			3151
Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser			
	905	910	915
gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt gag ccg gag aag			3199
Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys			
	920	925	930
aga ccc tcc ttt tac cac ctg agt gag att gtg gag aat ctg ctg cct			3247
Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro			
	940	945	950
gga caa tat aaa aag agt tat gaa aaa att cac ctg gac ttc ctg aag			3295
Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys			
	955	960	965
agt gac cat cct gct gtg gca cgc atg cgt gtg gac tca gac aat gca			3343
Ser Asp His Pro Ala Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala			
	970	975	980
tac att ggt gtc acc tac aaa aac gag gaa gac aag ctg aag gac tgg			3391
Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp			
	985	990	995
gag ggt ggt ctg gat gag cag aga ctg agc gct gac agt ggc tac			3436
Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr			
	1000	1005	1010
atc att cct ctg cct gac att gac cct gtc cct gag gag gag gac			3481
Ile Ile Pro Leu Pro Asp Ile Asp Pro Val Pro Glu Glu Glu Asp			
	1015	1020	1025
ctg ggc aag agg aac aga cac agc tcg cag acc tct gaa gag agt			3526
Leu Gly Lys Arg Asn Arg His Ser Ser Gln Thr Ser Glu Glu Ser			
	1030	1035	1040
gcc att gag acg ggt tcc agc agt tcc acc ttc atc aag aga gag			3571
Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu			
	1045	1050	1055
gac gag acc att gaa gac atc gac atg atg gac gac atc ggc ata			3616
Asp Glu Thr Ile Glu Asp Ile Asp Met Met Asp Asp Ile Gly Ile			
	1060	1065	1070
gac tct tca gac ctg gtg gaa gac agc ttc ctg taa ctggcggatt			3662

-continued

Asp	Ser	Ser	Asp	Leu	Val	Glu	Asp	Ser	Phe	Leu	
1075					1080					1085	
cgaggggttc	cttccacttc	tggggccacc	tctggatccc	gttcagaaaa	ccactttatt						3722
gcaatgcgga	ggttgagagg	aggacttggt	tgatgtttaa	agagaagttc	ccagccaagg						3782
gcctcgggga	gcgttctaaa	tatgaatgaa	tgggatattt	tgaatgaac	ttgtcagtg						3842
ttgcctctcg	caatgcctca	gtagcatctc	agtgggtgtg	gaagtttgga	gatagatgga						3902
taagggaata	ataggccaca	gaaggtgaac	tttgtgcttc	aaggacattg	gtgagagtcc						3962
aacagacaca	atttatactg	cgacagaact	tcagcattgt	aattatgtaa	ataactctaa						4022
ccaaggctgt	gtttagattg	tattaactat	cttctttgga	cttctgaaga	gaccactcaa						4082
tccatccatg	tacttccctc	ttgaaacctg	atgtcagctg	ctgttgaact	ttttaagaa						4142
gtgcatgaaa	aaccattttt	gaaccttaaa	aggtactggg	actatagcat	tttgcctatc						4202
tttttagtgt	taagagataa	agaataataa	ttaaccaacc	ttgtttaata	gatttgggtc						4262
atttagaagc	ctgacaactc	attttcatat	tgtaatctat	gtttataata	ctactactgt						4322
tatcagtaat	gctaaatgtg	taataatgta	acatgatttc	cctccagaga	aagcacaatt						4382
taaaacaatc	cttactaagt	aggtgatgag	tttgacagtt	tttgacattt	atattaaata						4442
acatgtttct	ctataaagta	tggtaatagc	tttagtgaat	taaatttagt	tgagcataga						4502
gaacaaagta	aaagttagtg	tgtccaggaa	gtcagaattt	ttaactgtac	tgaatagggt						4562
ccccaatcca	tcgtattaaa	aaacaattaa	ctgcctctcg	aaataatggg	attagaacaa						4622
aacaaaactc	ttaagtccta	aaagttctca	atgtagaggc	ataaacctgt	gctgaacata						4682
acttctcatg	tattattacc	aatggaaaat	ataatgatca	gcaaaaagac	tggatttgca						4742
gaagtttttt	ttttttttct	tcatgcctga	tgaaagcttt	ggcaacccca	atatatgtat						4802
tttttgaatc	tatgaacctg	aaaaggggtc	gaaggatgcc	cagacatcag	cctccttctt						4862
tcacccctta	ccccaagag	aaagagtttg	aaactcgaga	ccataaagat	attctttagt						4922
ggaggctgga	tgtgcattag	cctggatcct	cagttctcaa	atgtgtgtgg	cagccaggat						4982
gactagatcc	tgggtttcca	tccttgagat	tctgaagtat	gaagtctgag	ggaaccaga						5042
gtctgtat	ttctaaactc	cctggctgtt	ctgatcggcc	agttttcgga	aacactgact						5102
taggtttcag	gaagttgcc	tgggaaacaa	ataatttgaa	ctttggaaca	gggttggaat						5162
tcaaccacgc	aggaagccta	ctattttaat	ccttggtctc	aggttagtga	catttaatgc						5222
catctagcta	gcaattgcga	ccttaattta	actttccagt	cttagctgag	gctgagaaag						5282
ctaaagtttg	gttttgacag	gttttccaaa	agtaaagatg	ctacttccca	ctgtatgggg						5342
gagattgaac	tttccccgtc	tcccgtcttc	tgcctcccac	tccatacccc	gccaaggaaa						5402
ggcatgtaca	aaaattatgc	aattcagtg	tccaagtctc	tgtgtaacca	gctcagtggt						5462
ttggtggaaa	aaacatttta	agttttactg	ataatttgag	gttagatggg	aggatgaatt						5522
gtcacatcta	tccacactgt	caaacagggt	gggtgggggt	cattggcatt	ctttgcaata						5582
ctgcttaatt	gctgatacca	tatgaatgaa	acatgggctg	tgattactgc	aactactgtg						5642
ctatcggcag	atgatgcttt	ggaagatgca	gaagcaataa	taaagtactt	gactacctac						5702
tggtgtaatc	tcaatgcaag	ccccaaactt	cttatccaac	tttttcatag	taagtgcgaa						5762
gactgagcca	gattggccaa	ttaaaaaacga	aaacctgact	aggttctgta	gagccaatta						5822
gacttgaaat	acgtttgtgt	ttctagaatc	acagctcaag	cattctgttt	atcgctcact						5882
ctcccttgta	cagccttatt	ttgttggtgc	tttgcat	gatattgctg	tgagccttgc						5942
atgacatcat	gaggccggat	gaaacttctc	agtccagcag	tttccagtcc	taacaaatgc						6002

-continued

```

tcccacctga atttgatat gactgcattt gtgggtgtgt gtgtgttttc agcaaattcc 6062
agatttggtt ccttttggcc tcctgcaaag tctccagaag aaaatttgcc aatctttcct 6122
actttctatt tttatgatga caatcaaagc cggcctgaga aacactatct gtgacttttt 6182
aaacgattag tgatgtcctt aaaatgtggt ctgccaatct gtacaaaatg gtcctatttt 6242
tgtgaagagg gacataagat aaaatgatgt tatacatcaa tatgtatata tgtattttcta 6302
tatagacttg gagaatactg ccaaaacatt tatgacaagc tgtatcactg ccttcgttta 6362
tattttttta actgtgataa tccccacagg cacattaact gttgcacttt tgaatgtcca 6422
aaatttatat tttagaaata ataaaaagaa agatacttac atgttcccaa aacaatgggtg 6482
tggatgaatgt gtgagaaaaa ctaacttgat aggggtctacc aatacaaaat gtattacgaa 6542
tgcccctggt catgtttttg ttttaaaacg tgtaaatgaa gatctttata tttcaataaa 6602
tgatatataa tttaaagtt 6621

```

<210> SEQ ID NO 6

<211> LENGTH: 1085

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1           5           10           15
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20          25          30
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35          40          45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50          55          60
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65          70          75          80
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85          90          95
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
100         105         110
Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
115         120         125
Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
130         135         140
Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
145         150         155         160
Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
165         170         175
Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
180         185         190
Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
195         200         205
Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
210         215         220
Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
225         230         235         240
Glu Val Val Asp Leu Gln Trp Thr Tyr Pro Gly Glu Val Lys Gly Lys
245         250         255
Gly Ile Thr Met Leu Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val

```

-continued

260							265							270						
Tyr	Thr	Leu	Thr	Val	Pro	Glu	Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr					
		275					280					285								
Glu	Cys	Ala	Ala	Arg	Gln	Ala	Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys					
	290					295					300									
Val	Thr	Ile	Ser	Val	His	Glu	Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr					
305					310					315					320					
Phe	Ser	Gln	Leu	Glu	Ala	Val	Asn	Leu	His	Glu	Val	Lys	His	Phe	Val					
			325					330						335						
Val	Glu	Val	Arg	Ala	Tyr	Pro	Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn					
			340					345					350							
Asn	Leu	Thr	Leu	Ile	Glu	Asn	Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu					
	355						360					365								
Lys	Ile	Gln	Glu	Ile	Arg	Tyr	Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala					
	370					375					380									
Lys	Glu	Glu	Asp	Ser	Gly	His	Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp					
385					390					395					400					
Ala	Val	Lys	Ser	Tyr	Thr	Phe	Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser					
				405					410					415						
Ile	Leu	Asp	Leu	Val	Asp	Asp	His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr					
		420						425					430							
Val	Arg	Cys	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met					
		435					440					445								
Ile	Cys	Lys	Asp	Ile	Lys	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile					
	450					455					460									
Leu	Ala	Asn	Asn	Val	Ser	Asn	Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp					
465					470					475					480					
Arg	Ser	Thr	Val	Glu	Gly	Arg	Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr					
			485						490					495						
Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg					
		500						505					510							
Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala					
	515						520					525								
Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val					
	530					535					540									
Leu	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg					
545					550					555					560					
Val	Ile	Glu	Ser	Ile	Ser	Pro	Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp					
			565						570					575						
Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly					
		580						585					590							
Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val					
	595					600						605								
Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val					
	610					615					620									
Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala					
625					630					635					640					
Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn					
			645						650					655						
Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile					
		660						665					670							
Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys					
	675						680					685								

-continued

Asn Arg Asp Ser Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu	
690 695 700	
Leu Asp Ile Phe Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr	
705 710 715 720	
Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln	
725 730 735	
Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser	
740 745 750	
Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr	
755 760 765	
Lys Lys Lys Ser Met Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp	
770 775 780	
Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr	
785 790 795 800	
Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His	
805 810 815	
Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val	
820 825 830	
Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ser Asn Tyr Val Ser Lys	
835 840 845	
Gly Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe	
850 855 860	
Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu	
865 870 875 880	
Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met	
885 890 895	
Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala	
900 905 910	
Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys	
915 920 925	
Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu	
930 935 940	
Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys	
945 950 955 960	
Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met	
965 970 975	
Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu	
980 985 990	
Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu	
995 1000 1005	
Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro	
1010 1015 1020	
Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser	
1025 1030 1035	
Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser	
1040 1045 1050	
Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met	
1055 1060 1065	
Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser	
1070 1075 1080	
Phe Leu	
1085	

-continued

```

<211> LENGTH: 6624
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (395) .. (3655)

<400> SEQUENCE: 7

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc      60
gtaagagcaa aaagcgaagg cgcaatctgg aactgggag attcggagcg cagggagttt      120
gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta      180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa      240
aacgcggttt ttgagcccat tactgttgga gctacagga gagaaacagg aggagactgc      300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg      360
cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg      415
                               Met Gly Thr Ser His Pro Ala
                               1             5

ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc      463
Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys
    10             15             20

cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg      511
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val
    25             30             35

cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg      559
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val
    40             45             50             55

agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc      607
Ser Trp Gln Tyr Pro Met Ser Glu Glu Glu Ser Ser Asp Val Glu Ile
    60             65             70

aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg      655
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val
    75             80             85

agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac      703
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn
    90             95             100

cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc      751
His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile
    105            110            115

tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat      799
Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp
    120            125            130            135

tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc      847
Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg
    140            145            150

aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg      895
Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val
    155            160            165

gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act      943
Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr
    170            175            180

gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag      991
Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln
    185            190            195

acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat      1039
Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp
    200            205            210            215

cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att      1087
Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile
    220            225            230

```

-continued

gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg	1135
Val Val Thr Cys Ala Val Phe Asn Asn Glu Val Val Asp Leu Gln Trp	
235 240 245	
act tac cct gga gaa gtg aaa ggc aaa ggc atc aca atg ctg gaa gaa	1183
Thr Tyr Pro Gly Glu Val Lys Gly Lys Gly Ile Thr Met Leu Glu Glu	
250 255 260	
atc aaa gtc cca tcc atc aaa ttg gtg tac act ttg acg gtc ccc gag	1231
Ile Lys Val Pro Ser Ile Lys Leu Val Tyr Thr Leu Thr Val Pro Glu	
265 270 275	
gcc acg gtg aaa gac agt gga gat tac gaa tgt gct gcc cgc cag gct	1279
Ala Thr Val Lys Asp Ser Gly Asp Tyr Glu Cys Ala Ala Arg Gln Ala	
280 285 290 295	
acc agg gag gtc aaa gaa atg aag aaa gtc act att tct gtc cat gag	1327
Thr Arg Glu Val Lys Glu Met Lys Lys Val Thr Ile Ser Val His Glu	
300 305 310	
aaa ggt ttc att gaa atc aaa ccc acc ttc agc cag ttg gaa gct gtc	1375
Lys Gly Phe Ile Glu Ile Lys Pro Thr Phe Ser Gln Leu Glu Ala Val	
315 320 325	
aac ctg cat gaa gtc aaa cat ttt gtt gta gag gtg cgg gcc tac cca	1423
Asn Leu His Glu Val Lys His Phe Val Val Glu Val Arg Ala Tyr Pro	
330 335 340	
cct ccc agg ata tcc tgg ctg aaa aac aat ctg act ctg att gaa aat	1471
Pro Pro Arg Ile Ser Trp Leu Lys Asn Asn Leu Thr Leu Ile Glu Asn	
345 350 355	
ctc act gag atc acc act gat gtg gaa aag att cag gaa ata agg tat	1519
Leu Thr Glu Ile Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg Tyr	
360 365 370 375	
cga agc aaa tta aag ctg atc cgt gct aag gaa gaa gac agt ggc cat	1567
Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu Glu Asp Ser Gly His	
380 385 390	
tat act att gta gct caa aat gaa gat gct gtg aag agc tat act ttt	1615
Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val Lys Ser Tyr Thr Phe	
395 400 405	
gaa ctg tta act caa gtt cct tca tcc att ctg gac ttg gtc gat gat	1663
Glu Leu Leu Thr Gln Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp	
410 415 420	
cac cat ggc tca act ggg gga cag acg gtg agg tgc aca gct gaa ggc	1711
His His Gly Ser Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly	
425 430 435	
acg ccg ctt cct gat att gag tgg atg ata tgc aaa gat att aag aaa	1759
Thr Pro Leu Pro Asp Ile Glu Trp Met Ile Cys Lys Asp Ile Lys Lys	
440 445 450 455	
tgt aat aat gaa act tcc tgg act att ttg gcc aac aat gtc tca aac	1807
Cys Asn Asn Glu Thr Ser Trp Thr Ile Leu Ala Asn Asn Val Ser Asn	
460 465 470	
atc atc acg gag atc cac tcc cga gac agg agt acc gtg gag ggc cgt	1855
Ile Ile Thr Glu Ile His Ser Arg Asp Arg Ser Thr Val Glu Gly Arg	
475 480 485	
gtg act ttc gcc aaa gtg gag gag acc atc gcc gtg cga tgc ctg gct	1903
Val Thr Phe Ala Lys Val Glu Glu Thr Ile Ala Val Arg Cys Leu Ala	
490 495 500	
aag aat ctc ctt gga gct gag aac cga gag ctg aag ctg gtg gct ccc	1951
Lys Asn Leu Leu Gly Ala Glu Asn Arg Glu Leu Lys Leu Val Ala Pro	
505 510 515	
acc ctg cgt tct gaa ctc acg gtg gct gct gca gtc ctg gtg ctg ttg	1999
Thr Leu Arg Ser Glu Leu Thr Val Ala Ala Val Leu Val Leu Leu	
520 525 530 535	
gtg att gtg atc atc tca ctt att gtc ctg gtt gtc att tgg aaa cag	2047
Val Ile Val Ile Ile Ser Leu Ile Val Leu Val Val Ile Trp Lys Gln	
540 545 550	

-continued

aaa ccg agg tat gaa att cgc tgg agg gtc att gaa tca atc agc ccg Lys Pro Arg Tyr Glu Ile Arg Trp Arg Val Ile Glu Ser Ile Ser Pro 555 560 565	2095
gat gga cat gaa tat att tat gtg gac ccg atg cag ctg cct tat gac Asp Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp 570 575 580	2143
tca aga tgg gag ttt cca aga gat gga cta gtg ctt ggt ccg gtc ttg Ser Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu Gly Arg Val Leu 585 590 595	2191
ggg tct gga gcg ttt ggg aag gtg gtt gaa gga aca gcc tat gga tta Gly Ser Gly Ala Phe Gly Lys Val Val Glu Gly Thr Ala Tyr Gly Leu 600 605 610 615	2239
agc ccg tcc caa cct gtc atg aaa gtt gca gtg aag atg cta aaa ccc Ser Arg Ser Gln Pro Val Met Lys Val Ala Val Lys Met Leu Lys Pro 620 625 630	2287
acg gcc aga tcc agt gaa aaa caa gct ctc atg tct gaa ctg aag ata Thr Ala Arg Ser Ser Glu Lys Gln Ala Leu Met Ser Glu Leu Lys Ile 635 640 645	2335
atg act cac ctg ggg cca cat ttg aac att gta aac ttg ctg gga gcc Met Thr His Leu Gly Pro His Leu Asn Ile Val Asn Leu Leu Gly Ala 650 655 660	2383
tgc acc aag tca ggc ccc att tac atc atc aca gag tat tgc ttc tat Cys Thr Lys Ser Gly Pro Ile Tyr Ile Ile Thr Glu Tyr Cys Phe Tyr 665 670 675	2431
gga gat ttg gtc aac tat ttg cat aag aat agg gat agc ttc ctg agc Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser Phe Leu Ser 680 685 690 695	2479
cac cac cca gag aag cca aag aaa gag ctg gat atc ttt gga ttg aac His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe Gly Leu Asn 700 705 710	2527
cct gct gat gaa agc aca ccg agc tat gtt att tta tct ttt gaa aac Pro Ala Asp Glu Ser Thr Arg Ser Tyr Val Ile Leu Ser Phe Glu Asn 715 720 725	2575
aat ggt gac tac atg gac atg aag cag gct gat act aca cag tat gtc Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln Tyr Val 730 735 740	2623
ccc atg cta gaa agg aaa gag gtt tct aaa tat tcc gac atc cag aga Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile Gln Arg 745 750 755	2671
tca ctc tat gat cgt cca gcc tca tat aag aag aaa tct atg tta gac Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met Leu Asp 760 765 770 775	2719
tca gaa gtc aaa aac ctc ctt tca gat gat aac tca gaa ggc ctt act Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly Leu Thr 780 785 790	2767
tta ttg gat ttg ttg agc ttc acc tat caa gtt gcc cga gga atg gag Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu 795 800 805	2815
ttt ttg gct tca aaa aat tgt gtc cac cgt gat ctg gct gct cgc aac Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn 810 815 820	2863
gtc ctc ctg gca caa gga aaa att gtg aag atc tgt gac ttt ggc ctg Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu 825 830 835	2911
gcc aga gac atc atg ccc tat gtg tcg aaa ggc agt acc ttt ctg ccc Ala Arg Asp Ile Met Pro Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro 840 845 850 855	2959
gtg aag tgg atg gct cct gag agc atc ttt gac aac ctc tac acc aca Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr 860 865 870	3007

-continued

ctg agt gat gtc tgg tct tat ggc att ctg ctc tgg gag atc ttt tcc Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser 875 880 885	3055
ctt ggt ggc acc cct tac ccc ggc atg atg gtg gat tct act ttc tac Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser Thr Phe Tyr 890 895 900	3103
aat aag atc aag agt ggg tac cgg atg gcc aag cct gac cac gct acc Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp His Ala Thr 905 910 915	3151
agt gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt gag ccg gag Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser Glu Pro Glu 920 925 930 935	3199
aag aga ccc tcc ttt tac cac ctg agt gag att gtg gag aat ctg ctg Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu Asn Leu Leu 940 945 950	3247
cct gga caa tat aaa aag agt tat gaa aaa att cac ctg gac ttc ctg Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu Asp Phe Leu 955 960 965	3295
aag agt gac cat cct gct gtg gca cgc atg cgt gtg gac tca gac aat Lys Ser Asp His Pro Ala Val Ala Arg Met Arg Val Asp Ser Asp Asn 970 975 980	3343
gca tac att ggt gtc acc tac aaa aac gag gaa gac aag ctg aag gac Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp 985 990 995	3391
tgg gag ggt ggt ctg gat gag cag aga ctg agc gct gac agt ggc Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala Asp Ser Gly 1000 1005 1010	3436
tac atc att cct ctg cct gac att gac cct gtc cct gag gag gag Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val Pro Glu Glu Glu 1015 1020 1025	3481
gac ctg ggc aag agg aac aga cac agc tcg cag acc tct gaa gag Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln Thr Ser Glu Glu 1030 1035 1040	3526
agt gcc att gag acg ggt tcc agc agt tcc acc ttc atc aag aga Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr Phe Ile Lys Arg 1045 1050 1055	3571
gag gac gag acc att gaa gac atc gac atg atg gac gac atc ggc Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met Asp Asp Ile Gly 1060 1065 1070	3616
ata gac tct tca gac ctg gtg gaa gac agc ttc ctg taa ctggcggatt Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe Leu 1075 1080 1085	3665
cgaggggttc ctccacttc tggggccacc tctggatccc gttcagaaaa ccactttatt	3725
gcaatgcgga ggttgagagg aggacttggt tgatgtttta agagaagtgc ccagccaagg	3785
gcctcgggga gcgttctaaa tatgaatgaa tgggatattt tgaatgaac tttgtcagt	3845
ttgcctctcg caatgcctca gtagcatctc agtgggtgtg gaagtgttga gatagatgga	3905
taagggaata ataggccaca gaaggtgaac tttgtgcttc aaggacattg gtgagagtcc	3965
aacagacaca atttatactg cgacagaact tcagcattgt aattatgtaa ataactctaa	4025
ccaaggctgt gtttagattg tattaactat cttcttttga cttctgaaga gaccactcaa	4085
tccatccatg tacttccctc ttgaaacctg atgtcagctg ctgttgaact ttttaaagaa	4145
gtgcatgaaa aaccattttt gaaccttaaa aggtactggg actatagcat tttgctatct	4205
tttttagtgt taagagataa agaataataa ttaaccaacc ttgtttaata gatttgggtc	4265
attagaagc ctgacaactc attttcatat tgtaacttat gtttataata ctactactgt	4325
tatcagtaat gctaaatgtg taataatgta acatgatttc cctccagaga aagcacaatt	4385

-continued

taaaacaatc	cttactaagt	aggatgatgag	tttgacagtt	tttgacattt	atattaaata	4445
acatgtttct	ctataaagta	tggtaatagc	tttagtgaat	taaatttagt	tgagcataga	4505
gaacaaagta	aaagtagtgt	tgccaggaa	gtcagaattt	ttaactgtac	tgaatagggt	4565
ccccaatcca	tcgtattaaa	aaacaattaa	ctgccctctg	aaataatggg	attagaaaca	4625
aacaaaactc	ttaagtccta	aaagttctca	atgtagaggc	ataaacctgt	gctgaacata	4685
actttctcatg	tatattaccc	aatggaaaat	ataatgatca	gcaaaaagac	tggatttgca	4745
gaagtttttt	ttttttttct	tcatgcttga	tgaaagcttt	ggcaacccca	atatatgtat	4805
tttttgaatc	tatgaacctg	aaaaggggtca	gaaggatgcc	cagacatcag	cctccttctt	4865
tcacccttta	ccccaaagag	aaagagtttg	aaactcgaga	ccataaagat	attcttttagt	4925
ggaggctgga	tgtgcattag	cctggatcct	cagttctcaa	atgtgtgtgg	cagccaggat	4985
gactagatcc	tgggtttcca	tccttgagat	tctgaagtat	gaagtctgag	ggaaaccaga	5045
gtctgtattt	ttctaaactc	cctggctgtt	ctgatcggcc	agttttcgga	aacactgact	5105
taggtttcag	gaagttgcca	tgggaacaa	ataatttgaa	ctttggaaca	gggttggaat	5165
tcaaccacgc	aggaagccta	ctattttaat	cctggcttc	aggtagtga	catttaatgc	5225
catctagcta	gcaattgcga	ccttaattta	actttccagt	cttagctgag	gctgagaaag	5285
ctaaagtttg	gttttgacag	gttttccaaa	agtaaagatg	ctacttccca	ctgtatgggg	5345
gagattgaac	tttccccctg	tcccgtcttc	tgcctccac	tccatacccc	gccaaaggaaa	5405
ggcatgtaca	aaaattatgc	aattcagtgt	tccaagtctc	tgtgtaacca	gctcagtggt	5465
ttggtggaaa	aaacatttta	agttttactg	ataatttgag	gttagatggg	aggatgaatt	5525
gtcacatcta	tccacactgt	caaacaggtt	gggtgtgggt	cattggcatt	ctttgcaata	5585
ctgcttaatt	gctgatacca	tatgaatgaa	acatgggctg	tgattactgc	aatcactgtg	5645
ctatcggcag	atgatgcttt	ggaagatgca	gaagcaataa	taaagtactt	gactacctac	5705
tgggtgaatc	tcaatgcaag	ccccaaactt	cttatccaac	tttttcatag	taagtgcgaa	5765
gactgagcca	gattggccaa	ttaaaaacga	aaacctgact	aggttctgta	gagccaatta	5825
gacttgaaat	acgttttgtg	ttctagaatc	acagctcaag	cattctgttt	atcgtctact	5885
ctcccttgta	cagccttatt	ttgttggtgc	tttgcathtt	gatattgctg	tgagccttgc	5945
atgacatcat	gaggccggat	gaaactttctc	agtcacagcag	tttccagtcc	taacaaatgc	6005
tcccacctga	atttgtatat	gactgcattt	gtgggtgtgt	gtgtgttttc	agcaaatccc	6065
agatttggtt	ccttttggtc	tcctgcaaag	tctccagaag	aaaatttgcc	aatctttcct	6125
actttctatt	tttatgatga	caatcaaaagc	cggcctgaga	aacactattt	gtgacttttt	6185
aaacgattag	tgatgcctt	aaaatgtggt	ctgccaatct	gtacaaaatg	gtcctathtt	6245
tgtgaagagg	gacataagat	aaaatgatgt	tatacatcaa	tatgtatata	tgtatttcta	6305
tatagacttg	gagaatactg	ccaaaacatt	tatgacaagc	tgtatcactg	ccttcgttta	6365
tattttttta	actgtgataa	tccccacagg	cacattaact	gttgactttt	tgaatgtcca	6425
aaatttatat	tttagaaata	ataaaaagaa	agatacttac	atgttcccaa	aacaatgggtg	6485
tggatgaatg	gtgagaaaaa	ctaacttgat	agggctctacc	aatacaaaat	gtattacgaa	6545
tgccctgtgt	catgtttttg	ttttaaaacg	tgtaaatgaa	gatctttata	tttcaataaa	6605
tgatatataa	tttaaagtt					6624

-continued

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
 1              5              10              15

Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
      20              25              30

Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
 35              40              45

Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
 50              55              60

Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
 65              70              75              80

Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
      85              90              95

Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
 100              105              110

Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
 115              120              125

Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
 130              135              140

Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
 145              150              155              160

Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
      165              170              175

Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
 180              185              190

Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
 195              200              205

Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
 210              215              220

Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
 225              230              235              240

Glu Val Val Asp Leu Gln Trp Thr Tyr Pro Gly Glu Val Lys Gly Lys
      245              250              255

Gly Ile Thr Met Leu Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val
 260              265              270

Tyr Thr Leu Thr Val Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr
 275              280              285

Glu Cys Ala Ala Arg Gln Ala Thr Arg Glu Val Lys Glu Met Lys Lys
 290              295              300

Val Thr Ile Ser Val His Glu Lys Gly Phe Ile Glu Ile Lys Pro Thr
 305              310              315              320

Phe Ser Gln Leu Glu Ala Val Asn Leu His Glu Val Lys His Phe Val
      325              330              335

Val Glu Val Arg Ala Tyr Pro Pro Pro Arg Ile Ser Trp Leu Lys Asn
 340              345              350

Asn Leu Thr Leu Ile Glu Asn Leu Thr Glu Ile Thr Thr Asp Val Glu
 355              360              365

Lys Ile Gln Glu Ile Arg Tyr Arg Ser Lys Leu Lys Leu Ile Arg Ala
 370              375              380

Lys Glu Glu Asp Ser Gly His Tyr Thr Ile Val Ala Gln Asn Glu Asp
 385              390              395              400

```

-continued

Ala Val Lys Ser Tyr Thr Phe Glu Leu Leu Thr Gln Val Pro Ser Ser	405	410	415
Ile Leu Asp Leu Val Asp Asp His His Gly Ser Thr Gly Gly Gln Thr	420	425	430
Val Arg Cys Thr Ala Glu Gly Thr Pro Leu Pro Asp Ile Glu Trp Met	435	440	445
Ile Cys Lys Asp Ile Lys Lys Cys Asn Asn Glu Thr Ser Trp Thr Ile	450	455	460
Leu Ala Asn Asn Val Ser Asn Ile Ile Thr Glu Ile His Ser Arg Asp	465	470	475
Arg Ser Thr Val Glu Gly Arg Val Thr Phe Ala Lys Val Glu Glu Thr	485	490	495
Ile Ala Val Arg Cys Leu Ala Lys Asn Leu Leu Gly Ala Glu Asn Arg	500	505	510
Glu Leu Lys Leu Val Ala Pro Thr Leu Arg Ser Glu Leu Thr Val Ala	515	520	525
Ala Ala Val Leu Val Leu Leu Val Ile Val Ile Ile Ser Leu Ile Val	530	535	540
Leu Val Val Ile Trp Lys Gln Lys Pro Arg Tyr Glu Ile Arg Trp Arg	545	550	555
Val Ile Glu Ser Ile Ser Pro Asp Gly His Glu Tyr Ile Tyr Val Asp	565	570	575
Pro Met Gln Leu Pro Tyr Asp Ser Arg Trp Glu Phe Pro Arg Asp Gly	580	585	590
Leu Val Leu Gly Arg Val Leu Gly Ser Gly Ala Phe Gly Lys Val Val	595	600	605
Glu Gly Thr Ala Tyr Gly Leu Ser Arg Ser Gln Pro Val Met Lys Val	610	615	620
Ala Val Lys Met Leu Lys Pro Thr Ala Arg Ser Ser Glu Lys Gln Ala	625	630	635
Leu Met Ser Glu Leu Lys Ile Met Thr His Leu Gly Pro His Leu Asn	645	650	655
Ile Val Asn Leu Leu Gly Ala Cys Thr Lys Ser Gly Pro Ile Tyr Ile	660	665	670
Ile Thr Glu Tyr Cys Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys	675	680	685
Asn Arg Asp Ser Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu	690	695	700
Leu Asp Ile Phe Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr	705	710	715
Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln	725	730	735
Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser	740	745	750
Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr	755	760	765
Lys Lys Lys Ser Met Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp	770	775	780
Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr	785	790	795
Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His	805	810	815
Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val	820	825	830

-continued

Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met Pro Tyr Val Ser
 835 840 845
 Lys Gly Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile
 850 855 860
 Phe Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile
 865 870 875 880
 Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met
 885 890 895
 Met Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met
 900 905 910
 Ala Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys
 915 920 925
 Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser
 930 935 940
 Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu
 945 950 955 960
 Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg
 965 970 975
 Met Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn
 980 985 990
 Glu Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg
 995 1000 1005
 Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp
 1010 1015 1020
 Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser
 1025 1030 1035
 Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser
 1040 1045 1050
 Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp
 1055 1060 1065
 Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp
 1070 1075 1080
 Ser Phe Leu
 1085

<210> SEQ ID NO 9
 <211> LENGTH: 6639
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395)..(3667)

<400> SEQUENCE: 9

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccttgattgc 60
 gtaagagcaa aaagcgaagg cgcaatctgg aactggggag attcggagcg cagggagttt 120
 gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180
 tttacttaga gcaaagtatt agtttttagaa ggatgggacta taacattgaa tcaattacaa 240
 aacgcggttt ttgagcccat tactgttgga gctacagggg gagaaacagg aggagactgc 300
 aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360
 cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg 415
 Met Gly Thr Ser His Pro Ala
 1 5
 ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc 463

-continued

Phe	Leu	Val	Leu	Gly	Cys	Leu	Leu	Thr	Gly	Leu	Ser	Leu	Ile	Leu	Cys	
		10					15					20				
cag	ctt	tca	tta	ccc	tct	atc	ctt	cca	aat	gaa	aat	gaa	aag	gtt	gtg	511
Gln	Leu	Ser	Leu	Pro	Ser	Ile	Leu	Pro	Asn	Glu	Asn	Glu	Lys	Val	Val	
	25					30				35						
cag	ctg	aat	tca	tcc	ttt	tct	ctg	aga	tgc	ttt	ggg	gag	agt	gaa	gtg	559
Gln	Leu	Asn	Ser	Ser	Phe	Ser	Leu	Arg	Cys	Phe	Gly	Glu	Ser	Glu	Val	
40				45					50					55		
agc	tgg	cag	tac	ccc	atg	tct	gaa	gaa	gag	agc	tcc	gat	gtg	gaa	atc	607
Ser	Trp	Gln	Tyr	Met	Ser	Glu	Glu	Ser	Ser	Asp	Val	Glu	Ile			
			60					65				70				
aga	aat	gaa	gaa	aac	aac	agc	ggc	ctt	ttt	gtg	acg	gtc	ttg	gaa	gtg	655
Arg	Asn	Glu	Glu	Asn	Asn	Ser	Gly	Leu	Phe	Val	Thr	Val	Leu	Glu	Val	
		75					80					85				
agc	agt	gcc	tcg	gcg	gcc	cac	aca	ggg	ttg	tac	act	tgc	tat	tac	aac	703
Ser	Ser	Ala	Ser	Ala	Ala	His	Thr	Gly	Leu	Tyr	Thr	Cys	Tyr	Tyr	Asn	
	90					95					100					
cac	act	cag	aca	gaa	gag	aat	gag	ctt	gaa	ggc	agg	cac	att	tac	atc	751
His	Thr	Gln	Thr	Glu	Glu	Asn	Glu	Leu	Glu	Gly	Arg	His	Ile	Tyr	Ile	
	105					110				115						
tat	gtg	cca	gac	cca	gat	gta	gcc	ttt	gta	cct	cta	gga	atg	acg	gat	799
Tyr	Val	Pro	Asp	Pro	Asp	Val	Ala	Phe	Val	Pro	Leu	Gly	Met	Thr	Asp	
120				125					130					135		
tat	tta	gtc	atc	gtg	gag	gat	gat	gat	tct	gcc	att	ata	cct	tgt	cgc	847
Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp	Ser	Ala	Ile	Ile	Pro	Cys	Arg	
			140					145					150			
aca	act	gat	ccc	gag	act	cct	gta	acc	tta	cac	aac	agt	gag	ggg	gtg	895
Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr	Leu	His	Asn	Ser	Glu	Gly	Val	
		155					160					165				
gta	cct	gcc	tcc	tac	gac	agc	aga	cag	ggc	ttt	aat	ggg	acc	ttc	act	943
Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln	Gly	Phe	Asn	Gly	Thr	Phe	Thr	
	170					175						180				
gta	ggg	ccc	tat	atc	tgt	gag	gcc	acc	gtc	aaa	gga	aag	aag	ttc	cag	991
Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr	Val	Lys	Gly	Lys	Lys	Phe	Gln	
	185				190					195						
acc	atc	cca	ttt	aat	gtt	tat	gct	tta	aaa	gca	aca	tca	gag	ctg	gat	1039
Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu	Lys	Ala	Thr	Ser	Glu	Leu	Asp	
200				205					210					215		
cta	gaa	atg	gaa	gct	ctt	aaa	acc	gtg	tat	aag	tca	ggg	gaa	acg	att	1087
Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val	Tyr	Lys	Ser	Gly	Glu	Thr	Ile	
		220						225					230			
gtg	gtc	acc	tgt	gct	gtt	ttt	aac	aat	gag	gtg	gtt	gac	ctt	caa	tgg	1135
Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn	Glu	Val	Val	Asp	Leu	Gln	Trp	
		235					240					245				
act	tac	cct	gga	gaa	gtg	aaa	ggc	aaa	ggc	atc	aca	atg	ctg	gaa	gaa	1183
Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys	Gly	Ile	Thr	Met	Leu	Glu	Glu	
		250				255					260					
atc	aaa	gtc	cca	tcc	atc	aaa	ttg	gtg	tac	act	ttg	acg	gtc	ccc	gag	1231
Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val	Tyr	Thr	Leu	Thr	Val	Pro	Glu	
	265				270					275						
gcc	acg	gtg	aaa	gac	agt	gga	gat	tac	gaa	tgt	gct	gcc	cgc	cag	gct	1279
Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr	Glu	Cys	Ala	Ala	Arg	Gln	Ala	
	280			285					290				295			
acc	agg	gag	gtc	aaa	gaa	atg	aag	aaa	gtc	act	att	tct	gtc	cat	gag	1327
Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys	Val	Thr	Ile	Ser	Val	His	Glu	
			300					305					310			
aaa	ggt	ttc	att	gaa	atc	aaa	ccc	acc	ttc	agc	cag	ttg	gaa	gct	gtc	1375
Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr	Phe	Ser	Gln	Leu	Glu	Ala	Val	
		315					320					325				
aac	ctg	cat	gaa	gtc	aaa	cat	ttt	gtt	gta	gag	gtg	cgg	gcc	tac	cca	1423

-continued

Asn	Leu	His	Glu	Val	Lys	His	Phe	Val	Val	Glu	Val	Arg	Ala	Tyr	Pro	
	330						335					340				
cct	ccc	agg	ata	tcc	tgg	ctg	aaa	aac	aat	ctg	act	ctg	att	gaa	aat	1471
Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn	Asn	Leu	Thr	Leu	Ile	Glu	Asn	
	345					350				355						
ctc	act	gag	atc	acc	act	gat	gtg	gaa	aag	att	cag	gaa	ata	agg	tat	1519
Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu	Lys	Ile	Gln	Glu	Ile	Arg	Tyr	
360					365					370					375	
cga	agc	aaa	tta	aag	ctg	atc	cgt	gct	aag	gaa	gaa	gac	agt	ggc	cat	1567
Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala	Lys	Glu	Glu	Asp	Ser	Gly	His	
			380						385					390		
tat	act	att	gta	gct	caa	aat	gaa	gat	gct	gtg	aag	agc	tat	act	ttt	1615
Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp	Ala	Val	Lys	Ser	Tyr	Thr	Phe	
			395					400						405		
gaa	ctg	tta	act	caa	ggt	cct	tca	tcc	att	ctg	gac	ttg	gtc	gat	gat	1663
Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser	Ile	Leu	Asp	Leu	Val	Asp	Asp	
	410					415						420				
cac	cat	ggc	tca	act	ggg	gga	cag	acg	gtg	agg	tgc	aca	gct	gaa	ggc	1711
His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr	Val	Arg	Cys	Thr	Ala	Glu	Gly	
	425					430					435					
acg	ccg	ctt	cct	gat	att	gag	tgg	atg	ata	tgc	aaa	gat	att	aag	aaa	1759
Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met	Ile	Cys	Lys	Asp	Ile	Lys	Lys	
440					445					450					455	
tgt	aat	aat	gaa	act	tcc	tgg	act	att	ttg	gcc	aac	aat	gtc	tca	aac	1807
Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	Leu	Ala	Asn	Asn	Val	Ser	Asn	
			460						465					470		
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg	
			475					480						485		
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala	
		490						495				500				
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro	
	505					510					515					
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Ala	Val	Leu	Val	Leu	Leu	
520					525					530					535	
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln	
				540					545					550		
aaa	ccg	agg	tat	gaa	att	cgc	tgg	agg	gag	agg	gtc	att	gaa	tca	atc	2095
Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	Glu	Arg	Val	Ile	Glu	Ser	Ile	
			555					560						565		
agc	ccg	gat	gga	cat	gaa	tat	att	tat	gtg	gac	ccg	atg	cag	ctg	cct	2143
Ser	Pro	Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	
		570					575					580				
tat	gac	tca	aga	tgg	gag	ttt	cca	aga	gat	gga	cta	gtg	ctt	ggg	cgg	2191
Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	
	585					590					595					
gtc	ttg	ggg	tct	gga	gcg	ttt	ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	2239
Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	
600					605					610					615	
gga	tta	agc	cgg	tcc	caa	cct	gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	2287
Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	
				620					625					630		
aaa	ccc	acg	gcc	aga	tcc	agt	gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	2335
Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	
			635					640						645		
aag	ata	atg	act	cac	ctg	ggg	cca	cat	ttg	aac	att	gta	aac	ttg	ctg	2383

-continued

Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	
		650					655					660				
gga	gcc	tgc	acc	aag	tca	ggc	ccc	att	tac	atc	atc	aca	gag	tat	tgc	2431
Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	
		665					670				675					
ttc	tat	gga	gat	ttg	gtc	aac	tat	ttg	cat	aag	aat	agg	gat	agc	ttc	2479
Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	
		680					685				690				695	
ctg	agc	cac	cac	cca	gag	aag	cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	2527
Leu	Ser	His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	
				700						705				710		
ttg	aac	cct	gct	gat	gaa	agc	aca	cgg	agc	tat	gtt	att	tta	tct	ttt	2575
Leu	Asn	Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	
				715					720					725		
gaa	aac	aat	ggc	gac	tac	atg	gac	atg	aag	cag	gct	gat	act	aca	cag	2623
Glu	Asn	Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	
		730					735					740				
tat	gtc	ccc	atg	cta	gaa	agg	aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	2671
Tyr	Val	Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	
		745					750					755				
cag	aga	tca	ctc	tat	gat	cgt	cca	gcc	tca	tat	aag	aag	aaa	tct	atg	2719
Gln	Arg	Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr	Lys	Lys	Lys	Ser	Met	
		760					765			770					775	
tta	gac	tca	gaa	gtc	aaa	aac	ctc	ctt	tca	gat	gat	aac	tca	gaa	ggc	2767
Leu	Asp	Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp	Asp	Asn	Ser	Glu	Gly	
				780						785				790		
ctt	act	tta	ttg	gat	ttg	ttg	agc	ttc	acc	tat	caa	gtt	gcc	cga	gga	2815
Leu	Thr	Leu	Leu	Asp	Leu	Leu	Ser	Phe	Thr	Tyr	Gln	Val	Ala	Arg	Gly	
				795					800					805		
atg	gag	ttt	ttg	gct	tca	aaa	aat	tgt	gtc	cac	cgt	gat	ctg	gct	gct	2863
Met	Glu	Phe	Leu	Ala	Ser	Lys	Asn	Cys	Val	His	Arg	Asp	Leu	Ala	Ala	
		810					815					820				
cgc	aac	gtc	ctc	ctg	gca	caa	gga	aaa	att	gtg	aag	atc	tgt	gac	ttt	2911
Arg	Asn	Val	Leu	Leu	Ala	Gln	Gly	Lys	Ile	Val	Lys	Ile	Cys	Asp	Phe	
		825					830					835				
ggc	ctg	gcc	aga	gac	atc	atg	cat	gat	tcg	aac	tat	gtg	tcg	aaa	ggc	2959
Gly	Leu	Ala	Arg	Asp	Ile	Met	His	Asp	Ser	Asn	Tyr	Val	Ser	Lys	Gly	
		840					845				850				855	
agt	acc	ttt	ctg	ccc	gtg	aag	tgg	atg	gct	cct	gag	agc	atc	ttt	gac	3007
Ser	Thr	Phe	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asp	
				860						865				870		
aac	ctc	tac	acc	aca	ctg	agt	gat	gtc	tgg	tct	tat	ggc	att	ctg	ctc	3055
Asn	Leu	Tyr	Thr	Thr	Leu	Ser	Asp	Val	Trp	Ser	Tyr	Gly	Ile	Leu	Leu	
				875					880					885		
tgg	gag	atc	ttt	tcc	ctt	ggc	ggc	acc	cct	tac	ccc	ggc	atg	atg	gtg	3103
Trp	Glu	Ile	Phe	Ser	Leu	Gly	Gly	Thr	Pro	Tyr	Pro	Gly	Met	Met	Val	
		890							895				900			
gat	tct	act	ttc	tac	aat	aag	atc	aag	agt	ggg	tac	cgg	atg	gcc	aag	3151
Asp	Ser	Thr	Phe	Tyr	Asn	Lys	Ile	Lys	Ser	Gly	Tyr	Arg	Met	Ala	Lys	
		905					910					915				
cct	gac	cac	gct	acc	agt	gaa	gtc	tac	gag	atc	atg	gtg	aaa	tgc	tgg	3199
Pro	Asp	His	Ala	Thr	Ser	Glu	Val	Tyr	Glu	Ile	Met	Val	Lys	Cys	Trp	
				920			925				930				935	
aac	agt	gag	ccg	gag	aag	aga	ccc	tcc	ttt	tac	cac	ctg	agt	gag	att	3247
Asn	Ser	Glu	Pro	Glu	Lys	Arg	Pro	Ser	Phe	Tyr	His	Leu	Ser	Glu	Ile	
				940						945				950		
gtg	gag	aat	ctg	ctg	cct	gga	caa	tat	aaa	aag	agt	tat	gaa	aaa	att	3295
Val	Glu	Asn	Leu	Leu	Pro	Gly	Gln	Tyr	Lys	Lys	Ser	Tyr	Glu	Lys	Ile	
				955					960					965		
cac	ctg	gac	ttc	ctg	aag	agt	gac	cat	cct	gct	gtg	gca	cgc	atg	cgt	3343

His	Leu	Asp	Phe	Leu	Lys	Ser	Asp	His	Pro	Ala	Val	Ala	Arg	Met	Arg		
970		975									980						
gtg	gac	tca	gac	aat	gca	tac	att	ggg	gtc	acc	tac	aaa	aac	gag	gaa	3391	
Val	Asp	Ser	Asp	Asn	Ala	Tyr	Ile	Gly	Val	Thr	Tyr	Lys	Asn	Glu	Glu		
985		990									995						
gac	aag	ctg	aag	gac	tgg	gag	ggg	ggg	ctg	gat	gag	cag	aga	ctg		3436	
Asp	Lys	Leu	Lys	Asp	Trp	Glu	Gly	Gly	Leu	Asp	Glu	Gln	Arg	Leu			
1000		1005									1010						
agc	gct	gac	agt	ggc	tac	atc	att	cct	ctg	cct	gac	att	gac	cct		3481	
Ser	Ala	Asp	Ser	Gly	Tyr	Ile	Ile	Pro	Leu	Pro	Asp	Ile	Asp	Pro			
1015		1020									1025						
gtc	cct	gag	gag	gag	gac	ctg	ggc	aag	agg	aac	aga	cac	agc	tcg		3526	
Val	Pro	Glu	Glu	Glu	Asp	Leu	Gly	Lys	Arg	Asn	Arg	His	Ser	Ser			
1030		1035									1040						
cag	acc	tct	gaa	gag	agt	gcc	att	gag	acg	ggg	tcc	agc	agt	tcc		3571	
Gln	Thr	Ser	Glu	Glu	Ser	Ala	Ile	Glu	Thr	Gly	Ser	Ser	Ser	Ser			
1045		1050									1055						
acc	ttc	atc	aag	aga	gag	gac	gag	acc	att	gaa	gac	atc	gac	atg		3616	
Thr	Phe	Ile	Lys	Arg	Glu	Asp	Glu	Thr	Ile	Glu	Asp	Ile	Asp	Met			
1060		1065									1070						
atg	gac	gac	atc	ggc	ata	gac	tct	tca	gac	ctg	gtg	gaa	gac	agc		3661	
Met	Asp	Asp	Ile	Gly	Ile	Asp	Ser	Ser	Asp	Leu	Val	Glu	Asp	Ser			
1075		1080									1085						
ttc	ctg	taact	ggc	ggg	attc	gag	ggg	ttc	ctt	ccac	ttct	gggg	cc	acct	ctggat	3717	
Phe		Leu															
1090																	
cccgttcaga aaaccacttt attgcaatgc ggaggttgag agggaggactt ggttgatgtt 3777																	
taaagagaag ttcccagcca agggcctcgg ggagcgttct aaatatgaat gaatgggata 3837																	
ttttgaaatg aactttgtca gtgtgtgcctc tcgcaatgcc tcagtagcat ctcagtggtg 3897																	
tgtgaagttt ggagatagat ggataaggga ataataggcc acagaagggtg aactttgtgc 3957																	
ttcaaggaca ttggtgagag tccaacagac acaatttata ctgcgacaga acttcagcat 4017																	
tgtaattatg taaataaact taaccaaggc tgtgtttaga ttgtattaac tatcttcttt 4077																	
ggacttctga agagaccact caatccatcc atgtacttcc ctcttgaaac ctgatgtcag 4137																	
ctgctgttga actttttaaa gaagtgcacg aaaaaccatt tttgaacctt aaaaggtact 4197																	
gggtactatag catttttgcta tcttttttag tgttaagaga taaagaataa taattaacca 4257																	
accttgttta atagatttgg gtcattttag agcctgacaa ctcathttca tattgtaatc 4317																	
tatgtttata atactactac tgttatcagt aatgctaaat gtgtaataat gtaacatgat 4377																	
ttccctccag agaaagcaca atttaaaaca atccttacta agtaggtgat gagtttgaca 4437																	
gtttttgaca tttatattaa ataacatgtt tctctataaa gtatggtaat agcttttagtg 4497																	
aattaaattt agttgagcat agagaacaaa gtaaaagtag tgttgtccag gaagtcagaa 4557																	
tttttaactg tactgaatag gttccccaat ccacgttatt aaaaaacaat taactgccct 4617																	
ctgaaataat gggattagaa acaaaacaaa ctcttaagtc ctaaaagttc tcaatgtaga 4677																	
ggcataaaac tgtgctgaac ataactctc atgtatatta cccaatggaa aatataatga 4737																	
tcagcaaaaa gactggattt gcagaagttt tttttttttt tcttcatgcc tgatgaaagc 4797																	
tttggaacc ccaatatatg tattttttga atctatgaac ctgaaaaggg tcagaaggat 4857																	
gccagacat cagcctcctt ctttcacccc ttaccccaaa gagaaagagt ttgaaactcg 4917																	
agaccataaa gatattcttt agtggagggt ggatgtgcac tagcctggat cctcagttct 4977																	
caaagtgtgtg tggcagccag gatgactaga tctgtgggtt ccacctctga gattctgaag 5037																	
tatgaagtct gagggaaaacc agagtctgta tttttctaaa ctccctggct gttctgatcg 5097																	

-continued

```

gccagttttc ggaacactg acttaggttt caggaagttg ccatgggaaa caaataattt 5157
gaacttttga acagggttgg aattcaacca cgcaggaagc ctactattta aatccttggc 5217
ttcaggttag tgacatttaa tgccatctag ctagcaattg cgaccttaat ttaactttcc 5277
agtcttagct gaggtcgaga aagctaaagt ttggttttga caggttttcc aaaagtaaag 5337
atgctacttc ccactgtatg ggggagattg aactttcccc gtctcccgtc ttctgcctcc 5397
cactccatac ccgcgaagg aaaggcatgt acaaaaatta tgcaattcag tgtccaagt 5457
ctctgtgtaa ccagctcagt gttttggtgg aaaaaacatt ttaagtttta ctgataattt 5517
gaggttagat gggaggatga attgtcacat ctatccacac tgtcaaacag gttggtgtgg 5577
gttcattggc attctttgca atactgtcta attgctgata ccatatgaat gaaacatggg 5637
ctgtgattac tgcaatcact gtgctatcgg cagatgatgc tttggaagat gcagaagcaa 5697
taataaagta cttgactacc tactggtgta atctcaatgc aagcccaac tttcttatcc 5757
aactttttca tagtaagtgc gaagactgag ccagattggc caattaaaaa cgaaaacctg 5817
actaggttct gtagagccaa ttagacttga aatacgtttg tgtttctaga atcacagctc 5877
aagcattctg tttatcgctc actctccctt gtacagcctt attttgttg tgctttgcat 5937
tttgatattg ctgtgagcct tgcattgacat catgaggccg gatgaaactt ctcagtcacg 5997
cagtttccag tcctaacaaa tgctcccacc tgaatttgta tatgactgca tttgtgggtg 6057
tgtgtgtgtt ttcagcaaat tccagatttg tttccttttg gcctcctgca aagtctccag 6117
aagaaaaatt gccaatcttt cctactttct atttttatga tgacaatcaa agccggcctg 6177
agaaacacta tttgtgactt tttaaacgat tagtgatgtc cttaaatgt ggtctgccaa 6237
tctgtacaaa atggctctat tttgtgaag agggacataa gataaaatga tgttatacat 6297
caatatgtat atatgtatct ctatatagac ttggagaata ctgcaaaaac atttatgaca 6357
agctgtatca ctgccttcgt ttatatTTTT ttaactgtga taatccccac aggcacatta 6417
actgttgcac ttttgaatgt ccaaaattta tatTTtagaa ataataaaaa gaaagatact 6477
tacatgttcc caaaacaatg gtgtggtgaa tgtgtgagaa aaactaactt gatagggtct 6537
accaatacaa aatgtattac gaatgccctt gttcatgttt ttgttttaaa acgtgtaaat 6597
gaagatcttt atatttcaat aaatgatata taatttaaag tt 6639

```

<210> SEQ ID NO 10

<211> LENGTH: 1091

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1           5           10           15
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20          25          30
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35          40          45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50          55          60
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65          70          75          80
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85          90          95
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu

```

-continued

100						105						110					
Glu	Gly	Arg	His	Ile	Tyr	Ile	Tyr	Val	Pro	Asp	Pro	Asp	Val	Ala	Phe		
		115					120					125					
Val	Pro	Leu	Gly	Met	Thr	Asp	Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp		
	130					135					140						
Ser	Ala	Ile	Ile	Pro	Cys	Arg	Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr		
145					150					155					160		
Leu	His	Asn	Ser	Glu	Gly	Val	Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln		
				165					170					175			
Gly	Phe	Asn	Gly	Thr	Phe	Thr	Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr		
		180						185					190				
Val	Lys	Gly	Lys	Lys	Phe	Gln	Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu		
	195						200					205					
Lys	Ala	Thr	Ser	Glu	Leu	Asp	Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val		
210						215					220						
Tyr	Lys	Ser	Gly	Glu	Thr	Ile	Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn		
225					230					235					240		
Glu	Val	Val	Asp	Leu	Gln	Trp	Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys		
			245						250					255			
Gly	Ile	Thr	Met	Leu	Glu	Glu	Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val		
		260						265					270				
Tyr	Thr	Leu	Thr	Val	Pro	Glu	Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr		
		275					280					285					
Glu	Cys	Ala	Ala	Arg	Gln	Ala	Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys		
290						295					300						
Val	Thr	Ile	Ser	Val	His	Glu	Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr		
305					310					315					320		
Phe	Ser	Gln	Leu	Glu	Ala	Val	Asn	Leu	His	Glu	Val	Lys	His	Phe	Val		
			325						330					335			
Val	Glu	Val	Arg	Ala	Tyr	Pro	Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn		
			340					345					350				
Asn	Leu	Thr	Leu	Ile	Glu	Asn	Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu		
		355					360					365					
Lys	Ile	Gln	Glu	Ile	Arg	Tyr	Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala		
370						375					380						
Lys	Glu	Glu	Asp	Ser	Gly	His	Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp		
385					390					395					400		
Ala	Val	Lys	Ser	Tyr	Thr	Phe	Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser		
			405						410					415			
Ile	Leu	Asp	Leu	Val	Asp	Asp	His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr		
		420						425					430				
Val	Arg	Cys	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met		
		435					440					445					
Ile	Cys	Lys	Asp	Ile	Lys	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile		
450						455					460						
Leu	Ala	Asn	Asn	Val	Ser	Asn	Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp		
465					470					475					480		
Arg	Ser	Thr	Val	Glu	Gly	Arg	Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr		
			485						490					495			
Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg		
			500					505					510				
Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala		
		515					520					525					

-continued

Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val
530						535					540				
Leu	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg
545					550					555					560
Glu	Arg	Val	Ile	Glu	Ser	Ile	Ser	Pro	Asp	Gly	His	Glu	Tyr	Ile	Tyr
				565					570					575	
Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg
			580					585					590		
Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys
		595					600					605			
Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met
	610						615					620			
Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys
625					630					635					640
Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His
				645					650					655	
Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile
			660					665					670		
Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu
	675						680					685			
His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys	Pro	Lys
	690					695					700				
Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser	Thr	Arg
705					710					715					720
Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met	Asp	Met
				725					730					735	
Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg	Lys	Glu
			740					745					750		
Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg	Pro	Ala
		755					760					765			
Ser	Tyr	Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn	Leu	Leu
	770					775					780				
Ser	Asp	Asp	Asn	Ser	Glu	Gly	Leu	Thr	Leu	Leu	Asp	Leu	Leu	Ser	Phe
785					790					795					800
Thr	Tyr	Gln	Val	Ala	Arg	Gly	Met	Glu	Phe	Leu	Ala	Ser	Lys	Asn	Cys
				805					810					815	
Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	Leu	Leu	Ala	Gln	Gly	Lys
				820				825					830		
Ile	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Met	His	Asp
		835					840					845			
Ser	Asn	Tyr	Val	Ser	Lys	Gly	Ser	Thr	Phe	Leu	Pro	Val	Lys	Trp	Met
	850					855					860				
Ala	Pro	Glu	Ser	Ile	Phe	Asp	Asn	Leu	Tyr	Thr	Thr	Leu	Ser	Asp	Val
865					870					875					880
Trp	Ser	Tyr	Gly	Ile	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	Gly	Thr
				885					890					895	
Pro	Tyr	Pro	Gly	Met	Met	Val	Asp	Ser	Thr	Phe	Tyr	Asn	Lys	Ile	Lys
			900					905					910		
Ser	Gly	Tyr	Arg	Met	Ala	Lys	Pro	Asp	His	Ala	Thr	Ser	Glu	Val	Tyr
		915					920					925			
Glu	Ile	Met	Val	Lys	Cys	Trp	Asn	Ser	Glu	Pro	Glu	Lys	Arg	Pro	Ser
	930					935					940				
Phe	Tyr	His	Leu	Ser	Glu	Ile	Val	Glu	Asn	Leu	Leu	Pro	Gly	Gln	Tyr
945					950					955					960

Lys	Lys	Ser	Tyr	Glu	Lys	Ile	His	Leu	Asp	Phe	Leu	Lys	Ser	Asp	His		
				965					970					975			
Pro	Ala	Val	Ala	Arg	Met	Arg	Val	Asp	Ser	Asp	Asn	Ala	Tyr	Ile	Gly		
				980					985					990			
Val	Thr	Tyr	Lys	Asn	Glu	Glu	Asp	Lys	Leu	Lys	Asp	Trp	Glu	Gly	Gly		
				995					1000					1005			
Leu	Asp	Glu	Gln	Arg	Leu	Ser	Ala	Asp	Ser	Gly	Tyr	Ile	Ile	Pro			
				1010					1015					1020			
Leu	Pro	Asp	Ile	Asp	Pro	Val	Pro	Glu	Glu	Glu	Asp	Leu	Gly	Lys			
				1025					1030					1035			
Arg	Asn	Arg	His	Ser	Ser	Gln	Thr	Ser	Glu	Glu	Ser	Ala	Ile	Glu			
				1040					1045					1050			
Thr	Gly	Ser	Ser	Ser	Ser	Thr	Phe	Ile	Lys	Arg	Glu	Asp	Glu	Thr			
				1055					1060					1065			
Ile	Glu	Asp	Ile	Asp	Met	Met	Asp	Asp	Ile	Gly	Ile	Asp	Ser	Ser			
				1070					1075					1080			
Asp	Leu	Val	Glu	Asp	Ser	Phe	Leu										
				1085					1090								
<210> SEQ ID NO 11																	
<211> LENGTH: 6618																	
<212> TYPE: DNA																	
<213> ORGANISM: Homo sapiens																	
<220> FEATURE:																	
<221> NAME/KEY: CDS																	
<222> LOCATION: (395)..(3649)																	
<400> SEQUENCE: 11																	
ttctccccgc cccccagttg ttgtcgaaagt ctggggggtg ggactggacc cctgtattgc															60		
gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt															120		
gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta															180		
tttacttaga gcaaatgatt agttttagaa ggatggacta taacattgaa tcaattacaa															240		
aacgcggttt ttgagcccat tactgttgga gctacagggg gagaacagg aggagactgc															300		
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg															360		
cggaataaca tcggaggaga agtttcccg agct atg ggg act tcc cat ccg gcg															415		
Met Gly Thr Ser His Pro Ala																	
1 5																	
ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc															463		
Phe Leu Val Leu Gly Cys Leu Leu Thr Gly Leu Ser Leu Ile Leu Cys																	
10 15 20																	
cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg															511		
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val																	
25 30 35																	
cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg															559		
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val																	
40 45 50 55																	
agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc															607		
Ser Trp Gln Tyr Pro Met Ser Glu Glu Glu Ser Ser Asp Val Glu Ile																	
60 65 70																	
aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg															655		
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val																	
75 80 85																	
agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac															703		
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn																	
90 95 100																	
cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc															755		

-continued

His	Thr	Gln	Thr	Glu	Glu	Asn	Glu	Leu	Glu	Gly	Arg	His	Ile	Tyr	Ile	
105						110					115					
tat	gtg	cca	gac	cca	gat	gta	gcc	ttt	gta	cct	cta	gga	atg	acg	gat	799
Tyr	Val	Pro	Asp	Pro	Asp	Val	Ala	Phe	Val	Pro	Leu	Gly	Met	Thr	Asp	
120						125					130				135	
tat	tta	gtc	atc	gtg	gag	gat	gat	gat	tct	gcc	att	ata	cct	tgt	cgc	847
Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp	Ser	Ala	Ile	Ile	Pro	Cys	Arg	
				140					145					150		
aca	act	gat	ccc	gag	act	cct	gta	acc	tta	cac	aac	agt	gag	ggg	gtg	895
Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr	Leu	His	Asn	Ser	Glu	Gly	Val	
			155					160					165			
gta	cct	gcc	tcc	tac	gac	agc	aga	cag	ggc	ttt	aat	ggg	acc	ttc	act	943
Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln	Gly	Phe	Asn	Gly	Thr	Phe	Thr	
		170					175					180				
gta	ggg	ccc	tat	atc	tgt	gag	gcc	acc	gtc	aaa	gga	aag	aag	ttc	cag	991
Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr	Val	Lys	Gly	Lys	Lys	Phe	Gln	
	185					190					195					
acc	atc	cca	ttt	aat	gtt	tat	gct	tta	aaa	gca	aca	tca	gag	ctg	gat	1039
Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu	Lys	Ala	Thr	Ser	Glu	Leu	Asp	
200					205					210				215		
cta	gaa	atg	gaa	gct	ctt	aaa	acc	gtg	tat	aag	tca	ggg	gaa	acg	att	1087
Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val	Tyr	Lys	Ser	Gly	Glu	Thr	Ile	
			220					225						230		
gtg	gtc	acc	tgt	gct	gtt	ttt	aac	aat	gag	gtg	gtt	gac	ctt	caa	tgg	1135
Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn	Glu	Val	Val	Asp	Leu	Gln	Trp	
			235				240						245			
act	tac	cct	gga	gaa	gtg	aaa	ggc	aaa	ggc	atc	aca	atg	ctg	gaa	gaa	1183
Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys	Gly	Ile	Thr	Met	Leu	Glu	Glu	
		250				255					260					
atc	aaa	gtc	cca	tcc	atc	aaa	ttg	gtg	tac	act	ttg	acg	gtc	ccc	gag	1231
Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val	Tyr	Thr	Leu	Thr	Val	Pro	Glu	
	265					270					275					
gcc	acg	gtg	aaa	gac	agt	gga	gat	tac	gaa	tgt	gct	gcc	cgc	cag	gct	1279
Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr	Glu	Cys	Ala	Ala	Arg	Gln	Ala	
280					285					290				295		
acc	agg	gag	gtc	aaa	gaa	atg	aag	aaa	gtc	act	att	tct	gtc	cat	gag	1327
Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys	Val	Thr	Ile	Ser	Val	His	Glu	
			300						305					310		
aaa	ggt	ttc	att	gaa	atc	aaa	ccc	acc	ttc	agc	cag	ttg	gaa	gct	gtc	1375
Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr	Phe	Ser	Gln	Leu	Glu	Ala	Val	
		315						320					325			
aac	ctg	cat	gaa	gtc	aaa	cat	ttt	gtt	gta	gag	gtg	cgg	gcc	tac	cca	1423
Asn	Leu	His	Glu	Val	Lys	His	Phe	Val	Val	Glu	Val	Arg	Ala	Tyr	Pro	
		330				335						340				
cct	ccc	agg	ata	tcc	tgg	ctg	aaa	aac	aat	ctg	act	ctg	att	gaa	aat	1471
Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn	Asn	Leu	Thr	Leu	Ile	Glu	Asn	
		345				350					355					
ctc	act	gag	atc	acc	act	gat	gtg	gaa	aag	att	cag	gaa	ata	agg	tat	1519
Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu	Lys	Ile	Gln	Glu	Ile	Arg	Tyr	
	360				365					370				375		
cga	agc	aaa	tta	aag	ctg	atc	cgt	gct	aag	gaa	gaa	gac	agt	ggc	cat	1567
Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala	Lys	Glu	Glu	Asp	Ser	Gly	His	
			380					385					390			
tat	act	att	gta	gct	caa	aat	gaa	gat	gct	gtg	aag	agc	tat	act	ttt	1615
Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp	Ala	Val	Lys	Ser	Tyr	Thr	Phe	
			395				400						405			
gaa	ctg	tta	act	caa	gtt	cct	tca	tcc	att	ctg	gac	ttg	gtc	gat	gat	1663
Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser	Ile	Leu	Asp	Leu	Val	Asp	Asp	
		410				415						420				
cac	cat	ggc	tca	act	ggg	gga	cag	acg	gtg	agg	tgc	aca	gct	gaa	ggc	1711

-continued

His 425	His	Gly	Ser	Thr	Gly	Gly 430	Gln	Thr	Val	Arg	Cys 435	Thr	Ala	Glu	Gly	
acg	ccg	ctt	cct	gat	att	gag	tgg	atg	ata	tgc	aaa	gat	att	aag	aaa	1759
Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met	Ile	Cys	Lys	Asp	Ile	Lys	Lys	
440					445					450					455	
tgt	aat	aat	gaa	act	tcc	tgg	act	att	ttg	gcc	aac	aat	gtc	tca	aac	1807
Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	Leu	Ala	Asn	Asn	Val	Ser	Asn	
					460					465					470	
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg	
					475					480					485	
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala	
					490					495					500	
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro	
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Val	Leu	Val	Leu	Leu	Leu	
520						525				530					535	
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln	
						540				545					550	
aaa	ccg	agg	tat	gaa	att	cgc	tgg	agg	gtc	att	gaa	tca	atc	cgc	tat	2095
Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	Val	Ile	Glu	Ser	Ile	Arg	Tyr	
att	tat	gtg	gac	ccg	atg	cag	ctg	cct	tat	gac	tca	aga	tgg	gag	ttt	2143
Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	
cca	aga	gat	gga	cta	gtg	ctt	ggt	cgg	gtc	ttg	ggg	tct	gga	gcg	ttt	2191
Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	
ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	gga	tta	agc	cgg	tcc	caa	cct	2239
Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	
600						605				610					615	
gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	aaa	ccc	acg	gcc	aga	tcc	agt	2287
Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	
						620				625					630	
gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	aag	ata	atg	act	cac	ctg	ggg	2335
Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	
cca	cat	ttg	aac	att	gta	aac	ttg	ctg	gga	gcc	tgc	acc	aag	tca	ggc	2383
Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	
ccc	att	tac	atc	atc	aca	gag	tat	tgc	ttc	tat	gga	gat	ttg	gtc	aac	2431
Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	
tat	ttg	cat	aag	aat	agg	gat	agc	ttc	ctg	agc	cac	cac	cca	gag	aag	2479
Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys	
680						685				690					695	
cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	ttg	aac	cct	gct	gat	gaa	agc	2527
Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser	
aca	cgg	agc	tat	gtt	att	tta	tct	ttt	gaa	aac	aat	ggt	gac	tac	atg	2575
Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met	
gac	atg	aag	cag	gct	gat	act	aca	cag	tat	gtc	ccc	atg	cta	gaa	agg	2623
Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg	
aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	cag	aga	tca	ctc	tat	gat	cgt	2671

-continued

Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg	
745						750					755					
cca	gcc	tca	tat	aag	aag	aaa	tct	atg	tta	gac	tca	gaa	gtc	aaa	aac	2719
Pro	Ala	Ser	Tyr	Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn	
760				765				770						775		
ctc	ctt	tca	gat	gat	aac	tca	gaa	ggc	ctt	act	tta	ttg	gat	ttg	ttg	2767
Leu	Leu	Ser	Asp	Asn	Ser	Glu	Gly	Leu	Thr	Leu	Leu	Asp	Leu	Leu		
			780					785					790			
agc	ttc	acc	tat	caa	ggt	gcc	cga	gga	atg	gag	ttt	ttg	gct	tca	aaa	2815
Ser	Phe	Thr		795				800					805			
aat	tgt	gtc	cac	cgt	gat	ctg	gct	gct	cgc	aac	gtc	ctc	ctg	gca	caa	2863
Asn	Cys	Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	Leu	Leu	Ala	Gln	
		810				815					820					
gga	aaa	att	gtg	aag	atc	tgt	gac	ttt	ggc	ctg	gcc	aga	gac	atc	atg	2911
Gly	Lys	Ile	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Met	
825					830				835							
cat	gat	tcg	aac	tat	gtg	tcg	aaa	ggc	agt	acc	ttt	ctg	ccc	gtg	aag	2959
His	Asp	Ser	Asn	Tyr	Val	Ser	Lys	Gly	Ser	Thr	Phe	Leu	Pro	Val	Lys	
840				845				850						855		
tgg	atg	gct	cct	gag	agc	atc	ttt	gac	aac	ctc	tac	acc	aca	ctg	agt	3007
Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asp	Asn	Leu	Tyr	Thr	Thr	Leu	Ser	
			860					865					870			
gat	gtc	tgg	tct	tat	ggc	att	ctg	ctc	tgg	gag	atc	ttt	tcc	ctt	ggt	3055
Asp	Val	Trp	Ser	Tyr	Gly	Ile	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	
		875					880					885				
ggc	acc	cct	tac	ccc	ggc	atg	atg	gtg	gat	tct	act	ttc	tac	aat	aag	3103
Gly	Thr	Pro	Tyr	Pro	Gly	Met	Met	Val	Asp	Ser	Thr	Phe	Tyr	Asn	Lys	
		890				895					900					
atc	aag	agt	ggg	tac	cgg	atg	gcc	aag	cct	gac	cac	gct	acc	agt	gaa	3151
Ile	Lys	Ser	Gly	Tyr	Arg	Met	Ala	Lys	Pro	Asp	His	Ala	Thr	Ser	Glu	
	905				910					915						
gtc	tac	gag	atc	atg	gtg	aaa	tgc	tgg	aac	agt	gag	ccg	gag	aag	aga	3199
Val	Tyr	Glu	Ile	Met	Val	Lys	Cys	Trp	Asn	Ser	Glu	Pro	Glu	Lys	Arg	
920				925				930						935		
ccc	tcc	ttt	tac	cac	ctg	agt	gag	att	gtg	gag	aat	ctg	ctg	cct	gga	3247
Pro	Ser	Phe	Tyr	His	Leu	Ser	Glu	Ile	Val	Glu	Asn	Leu	Leu	Pro	Gly	
			940					945					950			
caa	tat	aaa	aag	agt	tat	gaa	aaa	att	cac	ctg	gac	ttc	ctg	aag	agt	3295
Gln	Tyr	Lys	Lys	Ser	Tyr	Glu	Lys	Ile	His	Leu	Asp	Phe	Leu	Lys	Ser	
		955					960					965				
gac	cat	cct	gct	gtg	gca	cgc	atg	cgt	gtg	gac	tca	gac	aat	gca	tac	3343
Asp	His	Pro	Ala	Val	Ala	Arg	Met	Arg	Val	Asp	Ser	Asp	Asn	Ala	Tyr	
		970				975					980					
att	ggt	gtc	acc	tac	aaa	aac	gag	gaa	gac	aag	ctg	aag	gac	tgg	gag	3391
Ile	Gly	Val	Thr	Tyr	Lys	Asn	Glu	Glu	Asp	Lys	Leu	Lys	Asp	Trp	Glu	
	985				990					995						
ggt	ggt	ctg	gat	gag	cag	aga	ctg	agc	gct	gac	agt	ggc	tac	atc		3436
Gly	Gly	Leu	Asp	Glu	Gln	Arg	Leu	Ser	Ala	Asp	Ser	Gly	Tyr	Ile		
1000				1005					1010							
att	cct	ctg	cct	gac	att	gac	cct	gtc	cct	gag	gag	gag	gac	ctg		3481
Ile	Pro	Leu	Pro	Asp	Ile	Asp	Pro	Val	Pro	Glu	Glu	Glu	Asp	Leu		
1015				1020					1025							
ggc	aag	agg	aac	aga	cac	agc	tcg	cag	acc	tct	gaa	gag	agt	gcc		3526
Gly	Lys	Arg	Asn	Arg	His	Ser	Ser	Gln	Thr	Ser	Glu	Glu	Ser	Ala		
1030				1035					1040							
att	gag	acg	ggt	tcc	agc	agt	tcc	acc	ttc	atc	aag	aga	gag	gac		3571
Ile	Glu	Thr	Gly	Ser	Ser	Ser	Ser	Thr	Phe	Ile	Lys	Arg	Glu	Asp		
1045				1050					1055							
gag	acc	att	gaa	gac	atc	gac	atg	atg	gac	gac	atc	ggc	ata	gac		3616

-continued

```

ctcccttgta cagccttatt ttgttggtgc ttgcatttt gatattgctg tgagccttgc 5939
atgacatcat gaggcgggat gaaacttctc agtccagcag ttccagtc taacaaatgc 5999
tcccacctga atttgatat gactgcattt gtgggtgtgt gtgtgttttc agcaaattcc 6059
agatttgttt ccttttgccc tctgcaaaag tctccagaag aaaatttgcc aatctttcct 6119
actttctatt ttatgatga caatcaaagc cggcctgaga aactatttt gtgacttttt 6179
aaacgattag tgatgtcctt aaaatgtggt ctgccaatct gtacaaaatg gtcctatttt 6239
tgtgaagagg gacataagat aaaatgatgt tatacatcaa tatgtatata tgtatttcta 6299
tatagacttg gagaatactg ccaaaacatt tatgacaagc tgtatcactg ccttcgttta 6359
tattttttta actgtgataa tccccacagg cacattaact gttgcacttt tgaatgtcca 6419
aaatttatat tttagaata ataaaaagaa agatacttac atgttcccaa aacaatggtg 6479
tggtgaatgt gtgagaaaaa ctaacttgat aggggtctacc aatacaaaat gtattacgaa 6539
tgccctgtt catgtttttg ttttaaaacg tgtaaatgaa gatctttata tttcaataaa 6599
tgatatataa tttaaagt 6618

```

<210> SEQ ID NO 12

<211> LENGTH: 1084

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1      5      10      15
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20     25     30
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35     40     45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50     55     60
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65     70     75     80
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85     90     95
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
100    105    110
Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
115    120    125
Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
130    135    140
Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
145    150    155    160
Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
165    170    175
Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
180    185    190
Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
195    200    205
Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
210    215    220
Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
225    230    235    240

```

Glu 245	Val	Val	Asp	Leu	Gln	Trp	Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys
Gly 260	Ile	Thr	Met	Leu	Glu	Glu	Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val
Tyr 275	Thr	Leu	Thr	Val	Pro	Glu	Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr
Glu 290	Cys	Ala	Ala	Arg	Gln	Ala	Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys
Val 305	Thr	Ile	Ser	Val	His	Glu	Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr
Phe	Ser	Gln	Leu	Glu	Ala	Val	Asn	Leu	His	Glu	Val	Lys	His	Phe	Val
Val	Glu	Val	Arg	Ala	Tyr	Pro	Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn
Asn	Leu	Thr	Leu	Ile	Glu	Asn	Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu
Lys 370	Ile	Gln	Glu	Ile	Arg	Tyr	Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala
Lys 385	Glu	Glu	Asp	Ser	Gly	His	Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp
Ala	Val	Lys	Ser	Tyr	Thr	Phe	Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser
Ile	Leu	Asp	Leu	Val	Asp	Asp	His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr
Val	Arg	Cys	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met
Ile	Cys	Lys	Asp	Ile	Lys	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile
Leu 465	Ala	Asn	Asn	Val	Ser	Asn	Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp
Arg	Ser	Thr	Val	Glu	Gly	Arg	Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr
Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg
Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala
Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val
Leu 545	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg
Val	Ile	Glu	Ser	Ile	Arg	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro
Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg
Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr
Gly 610	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu
Lys 625	Pro	Thr	Ala	Arg	Ser	Glu	Lys	Gln	Ala	Lys	Leu	Met	Ser	Glu	Leu
Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu
Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys

-continued

Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser Phe
 675 680 685
 Leu Ser His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe Gly
 690 695 700
 Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr Val Ile Leu Ser Phe
 705 710 715 720
 Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln
 725 730 735
 Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile
 740 745 750
 Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met
 755 760 765
 Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly
 770 775 780
 Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly
 785 790 795 800
 Met Glu Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala
 805 810 815
 Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe
 820 825 830
 Gly Leu Ala Arg Asp Ile Met His Asp Ser Asn Tyr Val Ser Lys Gly
 835 840 845
 Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp
 850 855 860
 Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu
 865 870 875 880
 Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val
 885 890 895
 Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys
 900 905 910
 Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp
 915 920 925
 Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile
 930 935 940
 Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile
 945 950 955 960
 His Leu Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met Arg
 965 970 975
 Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu
 980 985 990
 Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser
 995 1000 1005
 Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val
 1010 1015 1020
 Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln
 1025 1030 1035
 Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr
 1040 1045 1050
 Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met
 1055 1060 1065
 Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe
 1070 1075 1080
 Leu

-continued

<210> SEQ ID NO 13
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Tyr Val His Arg Asp Leu Ala Ala Arg Asn Ile Leu
1 5 10

<210> SEQ ID NO 14
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu
1 5 10

<210> SEQ ID NO 15
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Phe Val His Arg Asp Leu Ala Ala Arg Asn Cys Met
1 5 10

<210> SEQ ID NO 16
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

Leu Val His Arg Asp Leu Ala Ala Arg Asn Val Leu
1 5 10

<210> SEQ ID NO 17
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Phe Ile His Arg Asp Ile Ala Ala Arg Asn Cys Leu
1 5 10

<210> SEQ ID NO 18
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

Phe Val His Arg Asp Leu Ala Thr Arg Asn Cys Leu
1 5 10

<210> SEQ ID NO 19
<211> LENGTH: 191150
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (1)..(49)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (50)..(2330)
<220> FEATURE:
<221> NAME/KEY: exon

-continued

<222> LOCATION: (2331)..(2648)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (2649)..(4902)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (4903)..(5163)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (5164)..(6154)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (6155)..(6285)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (6286)..(8524)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (8525)..(8696)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (8697)..(8787)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (8788)..(8977)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (8978)..(166510)
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (10577)..(10676)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10577)..(10676)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (14335)..(14434)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14335)..(14434)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (16247)..(16346)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (16247)..(16346)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (17457)..(17457)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (21818)..(21818)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36293)..(36298)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36314)..(36314)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36316)..(36316)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36432)..(36433)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (36774)..(36873)
<223> OTHER INFORMATION: n = any nucleic acid

-continued

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (36774)..(36873)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59740)..(59740)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59740)..(59740)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59742)..(59742)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59742)..(59744)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59744)..(59744)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59749)..(59755)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59749)..(59755)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59759)..(59760)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59759)..(59760)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59765)..(59766)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (59776)..(59875)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (59776)..(59875)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (82745)..(82844)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (82745)..(82844)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (96508)..(96607)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (96508)..(96607)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (147675)..(147774)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (147675)..(147774)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (157152)..(157251)
<223> OTHER INFORMATION: n = any nucleic acid

-continued

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (157152)..(157251)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (161475)..(161574)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: Unsure
<222> LOCATION: (165240)..(165339)
<223> OTHER INFORMATION: n = any nucleic acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (165240)..(165339)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (166511)..(166626)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (166627)..(168271)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (168272)..(168398)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (168399)..(169414)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (169415)..(169608)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (169609)..(170408)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (170409)..(170503)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (170504)..(170718)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (170719)..(170851)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (170852)..(173265)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (173266)..(173370)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (173371)..(173773)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (173774)..(173884)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (173885)..(174239)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (174240)..(174393)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (174394)..(176193)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (176194)..(176360)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (176361)..(181248)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (181249)..(181364)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (181365)..(181718)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (181719)..(181841)
<220> FEATURE:

<400> SEQUENCE: 19

atg ggg act tcc cat ccg gcg ttc ctg gtc tta ggc tgt ctt ctc aca g	49
Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr	
1 5 10 15	
gtacggagacc cagtcctctc tgagttcctt gtttggtgtg cttgtttttt taagctttgt	109
gctgcatggg tttattacca gtactctgca tacacagtcc aaaagagtga aaagaaatag	169
aaaactatag gacgttatcc agaatgacca caaaccttca gttccctttg ctgtattgca	229
cttactccat ttcaaaagga atgctctcca gtggcagttt tagtacatat ataatgttgg	289
cattgaaatg ttgttagtaa taatgtctaa atttacttac tactctcttc cttttcctag	349
gacaaggctt ctattagagc tggattagat aaattcagga atggtcagct gtgggagggtg	409
gcacatctgt tgtcccagcc ccttgagcag ctgagggtggg atgatccctt taaggccagg	469
agttcaaggg ttgcagtgca ctgtgattat gctgtgtact agccaccaca ctccagcaac	529
atagcaagac ctcatntaaa aaaaatgttc aaaggaaata aataatagaa aattcttgcc	589
caagaaatca tacttgtctt aaatcataac tctcttgagg aaagatgctt acattgcttc	649
taaatctcag agtcaccttt atcttctcta ggaatcaaat tgatagatga atgtttggct	709
cttggaatat cttaaaaaat ttcccaccaa aaggatcatt ggggtaattt gttgaagtgt	769
gtattggact gtcttagttt tctccagat atttatgcac tgcagatgtt cgccatgaaa	829
ccagtgtctt tctattctga ggagttagct cagcccgttg gtgtctttgt cttacccatt	889
tggatatggt agaattgagc aagaccagag attcaacagt tctaaagtcc actaagtata	949
ccccatctac agagtaatat gtgattcaga tgtacttaca aatctatct taacaagctt	1009
taggaattat agtggctata tattgaagtt ggggtgggagt ctacaccag gttccaaggg	1069
agattacaaa tcactaatta ataattaagt cataatatct cttctatcag tctcggtttt	1129
cttgttttct aagttctgtg ctccatgggtt ttattatctg tactctgctt acacagtcca	1189
aaagagtga aagaaataga aaactacagg acgttatcca gaatgaccac aaaccttcag	1249
ttcctttgct gcattgcact tactctattg caaaaggagt aagtgcatt tcagtctaaa	1309
taagcgagac tgaattttga gcttcgaaga tgaacttaga gttttcactc ttgggtttta	1369

-continued

cttaccaatt gtgaattaaa atccgtatca tctggcacca ctgcactcca gcttgggtga	1429
cagagcaaga ctccatctca taaaaataaa gaaataaata aacaaataaa tccacatcat	1489
cctgcttttg ccttggaagt catgaggag agacggcatg cccgagggt ataagaaatg	1549
gaagatgtgg aattcttgag cacagatgtg ctttgtgttt tcttcagtct gtgtccttgc	1609
ctccattctt attccatgtg ggtttttttt tttttttttt tttttttttt tgagacaggt	1669
tttttttctt ttattgcccc ggggggagtg caaaggctga ctgcaacctc aatcccctgg	1729
gctccagtga tctctccacc tcagcctcca aagtagctag gactacaggt gtacaccagc	1789
acacctgggt aattttttta tttttttatt tttgggggag accaggtctc actacgttgc	1849
ccaggctgggt ctgcaactcc tgagctcaag cgatcctccc acttccacct aacaaagtgc	1909
tgggattata aacatgagcc tttgcgcccc agcctttttt ttttttaact aaaggaaacc	1969
tttgagtgga ttgtgaacca taaagaaccc atatgtgctt gageccgtgc catcttggga	2029
tatttttatg gttacacata agagtctgaa atatggaatt ggaatcagac atcctctgtc	2089
tatttgagtg tttggagggg tgaatctagt ggggcttggg ggagctatgt ggaacatttg	2149
ctgctctcag cagatgcagt ggctgttata atgggggagc tttcatgggc atccaggcta	2209
acggattttt gtgtagaat ggtcattgtt catctaagct gctactgttg cttctctcag	2269
ttgtcgggat gagactgtcc tttctgactg catcctatcc agagcgtgct tccttttgca	2329
g gg ctg agc cta atc ctc tgc cag ctt tca tta ccc tct atc ctt cca	2377
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro	
20 25 30	
aat gaa aat gaa aag gtt gtg cag ctg aat tca tcc ttt tct ctg aga	2425
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg	
35 40 45	
tgc ttt ggg gag agt gaa gtg agc tgg cag tac ccc atg tct gaa gaa	2473
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu	
50 55 60	
gag agc tcc gat gtg gaa atc aga aat gaa gaa aac aac agc ggc ctt	2521
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu	
65 70 75 80	
ttt gtg acg gtc ttg gaa gtg agc agt gcc tgg gcg gcc cac aca ggg	2569
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly	
85 90 95	
ttg tac act tgc tat tac aac cac act cag aca gaa gag aat gag ctt	2617
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu	
100 105 110	
gaa ggc agg cac att tac atc tat gtg cca g gtgagttggc tgggtctcca	2668
Glu Gly Arg His Ile Tyr Ile Tyr Val Pro	
115 120	
ggaccaagct tcttctcttc ctgtctctcc tgttaaatgt actaaggttt taaacatata	2728
tataaataat taatatattat tgcgggaagt ttgaaaaatg taagcgaaca cacacaaaaa	2788
tcatttgtaa tattatcaag aaatatcat tgttagcatt tcagagctgt attaagtttg	2848
gaaagtcatc tttgttatga catgtcctgt attgatactg tataaacaat ctgaaatata	2908
ctcatctcta ttcagttcat tcaagttgca cacatactca cagtgtgtcc agcactgggc	2968
taagtgttga gtacacaaaa attaataggt aagccctgtc ttggagttgc tgatagttca	3028
ttataatata ttccaaataa aactcagatt tttcagattc actatcaaca tacatttatt	3088
cttgagagag ttggaaggaat tttctttttc cttttaaaaa agttacatat atatatatat	3148
atatatatat atatatatat tttttttttt tttggtaaca gggctctcact ctgttgccca	3208
ggctggaatg cagtggcatg atcatcatag cttactgcaa tctcaactcc cttggttcaa	3268

-continued

gcgattctcc cacttcagcc tcccagtag ctgggattac aggcattgcac caccacgccc	3328
agctaatttt tatattagtt gagacggggg tttcaccata ttgaccaggc tggctctgaa	3388
ctctgacct taagtgatct gcctgcttcg gcctcccaa atgctgggat tacaggcgtg	3448
agccactgtg ccctaatttt tttttttatt tttgtagaga tagggtttca ctgtgttgcc	3508
caggctggtc tcaaactect gggctcaagt gatccacagc cacctcagcc tcccaaagtt	3568
ctgggattac aggcacgagc cactgggcct ggcctactcc tgcattttaa ttaaaaggac	3628
aaaagggtcg agcacaagtg atggcaattt cagtatgcag ttgggtaaat taaaaaggac	3688
tatggctaga atccttggtt ttagaacaaa acctaaactg tttatgattc ttgccatcct	3748
tgctgttttg gcataggtgt gtcttctac cttctgcct tttcttttc agtttttaat	3808
gggctcctct ttctaccctg tataactacg agtgtccca gggatctaga cctctttac	3868
tttttcatga tactcttatt catatgaacc ttcttctta acaattaaaa aaaacaaaa	3928
actttgtttt gaaaaggaa ggtatttaga atgtcactcc aacttcattc acacttagat	3988
tccttcagga aaatcctcta ggtgtggagg gattttccc tgctgtgaag agaatggtag	4048
gaacgtgaat gtgttaaagg cacacgagtc cctgaagttt taatccgtgt aagattgtcc	4108
aaaaattttt ctgttccag cacagatgcc atccaagtag cccctgcac gctgtctgac	4168
tgagatcttt ttattcgaa tcatgcagac gtaggggccc tttctgcagc tgatgtttga	4228
gactgttaga acttcttacc accgtagctt aagtagctgt tttcttttg gaaaggaaat	4288
tctcaggtc cttctccttc tttaaatttt atgtatttct caaaggatta ctttttaata	4348
aacagatttc tatgctattt ttgaatcata ctgactatag gtggtaaag tttttaaag	4408
catttcataa taaaactcga aatatttttt cctgttttaa acagagttgg actgtattat	4468
tttattgtta atttttgtt ttagtgttt aaattttgat ttagattcct ggtagtatt	4528
tattttatta tttgtagaga cagggtctct ctatgttgcc caggctggtc tcaaactcct	4588
gaacacaagc aacctccca ccttggtctc ccaaagtgt gggattacag gcatgagcca	4648
caactcctgt ccagtattga ttttatcat cagtattatc catcaggaga caggcaattt	4708
ggtattatc atacttaaaa atcactttgt agctgtcatg ataactaatg ccagtggggc	4768
aattctcttg gatatatgtg taaagggtgaa cttcatacct aatatcaata atgccagtgg	4828
gatagttttt ctggatttat gtgtaaaggt gaaattaatg tctaataagag tcttcattct	4888
tttttaaacc acag ac cca gat gta gcc ttt gta cct cta gga atg acg	4937
Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr	
125 130	
gat tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt	4985
Asp Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys	
135 140 145 150	
cgc aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg	5033
Arg Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly	
155 160 165	
gtg gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc	5081
Val Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe	
170 175 180	
act gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc	5129
Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe	
185 190 195	
cag acc atc cca ttt aat gtt tat gct tta aaa g gtacttgtat	5173
Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys	
200 205	
catctccttc cttctttaaa taagagtaac aggcaaaatc ataagggtgcg tgtaggattt	5233

-continued

tttttttttt	ttaaatcatt	atcactgggtg	atcctaaatt	ctgatttggg	gatttaggac	5293
cccagcta	acaatgtctg	tggctataat	aataagctta	aaattactaa	aggccaaagc	5353
ttgattcccc	atgcaagatt	tcattgtttca	tcagttgact	tcaaaatact	gtaaggaatt	5413
cttttcttac	ataagcctct	tactttcatt	cacattcctg	actatggcgg	ccctaaaaac	5473
aaacatacac	ccaggggggt	agatgcctag	attaatttta	gtaacttaag	aaaagtgatt	5533
tgaagaaagt	agtttagact	tcaacccttt	gatgtccaca	gttagtacgc	ttggggaagt	5593
ataatacatg	ctgaggtcaa	cagatatttc	ctgaacacta	tattacatgg	aggaatgggt	5653
agcagcaaga	gtacactggt	ttaaaatcag	agcacagcta	attttgtgcc	aggcactgtg	5713
ctaggttctg	ggaaagtact	gagaataact	gaggagcaga	gtggaagaga	agaagagaag	5773
aaacaattgg	atagaacaa	agtgtctaga	gcagtgtgga	tcagcaaatg	ttggttgatt	5833
aatgaataa	atattattagt	caaggagatt	gtggacgagt	ataaccataa	ctaaccact	5893
gctgaggaat	gcggtgttct	gtttgattgg	aatttatatt	tattgttatt	attttghtaat	5953
tctgtattat	aactatatgc	ctaattgttg	tacaccatct	cacaatcaag	ccttgtgaga	6013
ttttccaaat	tttatcttga	tcaaactggg	ttgcaaatta	tttttcaggg	ttttcttaaa	6073
aaaaaaaa	aaaacccaaa	ctttataaga	tcctggctat	cctgtggatt	tttaggccct	6133
tgattttggt	cttttttata	g ca	aca tca	gag ctg	gat cta	gaa atg gaa
		Ala Thr Ser	Glu Leu	Asp Leu	Glu Met	Glu
				215		
gct ctt aaa	acc gtg tat	aag tca	ggg gaa	acg att	gtg gtc	acc tgt
Ala Leu Lys	Thr Val Tyr	Lys Ser Gly	Glu Thr	Ile Val	Val Thr	Cys
220	225		230			235
gct gtt ttt	aac aat gag	gtg gtt	gac ctt	caa tgg	act tac	cct gga
Ala Val Phe	Asn Asn Glu	Val Val Asp	Leu Gln	Trp Thr	Tyr Pro	Gly
	240		245			250
gaa gtg	gtaggtacct	tcaaaacgtg	caatggcttg	gagcagagca	acagggctca	6335
Glu Val						
gaagacctgc	atttgagctc	ggtctgtcac	tgatgggcac	atcactgagt	ttctctagac	6395
cttagcttcc	cacctctggg	atgaacacat	ttgattaaat	ggcctttagg	actccttgat	6455
caatgggaga	gtttgaaatg	atagttcctg	gaccaggccc	ttcagaatac	ataaagagtg	6515
tgccgtaagc	cttctttttc	agaagtcaga	cagaaatagg	aaggttctct	ggctacaaga	6575
tatcaaccaa	aaaattagaa	gagcaaaaaa	accactggat	tttactattg	cggagacagt	6635
gattgattct	catcgtcttg	gcttctgtgc	cctgaggttt	gattcatctg	atagtgttga	6695
ttgcccgcac	cccttctctc	tctgccttgc	tggcacccag	gacaatgtgt	cttctctgtc	6755
cacctcctat	gtgcctgacc	tttgcattgc	tcaccttcag	tgaaccgtta	tgatgtaatc	6815
attcagcaaa	ggtttaatga	agtttgcctc	atcccaagca	ctgtaccaga	agctgggttca	6875
gtattgcagg	aagaaggagg	gaggggagat	ggaagtgggg	aaggggagcc	accatgctgc	6935
ctcttggtca	ctggagattt	acagagcttc	agtcattcta	atgcattgtc	actaagtgtg	6995
taagacagcc	atgtgtgaaga	ggctatgaat	gccccaatgc	aggaatgact	aatattctta	7055
tggaagaaca	aaacgagata	tatatatttc	ttgcctccac	tcctgacttg	taaatttctg	7115
ctcctgttcc	ttttaggcat	ttgacagctt	tctgtccttc	tatccattga	tctccctcct	7175
tttatecgtt	tctctctccc	atgcatttgc	cgtgtctttt	catttgcctc	ggggcatctg	7235
ataggaagtt	gggcattttc	actattgcct	cacaaacttc	acacagtga	gggacattta	7295
cagtccaaca	aatgtacatc	ttccctgaaa	tatgaagtga	tttggttctt	ctgttcatac	7355
ttgattgact	ttaatcctta	acacataaac	actgctttct	atttatagga	gacagcaatt	7415

-continued

tttttttcca aaccgaagta catgctattt ggcttacaaa tatataatca aagtattgtt	7475
tcatacagta tgtttttttcc gattataaaa gtaatgcagg tttattgcag aaactttgta	7535
aaatatggag agacaaagga aaggctactt cccagagcat cactgtttat attttaggga	7595
gataaagctt ttattttttca tttgtatttc tttctttttt tttctttttt tctttttttt	7655
ttttgtgtg gagatgagga tctcactaca ttgccaggc tgggtctcaa ctctgggct	7715
taagtgatcc tcccacttg gcctttcaaa gtgttgggat tgattacaca tgtgagctc	7775
tgagcttgac tgagataaag ctcttaagta tttcttatcc atagataaac attgaataat	7835
aggtgttatt ctttaaatgg taatttatta cattctttat ccttcagcag tatagcacia	7895
acaccttata tgtgtcatta actgtccttt taaaaaatgg gctgggtgtg gtggctcatg	7955
cctgtaatcc cagtactttg ggaggtgag gcaggagagt cacttgaggc caggagtgtg	8015
agatcagcct gggcaatgta tcaagactcc gtctctacaa aaatttttaa aaattagcca	8075
ggtgtggtgg catgagcctg tagccccagc tactcaggag actgaggtgg gaggatcact	8135
tgaacccagg aggttggggc tgcagtgagc catgattgtg cactgcact ccagcctggg	8195
cagcagagtg agattctgtc tctaaaaaaa ttaaaaacaa aataaaaaat ctcattgattt	8255
tetaagcagc tagctttttat tcttttaggtt ttatctttta gacagtttt aggtttacag	8315
caaaattgag aggtacagag atttcccatg tgttccttac acccacacat gtgtagctc	8375
ccacctgtgc aacatcccta ccatccattt gttataactg ctgaacctcc attgacacat	8435
ccatatcatc cagagtccat agtttatctt agagttcact cctaggagcg agcttttttaa	8495
aagtcggttt tcttccctt ttgctgtag aaa ggc aaa ggc atc aca atg ctg	8548
Lys Gly Lys Gly Ile Thr Met Leu	
255 260	
gaa gaa atc aaa gtc cca tcc atc aaa ttg gtg tac act ttg acg gtc	8596
Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val Tyr Thr Leu Thr Val	
265 270 275	
ccc gag gcc acg gtg aaa gac agt gga gat tac gaa tgt gct gcc cgc	8644
Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr Glu Cys Ala Ala Arg	
280 285 290	
cag gct acc agg gag gtc aaa gaa atg aag aaa gtc act att tct gtc	8692
Gln Ala Thr Arg Glu Val Lys Glu Met Lys Lys Val Thr Ile Ser Val	
295 300 305	
cat g gtacattccg ctttctaaaa tgtcagttgt ccatgctgct cgggatccat	8746
His	
310	
atgtggtaat cattatttaa tggaaactct tccctgtaca g ag aaa ggt ttc att	8801
Glu Lys Gly Phe Ile	
315	
gaa atc aaa ccc acc ttc agc cag ttg gaa gct gtc aac ctg cat gaa	8849
Glu Ile Lys Pro Thr Phe Ser Gln Leu Glu Ala Val Asn Leu His Glu	
320 325 330	
gtc aaa cat ttt gtt gta gag gtg cgg gcc tac cca cct ccc agg ata	8897
Val Lys His Phe Val Val Glu Val Arg Ala Tyr Pro Pro Pro Arg Ile	
335 340 345	
tcc tgg ctg aaa aac aat ctg act ctg att gaa aat ctc act gag atc	8945
Ser Trp Leu Lys Asn Asn Leu Thr Leu Ile Glu Asn Leu Thr Glu Ile	
350 355 360	
acc act gat gtg gaa aag att cag gaa ata ag gtaaagaaac tctctgccca	8997
Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg	
365 370	
agtatgcctt tttttagtgt gcatcagagg cggactgagg tttgtgtgtg tcttacaacc	9057
cagacccaaa gtcagtctag aaaatgtaac aatctgagtt aagagatgct tgaatcaca	9117

-continued

tccctttaat gataacattg caaagtggta ttagtatgct ggtaagtatt taatgagaag	9177
atgagaagaa agaactaaaa gctctggccc ctggggaaag acaggtcact ggattcagct	9237
agggtggaag aaaggaagta aaattggact caccaggatt gaatagattg aatatattcc	9297
ctgatgttca tcatccatat cgcaagtaga cagatatggg gattacaccc atgaggcagt	9357
tatcacatca ccttacgtga aagttaacgt cataggctta atctggaacc catttgccct	9417
aattgaggac tccacaggaa agaagagtag agcctggcta atcaggagag agatgtgcag	9477
tgagttgctt ggatccctac cttttaatca gaatggtaga ttgctctcat ctcttaattg	9537
gtggtggagt ttgtaatgag tcacccctca gccacagttt cctcatctac aatgtaggat	9597
aaacaatacc ttatgtcctt caaggcaagg aattggatca gatgatatca tgaggcctct	9657
taaggtttta agctgtgatt agaacccaag agtcagaaga tacatctcac agcaccagc	9717
taaccagccc tatacttttg tcagaaatca tctcagaaag acaaagtcag tcctgtatct	9777
caagccttca ggaggaagaa cagagccttt ctcatcagtt ccattcacct caggatttgc	9837
ttctctcttt gtgaactaaa ttccacgtgt aattgagaag caatgtctga gaaaatggaa	9897
ttttacagcc tctatagaat agtaaaggaa aaatgaagtg ggatactgaa tctggaaggc	9957
tttctgttga cacaaaaatga aggtgtacaa caaggagggc agctttccac gaggaacttc	10017
catgaggctg tgcagccaga gaggaatagg gtaacaaccc tggtagagct aacacctcca	10077
acacgtgtgt gagcactgtc tgcaagccat aatccatagc agtggcagga caggctcgcc	10137
aactgagtggt ttctggaaaag ctgccttttc ctttttagtga ttcaaggatg cttcaacgtg	10197
gatttttttag ttctgtttat gagccagtga atacaaagat gaacatggta gatgggggat	10257
ctggcttcct ggagcttaaa actccaggat gggggatctg gctttcctgg agcaagaaaa	10317
ccagtgggtt ttctggccga agaagtgaag agaacaaaca gcagaggata atttggtaat	10377
cagcatccta gtgtgcccca gggtagcttc ttaaggaaat ccagtcctgg agcacacca	10437
gtatggtcca gcctgctgtc ttcgtaggtc tgagtgcctc agtatttga aagtgttttg	10497
gagcctatga aatgctttca cacatacaat ctcttttaat taactctcac aatgactctg	10557
tgctatgtgt acaattatcn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	10617
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnng	10677
tatgaaaccc acttgatcat agtggattat ctttttgata tgttgttga ttgaggtagc	10737
tagtattttg ttaaggattt tagcatctat gttcatcaag gatttcagcc tgtagctttc	10797
ttctctggac gtgtcctttt ctgggttttg tattagggtg atgttggctt cacagaatga	10857
attaggaagg gttccttctt tctctatctt gtggaatagt gtcaaaagga ttggtaccaa	10917
ttcttctctg aatgtctgtt aggattctgc tgtgaatcca tctgggtccg gacatttttt	10977
tgggtggtaa ttctttaatt accattccag tcttgctgct tgttattggt ctgttcagga	11037
tatccagtgc ttcttgattt aggcaggag ggttgattt ttacaagaat ctatctatct	11097
cttctaggtt ttctagttaa tatgtgtaaa ggtgttcatt atagcctgc attatctttt	11157
atatttcagt agtgctactt gtaatatcgc ctgtttaatt tcttagtgag gttatttga	11217
ttttctctct tcttttcttg gttaatcttg ctaatggtct atctatttaa tttatctttt	11277
caaaaaacca gtttttctct catttattat ttgtgtgttt ttgtttgttt caatttcatt	11337
tagttctgct ctgaccttg ttatttctt tctctgctg gggttgggtt tggttgtttt	11397
ttgtttctct aattccttga ggtgtgacct tagattgtca gttgtgctc tttcagactt	11457
ttgatgtag gcatttactg ctttgaactt tctcttagc actgcctttg ctgtatccta	11517

-continued

gagggtttga taggttatgt cattattatc attcagttca aagaattttt taatttctac	11577
cttgattttg ttttcgaccc aatgctcatt caggagcagg ttattttaatt tccatgtatt	11637
tggaagggtt tgaaggtttc ttttggaatt gatttccagt tttatttcac tgtgggccga	11697
gagagtgcct gatataattt caattttctt aaatttatcg aggctcattt tatggcctat	11757
catatggtct atcttgagaa aagttccatg tgcgttgtaa tgtgtactct gtgggtgttg	11817
gataaaatgt tctgtatata tttgttaggt ccatttgcct caagaaacaa tccaatgttt	11877
ctttgttaac tttctgtctt gatgaacctg ctagtgtctg cagtggagta ttgaagtccc	11937
ctactattat attgctctct atctcatttc ttaggtctgt tagtaattgt tttataaatt	11997
tggaatctcc agtgttaggt gcatatatgt ttaggattgt gacattttcc tattggacaa	12057
ggccttttat cattatataa tgtccctctt tgtctctttt taccattgtt gctttaaagt	12117
ttgttatgtg tgtacttttg tttttttgtt tttgggtttt gctttataac ttgtattttt	12177
gtttcatagg tcctgtgtga tttatgcttt aaagaggttc tgttttcatg tgtttccagg	12237
atttgtttca agatttaggg ctcccttttg cagtctctgt agtggcggtg atggcaaatt	12297
ctctcatcat ttgtttgtct gaaaagacct gtatctttcc ttcataatg atgcttagtt	12357
tcactggata caagattctt ggctgataat tgttttgtt gaggaggctg aagataggcc	12417
ccgaatccct tctagcttgt aggggtttctg ctgagaactc tgcgtgtaat ttgatagatg	12477
tacctttata ggtaacctgg tgcctctgtc tcacagctct taagattctt tccttcatct	12537
taactttgga taaccttatg acaatgtacc taggtgaaga tctttttgca gtcaatttcc	12597
cagggtgtct ttgtgcttct tttatttggg tgtctaggtc tctcacaagg ccagggaagt	12657
tttccctaat tagtccccca gatataattt gtaggccttt agaattctct tctttttcag	12717
gaacattgat tattcttagg tttggttgtt taacataatc ccagacttct tggagccttt	12777
gttcataatt tcttattatt tttttctttg tctttgttgg attgggttaa ttcaaagact	12837
ttgtctttga gctctgaatt tctttctctt acttggtcaa tctattgct gagactttcc	12897
acagcatttc gcatttctaa aagtatgtcc aaagtttcct gaatttatga ttgttttttc	12957
tttaagctat ctatttcctt gaatatatct cccgtcactt cttctattat tcttgattt	13017
ccttgcatcg tgccttgtct ttctccgac cctccctgat caccctaata actaacctcc	13077
tgaattcttt ttcaggtaaa tcagaaattt cttcttggtt tggatccatt gctgggtgaa	13137
tagtgtgatt atttgggggt gttgtagagc cttgttttgt catattacca ggggtgggtt	13197
tctgattcat tctcatttgg gtaggcctctg tcagagggaa ggtctaaggc tgaagctgt	13257
tgttcagatt cttttgtccc acgggggtgt cctttgatgt agtactctcc ccttttctca	13317
tggaatgtgc ttctgtgag ccgaacttca gtgactgttg tctctcttct gaactagacc	13377
accagcagag tctacctgac tctaggctgg taccaagggt tgtctgcaca gaatccagt	13437
atgtgaacca tctatgggtc tctcagtcac ggataaccagc acctgttcca gtggagggtg	13497
tggaagggtc aatgaactct gagagggtcc ttagcttcgg tggtttaatg ctctattttt	13557
gtgctgggtg gcctctgtcc aggaagggtg gctttccaga aagcattaac tgcagtagtg	13617
tgaagaggaa ccggcggtga gctgggcctt agattcccaa gattacatgc cctttgtctt	13677
cactactagg gtgtataggg aagtaccatc aggttggggc agggctagggt gtgtctgagc	13737
tcagactctc cttgggttga tcttgttgca cctgctgtca gggatggagg tgagattctc	13797
aggtcactgg agttgtgtac ctaggaggat tatggctgcc tctgctgagt cttgcagggt	13857
gtcagggaag cagggtaaag ccagcagtc caggcctcac ccagctccca tgcaaaactga	13917

-continued

```

nnnnnnnnnn nnnnnnnnnn nnnnnnnnna aggtatgtag ggtatctagt aggaaaagca 16377
ccctgggagg ctaaagcagg aggatcactt gagctcagga gttcaagact agccttggca 16437
acacattgag atgctgtctc tacaaaaaa attaaacatt agccaagtgt ggtggtgcat 16497
acctatagtc ccagctactt gggaggctga ggcagaaggg ttgcttgaga ccaggggggtg 16557
gaacctgcag taagccatga ttgtgccact gtactccagc ctgctgaca aagagagaac 16617
ttaacaaaac aaaaacctca tagattctga caaaaaagac acgatgcaaa ataatactgg 16677
tgtgaggggg aattacggga gacactcatt tatgttttgt cttctctgtt taggaggtgt 16737
ggtgtaagga gtgacatttc ggccctcac actgtttatt cttttgcagg tgggtgagat 16797
agaagtctat aaaggggaaa gagaagaagc tgatgctgaa acttaagaga tatttctcca 16857
agactagaga aagacaagaa gaaaggagcc tctgagagtg ataaggagcc caaggtttgc 16917
atgcatggag caccagtaag agatggcttc aggaagccag agagctaggc cggggacaca 16977
gataccttgg gaaccacagc gagagtgtcc gtgggctgag gcagtggtea gtggagagac 17037
ccattgagag gtgacaacat gctagtagcc ctgcctcget ctcggcacct cctcaagcca 17097
cgggtgtccac tctggccgag cttgaggaa ccttctgctt gcagggaggt gtggagggag 17157
aggcgcgggc gggaaacggg gccgtgcccc gtgctcgccg gccagcgcca gttccggatg 17217
ggcggtggct cggcgggccc cgcacttgga gcggccggcc ggccgccagg caccagtcag 17277
tgaggggctt agcaccggg ccagcatctg cagagggtgc gccgggtccc tcagcagtgc 17337
tgccccaccg ggtcgcgct cgaattctcg tcgggctca gctgccttc tccccggt 17397
cccccgactc ccattgctgg cgaactggcag cccgccatgc gcgagcccc ggagccccgn 17457
cgccccgccc cctccccacc ccctgctcgg cgccgcccgg ccccatcgat gcccacggc 17517
tgaggagtgc gggcacatgg cggggcactg gtgggcagct ctgccagcag ccttggggcg 17577
ggaatccact aggcaagcc agctgggttc ctgagtggag tggggacttg gagaactttt 17637
atgtctagct ggaggattgt aaatgcacca atcagcactc tgtgtctagc attggtggg 17697
ggcaggggtt cgtagacgca ccaatcagca ccctgtgtca agctcaaggt ttataaatgc 17757
accaatcagt gctctgtgtc tagctaactc agtagggact tggagcactt ttatgtctag 17817
ctagaggatt gtaaatacac caatcagcac tctgtgtcta gctcaggat tgtaaacgca 17877
ccaatcagca ccctgtcaaa acggaccaat cagctctcta taaaacagac caatcagctc 17937
tttgtaaaat ggaccaatca gctctctgta aaatgggcga atcagcagga tgtgggtgga 17997
gtgagataag ggaataaaag cagggtgcca gagccagcag cgccaatctg cttgggtcgt 18057
ctaccatgtt gtggcaggtt tgttcttttg ttcttcctaa taagacttgt ggtgctcac 18117
tttttgagc cttgtgcct ttatgagctg tgacactcac ctgaaggtat gtagcttcac 18177
tcctgaagct agtgagatca tgaaccact gagaggaaatg aacaactcca gtgctgcctt 18237
aagaggtgta acactcccag cgaatgtctg tagcttcact cctgaagcta gtgggaccag 18297
gaaccagca gaaggaagaa actccgaaca cgtccaaaca tcagaaggaa caaactccag 18357
tcacactatg tttaagaact gttaacagtc accatgaggg tctgcagctt gattattgaa 18417
gtcagtgaga ccaagaaccc accaattacg gacataccat gggaaacagtg tccctcagcc 18477
tgctgaaaga atccctgtgc aagggcaggg agggctggtc tgagtaacaa agtccgtag 18537
cagagcagac tgaggcaatg aaacccaatg cttccagtta agactgggccc ccgccccact 18597
ggctggatag gacaacgacc cttcccaact tcgattatat tttctgtatt tatttattta 18657
ttttgagatg gagttttgct cttgttgccc aagctggact acaatggcat gatcttagct 18717

```

-continued

cactgcaacc	tccacatcct	gggttcaagc	gattctcctg	cttcagcctc	ctgagtagat	18777
gggattacag	gcaagcgcca	ccaggcccag	ctaatttttt	gaatttttag	tagaaacggg	18837
gtttcaccat	gttagccagg	ctggtctcaa	attcctgacc	tcagggtgtc	tgccctcctt	18897
ggcctcccaa	attgtctggg	ttacaggcgt	gagccactgc	gcccagctta	tttgaagag	18957
gaactactca	gactgtgttc	tctccctttt	actctcccca	aggaagcgaa	gaaaattatc	19017
aatagaaaat	ggcaggccga	gcatagtggc	tcatacctgt	aattccagca	ctttaagaga	19077
ctgaggcagg	tgggaatact	aaggttagaa	gttcaagacc	accctggcca	acagagcggg	19137
tttcatttaa	aaaaaaaaaa	aaagcaagtt	tattaaggta	aatgaataaa	acaatggcta	19197
ctccataggc	agagcagctg	aaaccctgtc	tctactaaaa	tacaaaaatt	agccaagcgt	19257
ggtggcacat	gactatagtc	ccagctactc	aggaggctat	ggcaggagaa	tcgcttgaac	19317
ccgggaggca	gaggttgtag	tgagctgaga	tcgcaccact	gcactccaga	ctgggcaaca	19377
gagtgcagct	ctgtctcaaa	aaaaaaaaatc	aataagtaaa	atcttaaaagt	agcaaatgac	19437
agttgcagcc	aagtaattcc	aaaagccagc	ttcactcgga	gaaccctgtg	cttctcttta	19497
tttcacgca	tccacatatt	tagagaaaact	tttccagtaa	taaaccatag	aaattatacc	19557
tggaaagtag	gtcttcaact	tggattttta	ggtgacctta	acaaaagggg	gaaatttccc	19617
aaaacatatc	cgaaatggac	tttctcactg	ctttggctag	tcgagggtta	gaatcagagg	19677
taattttaga	acatatagat	gaggtgacaa	ctcatacacc	caagtatgta	gagcaactca	19737
tatctacccc	actgcatttg	gagggaaaagt	gtttccctgg	tgaacttggt	agtataaata	19797
gatggaagaa	gatgtactca	aaacagcaaa	cttctaatta	tacaaaatgt	tatatatttct	19857
gcttagtgaa	gccacatcca	tgtagattat	gatgctctaa	tcattacacc	tgtcaacaca	19917
atgaaatagc	tcaaattctct	gaaaaacttt	gcttcactct	taatgatgtc	aaaaattaca	19977
actcaaatca	aattctcatg	tctctaata	aacctcaact	ctgcaaat	cttatttta	20037
aaatgctgtt	ttagccaaag	aaatgtttca	aaaattctgt	attcaggcca	ggcacggtgg	20097
cttacgcctg	taatcccagc	actttgggag	gccaaagtgg	gtggattgct	tgaggtcagg	20157
agttcgagac	cagcctggct	gacatggtga	aaccccgctc	ctactaaaaa	tacaaaaagc	20217
cggatgtggt	ggtgcatgcc	tgtagtccca	gctactcagg	agactgaggc	aggagaaatca	20277
cttgaacgca	ggaggcggag	gttgcagtga	gccgagattg	tgccactgca	ctccagcctg	20337
ggtgacagag	cgacgctccc	tctgaaaaaa	gaaaaaaaaa	ttctgtattc	acaaatagct	20397
tgatactagc	aatcacttgt	ttacattgta	aataggcagc	aggctgaaaa	tttttgatga	20457
cttaattgca	ggttcacagc	tatgaaggca	agccaaaagg	ctaccttgcc	aggtctgtaa	20517
aactgatgta	catagtatga	gctgcttgat	ctttgagtaa	tcacaaaaga	caaatcaggc	20577
tgggcatggt	ggctcatgcc	tgtaatccca	gtgctttggg	aggccgaggc	aggtggatta	20637
cttaagggtca	ggcattggag	accagcctgg	ccaacatggt	gaaatcccat	ttctataaaa	20697
aaaacaaaag	ttagctgggc	atggtgggtg	gtgcctgtag	tcccagctac	tcaggaagca	20757
gaggcaggag	aaccgcttga	acccgggaag	tggagtgtgc	agtgagccga	gatcatgcga	20817
ctgcactcca	gcctggggaga	cagagtgaaa	ctctgtctca	aaagaaaaaa	aaaaaaggaa	20877
agaaataaaa	gacaaatcag	caaaaagagg	aattcataaa	aagagaataa	agctttgcaa	20937
aaaaagaacc	tgtctttgga	tcttcagaag	tgactaaaaa	attttaaatag	gtccctttta	20997
gtgcctcttt	ttgcttgctt	atgaaatatt	gacagatctt	cccaactggg	ggaaaaaaa	21057
cccaaaatc	attaaactca	ctgtgtctta	tttggttaaa	taaaaagagg	tagaaagact	21117

-continued

attatgagaa aagagaagca atagaaactg tggaaattgg agttccaaac atcaatctta	21177
atttgattga atagtagaaa gtatataaac tatggaaatt gatgttccaa acatcaatcc	21237
gcattcctga gcaattttca aattgggtcac cagctctcca ctctcctgt catgagtcac	21297
ttatacctta aaaagtatat cctctgagaa ttctgaaagg tatccagacc ttccattaga	21357
caacttccaa tccatatgtg cctcaaagt gtgtcttcat ttctcctctg ttccatttcc	21417
ttcagatttc caccaagata tgcattgtga gctttgttt gagactacat ccagatgtca	21477
cctacctctc ctgtggcctt aaaaagattc tataagcaca gagagatcag cctgagacat	21537
ctgaagacct aagcctgcat ccttctggt ttttgatta agggaatgta aagatgagag	21597
gaaaatgagc aaggcgaggt gataactcat ttctaaataa aacaggaata tttttaaaaa	21657
tctgacactg ctaaaggcca agtcatacag taggattccc accaggccag gctgtaata	21717
ttgattctcc tctctgcaac cccagtgttc aggcctcaga gtaacagtct tagttcctcc	21777
aaccacattt ctaaccacaa ggtcactgca cacttcacca nctggcctct tctttagcac	21837
aacaattgta agtttagaga tgttatcatt tatttgcagt cgtccacag atgttgggac	21897
ttggaaaaac ctctttata atcaaatagt tccggtgttt ttagtattga aaagcactgt	21957
tcgaaagtta tctcatttaa tctttacaac tgttgacttt acagataaag aaaactgcag	22017
gatcagaaaa gttaataaa tgcccaagga cacacaactt gtaagaaaag aagccagggc	22077
taggctaggc cggctgcagt ggctcacgcc tgtaatccca gaacctggg aggccaaagc	22137
aggcggatca tctgatgtca ggagtctgag accagcctgg ccaacatggt gaaacccct	22197
ctctacaaa aatacaaaaa ttagctgggt gtggtggtgg gaacctgtaa tcccagctac	22257
tcaggaggct gaggcaggag aatcacttga acccaggagg tggaggttgc agtgagccaa	22317
gatcgtgcac tccagcctag gcaacaaaag tgaactccg tttcaaaaaa gaaaaaaaaa	22377
aaaagaagcc agggctaaaa cccacctgtg ccttcatct tctagttctg ggttcttttc	22437
atgccaccaa ttgcacttca aagaagtga aacattttga agttttgat aagactagta	22497
gcaaggctta ttttcaaata gtctatgaat ttttatagct tgtagaaggt ctgaggaaga	22557
tataatttca ttgtatcac ttcagaagca atacaaaaa agtattatc ctatttcttt	22617
attttatatt ctaggcctat tagagaacaa taaattagat aaactcaaaa tccacttagg	22677
ccttcatgta tccttttttt ttttttttt tttgagacca agtctcactc tgtcaccacg	22737
gctggagtgc aatggcatga tctaggtcca ctgcaacctc ctggtttcaa gcgattctct	22797
caactctgcc tccggagtag ctgggactgc aggcacgtgc caccatgccc agctaatttt	22857
tgtattttag tagagatggg gtttcacagt gttggccagg ctggtcttga actcctgacc	22917
tcaagtgatg agcctgcctc agcctcccaa agtgctggga ttatagacgt cagccaccac	22977
acccacctg ctctgatatt tattattct tttcttctgc taattttgag tttggtttgc	23037
tcttgctttt gtagttcttt aacacgtacc attaggttat ttatgattat tagattagtt	23097
tttcttcttt ttaaatgtag atacctataa ttataaaatt ccctcttagt actgcttttg	23157
ctgtattcca tagttttggt atgttctgtt tccattatca tttgtttcaa caaatttttc	23217
aatttccctc ttaatttctt cattgaccca ctggctcatc agaagcatat tgtttaattg	23277
ctgtgtattt ttatagcttc caaatctctt gttttgttac attgtggtca gagaagatgc	23337
ctgatgttat ttcaattttt ttgaattttt taaagccttg tttgtgatt taacatatgg	23397
tctattcttg agaataatcc atgtgctgag gagaagaatg tgtattctgc agccttcaga	23457
tgaaatgctc tgtaaatatc tattaggtcc atttgttcta tagtcagtt taagcctgat	23517

-continued

gtttccttgt	tgattttctg	tctagaagat	ctgtccattg	gtgaaagtgg	gatgttaaaa	23577
tctccagcta	ttattgtact	gagggctgtc	tttttacctt	aaataatatt	tgctgcttca	23637
tatatctgga	tgctccagtg	ttgggtgcat	atataattgt	tatatcttct	tgctaaactg	23697
actccttgat	tattatataa	tgaccttctt	tgtttctgcc	gcctatagag	acaagaagg	23757
ttattatata	atgatgaaag	agtccagttt	tttgtgtgtg	ttgtcatttt	ttgagatgaa	23817
gtctcactct	ttcaccagg	ctggagtgc	gtggcacaat	cttggctcac	tgcaatctct	23877
gcctctaggt	tcaagtgtat	cccctgcctc	agcctccga	gtagctggga	ctacaggtgc	23937
ccactaccac	acttggctaa	tttttgattt	tttagtagag	acagggtttt	caccatgttg	23997
gccaggctgg	tctccaactc	ctcatatcaa	gcgatccgtc	cgtctcagcc	ccccaaagtg	24057
ctgggattac	aggcgtgagc	cactgtgcct	ggccattgt	atgtttttca	atttgggggt	24117
accatgaggc	ttgcaactac	tgtttcataa	ccattgtttt	caaactgatg	acaacttaac	24177
actgattgca	taaacaaca	aataagcaaa	aagaaaacta	ataaaaactc	taaacttcat	24237
cctcctgctt	tttaactttt	tgttgtttct	cttcattgtc	tattgtactg	tctgtcatga	24297
caaattgctg	tagttattat	ttttgattag	ttcattgctt	agtctttctg	cttaagagta	24357
ttttgaacac	cgtaattaaa	gtgttataat	attctatgtc	tttctgtgtg	ctattaccag	24417
tgagttttgt	agcttcacgt	gacttcttat	tgctcatcaa	tgctcttttc	tttcagatgt	24477
aagaactttc	tttagcattt	cttttttttt	ttttgagatg	gagtctcact	cttttgccca	24537
ggctggagtg	cagtagcatg	atctcagctc	actgcaacct	ctgcctccca	tgttcaagca	24597
attatagtgc	ctcagcctcc	caagtgttg	ggctctacag	catgcgccac	cacaccagc	24657
taatttttgt	atttttagta	gagacacctg	accatgttgg	tcaggctggg	ctggaactcc	24717
tggcctcaag	caatccaccc	gcctcagcct	cacaaactgc	tgggattaca	cgcagtagcc	24777
accacgcttg	gcctccttta	gcatttctta	taggacaggt	ctagtgttga	tgaaaatccc	24837
ttagcttttg	ttgtctggg	aaggctctta	tttcccttc	atgcttaaaa	gatatatatt	24897
gctgaatata	ctattctag	gttaaagttt	tttttttccc	ttcagcattt	aaaatatgtc	24957
atgctagttt	ctcctggcct	ataaggtttc	cactgaaaag	tctgaggcca	gatgtattgg	25017
agctctatta	tattttattt	gtttcttttc	tggtgctggt	tttaagatcc	tttctttatc	25077
tttgaccttt	gggagtttga	ttattaaatg	ccttgaggtt	gtcttttttg	gattaaatct	25137
gcctgatggt	ctataacttt	cttgtacttg	aatattgata	tctttctctg	ggtttgggaa	25197
gttctttggt	attatccctt	tcaataaaact	ttctatcccc	atctcttctc	caacctcttc	25257
tttttggcca	atagtgttta	gatttgccct	tttaaggcta	ttttctatat	cttgtagaca	25317
tgcttcattg	ttttttactc	tttctttttg	tctcctctga	ctgtggattt	tcaaatagcc	25377
tgcttccaag	ctcattaatt	ctttcttctg	cttgatcacg	tctgttatta	agagaccag	25437
atgcattctt	cagcatggca	gttgtacttt	tcagcactag	aatttcattt	ctttttaata	25497
acttcaatct	ctttgttaaa	tttgtctgat	agaattctga	attcctggcc	aggcgcagtg	25557
gctcacacct	gtaatcgag	cactttggga	ggctgatcac	ttgaggtcag	gagttcaaga	25617
ccagcctagc	caaatggca	aaactccatg	tctactaaaa	acataaaaaat	tagttgggtg	25677
tggtggcaca	tacctgtaat	tccagctact	taggaggtg	agggtgggaag	atcactgaa	25737
cccaggaggc	agaggttgca	gtgagccaag	atcgtaaccac	tacactccag	cctgggcgtt	25797
catctcaaga	aaaaaaaaa	agaattctga	atttctgttt	tggtgttctt	ggatttcttt	25857
gagtttcttc	gacacagcta	ctttgaattc	tctgtctgaa	aggtcacata	tctgtttctc	25917

-continued

caggattggt ccttggttcc ttatttattt tgtttggtga ggtcattttc tcttgatgg	25977
tcttgatgct tgtatagttt cgttaatgtc tgggcattga agagttaggc gcttattgta	26037
gtcttcacag tctgggctta tttgtgcccc tctccttggt aaaggctttc cgggtatttt	26097
gaaggaaactt gggccccaag tccaataata ttatgtttct tgcagactca tagaggtgct	26157
gctctggtag tcttgataa gatctggaag aattctctag attaccaggc agacactttt	26217
atTTTTTct cttatttttt cacaagcagc gtctctccct gactctgtgc tgaagtccct	26277
ggaactggag gtggagggac acaagtaccc tgtagccacc accaccagga ctgtgctggc	26337
tgagacatga aaccagcaca gcaactgggc ccaccaagg cctgctgtaa ctactatctg	26397
gtaccacct aagttcactc taggacctag ggctttatga tcagcatatg gcaaagccag	26457
tctgatttat gtccctccat tcagggcagt gagttcctcc agacctagggt tgggtccagag	26517
atgttgtctg agagccagggt atttaagtca aataccttag aaatttaccg ggtattctac	26577
tctactgcag caaagctggc actcaaacca taagacaaag tcttcccaac ttttctctcc	26637
ctgtggccac caccataagc accccacgag gggttctgcc aggtaccgc tgatgttcac	26697
ttaaagccca agggcccttt tgtcagcttg tgatgagtgc tgccagacct gacactcact	26757
cttcagagta gtgggcttcc ttctgggtcca tggcagggtcc agaaatgcta accaagagcc	26817
taggcttgga cgtggggacc tgaagagtct gcttattgct ccacccact gtggctgagc	26877
tggtagctga agtgcaagac ggagtcacct ttactttccc cctgttttt ctcaaacaga	26937
aaagatcttc gctgtagcca ccacagctgg gaatgtgctg ggtcacactt gaagccagca	26997
tgtctcagag cccaaggccc atagtgtatt acctgggtat tgctgggtgt tattcagggc	27057
ctaggggctc ttttgcagc aggagatgaa tctgcccagg tctccactgt gagacggcag	27117
cactaagttc aatgtaaagt ccccggttg ctgtgctctc cctctcccaa gcacaaagat	27177
ttctctgcac cacatggcca ctgctggggg gtgaggggag ggtgacaaaa gcacctccc	27237
aaagcccccc ggctggtgct tcagtagggt tcatgcctgc ccagtcactt ggctctgagc	27297
ccagctcagc actaggactt gcctaggaat tgcactcctt gtgacctaga ctgacctta	27357
agttcactta gtgccccaga gcactccagc ccacggtaat gaggttgcct ggaactcaag	27417
ctccaccag tgggatggac aatttctctc tggctagagc tgggccaaat gaacatcagc	27477
tgagtagaac ctggttctgc tttccactgt aacaggggag cactgggttc aatgaaaagc	27537
ctcacaattg ctgcacttcc cctctcccaa gcaccagat tctctgtgct acatggccgc	27597
tgtgtgggga tgaaggagggt gtggcgctag tgcttcaatg ctgtcttccc tgccctcttc	27657
aatgtctctt tcagtgatat aaagttaaaa tcaggtaacta tgattgctca cctgattttt	27717
ggttcttatg atggtgcttg ttgtgtgtag ttagtagtta aaatttggtg ttgctatgtg	27777
gaggatgaac agtataagcc tctatcagcc gtcttgctct acccattct ctgttaattt	27837
ctcaggcacc aataagtgtg tgtaactgta atatgcccac taccatgt gcacagcaag	27897
tcaacgtgct gatataattg attgcagcag agaaagaggt ttaagcgaag ggttgcgtgaa	27957
tgaggaaatg agagtaaacc taaaatccat ctccctgaga aatttggggc taggattgtt	28017
aagggttttg gagttggctg aagtgtggag atattgattg gtcgaagagt gcagggtgaa	28077
atcatggccc aggaagatga aaaaatgtgt tttcatgctg attcagttct gctgtggggg	28137
tcttcaact ggttgccatc agccattcca ctggaattca gactctgctt aagcaattct	28197
taaaacaagtc ttatgaatct aatgtcagaa atcctatcta taggaaaaac aggggttcaa	28257
attgtgagta tctagtgcta tgtgactttt gggtacaaag aagtgggtca aatatagca	28317

-continued

tgattaatgc ttaattatag ctatatctct gtccaaaatt cttattaacc ctgtgagaat	28377
ggctttatta gtaattgga agtcaagtct gtgctttcta gcaatagcac tgggtatttc	28437
taccctagta gaaggcacgc acatatagcc aatgtcttat ccttgcttct ctgctcttct	28497
atgtgttgaa ttaatttttag ctgggctggg aacagtgacc ttcagcatgg ctccaatcac	28557
tttatactta ccaggaagc tttttaaaca tttcattcct aggccttgct ttatatgtac	28617
ataagtcaaa gttcctggag gtgggtgtct aaaatctgta tctttatctt tatcttctg	28677
aataatttta ggaccatatt tagcatttga aaacctctgg cataggctat gcaaacagaa	28737
actctcttat ccgacctcta cttaactggc ttttcaattt tgtaaaatgt aagaaatgag	28797
gctcacagca tgttgctacc ctctctgtat tctccagtgg taattattgc ttagtgtgta	28857
ttctttcagg ccacttctaa tgtacttcaa tggataaata tgtgcttatt aaatatatat	28917
agtagaaaa atgcttttaa gaaaatggca tgctgatga atccttctgc aacttgcttt	28977
ttacacctac caatggaatt tggagatctt ccagataag aatacatggc tccatctcat	29037
ccttattaat agctgcctag tttttcaaag ttggacctgg tttatttagg tggtcattta	29097
ttgatggaca ttttaagctt aacatctctt cctattttta acaatggtcc aatgaatatg	29157
ctgtacatt tttcctgtg tgcattggag ttaaaatgca gtcattgagt gtgcatttta	29217
aacatttcag tagaatctgt caaatccgc ttacaggtta ctgcaccaat atatattccc	29277
accagcagag catgaaatat ctattttatc catgggcttg ccagtatttg ataatatcaa	29337
acttgattat ttattttatt atttgacaca gggctcttgc ctgtcaccca ggctggagtg	29397
cagtgtgtgc atcactgctc actgcagcct caatcttcca ggttcaagtg atcttccac	29457
ctcagctttc caaggagccg ggactacagg tatgcaccac tatgtccagc taatttttgt	29517
atttttttgc agagatgggg ttttgccgtg ttgcccaggc tggctcctaaa ctctcagct	29577
caagcaatct gccacctca gcctcctaaa gtgttgggat tacagacata agccactgca	29637
tttgcccaa acttgatttt tttttcttg ccgatatac taataagtgt tacttcattt	29697
taataaaaa ttgcattttg ccatttttaa tgaggctgtg tttttgcata tgtttattga	29757
ccatttctat ttccactttt ttgaactgcc tgttgatgca ttcttataca taattgtgtc	29817
agtaatat ttgtttttga aaattaaact tttctcttaa ttttaattt ttaaaaatgt	29877
acatttgggg catatgtgat aatttaatac atttatatta tttgtaaaga tcaaatcagt	29937
gtaattgaga tatccattac cttaaataat tgtcttttat ttatgctaga aacacttgca	29997
ttattgtttt ctagctattt tgaaatatgc aataaactat tgtaagctat agtttacaaa	30057
tatagtcact ctactgatct agcaaacact agatcctatt tcttctatca gactgtatat	30117
ttgtacccat taaccagct ttcttcatc ccctcaccct tcttggtctc tggtaatgac	30177
aaatttattt tcatcttcat gagatccact ttttaagctc ccacataaga atgagaacat	30237
gtgataattg cctttctgtg cttggcttat tttgcttaac atagtaacct ctagtcccat	30297
ccaagttcct acaaatgaca ggatgtcatt ctgttttata gattaacaat attccattgt	30357
gtatatatac cacattttct ttatccttcc gcccaatgat gggtaacttag gttgattcca	30417
tagtttggtt attgtgaata gtgctccagt aaacatgaaa gtgcagatat ccttttgaca	30477
tattgatttt gcttcttttg tatatatacc cagtagtgaa attgctggat catatagcag	30537
tttttagtta tttagaaaac ctctatatag ttttcataa tagccgtact aatttacatt	30597
ctcaccacca gtgatgagt gttcctcttt ctccacattc tcaacagagt ctgatattcc	30657
ctgtcttttt aataaaagcc attttaactg acttgatgata attcattgtg gttttgattt	30717

-continued

gcatttctct gataatgagt gatgttgaac atttttttat atacctgttg gctatatgta 30777
tgtatttttt tttagagaaat gtctattcag attgcttgcc cattaaaaca attgaatcat 30837
ttgtgtgggt ttttaaattt aaattaattt aatttttttt tttttttacc attgagttgt 30897
ttgagctcct tatatattct ggttattaat ttcttggttag gtggatagcc gtaaataattt 30957
tctcccatte tgtgggttgt ctctttgctc tgttgcttgt ttcttttgct gtgcagaagc 31017
cttttcagct tgatataatc tcatttgtca atggcagctt ggttggcctg tgttctggag 31077
gttcttacac aaaaatcttt gccagacca atatcttgga gagtttcccc aatgttttct 31137
tccagtagtt tcatgtctta gatttaagtc tttaatctat tttggtagt tctgttgtat 31197
acggaagaa ataggggctc agtttcattc ttttgcataat gggtatccag ttttcccagc 31257
accatttatt gaagagactg tcctttacct aaggtatgtt cttgggtgct ttgtcaaaaa 31317
tgagttggct gtaaagtgtt ggatttatat ctgggttccc tattttattc cactggtgta 31377
tgtgtttgtt tttatgccag tactatgctg atttggttac tatagctttg tagtacattt 31437
tgaagtcagg taatgtgatg cctccagctt tgttctcttt aattaaaaaa aaaatttaga 31497
ggcaggttct ttctctgtca ctctggctgg agtgacagtg tgctatcatg gctcacggca 31557
gctcaacct tctgggctga aatattcttc ctgccttggc ctgccgaagt gctgagatta 31617
caggttcaag ccatcacacc tggcctagct ttggtttatt ttgctcacga ctgctttgcc 31677
tatgtaaggt cttttgttgt ttcattgtaa ttttaggatt ttgtttctat ttctgtgaag 31737
aatgtcattg gtattttgat tgagattgca ttggatctat aaattgtttg gagtaagatt 31797
atcattttca taatattaat gatttcaatt catgagcctg gaacatcttt ccactctttg 31857
tgtctcttc aatttcttta atcagtactt tatagttttc cttatatata tatctttaac 31917
ttctatggat atatttggtc ctgatattt tatattcttt gtagccattg taaatgagat 31977
tgcttttttg atttgttttt cagattgtta ctgcccactt acagtagctt atgtaagtgc 32037
tactgatttt tgtagtttga ttttgatcc cacaattgta ctgactttgt tatttctaac 32097
aatgtttagg tgaagctttt aggtttttct aagtataaga ttatattggc taggcatggt 32157
ggctcatgcc tataatccta gtactttggg aggccaaagt ggggtggatca cttgaaccca 32217
ggagttcgag accagcctgg gcaacaaggc aaaatcccat ctctatgaaa aatacaaaaa 32277
ttagccagac ataatggtgt gggcctgtag tcccaactac tcaggaggct gaggcaggag 32337
gattgcttga gcctggaagg ttgaggctgg tgtgcagtta caccactgta ctccagcctg 32397
ggtgagacag agaggagac cctgtctcaa aaaataaaaa ataaaaatga aaataaaatt 32457
atgtcatctg tgaaccagac tgagttgact tcttcccttg ccatttggaa gccctttatt 32517
tctatctctt gcctaattgc tctggccaaa ataaaactct ttttaacctt agagaaaact 32577
gagcagccat agtctaccaa tgagttaggc tttggagatg gtgtgtcctg tgttctgaat 32637
atttgcaccc ctcaccaa ccaaattgtt aaatccctaat ccctaaggca atgggtactag 32697
gtggtcaaa cctttaggag gtgattatat taaaaagtt gaaccctcat gaatgagatt 32757
tgtgtcctta taaaataggc ctgagacccc ttacttcac cttgtgagga catagtgaga 32817
agtttccctc cattaggaag gtggccctca accagacacc aaatctgctg ttgccttaat 32877
cttggaactc ccagtttcag aactgtgaga aataaaattt ctgttatcta taagcgaccc 32937
agtttatgat attttgtgat ggcagcctga gtgaactaaa atggtggggt atgacatctt 32997
tgagctcatc aggatattgt gcagtacagt taagactgat tgaatttgca acagtaggac 33057
tgatccattg attacgtgac ctattgcagt atgcagaaag acaagggggt agaaccctc 33117

-continued

```

accttacacc aattagtacc tgtcagggtt tagtgcagga aaaagctatt ttaatcagga 33177
aggaacttag tagagaaagt tagatgctta caaaaccatt gaaagatggt ttgaaagga 33237
gcaaaaattg gtcactagga ctaggctttt ggcttcaagg tgatacattg ccacttctgg 33297
ggtccagagg tcaggaagcc actgtggcag tagaataggc aatgttgccc agcactgccc 33357
acactcacat ctattggagc ctacatgtgc tctgcacct ccacaggaat acaatggggc 33417
tccacctctc tccgcttctc ttttccttcc ttcgtccctc cctccctccc ctctctctct 33477
ctttctctct ctgtttttct tcttttcttc tttctttctt tctttcttct tttctttctt 33537
tctttcttct tctctctctc tctctctctc tctctctctc tatttctttt ttgacaaggt 33597
ctcactatgt tgccaaggct ggtctcagac tctaagtctc aagtgatctg cctacttcag 33657
cctcccaaa gtttaggatt ataggcgtga gccaccgtgc ccagcctagc cactgtgcct 33717
cactttcttc tattttcaaa tgtcatgtaa ctgcctcaag ggagagact acatctaaac 33777
tctagctgc aaggagcct ggatactgta gtttttagct atcaatgcaa aaaatagagc 33837
atgtgaagag aatagcagta gatgtgaat atcaaaagtc tccatccttc caaaatacag 33897
tcatgtgcca cataaccatg ttttggtcaa tgatgaacca catgtatgat ggtgatacca 33957
taagattata atggagcaca tatagaaacc tgatacctgg cacaagatac tggcactgca 34017
cattaagtgg gggaaaagat tgatattcaa taatggtgat agggcattta gttttccatg 34077
tgaagaatat atataataa taatatatat accttctagg tctgtggaag tacatgctac 34137
gatctttgca caatgacaaa atctagtgat gcgtttctca gaatgtgtcc cagttgttaa 34197
gtccgcgatg actgtattga aacttaagtt gccatctggc acttactagg tgcctacctc 34257
ctgcaaagca ttctcattta tctaatagat gaatgaataa tcacttaata ggtagaattt 34317
ccattaagtg tatcaaacctc tgctgataga cagtactcag tatctgtagt actctgcaaa 34377
tctcccatc ccccatttaa ggtatcaggg tctggcaggc gcagaagtga aatgggaggc 34437
aacagaagct ctcttagtcc ctctctctc caaatcagat ccttttacag ctgctcatct 34497
tcaggtcaga ggcagtgcac ctgtataact tgaaatcatg atagtctatt ttctaacatt 34557
ttattatcag tagatcatgt tttctttact caaacacact atgtgtaata gtcctcttct 34617
agccactctc atggcatatt actctatgaa acactttaat caaagataaa atgtgactct 34677
ttttgacatc ttaaaggcat ctaccccaaa aaggtatcta cagcaaacat ttattgctgg 34737
tgaaatcttt ctagtagatt acagttaata cattattggt ttattatcat ttgcatatgt 34797
atgggcaaca ctacgttttt tcaaaaaagg caacctagaa ataccatttg acccagccat 34857
cccattactg ggtatatacc caaaggacta taattcatgc taccataaag acacatgcac 34917
acgtatgttt attgcggcac tattcagaat agcaaagact tggaaccaac ccaaatgtcc 34977
aacaatgata gactggatta agaaaatgtg acacatatac accatggaat actatgcagc 35037
cataaaaaat gatgagttca tgtcctttgt agggacatgg aagaaattgg aaatcatcat 35097
tctcagtaaa ctattgcaag aacaaaaaac caaacaccgc atgttctcac tcatagggtg 35157
gaattgaaca atgagaacac atggacacag gaagggaac atcacactct ggggactgtt 35217
gtgggggtgg ggtagggggg agggatagca ttaggagata tacctaatagc taaatgacga 35277
gttaatgggt gcagcacacc agcatggcac atgtatacat atgtaactaa cctgcacatt 35337
atgcacatgt accctaaaac ttaaagtata ataataataa aataaaataa gaaaattaaa 35397
aaaaataaaa taaaaaata aaataaata agatcatatc attaaaaaaa aaaaaaaaaa 35457
ggctagcttg gaaccaggc accacacgcc attactggct tctgagtac acatccttta 35517

```

-continued

gctcttacct acaattctct cctagaaatt attgtttgaa tgctgtgtcc agaaggtaac 35577
 atatatatgt gtatacacac acacatacac acatgtatga aaaactaaat tgctgcttag 35637
 acatatagaa aagttttcca aatttttgaa ttcataaagt ctatcaacct gatagcattt 35697
 ctcaaaaaat tttttcaatg ggtagaggac ttgtgctttt cttttattct attgagaaat 35757
 tctcaaacct ctaagaaatt gtgcaaagga aatttaaadc atatgaagga catagtcaaa 35817
 atgtgtagct acaaggacta cacatttcaa ttgttgagaa acagtttact ctcaataatt 35877
 tgtgaatggt tgttttaate tgccaaatcc tgaggaagat agtgtaaaaa gatataattt 35937
 ttaagggtatt ttaataaat ctggtaactt tttgatcaga ggacattcaa ataaaaatgta 35997
 gagtatagag cagaaattca gatgcagttt ttttaaaatg taatgtatgg gccgggcttg 36057
 gtggctcaca cctgtaatcc cagctaggag ttcaagacca gcctggccaa catggtgaaa 36117
 cccagctctct actaaaaata caaaaattag ctgggtatgg tgacgtgcac ttgtaatccc 36177
 agctacacaa gaggctgagg caggagaata gcttgaaccc aggaggtgga ggttgcaactg 36237
 agccaaaatc acacctctgt gcctcctgag tgacacagcc agattctatc taaggnnnnn 36297
 ntttgggggg gccccnana aaaaattctg gcccagtggt gtggtttttt tttggcccga 36357
 aaattccaaa aatttgccca aaaaaaagt gggttttttg aaattttaaa ttgggcggtt 36417
 tttttcccc cctcnnggtt gtggggagggt gggcccccct tttttctctc cccctttgaa 36477
 aagggggggt ttccccctgt ttccccgaa tttccccggg tctttttggg tatctcttgc 36537
 caccggttcc cccccccctt ggaagggtta aggggggggtg gggtaaaatt ttttaagcc 36597
 cttttcaacc ctcttcccc gggttttggg cccttggggg ggagtcctaa aactcttgcc 36657
 cgccccccct tccccattt tgtgtggaac taaaaggccc gtctttctat agggggtctc 36717
 cccgccgggg taaaaagccc ccacacccca aaaaactctg ttgtgtgggt ggtttttnnn 36777
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 36837
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnacag ccttttaaaa ataatttct 36897
 aatattgtca tgcacacatt aattatttct tgattaaaag aatcaaaatg gtttcagttt 36957
 ctttattcaa tttctataca tatagtttta caatttattt ttaattttt tagggaggaa 37017
 aaaaaacagg ttgtcctggg atattgatcg tgaagctgat cattcctctt gctgtgtgaa 37077
 gagcttttat gacaaaaatgc attctcccaa aacaaagtac ataatgatta taaatgcagc 37137
 aaaaattgcac actatgaaaa accaaaatgc aatgagggat gaaaaagaa acccttttca 37197
 acatttaaac aataatgtag caaaaccctg tgtacattat aaggagcagc tttactaagg 37257
 atttgtaaga attctaactt gtgatatgac aaagataaac agaaaagtgg acagtctact 37317
 tagtacttgg ttcagtagt ccttaggata aaatgatact ggggttggtc aagtatccaa 37377
 ctcaacctg gttgatctca tcgtccctct gcctgcttag tctcccttat tcttctgaat 37437
 gaagagattc agaagattca tggtatagga taatgtggat attggttcac atagcccggc 37497
 cagtattcat tcaactctct tggagttaag taaagggtgc cttcctttct cttgggaaat 37557
 tttgtccctt gccattgtc agtcctgtga gctgagtaag tgggtgcaac cacattctca 37617
 gctccttttg ttgactgtta actaagacca gaccaatcgg agcatccctt cccttagcca 37677
 cagtgactga ttcaggaatg gcaccacccc aatcagaccc actctgaacc aatcccacaa 37737
 ctattgtcga agggaccaga aaagaggat tatttttttt gttgctggat gaaagttgtg 37797
 aagattaggc cagctgttct gctgggcttc acctttctga cgatgacctt ccagagagta 37857
 aagtgtacat gagggaaatt ctagccaaga gatggacctg actcagtaac ataattgaat 37917

-continued

```

cccgaaatcc ggctgtgtgc aaactggctc gtgttaaaag ccagtagaga tccccatttt 37977
gctatgggaa attttattaa tagagttttt ctageccttg caactacaag aatccaaaca 38037
aagagaagga aaggggaggc caagttgcat gccttgaaga gaaagagcac atttctctat 38097
gcccattcaa atctcactag ggtagggaca gtgccattgg tttcatcata ttccctacac 38157
tgcaaagaca ttattttcta gaaatttgat acacgtatat taatatgact taacagcaaa 38217
gcaagtgaag gcagccattc acagtccatg tggtagcag tgaagatcta ggtagtgggt 38277
taatacgggc aaagtcaaaa aatgagataa gaaaatgcaa tgtccagatg cccctgcagt 38337
ttctgtacct gccagctaata aattctgccc cagccaagca aaaggatctc cttccactgg 38397
gtaggagagg cactctctga tgatccagac tggttagctg cttctttctt gtgaggaaac 38457
acaacacaaa gcattttttc aacttttatt ttatgttcag gagatacatg tgtaggtttc 38517
ttacttgaca tattgcata cactgaggtt tggggtagac atagtcccat caccaggtta 38577
gtaagcatag tgctctatag gtcattttcc aggccttgcc tctctccatc tgctcttcta 38637
gcagttgtca gtgtctactg ttcccatctt tatgtccata tctaccaat gtttagcttc 38697
catttaaagt gaaaacatgc agtatgtgtt tttctgctcc tgtgttaact tccttaggat 38757
catggcctcc aactgcattc atattgtcac aaaggacatg atttcattct tttttatggc 38817
tgtattgtat tccatgctgt atagtatca cgttttcttt atccagtca ctgctgatgg 38877
gtatctaggt tgattccata tatttgcgtt tgtgaatagt gctgtaatga acatacaagt 38937
gcctgtgtct ttttggtaga acaatttatt ctcttttggg tatataccca gtaatgagat 38997
tgctggatgg aatggtagtt ctatttttag ttctttgaga aatctccaaa ctgctttcca 39057
tagaggctga accaatttac attccacctc tcagtatata agcattccct tttctccgca 39117
gcctctccag catctgttat tttatgtttt ttgagaccaa gtttcgtctt tgttgcccag 39177
gctggagtgc aatggcatga tctcggctca ccacaacctc tgccttcttg gttcaagcga 39237
ttctctgctc tcagcctccc tagtagctgg gattacaggc atgtaccacc acgcccggct 39297
atttttgtat ttttagtgtt tgccggattt ctccatgttg gtcaggctgg tcttgaactc 39357
cccacttcag atgatctgcc tgcctcagcc tcccaaagtg ctaggattac aggcgtgagc 39417
tgctgcaacc agccagcatc tgttattttt tgtcttttta atagtaacca ctctactggt 39477
ataaggtggt atctcattgt ggttttgatt tgcattttct tgaagattag tagttttgag 39537
cattttttca tatgtttgtt ggccacttgt atgtcttctt ctgagaagtg tctgttcatg 39597
ttctttgctc attttttaat aaggttggtt tttgcttggt aagttcctca cagattctag 39657
acattagact tttgtcaaat gcatagtttg caaaaatttt ctccattctt gtgggttata 39717
tgttttagtct gttgagagtt tctttgctgt gcaaaacctt tttagtttag ttaggttcca 39777
cttgtcaatt tttttttatt gcaattgctt ttgaggactt aatcaaaagt tctttgctaa 39837
ggccaatgtc cagaatggta tttcctaggt tttcttccgg gatttttatt gtttgaggta 39897
ttacacttaa atttttaatc catcttgagt taatttttgt atatgatgaa agggagggat 39957
ccagtttcat tcttctgcat atggctagcc agtaattcca gcacctttta ttttattaaa 40017
tagagaatcc tctccccatt gttgtttttg tcaactttat tgaagatcag atgggtgtag 40077
gtgtgcagct ttatttctgg ggttttcatt ctgttccatt ggtctgtgtg tctgttttta 40137
taccagtgtc atgctgtgtt ggttctttct aaccttatag tataatttga agttgtataa 40197
tgtgatgtct ctggctttgt tctttttgct taggattgct gtagctattc aagctttttt 40257
ttctttttgt ttttttttgg ttccatatga atttgagggc cgggcacagt ggctcacacc 40317

```

-continued

tgtaagtgtg cctcagcctc agacgccgag gtgggtggat cacctgaggt caggagtcca	40377
agaccagcct ggccaacagg gtgaaacccc gtctctacta aaaatacaaa aatttgctgg	40437
gcatgttggg ggggtgcctat aatcctagct acttgggagg ctgaagcaga aaaattgctt	40497
gagtcctggga ggcagagggt gcagtgcctc gagatcacac cattgcactg agcgagactc	40557
cgtctcaaaa aaaaaaaaaa agaaaaaaga aaaaaaagaa ttctgggata gtttttttct	40617
aattctgtaa aaaatgacat tggtagtttg ataggaatag tgttgaatct gtagattgct	40677
ttgggcagta tggccattcg aatgatatta attcttgcaa tccatgagca tggaatgttt	40737
ttccatttgt ttttatcctc tatgatttta aatatttttt tagaacaag gaatcattgg	40797
atgtcctgcc aaaaccagat gggagaaaagc catgtgtatc tatcaattgt gactttgcat	40857
tttttcttgt gaagtgtctc ttgtgttgta aagaagaaaa aggaaaagga aataaaaaag	40917
aatcatgggt ttgactatta caactgaaac agagcttcat aatcattttg ttccatcttt	40977
tttccatccc tcccttttct ttcttctctc ttcctctctt cctttactcc ctttctccct	41037
tcactactct ccttttcttt cctctctctc ttctcttttt tgcgccaccc ttcctctctt	41097
cctctcttcc ttccttctct ccttctcttc ctctctctct ctctctctca atcactcact	41157
ctctctccct ccttctcttc ctctctctgag gtctgacagt gagatacgcc caagggcaca	41217
tagctaaact gttggcaggg ccaggactca agtgaactca gctgaccact gattctgtta	41277
cattgttttc tccatatttt gacagacact aaggaccatc aaaagctgtt ctaaatgtgc	41337
aaatcaacca gtctgttggg ttataccta atggtataaa agagtaagga actggctggg	41397
cgccatggct cgcacctgta atcccagcac tttgggaggc tgagaggggc agatcacctg	41457
aggtcaggag ttcgagatca gtctggccaa catggtgaaa ccctgtctcc actaaaaata	41517
taaaaaatta gcccgcgtgg tgggtgcctc ttgtagctcc agctaccag gaggctaagg	41577
caggagaatc tcttgaaccc aggtggtgga ggttaaaatg ggcaaagatc acaccactat	41637
actctgcct gggtgacaaa aggagactct ttcaaaaaaa aaaaaaaaaa aaggaaagaa	41697
aataaagaaa caaaaaagaa aagaaaggtc aggtgtggtg gctcactcct gtaatttcag	41757
cacttcggga ggctgagggt ggtggatcac ctgagggtcag gagttcaaaa ccagcctgac	41817
caacatggag aaacctgtgc tctactaaaa atacaaaaca ttagccaggc atggtggcac	41877
atgctgtaa tcccagttac tcggtaggct gaggcagggt aattgcttga acctgggagg	41937
cgaagtgtg ggtgagccaa gatcatgcc a ttgcactcca gcttgggcaa caagagcgaa	41997
actctgtctc aaaaaataat aaataaataa ataagaaata aaacaataaa aaaaaagtag	42057
ggaatagtcc agtatgatat gtgagttgaa agattactaa acttttcaac acaggacaaa	42117
ccatgatttc acctttccct taattctcga gagctgatga tcccagaag aaaaatctgg	42177
gtctactca gagttcccca tacctcacgc atttctctag gaaatgtgt caggccactt	42237
accttttagc acctatttct tttcttgcaa gatacaaagt gtcttgatct aagcatatac	42297
ttcccttctc gtctcatggg gctcagagta agcttggcta ccagggtgta tgaaatgtat	42357
tcaaccacag gaaaataagg ctatttgtgt ttgctggtea tgaaagggt gcagatgaca	42417
agcattgtag aaattacaaa tatttattat ggggtgggtg ttggtggctca cgcgtgtaat	42477
tgcaacactt tgagaggctg aggcaggagg atcatttgag ccaggaggt agagaacagc	42537
ccgggcaata tagtgagacc ctgtctcaac aaaacatcaa aaaaaaaaaa aaaattagct	42597
gggtgtgggt gcatgcgctt gtagtcccag ctactcagga ggctgagggt agaggatggc	42657
ttaagccag gaggcagagg tttcagtaag ctggcggtgc atgctgcact ccaggctgga	42717

-continued

tgacagagca agctcctgtc tcaaaaaaaaa aaaaaaaaaa attactgtat gaactagttt	42777
cattttaagg tctagactaa tgggttgttg tcatatccaa ctgtgacaag aatttttgta	42837
acttaatttc tgccctggca tgttacataa gcttaataac caaaacaaat cttaaatatt	42897
aaaaatattc acaggcagtt tccaaagaaa atcgtattta ttaactgttg agagacttct	42957
tagaatgtca agacatttga aaaatactac ccactgcctt ttttcctgtg cagagtttag	43017
ttctcttttt cctctgattt tttttttcag tgttatgggt tttgagagta ctatacatcc	43077
accttataat tccatttgct gaagctgccg cttgtttttt gtgttgttgt ggttttgaga	43137
cagggtcttg ctttgttgcc taggctgggt ctccaactac tgggctcgaa cgatccttct	43197
gcctcagcct tctgagtagc cgggactata gatatgcacc actgcacctg gccatatcca	43257
tccttacgaa tgggattatt gttcttataa aaaaaaata aggggggtgct gggcacgggtg	43317
gctcatgcct gtaatccag cattttggga ggtggaggca ggcagatcac ttgaggtcag	43377
gagttcgaga ccagcttggc caacatgggt aaacctgtc tctactaaaa atacaaaaat	43437
tagcctgggt tgggtggcagg cgcctgtaat ccagctact tgggaggtg tggcaggaga	43497
atctcttgaa ccagagggc agaggttgca gtgagccaag atcacgcctt cagatttcag	43557
cctgagcaac tgaggggagac tccatcaaaa ataaaaaggt tgaagagagc accctagtct	43617
cttttgtcta ccatcacttc caccacatga gaacatagtg ttcattccct ctggaggatg	43677
tagcaacaag gctgctgttt ccaagcaaca tcttggaaaa cagagacagg gtccctacaa	43737
gacaccaaat ctatctgagc ctttaacctg gtcttccaga tatatatatt tggaacagca	43797
ttgtatgacc acacatttga aaatgaagat ggaaatggga aatagcagcc ctttgattca	43857
aaatacatga acagggaaa gagaaccatc tcttatcaga taaaaagatt aagaatttga	43917
agaagccaag agagtagagg aactaggaaa aaatgaaaaa ggggaagagaa aaaaagggaa	43977
cagaacagga agggtaaata caaatgcac ctcagtgtca ttaatctatc caataaaaat	44037
atcgaggca ccatctaagt gcctggcact gttagattct gggatacaat gctgtgcaaa	44097
atcagtgttg agcctcacct ttgcagaact tatgagtaac aaggaagaca taaataatcc	44157
aaataatcac ataagcagat gtaaaggaa tgctactcag taccagaag gtccatcaga	44217
gatagtggga gaaaaggcag aaaaaccaac aaagtggatc catcacccgc cctgagttcc	44277
aggggtggaat ggaggctggc acgatagagc tgccaaatag aggtactgac tggactggca	44337
caatgtccaa gaaacacaac ggatttggt ctcagggttt tgttcgaaa tggtcagctc	44397
ctgtgacttg caatccaggt aggctaaatg agagggaatc cagccgcaga cactacacag	44457
agggcagggt agggcagggg atctggaact caatcccctg atctgcaggg caaaactcca	44517
gtgccctatg gcaggactgg caagaggaaa gcaaagcagc aggagctcaa ttctaggcag	44577
ggatttggag cagggtttca gtcagtaggg cctgaaccag taggggccag gatccagat	44637
acagacagga aaggatcaga ggtggaggat agagactggg agcactgtga ggccagccca	44697
tccttcaggc cactgagttc aggactttag atacttaggg gttccaggag ggtgaggcca	44757
agacaggcgg atcacctgag gtcaggagtt tgagaccagc ctggccaaca tagtgaaacc	44817
ccgtctctac taaaaataca aaaattagcc tggaatggtg gcacacgcct gtagtcccca	44877
ctacttggga ggctgaggca ggagaatcac ttgaacctgg gaggtggtgg ttgcaatgag	44937
ctgatattgt gccactgcac tccagcctgg gtgacagagc aagactctgt ctcaaaaaa	44997
aaaaaaaaa agggtaataa taatactac ctctagaaga ctgtgagaag taaatgtcaa	45057
gtgcttagaa cagtgaacag tacctggcac agagaaaaat actaagtaag tgtctgttga	45117

-continued

atgaatggat	gaatgaacaa	atacatagat	aatatgggca	gaggettcca	aatgtaaatg	45177
gatgaagcct	taagaaagtc	tcagaatgac	tctggactaa	cgggagttta	gggatgggag	45237
caaatggaaa	aggaagtaac	taaacagctg	agctgagtca	ttaaagcatt	ctagggtcac	45297
tctagaaatt	gcatccaagt	cttaacagtc	ttaactgcttc	ccggttgccc	tctctaatcc	45357
attttctggt	ctgcagtcac	atcatcttta	aaacataggt	cagattatgt	catctcaatg	45417
aattcccata	aaacttgagg	gaaaaaatcc	aaactatggg	ccatatgagg	caccaaataa	45477
aagactgtaa	actagtgacc	ccccccaagt	cataaagagt	tcacaaatgg	agtaaataac	45537
tcagtttggg	tttttttgtt	tttgtttttt	ttcaaggcag	ggtctcactc	tgtcacccat	45597
gcttgagtgc	agtggcgcca	tcatagctta	ctgcagcttc	aacctttccg	gctcaagcaa	45657
tcttcccacc	tcctctctcc	aagtagctgc	agccacagac	acatgccacc	acacctggct	45717
aatttctgta	ttttttgtaa	agacgggggt	ttgccatgta	gccaggcta	attttttttt	45777
ttttgaggtg	gagtcttgcc	ctgtcacccc	aggttcaact	gattctcctg	cctcagcttc	45837
ccgagtagct	gggattactg	gtgcacacca	ccacgcccgg	ctagtttttt	gtacctttag	45897
tagagatggg	gtttcaccat	gctggccagg	caggtcctga	cctcatgac	tgcctgcctt	45957
ggcctcccaa	agtgcgggga	ttacaggcgt	gagccacgac	gcctggccac	ccaggcta	46017
cttgaactct	tgaactcttg	aactcaaggg	atccaccgcg	ctctgcctcc	caaagtgtg	46077
agattacagg	cgtgagccac	tgggcccctg	caatttactc	agtttttttt	tttttaactc	46137
ttccaaataa	gtgaccaaaa	tttaaaaatt	gggagagttc	atgttaaaaa	gtgggtttat	46197
ggcttctcct	gaaaccttat	gagacaagta	ttatgtttaa	cctccatttt	atagatgaga	46257
caactgaaaa	attgaactcg	aagcttacat	gaaatcacag	cgttagcaga	ggcagagtgg	46317
agacttgaac	cagggtcaatc	tgggttctga	gtctgtactc	tttaactccc	atgtcatatc	46377
cctgccagtt	agatgggggt	agtgtctctc	agccctcttc	tctccctgtc	ccccatcct	46437
gggacctctc	catacacaca	gttctctctt	tcctgggaca	ctccctctac	tctaaggctg	46497
cctggctctt	cctcatcttt	ctgccaaact	taatgtcacc	tccttggaac	acacttctct	46557
gggcaaacac	agagagtctc	acctaatttt	tctctgttgc	tgacatttgt	gcttccttga	46617
taaaacctat	cactgtttct	aattaattct	tgtttgtgac	tctattttat	ctgtgtcggc	46677
tccaaaaagg	taaacaccat	tcctgtgatt	gctatggttt	gaatgtgtcc	ctccaaaatt	46737
catgttgga	cttaaccctc	aaggcaatga	catcaatagg	tggggcttgg	gccaggcttg	46797
gtggcacatg	ccagtaatcc	cagcattttt	tgggaggcca	aggtggaagg	tttgcttgag	46857
cccaggagtt	caagaccagc	ctgggcaaca	tagtgagacc	cccattctct	caaaaacaat	46917
ttttttaaat	tagccaggta	taatggtgca	catctgtagt	cccagctact	caggaaattg	46977
aggtaagagg	atcgtttcgg	tttgagactg	cggtgagcca	tgatcatgcc	actgcattcc	47037
agcctgggtg	acagaatgag	accctgtctc	aaaaaaaaaa	aaaagagggtg	gggctttggg	47097
gagggtgatta	ggtcatgagg	gctctatgaa	taggataaat	ctccttataa	aaaaagctca	47157
agtgaattgc	agagccccct	ttttgtcctt	ccaccatgtg	cagacatggg	attcatcccc	47217
tctggaagat	acggcaacaa	ggcaccatcc	gaaagcagag	agcagccctc	gccaggcact	47277
gaccttgcca	gcaccttaat	cttggaactc	tcagcctcta	gaactgtaag	aaataaattt	47337
ctcttgttta	taaattacct	agttttggat	attttgttat	agcagcacia	atggactaac	47397
agtgaattac	tctgagcctc	tggcagacaa	tagaccttca	acaagtaact	gttgaataaa	47457
gcaataaatg	gtctcattta	actggatgta	caggtgagga	atatcataga	tgcagcgtaa	47517

-continued

```

aagagctggg atgtcatccc attaggggca gattctcaag actagttttt cccctttcct 47577
aattaactga actctaggca aaagtcctca gaggcaggaa agggttttcc ttctttaaca 47637
catgaaatca gcgacatcca gcaggctttg aggtatggac cttatgagaa gggaaagagaa 47697
atgaaaaatc ctacatataa gattcccact tgcctatgat ttgaatgtgt gttttttctcc 47757
aaaattcatg ttggaacctc acacccaatg tgataaacagt aagaggtggg ggccttttgg 47817
gaagcaatta agtcataagc actccatcct taggaatgag attagtgttc ttataaaaaa 47877
ggttgaagac agcatcttag tctcttttat cctacaatcc tttccaccag gtaagaacat 47937
agcgttcac cctctctggag gatatagcaa caaggcgcta tcttggaaac agacagtggg 47997
tccccaccag acaccaaatg tgtctgagcc ttgaacttgg actccccagt ctccaaaact 48057
aggagaata aattttctaatt atttataatt actcagtctg tggcatttta ttacagcagc 48117
aggaatgcac taagacacgt cccccatca aaaataacat aatctttaaa agttttacca 48177
tcttttcttt tgagtactgg gtgttacctg aatagtatcc tctttttatt ctatttttat 48237
tttatgtatt tatttttatg tatttttttt tttagacag gatctctttt tgtcactcag 48297
gctggagtg cgtgaacaat catagctcac tgcagcctcc aactcctggc ctcaagcaat 48357
cctcccacct taacctccca agtagctagg atcacaggca catgccacca tccctggcta 48417
ttttgtgtgt gtgtgtgtat tttttgtaga gatgaggttt caccatgttg cccaggtctg 48477
tcttgaactc ctgggctcaa gagaatcacc caaagtgcta ggattacagg cataagccac 48537
tgtgctggc cttgaatact atcactttat tctccagaca tccattcttc accaatcacc 48597
caggctttgg gaagtagacc atgtactgca gcaatttcct gactcctgga acaccgtctt 48657
caaggtaggg gtctatatgt acccattgta aatttgaatt gcaaaaaaaaa ttctaattca 48717
ttagggcctg acaatttttc ctaacattcg gtagttttaaa aacatccaca catgtgaata 48777
ctgcagacaa attcatgaaa agactaatgg tttctctaga gtgacagaaa aatcaattgt 48837
gaaaatcatg agttatcacc tacaaggaa ttatgtgatt ctttagggga tcattggtca 48897
atgtggaaat gtcaagtata agcccttttc agttccccta ggtaagggtta gctattcttt 48957
ttctgtctgt ggtccacta aagccattat catattgaat tgcaataatt tgcctttgtg 49017
tctatatccc catgtgagca acttaaaagc agtgagcaca ccacaaacca atttgaacc 49077
ccagcagagg gccaaaaaca ttccagagggt actcagtcac tatggaatga ataagtaaatt 49137
gacatagtcc ctgactccag gaatgtacaa tctagctgga aactaagaca tagaaaagtg 49197
gaaaaataat tccaagacag ttatttgcta agaagtaaaa gagagattta caataattac 49257
taaaagagaga aaagagagac atcagtgtgt gctgcaatcc acaggaagat gtgtaggagg 49317
agatagtga gagagagaga aaggctgtcc agatatagga aatcgcatgg ccaagatatt 49377
caggcaggaa aacacaaggc atttaagtgt tttaatagat acagatggag tggagtggat 49437
ggttgactct gttgagatta atcaactgat atggaaacta aaaatgtcgg ctagtgtctgt 49497
ggtttgaata ttgcatccc tccaaaatc atgtcaaat gtaatctccg gctgggtgcg 49557
gtggctcatg cctgtaatcc caacacttcc caaggctgag gcagggtgaat catttgaggt 49617
caggagtcca tgaccagctt gaccaacatg gtgagacccc tgtctctact gaaaatacaa 49677
aacttagcca gccgtgggtg catgcacctg taatcccagc tactcgggag gctgaggtag 49737
gagaatcgct tgaacgggga gccagagggt gcagtgagct gagatcgtgc cattgtactc 49797
cagcctgggc aacaagagtg aaactccagg ttgaaaaaaa aaaaaattaa tctcatcgt 49857
ggtggtatta agagggtggg catttgggaa agtgattaac tctcaacaa tggaattaat 49917

```

-continued

aatggccttt	tacaagtcca	ttagagagct	tectggcctt	tccatctctt	ctgccatgtg	49977
atggcacagc	atttgttccc	acttttgccc	ttctgccatg	tgaggacaca	gagtttgccc	50037
cttcaccgt	gtgaggacac	agcaagagat	gtcatctatg	aaccagaggg	taagccttta	50097
ccagactcaa	atctgctagt	gccttgatcg	gggacttccc	agccttcaga	actgtggaaa	50157
aatacgtttc	tcttatttat	aatttaccca	gtctaagata	ttttgttata	gtattccaaa	50217
caaaactaaga	gtaaggaata	gatcaagagg	gcctctgaca	tttagctaag	aatttttagaa	50277
attatttaaat	aagctagagg	gtattggaaa	ggaaagtgc	agaagatatt	ttaagtttag	50337
tttagcaaga	tagaacagta	tgaattggag	gtagaggtaa	aaatattaag	agtctaagtt	50397
ggaataatga	caataaaaaga	gatgaaaagt	aaaagctacc	ttatatctct	taagcctgag	50457
ttactgagga	gtaggagttt	catacagaag	gactgatcag	ccatagcaca	actaagaaaa	50517
gtatccacta	cagctggaag	tgtggagatg	gagcttagaa	gagaagctct	tatacgagat	50577
gtagaaaaag	aaactttggc	caggcacagt	ggctcacgcc	tgtaatccca	gcactttagg	50637
aggccgagac	gtgcggtatc	cttgagggtc	ggaattcaag	atcagcctgg	ccaacatgat	50697
gaaactccat	ctctactaaa	aatataaaaa	ttagcagggc	atggtggcag	gcgcctgtaa	50757
ttccagctac	tctggaggct	gaggcaggaa	aatcacttga	actcgggagg	tggaagtgtc	50817
agtgagccga	gatcatgcc	ctgcactcca	gcttgggcaa	ccgagtgaga	caccatctca	50877
aaaaataata	aataataaaa	ataaaaaaac	aaaagttagc	cagatatggt	ggtacccacc	50937
tgtaatccca	actacttggg	aggctgaggg	aggagaatca	cttgaatccg	ggaggcagaa	50997
gttgacgtga	actgagatca	cgccactgcc	ctccagccta	ggtgacagag	tgagacctta	51057
tctgaaaaaa	aaaaaaaaat	catagagtca	aaaagtggaa	tggtggttgc	caggggcttg	51117
gagaaggaag	gaatgggaag	ttactgttta	atgggatgga	gtttcagttt	gggaagataa	51177
aagtctctga	gatgtgtgat	ggtggtgatg	gttgacacat	aatgtcactg	aatgttatgc	51237
ttaaaatggc	taaaatagta	cattttatgt	tatatataaa	atacacaatg	ttacatataa	51297
gaacacaaac	atagtaagat	gatagtctta	ccaaccatct	ttatgaaagg	aatcattgat	51357
cccacgggag	aggtgagagc	tctgaggaag	aaaattagga	gcaagaaaag	gacagagtct	51417
tagggatgcc	cacattgagg	ggaaggagaa	ggaagtgggg	tttagtcaaa	ccttccaaga	51477
tttgacatcc	ctaccaatca	aagttctacc	ctacaagtta	agaggaaaat	ctgagtccta	51537
ttgattatc	ctgagatgtc	cagtgaagca	ctgaaatgca	aaattgctgt	gggatatgcaa	51597
ggatggtagt	gatttttaaac	tactttccaa	gttggttagag	tggcaagcta	tgaatatggt	51657
ttgaacaaat	accagtagct	acttggcaa	aaaggagtta	ttaatggtca	ctggcttcta	51717
gacagttttt	cttgacagac	ttggagagaa	aaataaatac	atcatgaaac	atattcattt	51777
cagtcagttg	taaaatttgt	gttctgtgca	tgagggaggt	agaaaaggat	gagtatatgt	51837
ttagatgtga	agaggaatat	aagacatggg	atgatttttag	gctttaatta	caaaaataaaa	51897
caccacagc	ccatgattat	gtttatttag	aaaaagtttg	tctagggag	caggagtatt	51957
aaaaatgggtt	agttcagttt	tcagcaagaa	aagctggttc	ttgtcactc	caaccaggta	52017
ggcagctaaa	acaataggcc	tctataaata	gcaataaagg	ctttcatatg	aaaagatgaa	52077
aaaaattgtca	atttaaaata	caacaaattt	ttcctggaaa	acatactcat	agctgtattc	52137
tctggcagat	cctattgcta	gagaagcaag	ttgtaggag	aaaatggttg	tgtttctcca	52197
agaatacagg	gcaaaattcg	tatatgtttg	tgtgataaaa	acattagaac	ttgtatgttt	52257
gagttgtttt	gtctatttcc	ttaattatct	ggagataata	ctaatacatc	tgtctttgca	52317

-continued

gtggaaaatc	tacacttaga	cataactgtc	ctctaaaatt	aatccaccat	gtctcattct	52377
actggatgaa	ctgtttttat	attttctttt	ctttctttct	tttttttttt	tctttttttg	52437
agatggcatc	tactctgtc	aaccaggctg	gagtgaagtg	gcacaatctc	ggctcactgc	52497
aacctctgcc	ttccagggtc	aaacgattct	cctgcctcag	cctcccaagt	agctgggaat	52557
acaggtgccc	acgaccatgc	ctggataatt	tttttgtatt	tttagtagag	atgggggttt	52617
accatgttgg	ccaggctggt	ttcaaactcc	tgacctcaag	tgatccaccc	acctcggggt	52677
gccaaagtgt	tcgattaca	ggcatgatcc	tagccctttc	taactttggc	aaaatatctg	52737
attaaaaacat	cttataataa	actggcaatc	aaatttaaaa	ttgtattaac	ttttaagaat	52797
tgatttttct	tagcttcagg	aagtccctct	ttctttttat	ttatttttag	ttactttact	52857
tattttattt	ttttgataca	gtcttgcctc	gtcgcacagg	ctcctggagt	gcagtggcgc	52917
gattctcggct	cactgcaacc	tctgcctccg	aggctcaagt	gattctcatg	cctcagcctc	52977
ccaagtagct	gggattacag	gtgcgcacca	ccacacctgg	ctaatttttt	gtaggaagct	53037
gtcttttctg	aactgagtta	ggttaagtac	tgtttgggcc	ttattaccta	acacgaagca	53097
gctggatgac	attggagact	gaaaactagt	gggccatgga	ctgaattaag	gaaaaagata	53157
tattttgtca	ggcctgagct	gtgctttgaa	agatttttaa	atgattagcc	aacagaaaat	53217
actgggaaat	acacataagg	atctgaattt	caggattctt	ttagaaaaga	aaaggaaaat	53277
ctgacaacca	ggactcaaat	tcttgaatgg	tgtcagtaga	atagagttga	tttgtgggtc	53337
ccctgcctct	ccagatcaca	atagtcacca	tctggctgac	tttacttggt	aaaattacct	53397
gcttgactct	cgtgaacaa	gaaactgatg	actgggctgg	aaagcatagg	gatctcatga	53457
tgctaaaatt	tcaaagccct	atcagagaaa	agaaactgga	tcatgcctaa	gacatacaat	53517
accataagtg	gattgaaactg	aaatcaacaa	aagtggcaac	ccaagttct	gatttagactg	53577
aagagattac	ccccaacaa	acctagcttc	ctgatagagg	aaagggaatc	atcttggtgc	53637
agtggggagc	aggggtggtg	gtggtaaata	ttatttataa	atactcatac	acacacggaa	53697
gtctaaaaca	agaaatgcaa	aatatgtaaa	aaaaaggggg	ggaaatatga	cccataatga	53757
aaagaaaaaa	aactcaataa	aagcagactc	acaggtaacc	ctagtgttag	aattagcaga	53817
caaaaatttt	caaataacta	ttacaaatat	gttaacaat	ttagataaaa	agatgagtga	53877
aacaagagat	aagagaatct	cagctaaaat	aagaaaatga	actaaaaaaa	taacaatatc	53937
taaaatgaag	tattgattgt	ataagtttaa	taacaaatca	atatagcaga	aaaaagaata	53997
agtgaactgc	aagataggtc	agtaaaaatt	attcaaattg	aaaacagaat	aaaagaatga	54057
ggaaaacaaa	aatggggaac	aaagaatcag	agactaaaag	taaatattag	gcaactgagt	54117
tgtcttttag	tctgttttat	gctgtataa	cagagtaccc	atgactgcat	aatgtataaa	54177
taacagagat	ttatttctta	catttctgaa	gtctgggaag	tccaaggttg	aaaggcctgc	54237
atgagttgag	gaccttcttg	ctgcgttatt	tcatgacaga	aggtgaaaag	gcaagagagc	54297
aggatatgac	atgagaatga	cagagagtga	gagagctaaa	attgatttcc	tcataaacta	54357
atgctcacta	taataaaccc	actctcatga	ttatattagt	ccattcacia	gggcagagcc	54417
cttgcgactt	aatcaccttg	taaatattct	acctctcaac	attgttgcat	tggggattaa	54477
gttttctatt	ttcttttttt	ctttttgaga	cagagtctca	ctctgtctct	gaggatggag	54537
tgcaactgaca	cagtctcgcc	tactgcaac	ctccgcctcc	caggccaag	cggttctcct	54597
gcctcatcct	cctgagtagt	tgggactaca	ggcatgcacc	accacaccta	gctaattttt	54657
gtatttttag	tagagatggg	gtttcactat	gttgggccag	tctagtctca	aatttctgac	54717

-continued

cttgtgatcc atccacettg gcctcctaca gtgctggtat tacaggcatt agccactgtg	54777
cccagccaag gattaagttt tcaatacgtg aactctggag gacacattca aaccatatat	54837
ctagcataca ggtaattgga atccaggaac agaggagaaa ctggggcaaa ataaatattt	54897
taaaagatag tggccaagag ttttctaaaa ttgatgaaag atatgaaccc atatatccaa	54957
taatcacagt gaacactaag ctagatttaa aaaaaaaaa ctatacctag agatatttta	55017
aaagaagcca gggcagggga aaggatctat tatgcttatg aatagaaaa taagaatgtt	55077
ggttaacttc ttaagagaaa aaaaacggaa gacagaaaat gatggaacga catctggaaa	55137
acaaacaaac aaacaaaacc tgtcaaccta gaaatctata ccttcaaaag caccctttaa	55197
aatgaaagc taaataaaaa cagaaacaga aaaaaattgt cacttgacga ccagcattat	55257
gagtaacact caacgaagt tttctccagg aatctgtgaa cgccaccaga atgggcaaag	55317
atgtgaaaa acataaagta ctcttagaa actttcttta ggagactatt gaccatttaa	55377
agcaaataga atagcaaaat aatcgataat gaaaaatac atgacatttg cacaagggca	55437
gaagggtaat aaaattatac tgtagtaagt ttcttacatt gtttatgaaa tgataaaata	55497
aggaaaaggt aagaacacat attgtaatct ttagtaacca ctaaaaaaat accaagagat	55557
attactagaa aaacaatagg taagataaaa tagaatactg gctgggcaca gtggctcatg	55617
cctatacttt cagcactttg ggaggctgag gtaggcagat cacttgaaac caggggtttg	55677
agactagcct gggcaacaaa gtgaaacccc atctctaata catacatata tatatatata	55737
cacacacata tacatgacta ctgaataatc cttatgtaac atataatata taatactgat	55797
atattgagaa tagtgaataa ttcttaattt ttactttttt ttaccttttt ttttttttga	55857
gatgtagtct cgccctgttg ccaggtctgg agtgacgtgg cgcgatctcg gctcactgca	55917
agctccgct tccgggttca cgccattctc ctgcctcagc ctccctagta gctgggatca	55977
caggcgccgg ccacacgccc cagctaattt tttgtatttt tagtagagac ggggtttcac	56037
cgtgttagcc aggatggtct caatctctg accttgatg ccgctcgct cggcctccca	56097
aagtgtggg attacaggcg tgagccaccg cgcccagcct attctcatcc atccttaaga	56157
ctggactctt tggctcattgt taactgactt tttcgatat gataaattct taaacatgag	56217
atagtagtca attctgcaa cattcagttg ttgtttctga atttccaca ttgcttaagg	56277
tcaactccac catgacgcta taaaaacact tttctccatt ttttcatata tttgtatagg	56337
tttgttttta catttaagtg aattttaaag ataaaactta cctatctata tggaatgagg	56397
aaggaaacct ctactttta tatacatac caattatggt acactattta ttacataaac	56457
catactttat caatgattgc agtgccatct ttgtcatata ttaagtccca acaaatacct	56517
aaatatgttc ctacaatctc tattctattt acagatctac ttgacagctg tcgaaccaat	56577
acatgccatt ctgaccataa tacctttaag ataagtttga ccatttaaca taagaagtaa	56637
taaccagacc gggctcagtg gctcacgcct gtaatcccag cactttggga gtccgaggtg	56697
ggtggatcac ctgaggctcg aagttcaaga ccagcctgac caacatggga gaaaccccat	56757
ttctactaaa aatacaaaat tagctgggag tgggtggcaca tgactatagt ccagcaact	56817
caggaggctg aggcaggaga atcgcttgaa cccgggaggc agagggttga gtgagctgag	56877
atcgaccac tgcactccag cctgggcaac agagtgaat tgtctcaaaa aaaaaaatca	56937
ataagtaaaa tcttaagta gcaaatgaca gttgcagcca agtaattcca aaagccagct	56997
tcactcggag aaccctgtgc ttcctcttat ttccagcgat ccacatattt agagaaactt	57057
ttccagtaat aaacataga aattatactt ggaagtagag tcttcaactt ggatttttag	57117

-continued

gtgaccctaa	caaaagggg	aaatttccca	aaacatatcc	gaaatggact	ttctcactgc	57177
tttggttagt	cgagggttaag	aatcagaggt	aattttagaa	catatagatg	agggtgacaac	57237
tcatacaccc	aagtatgtag	agcaactcat	atctacccca	ctgcatttgg	agggaaagtg	57297
tttccttgg	gaacttgtga	gtataaatag	atggaagaag	atgtactcaa	aacagcaaac	57357
ttctaattat	acaaaatgtt	atattttctg	cttagtgaag	ccacatccat	gtagattatg	57417
atgctcta	cattacacct	gtcaacacaa	tgaatatagct	caaactctctg	aaaaactttg	57477
cttcaactct	aatgatgtca	aaaattacaa	ctcaaattaa	atcttcatgt	ctctaatagaa	57537
acctcaactc	tgcaaatctc	cttattttaa	aatgctgttt	tagccaaaga	aatgtttcaa	57597
aaattctgta	ttcagggcag	gcacgggtggc	ttacgcctgt	aatcccagca	ctttggggagg	57657
ccaaggtggg	tggattgctt	gaggtcagga	gttcgagacc	agcctggctg	acatggggga	57717
aaccccgctc	ctactaaaa	tacaaaaagc	cggatgtggt	gggtcatgcc	tgtagtccca	57777
gctactcagg	agactgaggc	aggagaatca	cttgaacgca	ggaggcggag	gttgacagtga	57837
gccgagattg	tgccactgca	ctccagcctg	gggtacagag	cgacgctccc	tctgaaaaaa	57897
gaaaaaaaa	ttctgtatct	acaaatatgct	tgatactagc	aatcaactgt	ttacattgta	57957
aataggcagc	aggctgaaaa	tttttgatga	cttaattgca	ggttcacagc	tatgaaggca	58017
agccaaagg	ctaccttgcc	aggctctgta	aactgatgta	catagtatga	gctgcttgat	58077
ctttgagtaa	tcacaaaaga	caaatcaggc	tgggcatggt	ggctcatgcc	tgtaaatccca	58137
gtgctttggg	aggccgaggc	agggtggatta	cttaagggtca	ggcattggag	accagcctgg	58197
ccaacatggt	gaaatcccat	ttctataaaa	aaaacaaaag	ttagctgggc	atggtggtgt	58257
gtgcctgtag	tcccagctac	tcaggaagca	gaggcaggag	aaccgcttga	acccgggaag	58317
tggagtgtgc	agtgagccga	gatcatgcga	ctgcactcca	gcctgggaga	cagagtgaaa	58377
ctctgtctca	aaagaaaaaa	aaaaaaggaa	agaaataaaa	gacaaatcag	caaaaagagg	58437
aattcataaa	aagagaataa	agcctttgca	aaaaagaacc	tgtctttgga	tcttcagaag	58497
tgactaaaat	attttaatat	gtccctttta	gtgcctcttt	ttgcttgcc	atgaaatatt	58557
gacagatctt	cccaactggg	ggaaaaaaa	cccaaatctc	attaaactca	ctgtgtctta	58617
tttggttaaa	taaaaagagg	tagaaagact	attatgagaa	aagagaagca	atagaaactg	58677
tggaaattgg	agttccaaac	atcaatctta	atttgattga	atagtagaaa	gtatataaac	58737
tatggaaatt	gatgttccaa	acatcaatcc	gcattcctga	gcaattttca	aattggtcac	58797
cagctctcca	ctcctcctgt	catgagtcac	ttatacctta	aaaagtatat	cctctgagaa	58857
ttctgaaagg	tatccagacc	ttccattaga	caacttccaa	tccatatgtg	cctcaaagtt	58917
gtgtcttcat	tttcctcctg	ttccatttcc	ttcagatttc	caccaagata	tgcattgtga	58977
gctttgtttt	gagactacat	ccagatgtca	cctacctctc	ctgtggcctt	aaaaagattc	59037
tataagcaca	gagagatcag	cctgagacat	ctgaagacct	aagcctgcat	ccttctcgtt	59097
ttttggatta	agggaatgta	aagatgagag	gaaaatgagc	aaggcgagg	gataaactcat	59157
ttctaataaa	aacaggaata	tttttaaaaa	tctgacactg	ctaaggcca	agtcatacag	59217
taggattccc	accagggcag	gctgtaaata	ttgattctcc	tctctgcaac	cccagtggtc	59277
aggcttcaga	gtaacagtct	tagttcctcc	aaccacattt	ctaaccacaa	ggctcactgca	59337
cacttcacca	tcctggccat	cttcctttag	cacatacaat	tgtaagttaa	aaaattttat	59397
cttttatttt	cagtccctcc	acagctgttg	ggacttggac	aaacctacct	tataatcaaa	59457
tatttgcggt	gttttctagt	ttgaaaagca	ctgttcaaaa	gttatctcat	ttaatcttta	59517

-continued

caactgttga	ctttacagat	aaagaaaact	gcagatcaga	aaagttaa	aatgcccc	59577
ggacacacaa	cttgtaagaa	aagaagccag	ggctaggcta	ggccggctgc	agtggctcac	59637
gectgtaatc	ccagaacctt	gggaggccaa	gacaggcgga	tcattctgatg	tcaggagttc	59697
gagaccagcc	tggccaacat	ggttaaacc	cgtttttacc	cnncnncccc	cnnnnnnncc	59757
cnnggggnng	ggcggggcnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	59817
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnt	59877
tttctttttc	cttttttttt	tttttttttt	tgagacggag	tctcgctgtg	tccccaggc	59937
tggagtacaa	tggcatgac	tcggctcact	gcaacctctg	cctcccaggt	ttcaagcgat	59997
tttctgcct	cagcctcccg	agtagctggg	attacaggca	cccaccaccg	tgcccagcta	60057
atttttgtat	ctttaataga	gatgggggtt	caccatcttg	gccaggctgg	tcttgaactc	60117
ctgacctcat	gatccacca	cctcagtctc	ccaaagtgct	gggattacag	gcatgagcca	60177
ccatgccccg	ccccaaaact	atctctaaga	gaagtgttga	aagtgaggct	tggtctccttc	60237
cgactgctta	tagtaaaata	acagaagaga	gaaatgactt	aaatatgaaa	ttgttaggta	60297
aaaaaggaag	cagaacgtaa	agatttagaa	aattcttaga	ctatccatat	tgcaaaacaa	60357
gataacagta	aagatgtgac	caagcaacca	tttgctaatg	aaatttgtat	ggatcagcca	60417
tctcaacaga	agccaggat	gatcctctaa	gacaatggaa	gaatgacccc	aaagatgatt	60477
ccagagatca	tcagggctgc	cttccttggt	ttcaaaagg	aagaccatca	ttgcacaatc	60537
agccagatct	cctccacca	aaatagtac	agcaggactg	ccaaaaggct	tgagagcctaa	60597
gcccctgctg	acagagccgt	gggagcagaa	cctctaacct	agcagttctt	gaaggcagga	60657
gtccactgt	agtgggcctg	gaaggagcat	caagccaaaa	aagatttttc	tcaagcctta	60717
agatctcatg	gagtttggt	tgtagcctgg	acttacatgg	gatttggtac	ccttttcttc	60777
tttgctat	ctcccttttg	gaatggatat	gtctattcta	tccctgtccc	accactgtat	60837
tttgaagca	tatggcttat	ttggtttcac	agtgtcacag	ctaggagca	atttgctca	60897
agatgaatca	tatcttgagt	ctcacccata	tctgatttag	atgatat	ggtgagactg	60957
tgggttttaa	attttaggt	gatgtggaa	tgaatcaaga	ttttgaggac	tgttgggatg	61017
caatgtcttt	tgcttgtag	aaaaacata	attttgggag	gcaaggggtg	gcaggctatg	61077
gattgaatat	gtatccccc	aaattcatat	gttgaaatac	taatctccaa	tgtgctggca	61137
ttaggaagt	ggcactttgg	taggtgata	ggccatgagg	gcagagtcct	tatgaatgga	61197
attagtctg	ttataaaaga	gactctggat	agcaccctca	cttcttctat	catgtgagaa	61257
cttagcaaga	cactatctgt	gaacctggaa	gaaggccctc	accagacacc	aatctgctg	61317
gcactttgat	ataggaatc	ccagtctcca	gaactgtgag	aaataaatct	gttactacaa	61377
gctacctagt	ctatggtagt	ttgtaatagc	agttccaaca	gactaaggca	aatgtctatt	61437
aaattttttg	ttcatttttt	aaatgggtta	tctttttatt	ggtcagtttt	aagagttcct	61497
tatctattct	gaatactaga	ctgttacctg	atatatggtt	tacaaatatt	ttccagctc	61557
ttttaattgc	cttttcgctt	tattgctagt	gtcctttgaa	gcaaaaagtt	tctaattttg	61617
atgaagtcca	attgtgctga	actgttttga	accacaaaat	ttctttatga	aaattttcat	61677
catgatgcag	gtaactaaaa	ttaaaatgca	gggcttttta	taattattca	tttgacaaat	61737
aactgaatat	ggaatcagct	tacaatttct	ctgctggtac	aaaagtcaaa	tttctttaat	61797
ttgtaaaaga	gacaaataac	tataaagtag	gcaaatataa	tatttaatag	tcaaaagata	61857
ccaaattaat	tttgtcatga	ggcattcata	acaaaagatt	tttttctata	caggctagga	61917

-continued

aaaaattgct	tgaagggat	caaaataaat	ataatcaatt	tcttgccaat	ggatagaggt	61977
taaggccatc	tctagatgtc	cgtttttag	aatttctata	ttcttaaatt	agttttggaa	62037
tctacatctg	gactaaatgc	taatattatt	aattcacaga	acatgtttgc	ttgccatcat	62097
ttcttaagat	gtgaagttaa	acaaacatat	ttccctgca	gcatttcaaa	acataactcaa	62157
ccattaaaag	gaaattaatt	ttaaagacat	ctgtgccaaa	atgtatgata	tatttgcttc	62217
ttctgcagag	agctacaaaa	gacagaactt	tgctttgta	ataataaaat	gtgttgactt	62277
ccaagcactg	catagttttg	caatggaaaa	caagctggag	aagcttttga	aggtttgta	62337
gaaactatga	tgtctgggtg	gcaagtggga	tttactaat	ccccaggac	attgcaaaac	62397
tgtcttccca	accatctgtt	gctaggactc	tagtcaaaaa	gaggatgaca	agtgaaaact	62457
attttgga	cagaacaaaa	aataagaaat	ccaaaacaaa	cctctcaca	acagttgggc	62517
ttctatttag	attcaaatca	tacatgacca	cattttttag	aatgcacata	ttcaactcac	62577
tgaaaatgcc	aaaagagata	gaatggaaaa	ggaaaggtaa	ccaggagggg	acacctcttc	62637
tggaagaaac	ctgtctatta	atacttgttc	atatgacaga	aaagttcatt	gagggcagtg	62697
attgtattct	tagaatgtca	gtgctggcta	aatgaatatg	tgaagagaga	gtacaagaaa	62757
ggatcataag	atccagatag	gaaagaaatc	agcttgaaaa	tatccacagt	atgtgacttg	62817
ggataaggaa	agaacactga	gcatggcagt	ggtatttctc	agtgggatct	ttagtaacca	62877
ttcattcact	tattcaacaa	atatttgtga	aactacaatg	ggtaccatct	tagacactag	62937
ggatgcagct	aaacaaaaca	gactagatcc	ctgccctcat	ggagcttaca	ttgaaaagct	62997
aataattatg	gagcactgaa	gtgtgccaa	cattgtgttc	agagcttcat	atatattctc	63057
tctgatcttc	acaccacccc	tatgggataa	gcactatcat	cattccatt	ttacagagga	63117
gacaattgaa	gtttacataa	agggacttgt	ttacgtccaa	gaattgataa	caaacacagg	63177
tctgcctaac	cactgaaact	ctaattctca	ccactgcaca	actcccctca	cagattcatc	63237
acatgactct	aagatcatat	ttctatatta	ataactgcta	tgccatgttg	tttatttttg	63297
gatggcaatt	atgcaaatgg	gtgttatacc	atttcatact	atattatact	attatagtca	63357
ttcacagatg	agagaaaaat	cttccatatt	ggtaaagttt	aatctatgg	gctgaagaaa	63417
ggaaattttt	tgtctctgaa	gattgctgaa	agaggagaca	gtgaggagat	acaaagttaa	63477
aagagatgca	catagcagaa	aggaataatg	ctatgagttt	ttctaagatg	gaagagagct	63537
gtctcccact	agagataaag	aattaactct	cagcaccacg	gcaaaagagg	aaactagggt	63597
aaaaaaaaaa	aaagaactct	ggcaactctg	tgctaggatg	gtgtgtaagt	cttaaagtaa	63657
ttattaatga	gattcagaat	attaaaaaac	taagaaaatc	atttgagtat	atattgtctc	63717
tgatgatttt	ccagtaattc	agaatctaga	aaataacata	taaaatatta	acatgaccct	63777
ccagggatat	ctacataaat	cttattgcta	aataagttaa	ttatgactta	ttattccata	63837
aaatgtcaat	ttagctcaac	tttcaactgt	tcaaattcag	aacacctaaa	gtctctccag	63897
agtcctgtag	atacaacttt	catagaaact	gcttaggtga	cctgtgatat	aacacaggca	63957
gacatgaaga	tttctgggag	gagagatgca	ctctgaaaaa	tagggctatg	gagtcgtgtc	64017
cttctacatt	catttttagca	atgctacatc	ttcactatta	gacactctag	atcatgctca	64077
cttcccactt	ccaataattt	atagcttttc	ttttaaaaat	aattttatta	attgatatta	64137
tgtctggaata	tcaaaactct	taaaagattc	aattactaaa	cacttaagaa	aatataaatc	64197
ttccagagtc	aatatcagta	tcactgtgag	tttttaggca	gatgtgacag	aaaagaagac	64257
gtcaaaatta	gaacaggaag	caaaataatc	tcattaaatc	aaagctatat	tagaaattgt	64317

-continued

catatgacat attgtgcaaa ttacagtgc tatttgtgct tcatttcatt caataaatat	64377
ttacagaata caataggcca agccttgtgc tagaagcata tatacaggac aaaatgacat	64437
agtctgagct tttggtggat ttacattata atttgcctga taaaacacgt catatgacac	64497
ataacaggtc gtatttttta acatcttgta agaaaaaaat tttaggtcta aggaaataac	64557
ctcaaaattg ttagttgaaa tgtataatgg tacagccact ctgaaaaaca gttgggcaat	64617
ttctttaaaa aataaacata cacttaccaa acaaaactagc aattacactc tcatgcattt	64677
aactcagaga agtaaaaatt tacaactcca caaaaacatg tacatgaata ttcatagtag	64737
ctttattttt aaagccccc aattggaac aacctacatg tccaataaga gataaatggt	64797
taaacaaact gtgctacata tataccacgg aatactactc aacaatataa aggaactgat	64857
tgatatatga tataaaaaga actatggata tatgaaacaa ccttgacaga tctcaagggt	64917
atttaagggg aaaaaagcta acctcaaaag gccacttaat gtatgattcc atttatataa	64977
caatcttgaa atgacaaaat tattaagaga gaaaacagat taatgatttc catgaggtag	65037
gtagggatga tgaataaaa aatacagtat gtcagatggg aatgttatca aaaaaataaa	65097
gcagactaaa aaaacaaaac agagggccca aatggggaag gagattattg ctactgtaca	65157
taggttggtg agaaaaggctg ctctgaagga ggtacaagag tgagtcacgt ggatattcga	65217
agcagagagg acagaagagt agtgtccatg gctggagtgt gcacagtgcc ttccagaggg	65277
ctcagtgtgg ttgaatgagg gaggacagag gagcaggaga tactgttaaa acattgggaa	65337
aaagaggaga gttgatcata agtgggtctg taggcaactg tatggatttt gacttttttt	65397
tgctgactga cctaggggaag ctgctgaaaa gtttgagca cagggtttat accagtgcc	65457
aaaaacagtga ctgcaaatga taggtgttca gcaaatagtt gttcaaggga tggcatgttt	65517
tgacttatat ttttaaaaaa ggatcaccat ggctgctgaa agaagaatga aatgtgttaa	65577
ggcaagagtc tgaagaaaca gtattgatgt gagagtaaat cagtgcatt tccattgaga	65637
gcaatttggc aataatttgg caatatctgt caaaaatata aatatatata acttttgatc	65697
caggaattct tcttctagga atatatccta cagatgtact cacacatgtg tgaataatg	65757
tatctggaag gcttctgtgt aatagcaata gattttaaac aacttcaatg gccactgtga	65817
gataagttag agaaactata gaatacccat acaacagaat accacgcaac cataaaaatt	65877
taatagaaag ctctttacat gctgatataa aacagtctcc aagatatata ttaaatgaaa	65937
aaccaaggca gatttcaatg ctatgatttg tattttaaaa ggtaatagaa aaaaaatatg	65997
tatttgtgtg tgtgtagaga tgtatatctt tgcaggagca ctcaagaaac ggtagcatca	66057
gtcatctcca ggaagaatag caggggtgaag gggctaggga tgggtggggg ccaggatgga	66117
gggaaaaacat ttcactgtat gtaattttta aacttttgga tttgaaacta tgtaactaaa	66177
aaatgaataa cattgaaatt ttctttaata tttttaaaat agattattta tataccttag	66237
ttaggaactg gggaaagaaa cacgagactt aaagttacaa ggatgtaggt ttaagaccac	66297
ttccagcatt agtaggggta taacattaga aaagtcacat aaccttttga gcctcagttt	66357
cctaactggg gaatggaatt gttgtagagt agcctaactc ttaaccaaag ttcactcttc	66417
cactgtgcat cacattccat cctttctcct ctactcaatt atgtggcttg tattagtttg	66477
ctacggatgc cataacaaat atcacagaca ggtgccctaa acaacagaaa tttatttcct	66537
tacaattctg gagtctagaa gtccaagatc aaggtatcaa cagggttggt tttctaagtc	66597
tctgtctcct tggctttag gtggccatgt gtctcccat gatcttccct ctgtgtatat	66657
ctgtgccctt atttcataag gatggtatga gataccaatc tcattggatt atcgccacc	66717

-continued

taatgacctc atgcagccat cattaacctc tttaatgacc ctatctccaa atacagttcc	66777
atthttgaggt actgaggggtg aggactttaa catataacat caggaggatc acaattcagc	66837
ccataacaaa gtattggcaa ctctgctctt tttcccaatg tcatcaattt ctttaacttc	66897
tgttggaacca ttttcatcag tgtacaatgt gcttttattt cttttatctt aaaaaaaaaa	66957
atctctgact ccactttctc gttcagcaac caccctatth tctgggtctc ctttacagca	67017
taagtcttcc aaagagttgt ccatattcac tgtctcaaat tctcttttta ttctcttaca	67077
ctcattccaa caaagcttht gccccctcac tccactgaag ctgctattgc ttttgtcacc	67137
aatcaactct atgtcacaaa atacaatggt caaaactcag tcttcacctt aacttgctct	67197
gtttagcatta ctgatgtact tttacttggt tttaaagaca catattctat tagttttcct	67257
cctaattcat tgggtgctgc ttctcaattt ccattttctgg tttctttctt ctccccctct	67317
attgaacgth acttcttgaa cttctttctt tctctaacta tactcaatcc cttagtata	67377
tcattgtctc atgactttga ataattgtct cattccaata gctcttgcat ttttgcttg	67437
gatgttcaat agatgtgtta cattcagcat gccccaaagt gaacttatgt tcttccctta	67497
aaaaccggct cacacatagc ctccccctatt ccagctgact ttaactccaa tccctctagc	67557
tgtctcaagtc aagtaattct tgacatgctt cttttctctta tatctcacat ctaatcctcc	67617
agagaatgcc taaggcataa tctgctatat atatataaa tctgatctct ttttacctcc	67677
ttcaccacta ccatctggtt tcaagcttct atcacctctc acttagatta ctctaaaagc	67737
ctcctaacaa gagtccatgc tcccagctct actccccctc tcagtatctt cttgacatga	67797
tagacactgt gatcctthaa aaatgtatga cagataattt cactcctctg ctgaacacac	67857
tccaacagct ctacatttca ttcagggtta aaacctaatg gcttaaaata ccctaagact	67917
cttcatgacc tactactaca tttttctctc ttgctcattt tttttttatt atactttaag	67977
ttctagggtta catgtgcaca acgtgcagat ttgttacata tgtatacatg tgccacgttg	68037
gtgtgctgca cccattaaat cgtcatttac attagggtata tatcctaata ctatccctcc	68097
ccccatcccg accccacaaac agggcccggt gtgtgatgtt ccccttctctg tgcccaggtg	68157
ttctcattgt tcaattccca cctattagtg agaacatgag gtgtttgggt ttttgtctt	68217
gcggtagttt gctgagaatg atggtttcca gcttcatcca tgtccctaca aaggacatga	68277
actcatcatt ttttatggct gcgtagtatt ccattggtgta tatgtgccac attttcttaa	68337
tccagctcat catagatgga catttggtgt ggttccaatt cactatttgt gaacagtgcc	68397
tcaaaaaaca taagtgtgca tgtgtcttta tagcggcata atttataatt ctttgggtat	68457
atacccagta atgggatggc tgggtcaaat ggtatttcta gttctagatc cttgaggaat	68517
cgccatgctg tcttccacaa tgggtgaact agtttacagt cccaccaaca gtgtcaaagt	68577
gttcttattt ctccacatcc tctccagcac ctgttggttc ctgacttttt aatgattgcc	68637
attctaactg gtgtgagatg gtatctcatt gtggttttga cttgcatttc tctgatggcc	68697
agtgatgatg agcatttgtt catgtgtctg ttggtgcat aaatgtcttc ttttgagaag	68757
tgtctgttca tatcctttgc ccactttttg atgggttgtt tttttctctg taaatttgtt	68817
tgagttcttt gtagattctg gatattagcc ctttgtcaga tgagtagatt gcaaaaaatt	68877
tctcccatc tgtaggttgc ctgttcaact tgatgatagc ttcttttgct gtgcagaagc	68937
tctttcattt aattagatcc catttgtcaa ttttggtctt tgttgccatt gcttttggtg	68997
ttttagtcat gaagtccttg cccatgccta tgcctgaat ggtactgcct aggttttctt	69057
ctagggtttt tatggtttta ggtctaacat gtaagtcttt aatccatctt gaattaatth	69117

-continued

ttgtataagg	tgtaaggaag	ggatccagtt	tcagctttct	acatatggct	agccagtttt	69177
cccagcacca	tttattaaat	agggaaatcct	tccctcattt	cttgtttttg	tcaggtttgt	69237
caaagatcag	atggttgtag	atgtgtggta	ttattttctga	gggatctggt	ctgttccatt	69297
ggtctatata	tctgttttgg	tatgagtacc	atgctgtttt	ggttactgta	gccttgtagt	69357
atagtttgaa	gttaggttagc	gtgatgcctc	cagctttggt	cttttggtt	aggattgtct	69417
tggcaatggg	ggctctcttt	tggttccata	tgaactttaa	agttgttttt	tccaattctg	69477
tgaagaaagg	cattggtagc	ttgatgggga	tggcattgaa	tctataaatt	accttgggca	69537
gtatggctat	tttcacgata	ttgattcttg	ctatccatga	gcattggaatg	ttcttccatt	69597
tgtttgtgtc	ctcttttatt	tcattgagca	atggtttgta	gttctccttg	aagaggtcct	69657
tcacatccct	tgtaaattgg	attcctaggt	attttattct	ctttgaagca	attgtgaata	69717
ggagttcact	catgatttgg	ctctcttttt	gactgttatt	gggtgataag	aatgcttgtg	69777
atttttgcac	attgatttgg	tatcctgaga	ctttgctgaa	gttgcttata	agctgaagga	69837
gattttgggc	tgagacgatg	gggttttcta	aatacacaa	catgttgtct	gcaaagagag	69897
acaatttgac	tccctctatt	cctaattgaa	tacactttat	ttctttctcc	tgcttgattg	69957
ccttgccag	aacttccaat	actatgttga	ataggagtgg	tgagagaggg	catccctgtc	70017
ttgtgccagt	tttcaaaggc	aatgcttcca	gtttttgtcc	attcagtatg	atattggctg	70077
tgggtttgtc	ataaatagct	cttattattt	tgagatatgt	ccaatcaata	cttaatttat	70137
tgagagttgt	tagcatgaag	ggctgttgaa	ttttgtcaaa	ggccttttct	gcatactattg	70197
agataatcat	gtggcttttg	tctttggttc	tgtttacatg	ctggtttacg	tttactgatt	70257
tgctatggt	gaaccagcct	tgcatcccag	ggatgaagcc	cacttgatca	tggtggataa	70317
gctttttgat	gtgctgctgg	atttggttta	ccagtatttt	attgaggatt	tttgcatega	70377
tgttcacag	ggatattggt	ctaaaattct	ctttttttgt	tgtgtctctg	ccaggatttg	70437
gtatcaggat	gatgctggcc	tcataaaatg	agttaggag	gattccctct	ttttctattg	70497
attggaatag	tttcagaagg	aatggtacca	gctcctcctt	gtacctctgg	tagaattcgg	70557
ctgtgaatcc	gtcaggctct	ggactttttt	tgggtggtag	gctattaatt	attgcttcaa	70617
tttcggagca	tgttattggt	ctattcagga	attcaacttc	tttggtgtt	agtcttgag	70677
gggtgatgtg	tccaggaatt	tgtccatttc	ttctagattt	tgtagtattt	ttgcgcagag	70737
gtgtttatag	tattctctga	cggtagtgtg	tattttctgtg	ggattggtgg	tgatatccca	70797
ttttgttctt	taaacattcc	agactcactg	ctgctttaga	gactgctcta	actgttccct	70857
ctctctggaa	agctcttccc	ctagatagcc	acttggttat	ctcctcagta	ctttaagatc	70917
aatgagcctc	ttccctgaca	tctctattta	atacttccta	catgcattgt	tgtgtgcaca	70977
cacatacaca	cacactctct	ctgactccct	taatgactat	atgattactc	acacacacac	71037
atgcacgcac	acattctgac	ttccttaacc	actatatgat	tatttttttc	ttagtctcat	71097
caactccctt	aaaactgtaa	tattatttgt	ttccatagac	ctattcttct	aacatactct	71157
atcattcctc	tagctttgta	tgtacctatc	tatcaatcat	gtttactgtt	tattggtctg	71217
ctcctccagc	taaactgtaa	gctctgtaag	ggaagtgaat	cattgtctgc	tttggtcact	71277
ggatatatct	aaaccccag	aacagtgtct	ggcgtcag	aagtattcaa	aaactgtttg	71337
ttaagtgaat	gaatacaagc	actggtacta	ttgcttctat	cacttctacc	accaccattc	71397
atattagaaa	tatacaaaac	gtaaacaatg	acaagtcttc	gccagttttc	caaataccta	71457
aggatgtcta	taagactact	tctacaatct	ccttttgtca	catgaggtca	caaaatttca	71517

-continued

caaagcggag	agttgaaga	gaaaagagta	agttatcatt	acattccttt	taacttgtaa	71577
ccatcaaacc	cataattatt	agcccatttc	ctcattaaat	atcctctaata	gggtagtaat	71637
cttttgagg	catcttagcc	tactttgtgt	tgctatgaag	gaatatctaa	ggctgggtaa	71697
tttatcaaga	aaagaggttt	attttgctca	aggttctgca	ggttgtacaa	gacgcattggc	71757
gccagcatct	gcttggtctc	tggtgagggc	ctcatgctgc	ttccattcat	gggtggaagg	71817
gaaggggagc	cagcatgtgc	agagatcaca	ttgtgagaga	ggaagcaaga	gagtctgagg	71877
agaggtgtca	gcctgttttt	aacaagcagc	tctagaagga	actattagag	caagtactta	71937
ctccccctac	ccacttaggg	agggcattag	tcttattcat	gaggtatctg	tccccatgcc	71997
tcaaacaaac	acctcccatt	agggactacc	tccaacaccg	gggatcaaata	ttcaacatga	72057
ggtttgagg	ggtaaacat	ccaaaccata	gcagaggatt	ttgtcctta	attttttaaa	72117
aaattattta	tgggtaagag	gtatgtgaaa	gtttataaaa	tactggaaaa	gacactgaat	72177
tgaacctcat	tctagttcag	tggacaagga	aaatatgaac	aaaaaactaa	tttgggaagtc	72237
tcataaatac	caataataa	tggataagc	aaactaaaag	gaaatcagaa	tggacatcag	72297
gaaactgatg	aagaaaaaa	taataataat	agcaatctgt	tgcttgctcat	gttagtaatac	72357
ttagccttca	cttcttctaa	ttgttactca	tgtggtagtt	aagagctcag	gaattaaatt	72417
gccaacattt	actacctggt	tgaacttggg	caagttattt	aatttgcctc	agttctctca	72477
tctgttcaat	gtaggataat	aatagcaact	acttactagg	gcttctaaga	agaataaata	72537
ccttgtttat	aatagtgtct	ggcacctagt	gatggctctg	aagtcaataa	tcagaagtac	72597
catcatagtt	atgaaatact	aaataaatta	tacaacaaa	aaataaatgt	gtacacatgc	72657
atgtgtgcat	atgtgaatga	atggatagaa	atggtttcat	aacgtgatta	tttaattagc	72717
cataagaacc	acttctatc	cacgctagat	agcaaaatta	cattaccttt	gttaaattag	72777
gtgttgaaag	gtcattagtt	ctatattaca	aattcttatt	attaaaaagt	tgcttttata	72837
actattccaa	caaagcgtac	tgtaagaata	aaatctggag	caggaaagaa	tgaacagaca	72897
cataaggctc	cctatggaat	cagcccaaac	ccagtaagtg	ttcaagatta	cagaaaactga	72957
atttctggct	ttacttcage	attattctgg	gtcccaaaaa	tttgctttct	ttttaagtat	73017
ttttcagtat	ctctttttta	gtgaatgtag	gatataacca	acgttagaag	taaattgtaa	73077
aaaatgggtt	gcaagttttc	attaaaaatc	catgactatg	caaatactca	gaatttttgc	73137
ataaataatc	accacgaccc	ccaaatgatg	ttttcgaatg	aatcatgcaa	accacagtt	73197
gagagattaa	gtataaaaa	agacagatat	ccacctctgg	cacaacttca	aatgcgtcga	73257
tggagacaga	aaaatgtcaa	acacaaagat	tacatgaagc	actgcagctt	ccatggacag	73317
ggaagaaact	accaataact	tctgtatggt	aaaatactta	aacacacttc	agctttctatg	73377
cattataaag	aggattgact	tgtagaaact	caggaccagt	ggctttatgg	atctgcaaca	73437
gggaccccta	tgctgtatat	gaacctagtc	aaagagctgc	acttccaaat	gctgacatac	73497
tgctaaggag	attggggcct	ctctctggtc	ctgttcctct	ctttgactct	ttgactctct	73557
ttgattcaaa	gagcaactca	gagttttcag	aatgatattc	taatttgata	gtagttgatc	73617
ttttaaatc	tagatagtga	agggttccag	tagattctag	ttaacagtaa	tgtgtgaagt	73677
ttaaaatgta	tctgctgata	gagaggaaat	tactcatgga	agaaatatct	ctgatgcata	73737
acacacagtc	tggctgtact	gagatagttg	tttcaaatgg	aaaagaatgc	agttggtagt	73797
gcttttaatc	agaactttaa	gaaccactgg	gtgacttaaa	agatataatg	gtagagaaaa	73857
acctcatttg	caacaacaat	ggaaaaaaga	gataataact	ggaataaaac	tccaaatggt	73917

-continued

tcaaacctat	aggaccaaca	ctttaataaa	acactctgca	aaacacaaat	gtagacttga	73977
acaaatggaa	agacattcct	ggttcttgat	taggatgtct	caatgtcatc	aaaagatggt	74037
tgtactcact	aagtcaattt	ataaatTTtg	tgacatccca	attaaaaaaa	aaccaataag	74097
ctttttctcc	cctgggaaat	aaacaaatga	actttactac	acatgaattt	tcacatgaaa	74157
caatagccaa	aagagaatat	caagaaaaac	aatgaaaaga	aagagttgtg	aggagataac	74217
agccacatca	gatattaaaa	cctaccacaa	aatctgtata	agtaaaacgg	tgtggctctg	74277
gaacatgaat	gcacatgcaa	atcaatgaag	cagaacagca	agtccagcaa	aagacctgac	74337
cacaggtgga	aattattcta	gtatatgata	caggtgcaac	tcaaaatgct	ggggcagcaa	74397
agaacatttt	aataagtgtc	gttgggacaa	ttggaaagcc	atttccaaaa	gataaatTTt	74457
catccattcc	tcattgtcatc	cagtaagcac	aaacttcaaa	tagatcagat	ttttaataag	74517
taaaagtata	caagtaattt	ttgatggata	aattcctcta	taattcctct	ataatctgag	74577
ggtagaaaag	gccttctgtg	actaaaaatc	cagatgcagt	ttttaaaaaat	tgacatatTT	74637
gactaaaaaa	aattgaatgg	caaaaacacc	ataagcaaaa	tgataggaca	aataaattag	74697
aagaaaaatat	ttgcaaaaaa	tataaagaac	taattattcat	aatttataaa	gaacttttaa	74757
aagttgatga	aaggagatca	aaagtactct	agaaaatggg	caaaagacag	gaatagaaaa	74817
tacacaaaaa	agatataaaa	ttacattaaa	atatgaaaat	atgttcaatt	ttacataaaa	74877
ggaaaattca	tattaaaaat	atattgaaaa	caattttctca	tccatcagtt	tgacaaaaaa	74937
acaaaagctt	gttggtgagg	ctgaagaaaa	acaggcccat	ttttatacat	gattttcagg	74997
aaggcaaaa	ggtgtaaatc	ttatgtaggg	gaatttcaca	atgtctaaca	aaaatatagg	75057
aaccagcttg	caggagctct	tacttgacaa	atgtaaaaca	ataaggtagc	caaattcatt	75117
cattacaact	cattgaatta	agaatccatg	agtctatact	tataataaat	aaatacatac	75177
atacataggc	agacagctgg	agagaaggaa	aggctcttcc	ttctggtaga	atgtcaactg	75237
atgagtgcag	ggtgtaaatg	aattgaaaat	caccctttac	aaccatcact	gtaagattgt	75297
gggaagaatc	aatggggaaa	agtttgatga	gaagcaggat	gtttgatgag	tctcaaagaa	75357
aatgaccaca	cattgcttat	ttcttgcaag	ggagaacata	ataaatataa	atcaatgtct	75417
tgactgggtg	atcaaaaatta	acataactga	aggagatga	ttagcaaaag	gctctggata	75477
taacacccca	agaaggctac	attacttagt	attgtgggtg	agtaggggtt	gggagtctga	75537
actgaatcta	aacaaataaa	tggatggaga	attatgggag	ccaagtTTTT	cactgttggt	75597
gtggaagtgt	gcagatgaac	aaggacataa	ggctataatc	catctattca	cacagaatgc	75657
tccacctggt	aatggattac	agctgaagac	attagtataa	acaaatgttt	agcttaaatct	75717
ggatatagaa	tgtttcataa	aaatatTTat	agatatctat	attttcatgg	tttttatata	75777
tattatatat	aaatatatat	ataatTTTct	tgctctgtca	actaagagga	tgtagaagaa	75837
caatgacatt	ccagtagcaa	tgagcatatc	tagtaccaga	tcttgatttt	caatatcctc	75897
cagtgaagg	aagcagggtt	ccctgaagaa	atagctgatt	ctaggacaaa	ggcaggaaat	75957
atacatgagt	ctgggtcttg	tagttccaga	aagtaaggaa	gtaaaaaaa	aaaaaaaaaa	76017
aaaaggcatg	gggtagggga	tgggagaaaa	gaaaaaaaaa	tgccgtaagg	gttgacaaca	76077
cagatgccac	tgaagagct	cccaatggcc	aaagctggaa	caatatgagc	taaaaaaaa	76137
aaaaaaaaaa	gaaatgacg	tattggagta	taacccaaaa	tacaaaataa	atatgtatca	76197
gtccatactg	atataataaa	ataattgatt	aagtaataaa	agggagaaga	gaaaactatc	76257
ttgtgcagaa	gaattcctaa	taattatgct	gaggttttat	agatgttatg	tatgtatatt	76317

-continued

```

gccttcaagg aggtggagca taactcctta tttattaagt gtgggctact tcctaaagag 76377
ttgagtatga aagcaggagt agtgggggaa gagtaattgt acagtagaga aaactgaaaa 76437
atgcttcttc agccagggtga taaagggtcaa catcatgtca atggtatata ctcttgatac 76497
gatgtaatga aaatgacact ttacctctgc agtctttctc cccaaaattt atatcaccaa 76557
tctaataatg agaaaaacat cagactcatc ccagctaaga gcatacaaaa tgctaataag 76617
tgttctctca tactgtcatg gtcacccaaaa ataagaaag tctaagaaac tgccataacc 76677
aagagaagcc aaagggtgacg tgatgagtaa atgtaatatg gcaccctgga tggaatccta 76737
gaacagaata aggatattag gtagaaacta aggaaatctt taaaaagtcc acactttagt 76797
taataatact gtattgttac ttgtaaatgt accatactaa cgtaagatgt aaataataag 76857
aaaaactgga tacaggttat atggaaactc tgtattagct ttgaattatt ctgtacatct 76917
aaaaccattc taaaaacaa agtttattta aactaaaaac aaatccatgt cagctgaaca 76977
gcttgtgcta atcattactg cagaatatca tcacaaaaca cagatgacct gacgtttcct 77037
cacagttagt tctccacagc tcatggggtc atacagcgca gcctaattaa gagatttgg 77097
agtaaaaaga gaattagaga gtggctggca agatggctga ataggaacag ctccggtctg 77157
cagggtccag tgagatcaac acaaaaggaa ggtgatttct gcatttccaa gtgaggtaacc 77217
tgctcatgt cattgggagt ggtcagacaa tgggtgcagc tcacaaaggg cgagctgaag 77277
tggggtgggg cattgcctta cccagaaagt gcaagcggtc ggggaactcc ctctctagc 77337
caaggaagcc atgagggact gtgccatgag gaatggtgca ctccggccca gatactatgc 77397
ttttccaga ttcttcacaa cctgcagacc aggagattca cttccgtgcc tacaccacca 77457
gtgcctggg tttcaagcac aaaactgcgc ggcggtttgg gcagacaccg agctagcttt 77517
aggagttttt tttcataccc cagtggcacc tggaatacca ccgagacaga gccgttccact 77577
ccctggaaa gggggctgaa gccagggagc caagtgtctc agctcagcag atcccacccc 77637
catggagccc agcatgctag gatccactgg cttgaaatc tcactgacag cacagcagtc 77697
tgaagtccac ctgggacct cgaccttggc cgggggaggg gtgtttacca tttctgacac 77757
ttgaaaaggt ggttttcccc taacagtgt aacaaagcca cagggaagtt caaacaagat 77817
ggagccact gcagctccgc aaagccgcag tagtcagatt gcctctctag attcctctc 77877
ttgggcagg gcatgtctga aagtaaggca gcagccccag tcaggggctt atagataaaa 77937
ctcccatctc cctgggacag tacacctggg ggaaggagcg gctgtgggcg cagcttcagc 77997
agacttaaat gtccctgcct gcaggctctg aagagagcag cagaagtcct aacacagtgc 78057
tcgtgctctg ctaagggaca gactgcctcc tcaattgggt ccctgacccc cccaccccc 78117
gcctcctgac tgggagacac ttcccagcag ggggtgacag acacctcaca caggagagct 78177
ctggctggca tctggtgggt gcccctctgg gacgaagctt ccagaggaag gaacaggcag 78237
taatctttgc tgttctgcag gctccactgg tgatacccag tcaaacaggg tctggagtgg 78297
accagtc aaacagggtctg gactggacct gcaaacacta gcagacctgc agcagagggg 78357
cctgactggt tagaaggaaa acaataaac agaaaggaat agcatcaaca tcaacaaaaa 78417
ggatgtccac acaaaaaccc gatctgaagg tcaccaacat caaagaccaa aggtagataa 78477
atccatgaag atgaggaaaa accagacaaa aaaggctgaa aattccaaaa accaggacac 78537
ctcttctcct ccaaacggtc acaactgctt gccagcaagg gaacaaaaat ggacggagta 78597
tgagtttgac gaattgccag aagtaggctt cagaagggtg gtaataagaa actcctctga 78657
gttaaggag catgttctaa ccaatgcaa ggaagccaag aacctgaaa aaaggttaga 78717

```

-continued

ggaattgata	actagaataa	ccgttttagag	aagaacataa	atgatctgat	ggagctgaaa	78777
aacacagaga	acttcgtgaa	gcatacacaa	gtatcaatag	ccgaatgatc	aagaggaaga	78837
aaggatatca	gagattgaag	atcaacttaa	tgaataaac	agtgaagaaa	agattagaga	78897
aaagagaatg	aaaacaaaca	aacaaagcct	ccaaggaata	ggggactatg	tgaagagacc	78957
aaacctacat	ttgattgtac	ctgaaagtgt	acctgaaagt	gatggagaga	atgaaaccaa	79017
gttgaaaaac	actgttcagg	atattatcca	ggagaacttc	cccaacctag	caagacaggc	79077
caacattcaa	attcagaaaa	tacacagaac	accacaaaga	taccctcga	gaagagcaac	79137
cccaagacat	gtaatcatca	gattcaccaa	aattgaaacg	aaggaaaaaa	tgttatgggc	79197
agccagagag	aaaggtcggg	ttaccacaa	agggaagccc	atcagactaa	cagcagatat	79257
cttggcagac	accctaaaag	ccagaagaga	gtggggggcca	atattcaaca	ttcttaaaga	79317
aaagaathtt	caaccagaa	tttcatatc	agccaaacta	agcttcataa	gcacaggaga	79377
aataaaatcc	tttacaaca	agcaaatgct	gagagathtt	gtcaccacca	ggcctgcctt	79437
acaagaactc	ctgaaggaag	cactaaacat	ggaaaggaaa	aaccggtact	atccactgca	79497
aaaaataacc	aaattgtaaa	caccattgac	actatgaaga	aactgcatcc	agtaatgggc	79557
aaaaatacca	gctagcatca	taatgacagg	attaaattca	cacataacga	tattaacctt	79617
aaacataaat	gggccaaatg	ccccaaata	aatacacaga	ctggcaaatt	ggataaagag	79677
tcaagaccca	ttggtgtgct	gtattcagga	gatctacctc	atgtgcaaag	acactcacag	79737
gctcaaaata	aagagatgga	gggatattta	acaaacaaat	ggaaagcaaa	aaaaagcagg	79797
ggttgtgatc	ctagtccccc	attaaacaga	ctttaaacca	acaagatca	aaaaagaaaa	79857
gaagggcatt	acatagtggg	aaagggatca	atgcaacaag	aagagctaac	tatcctaaat	79917
atatatgcac	ccaatacaga	agcaccocaga	ttcataaaat	aagttcttac	agatctgcaa	79977
agagacttag	atgcccacac	aatcatagt	gaagacttta	acccccact	gtcaatatta	80037
gacagatgaa	tgagacagaa	aattaacaag	aatattcagg	acttgaactc	agttctggat	80097
caagtggacc	taactgacat	ctacagaatt	ctccacccca	aatcaacaga	atataccttc	80157
ttcacagcac	cacatcgcac	ttattctaaa	attgatcaca	taattggaag	taaaatactc	80217
agcaaatgca	aaagaacgga	aatcagaaca	acagtctttc	agaccacagt	gcaatcaaac	80277
tagaactcag	gattaagaaa	ctcactcaaa	acccacacaac	tacatgaaag	ctgaacaacc	80337
tgctcctgaa	tgactactgg	gtaaataatg	aaattaaggc	agaataaat	aagttctttg	80397
aaatcaatga	gaacaagac	acaatgtacc	agaatcaacg	ggacacaact	aaagcagtgt	80457
ttagagtga	atttatagca	ctatatgccc	acaggagaaa	gtaggaaaga	tgtaaagttg	80517
acatcctaac	atcaccatta	aaagaactag	agaagcaaga	gcaaacaaat	tcaaaagcta	80577
acagaagaca	agaaataact	acagcagaag	tgaaggagat	atagagacac	gaaaaaccct	80637
taaaaaatca	ataaatccag	gaggtgcttt	ttttaaaga	ttaacaaat	agataagtga	80697
ctagtcagac	taataagaa	gaaaagagag	aagaatcaaa	tagacacaat	aaaaatgata	80757
aagggaatat	caccactgat	cccacagaaa	tacaaactac	catcagagaa	tactataaac	80817
acctctacac	aaataaacta	gaaaatctag	aagaaatgga	taaactcctg	aacacataca	80877
ccctcccaag	actaaaccag	gaataagttt	aattcctgac	tagaccaata	acaagttctg	80937
aaattgaggc	agtaattaat	agcctaccaa	ccaaaaaag	cccaggacca	gacagagtca	80997
cagctgaatt	ctaccagagg	tacaaagagg	agctggcacc	attccttctg	aaactattcc	81057
aaacaatgga	aaagagggac	tcccccttaa	ctcacttgat	gaggccagca	tcacctcgac	81117

-continued

```

accaaaacct ggcagagaca caacaaaaaa agaaaagttc aggccaatat cctgatgaa 81177
catcgatgag aaaatcctca ataaaatact agtaaagcaa atccagcagc acattgaaaa 81237
gctcatctac catgatcaag tcagcttcat acctgggatg caagactggt tcaacatatt 81297
caaatcaaca aatgtaatcc atcacataaa cagaaccagt gacaaaaacc acatgattat 81357
ctcaacagat acagaaaagg ccttcgataa aattcaacac cccttcatgc taaaaactct 81417
ccataaacta ggtattgata aaaagtatct caaaaataatg agagctatct atgacaaacc 81477
cacagccaat atcactactga atgggcaaaa actggaagca ttccctttga aaaccagcac 81537
aagacaagga tgccttctct caccactcct attcaacata atattggaag ttctggccag 81597
ggcaatcagg caagagaaat aaataaacgg tattcaaata ggaagagagg aagtcaaatt 81657
gtctctgctt gcagatgaca tgattgtata tttagaaaac cccatcgtct ctcagcccaa 81717
aatctcctta agctgataag caacttcagc aaagtctcag gataaaaaat caatgtgcaa 81777
aaatcacaag cattcctata caccaataat agaaaaacag agagccaaat catgagttaa 81837
ctccattca caattgctac aaagagtata aaatacctag gaatacaact cacaacgaat 81897
gtgaaggacg tcttcaagga gaactacaaa ccactgctca aggaaataag agaggacaca 81957
aacaatgga aaaacattcc atgcttatta ataggaagaa tcaatatcat gaaaatggcc 82017
atattgtcca aagtaattta tagcttcaat gctataaatc aagctatcac tgacttcctt 82077
cacagaatta gaaaaaatta ctttaaatTT cecatggaac taaaaaagag cctgtatagc 82137
caagacaatc ctaagccaaa aaaaataaat aaataaatct ggaggtatca cactacctga 82197
cttcaaaacta tactacaagg ctacagtaac caaacagca tggtagtggt accaaaacag 82257
atatacagac caatggaaca gaacagaaca gaacagaaca gaggcctcag aaataacacg 82317
acacacctac aacctctga tctttaacaa atctgacaaa aacatgcaat ggggaaagaa 82377
ttccctactt aataaacagt gttgggaaaa ctggctagct atatgcagaa aactgaaact 82437
ggatcccttc cttacacctt acacaaaaat taactcaaga tggattaaaa tattaaatgt 82497
aagacctaac accataaaaa ccctagagga aaacctaggc aatagcattc aggagatagg 82557
catgggcaaa gacttcatga ccaaacaccc aaaagcaatg ggaacaaaag ccaaaattga 82617
caaatgggat ctaattaaac taaagagcac agcacagcaa aagaaattat catcagagtg 82677
aatgggcaac ttacacaatg ggagaaaatt tttgcaatct gtccatctga caaagggcta 82737
atatccannn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 82797
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnggc tgagggtggca 82857
gaattgcttg agccctggag gtctaggttg cagtgaagtc tgatcatgcc actgcactcc 82917
aaactgggca acagagttag accctgttcc aatttattta tttattttaa agaagagtga 82977
tattgttttg aatgcagggt aatagtcctt aatccctga ggtcggtgtt gccagtgcc 83037
ataactttag gactaccttc tttcacaaaa tagatgagaa aggaaaaaac agagtggctc 83097
acgcctgtaa tccctacact tgggaggctg aggcaggtgg atcacttgag gtcaggagtt 83157
caagaccagc ctggccaaca tagtgaaacc ccatctctac taaaaatata aaaattagcc 83217
aggcatggca acagggtatct gtagtccag ctacctggga ggctgaagca ggagaatcac 83277
ttggacctgg gaggcggagg ttgcagttag ccaagattgc accactgcac tctagcctcg 83337
gcaacggagc gagactccat ctcaaaaagaa aaaaaaaaaa agaagaaag aaagaaagaa 83397
aagaaaggaa aaaacagaaa aaaatatcct gaagaactca gaacagtctc taagtgttta 83457
gttgtgtatg ttcataagca tgctgatgct gacaacaaat ccaaaaggat cacaccaaac 83517

```

-continued

atTTTTtcaa	ttaaaaaatta	taataaataa	cgtaaggtaa	tacatagget	aattagcttg	83577
atttagccac	tccaaatttc	aaaacattat	gttgatatgcc	ataaatatat	acaattttta	83637
tttgtcaatt	aaaaaataga	agataaaata	attaggtaaa	taggctcaaa	aacattttaag	83697
aaattacacg	tgaatggggc	ttcattaaaa	aaaattccat	cctagccagg	cacggtggtt	83757
tatgctgtga	atcccagcac	tttgggaggc	caaggcgggt	ggatcacccg	cggtgaggag	83817
ttcgagacca	gcctggccaa	gatggtgaaa	cctcatctct	actgaaaaata	taaaaattag	83877
ccgggcgtgg	tgggtggcac	ctgtaatccc	agctacttgg	gaggctgagg	cagagaactg	83937
cctgaacctg	ggagggtggag	gttacagtga	gctgagatcg	tgccactgca	ctccagcctg	83997
ggtagtaag	caagacatca	tctcaaaaaa	aaaagaaaaa	aaaattccat	cctaagtaaa	84057
tctttgggaa	taaaggctag	gttttttccc	cctgctttt	atgtctattg	agtttcttcg	84117
ctttagaatg	agcctctgca	ttaataagat	cctctgggat	catatccaca	aaagggtatt	84177
aaatccttga	agggttgtta	taaatcttct	gtcttggccca	cactaataga	aatccagcct	84237
aggaacacct	tcctcacccc	tgagccctt	ctctaaggaa	ctctacagtg	tcagtcagtc	84297
atccaaatca	atgactttac	ccatcaccta	caggcagcca	gtctgcctgg	ctgaaccatg	84357
gcagtcattc	tgctcagaa	ataactctga	tggacaaccc	gggcaggagg	gaatacggga	84417
aattataaga	aggacctagg	catggaggta	gaccagctga	aagttttcca	ggaacatttg	84477
aaacactctt	ttttacactt	gagacaagtg	acatggtttt	cttaatgagc	acatgcagcc	84537
aaaatcccag	ttcatatact	ggaaggaaaa	gtctcataga	acaagcagca	gacctctgag	84597
gaatggattc	agaaacaatt	ccagaccag	aatgtgaaaa	gtagcttta	aataccctgc	84657
tctcagacca	cccaggaatg	gtatccagac	ctcatcctgg	cctctagaga	attcccaggg	84717
ccacctgtca	aagtggcttg	tcaggcatgg	ataaaaaatgc	cattggggga	aggaaaatgc	84777
aacataaagc	cttctagcag	aggaaatatg	aagaatagta	ttttctacac	gactgcgcta	84837
aagggttcat	ttaaagaaaa	aaacacttct	aactattagg	gaaaattcca	ggttaactat	84897
acttaaaaaa	aaaaaaaaag	cccaaaaatc	tagtaaatat	tttgctggga	aattcacact	84957
taagaaatg	gtctttcagg	cccctgggga	gaaggcatta	agctgacaca	tttttcaa	85017
caaaatggct	gctctaaaaa	cataaacctt	caaaatgaac	accacagaga	gcccctttct	85077
tctgtgctg	agcacgctca	ctaccactc	agagcgccct	gtgccaaagg	gaagtcaaac	85137
cccatagaaa	cctgatcccc	actgtggaga	aaactgtgca	gcgcccttgt	tttctgtcgt	85197
gctttgtttt	gtatttcaga	tgtgtggtc	acatctgttc	tttatctccc	ctcttccact	85257
gtgatattgt	ttacaggatc	ccagaacaat	ggggactgca	gaatctccac	acagatgaca	85317
ggagacaagg	ctctcagggg	gtagtcaactg	tctgcaaaac	gtggagccaa	aggcgtggtt	85377
ttcagagtag	ctgccaacac	tccaagttac	tcaggctcat	ggaccaggaa	tgactggaaa	85437
ggagactgcc	ttgtctgggg	aagatccaga	cccacagatg	caattttttg	aaagtaatct	85497
ctttacaatg	gcctgcccc	ctcctctctc	tgcttagaag	tttttgtgtt	ctgtaaggag	85557
ccttctaagt	ggcttctgtc	tgccctgggt	tctgtccctt	tggttctccc	agtctgctct	85617
ctgtctcttt	tgtttctttc	atccctggat	tccaggaagt	caaggtcagg	gcagcttacc	85677
agtcctaaa	caccattatt	ttggcaggat	gctttggcag	tggaaatgaat	gcctgcagaa	85737
ggcctcacct	agtcacccac	aaattcatga	acacagctgt	gacttttcga	agcagaagcc	85797
agactcttag	tctttgtttt	ttatcttttt	tttctttttt	tttttttttt	gagacggagt	85857
ctcactctgt	cgctaggct	ggagtgcggg	gacaccatct	tggctcactg	caacttctgc	85917

-continued

ctcctggggt caagcagttc tcctgectca gcctcccgag taggtgggat tacaggcacc	85977
caccactaca cctggctaag ttttgatatt ttagtagaga tgggggttca ccatcttggc	86037
caggctgggc ttgaactect gacctcatga tctgcccacc tcggcctccc aaagtgcctg	86097
gactagagggt gtgagccacc gcacctggcc tgtttttcat cttattttta aaagtcatat	86157
gtcgagcaag aaaaaatcta gactacagt ttactcaaac tgtgggttgc taacagacag	86217
tgctcctcat ggctcttact actggtcagt ggagaaacga agaaattgag agaatgcatt	86277
tagaaaaatt catagtgcct tcacagaata atcttatgtc tcttgaatct aataataaaa	86337
attggggagc ctatatttta catgtctttg gtttgctatt tcacttttct atttattcat	86397
ttttagtata ttataagaa tgtcagtcga taatggcatg gaaataattc aagaagaagg	86457
aaacctatc acacatagta tgaaaagcaa accacagacg atacaaaaaa agaaagaaaa	86517
aaaaccacc aaacactcat ttagccatta ccagccttt gtcaaaactt aacattttat	86577
catgtttgcc tttgcttttt taatttttat tgattggttg attgattgag acagactctc	86637
actttatcac ccaggctaga gtacagaggg ccacatggct cattgcagcc tcaacctcct	86697
gagctcaagg gatcctcaca cctcagcctc ccaattagct gggactaaag ctcatgccac	86757
catgtttggc taattaaata tttttttttg tagagacagg gtctcactat gttgtccagg	86817
ctggtctcaa actcatgtga tcctcccacc ttggcctccc aacgtgctgg gattataggc	86877
atgagccatc gcacctggac attgcctttt tttctttttt ttttttgaga cggagttag	86937
ctctgtcacc ccagagctgg agtgcagtgg cccaatcttg gctcaactga acctccgcct	86997
tcctagtcca agcaatactc ctgcctcagc ctttcagata gctgggacta caggcatgca	87057
tcaccatgcc cagctaattt ttgtattttt agtagagaca gtgtttcacc atgttgacca	87117
ggctgggtct gaactcttga cttcaagtga tccgcctgtc ttggcttccc aaagtgcctg	87177
gattacaggc gtgagccacc atgccagcc tagccattgc cttttttaaa gagattaa	87237
attacacatt ttctctcacc ttctctctct tccaccttc tctttacctc tccctccctc	87297
ttcattctct ttcttttccc cctcttctct ctctcttcca ttctcttctc acccacccca	87357
cttctcttct attccctccc ctccctcctt catctgcctt ccacttctca ctctccctaca	87417
cttctacctc ccttctctct tctccccctc cctctaattt ttaggtaaat tgagcatggt	87477
agacctccaa ggttgggaga cagaggaatc cacagtggcc cagcatgagg aagcagagcc	87537
tgggcaggat gcataagtgg gatgccaggt gaagggatgt ggggtgtcag caccaggag	87597
aggtagagca gttgtccatg aagcagggca gcctctggca tgggaagtca ggactcaaac	87657
aggagagaaa gcctgtcaca tgggagaatg agatgggata ttgaccgtac tccagaggat	87717
tgatcaaata aataaatgcg ataagaataa tgacagccag gtctctatgg aaataaggaa	87777
aactaggata aattctgaat tgttgaacca gaattagatg tgttggtgaa aacttaaagt	87837
ttatcatata tagagatcaa cgaataatat agttttaaat gtgtatatat gcatatacat	87897
ttctattccc tagctccgtg tgccgagagc agcgacaccc catgagcaat gaacacacct	87957
agtgtcaga tctggtttct aaatatgttt tttcactaaa aggaatgagg acttcttggg	88017
gagctggcag attctagagt taagactgag aatgcacacg atgagcctgg aacatcttgt	88077
accagaaatc aagacagtac tccaacaatg atgaggatct gtcaaaggac acagaagtga	88137
acttgaatgg gcttccccctg gccgggtgtg tcaggatttg aacattaaat taaataatta	88197
tagtaacaaa ttataatcta tttgctaaaa tagaaatcat gagcccattc agatgtacat	88257
taaaacatga gtaaattaag agtttgaagg gatgggacat ttacatagtt attcattata	88317

-continued

aaggaaaaga	gagtctcttt	acagtgaaaa	agcgggcaga	caccacagta	atcatgtgat	88377
ccagctgaac	atcatcattg	cttgagccca	agagtttgag	cctgcagtga	actgcgatca	88437
tgtcactaga	ctccagcctg	agtgacagac	caagatccta	tctctaaaac	aacaacatta	88497
ttctggtttc	ttagagtgtg	ttaaaaaaat	tatacaaaat	gaacatcatc	agtgttaatt	88557
aaataaaact	taataggagg	gcattgggtc	agactgggct	cctaccctag	gcctaacaga	88617
ccaaaatgga	gttaaaccaa	gccaaaacta	agttgtttat	ctgaccttcc	aagaaatcag	88677
gaaagaaaaa	tagccaaatc	cctaaacagg	ccagttttat	acagcatgat	aaggaagtcc	88737
cctctgcttt	aacccttaca	aaaaggtaat	ctggactggg	tgtggtagct	catgtctgta	88797
atttcagcac	tttgggaagc	cgaggtgggt	ggatcgtttg	agaccaggag	tttgagacca	88857
gcctggccaa	catggcgaaa	ccccacctct	actaaaaata	caaaaattag	ccgggtgtgg	88917
tggcacacac	ctgtagtccc	agctactgtg	gaggtcgagg	catgagaatc	gctggaaccc	88977
aggaggagga	ggttgcagtg	agccaagatc	atgccactgc	actccagctg	ggctacagag	89037
tgagactttg	tctcaaaaaa	aaaaaaaaaa	aagaagaaaa	gaaaagggaa	aaaagtaacc	89097
tgaagtaact	tgacattggt	caatcagctt	tatttctatt	gttctgtttc	cttgttctca	89157
cettacaaaa	cccactttct	ttttgcccc	tgccaatcta	ttcttctatt	ttgtagaata	89217
gaggtctatc	taactcataa	attccaaata	aaagccaatt	aggtctataa	ctaaactcat	89277
gattttgtct	tttgacatca	gtaatgggac	aaattgaaac	tgtgcaccat	tggtaccata	89337
caatgagaag	tacacgacat	cacttctgtg	atcatcctgc	tacatgaatc	taatcacaag	89397
gaaatatcag	aaaaacccaa	attgaagggc	attttacaaa	ataagctaac	tacaagcttc	89457
aaaattatca	gggtcataaa	agtcaataga	agaccaagga	atctttcttt	tttatgtata	89517
tatttcccaa	tttaaaactt	ttaattaaaa	agtaaacttt	aatgtcgaaa	atgcaaactt	89577
ggggaagaca	gaaaagatca	cacacaaggc	tgtcacttca	cacttggaag	gttgcacaat	89637
ggccggacag	aggcgctcct	cacttcccag	atgggggtggc	tgggcagagg	cgctccttac	89697
ttcccagacg	gttggcagcc	aggcagaggc	gcctgctcct	cgcttccctag	acgggttgga	89757
gccgggtaga	ggcgctcctc	acatcccagt	cagttggcag	ccagacagag	gcgctcctca	89817
cttcccagac	ggggcagtg	ccaggcggag	gcgctcctca	cttcccagac	ggttggcggc	89877
cggggcagag	gcactaacca	aggaaacttt	ctataatgga	gtagggttaa	ggaacatgat	89937
aaactaaaca	taatgcttga	tttggcattg	aatccttttg	atctaagtgg	caaaacttga	89997
atggggtatg	aatatgagat	actagcaatg	tcaatattaa	tttcttcttt	tttttttttt	90057
tttctgatga	tggagtctcg	ctctgttacc	caggctggag	tgcagtgggtg	caattttggc	90117
taactgcaac	ctctgcctcc	cgggtccaag	agattctcct	gcctcagcct	tctgagtagc	90177
tgtgactaca	ggtgcccgtc	accatgcctg	gttaattttt	gtatttttag	tagacacggg	90237
tttctccatg	ttagcaaaagc	tgggtctcgaa	cccctgacct	caggtgatct	accagctcag	90297
cctcccaaa	tgetgggatt	acaggcatga	gccatgcacc	cagcctatct	atttatttga	90357
gatggagtct	tgctctgtca	cccaggctgg	tgtgcagcag	ggcaatttca	gctcactgca	90417
acctccacct	ctggggctca	agtgatcctc	ctacctcagc	ctcccagagta	gctgggacca	90477
caggcgcatg	ccaccatgcc	caactaatct	ttgtattttt	tggtagagat	ggagtttcac	90537
catgttggcc	aggctgggtc	caaaactctg	acctcaactg	atctgcctgc	ctcagcctcc	90597
caaagtgtg	ggattacagg	tgtgagccac	tggaccacgc	cctcagcctc	gttttttctt	90657
ttcttttctt	ttcttttctt	cttttttttt	tttttttttt	tagaggtgga	agcttggcta	90717

-continued

tggtgtccag gctggcctca aacccctggg tttgaactcc tgggctcaag ggatcctcct	90777
gcctcagccc ctggagttgc tgggaccaca gggatgtatt accacacaca gctcattttc	90837
ttaatctcct cacccttaat aattttgtct ctaccctatc ttaaccatac actcccatgg	90897
gcctctctgg attttgtctt tcttaatat ttcttaagcc tttttctata gcctcaatca	90957
agcatcccat tttcatattt ccagctcatt cccattcctt tccatattca gacctgcatt	91017
cttctgggtg ctcagatcaa atactttgga accattcttg atccattcct tgtggcagag	91077
gagaggaaat gtgtaaagga gggtagggcc ctacagtcaa gaggtgggat agcatgaatg	91137
caaagaagag tagcactggg gccagccaca gtggctcaca cctgtaatct cagcactttg	91197
agaggccaag gcatgcagat caccctgacca gtctggccaa catgttgaaa ccccatctgt	91257
actaaaaata caaaaattag ccaggcatgg tggctcgaac ctgtaatccc tgctactcag	91317
gaggctgagg cagcagaatc acttgaacct ggaaggcgga ggttgcatg agctgagatc	91377
gcaccactgc actccagcct gggtagacaga gtgaggctcc gtctaaaaaa aaaaaagag	91437
tagcattgga tttgggaatg taagcttata ggtgaacttg caaacaggaa tgttattgga	91497
aggtagggac aaaatcctga ttttttcaat gttttggaga tagtctgtca ctaaggctgg	91557
agtacagtgg tgcaatcatg gctcactgta gcctcaaaat gttgggctca agctatcctc	91617
ctgctcagc ctccagagta acagggtcta cagggtgcacc accacacctg actaattttt	91677
attgtttatg gatatggggg tctcactatg ttgccaaaggc tggctctgaa ctctggcct	91737
caagcagtc tccctgtctt ggcttcgaa agtattggga ttacaggcat gccagccaa	91797
tctgatattg aattgaggaa ataatcatag tatttctcaa ggaattgctt gaatctgaat	91857
actcaagaag cacttattaa gcaatcaaat gatgtgggct aagtcatttt cgaaagtctt	91917
gaacctttag ccttgaaagt cggaccaatg agtttggtcc ttattttgtt ctgaaggctt	91977
ttttgagtct tgcgttagga aattaatccg gcaaaagcag gcacaaaaga tcttgtgggt	92037
tgaggagtca gtaaaaagac tactggaata gcccggttac aagcttatga gacactgaga	92097
tgggagccgg ggggttaggg ggtgggcaga agcgggaaga gcagtggcac tgggaatcaa	92157
tacaagagga aggaaaaatca acaaccatac catagaaaat gagtcagatt tggaaatgat	92217
tagatgtgga tggggagaca gaagaatcag agaataagtc aaagctagcc aggagtgtt	92277
caacctggat tcctgagaat cctgttacct aggaggagac actgtttctt agatttagtt	92337
tgaggagaag atgatagctt tggctctaaa ttgctttttt tttgtgttt tttttctcg	92397
agatggagtt ttgctctgct tccggggctg gagttcaatg gcctgatctg ggctcactgc	92457
aacctccacc ccctgggttc aagtgtattc cctgcctcag cctcctgagt agctgggatt	92517
acaggcatgc accaccacgc ctggctaatt ttttgtattt ttagtagaga tggggtttca	92577
ccatgttgac caggctgac tcgaactcct gacctcgtga tccaccgct tcggcctccc	92637
aaagtgtgg gattataggc atgagccacc gcgcctggcc ttaaatgtt ttttgtttg	92697
tttttcagac agagttttgc tctgttgccc aggctagaag ctcagtgggt ccatcttggc	92757
tcactgcaac ctccgcctcc tgggttcaag cgattctcct gcctcagcct cccaagtagc	92817
tgggattaca ggtgcatacc accacaccgg gctaattttt tgcattttta gtagagacgg	92877
ggtttcacca tgttgccag gctagtctgg aactcctgac ctcagggtgat ccaccccct	92937
cggcctccca aaatgcaagg atcacagggt tgaaccactg tgcttgcaa aaaatatatt	92997
taattttaat tttttaatt tgtttttgag acaggaaatc actctgtcac ccacactgga	93057
gtgcagtggc atgatcacag ctcactgcag cctcaacttc ctgggctcat gcgatcctgc	93117

-continued

tatccacccg	agtagctgga	ataacaggtg	tgtgccacca	tgcttggeta	atTTTTtaat	93177
TTTTttaga	gatgaggtct	cattatgttg	cccaggctaa	tctcaaacctc	ctgagctcaa	93237
gggatccttc	caccttggcc	tcccaaagtg	ctgggatgag	agacgtgagc	cacctcatcc	93297
tctagtattt	ttcactgata	gagctagaag	acaacctggg	aaaggcagca	attagaaatt	93357
aggatcataga	agtagaaaga	gtacttgagg	ctgcagtctg	tcaagctgca	tggaaatgaa	93417
agttgaagcc	ctaagatatg	atgaaccaca	gtcataacta	taacttcctt	ttaataaggc	93477
ttgctttctt	ccaacagctg	ccttaaatat	ttgaaatatt	tctctcccag	tcgttatggg	93537
acagtgttaag	taagtgttgt	taactcagta	ctgcagacca	gaaagctaag	gttcaggggga	93597
atcaaataac	ttgtcatgtt	aacagaactc	acaagtaaag	aactagatct	tgaaccaga	93657
tccacctgat	cccatgcagt	ttgatgtcag	aatttggttag	tcaaaggagt	caatgaaaca	93717
gacagagaag	aatttgtttag	gagaaagaaa	attatgtatt	tattttaatt	ttatttatTT	93777
ttatttttat	TTTTttgaga	tggagtcttg	ttctgttgcc	caggcgggag	tgacgtggcg	93837
caatcttgcc	tactgcaac	ctctgtctcc	tgggttcaag	tgattctcct	gtctcagcct	93897
ccatagtagc	tgggactaca	ggcgtgtgcc	accatgcctg	gctaattttt	ttgtattttt	93957
taaaagagac	agggtttcac	catattggcc	aggctgcctc	cgagctcctg	acctcgcgat	94017
ccaccacctc	cagcctccca	aagagctgag	attacaggcg	tgagccaccg	aaccagctt	94077
atatatttat	ttatttatTg	tatttatTTa	tttattttga	gatagagtct	cactctgtca	94137
tccaggttg	agtgacgtgg	tgtgatatcg	gcttactgca	acctccacct	cccaagtcca	94197
agtaattatc	gtgtctcage	ctcctgagta	gcacagaaac	acccaccat	acccgcccat	94257
accgtacacc	ataccattac	agaagcacc	caccataccc	agccatactg	tacaccctac	94317
cattacagaa	gtacccacc	ataccagcc	atactgtaca	ccctaccatt	acagaagtac	94377
cccaccatac	ccggccatac	cgtacaccat	accattacag	aagcacccca	ccatagctgg	94437
ccaatttttg	tatttttagt	agagacacag	ttttgccata	ttggccaggc	tggtctcgaa	94497
cttctgacct	caagtgatcc	acctgcctca	atctcccaaa	gtgttgggat	ttcaggcatg	94557
agccacctag	aagaaataaa	attataactt	tgtggggcta	ctgaggggtga	agaaagaaac	94617
caaggaattt	caagaaggaa	aagttcacca	gtcaaagtct	ccagaactaa	gaaaacacaa	94677
caaaaccac	tgagtttagg	tgtagtggtt	ggtttcagt	gatggaggag	aaaggcagat	94737
tcctaagggt	aaatctgaac	ataagcccag	agtaaggaga	ggatcctctt	ggtattatgg	94797
tcaccaactg	tcctaattcg	tctaggactg	tccccttttt	agcacagaaa	gtcacacatt	94857
tcaggaaaact	cctatgtcct	gggtaacca	gggccacct	acctatggca	gctagtgtaa	94917
ccaccctacc	cccgccctct	ccttttttct	gagacagagt	ctgctctgtg	accaggtctg	94977
gagtgcagt	caacctccac	cacccaaatt	caagtgatc	tcctgcctca	gcctccttag	95037
tagctgggat	tacaagcgtg	tgccaccatg	cctagctcat	atttgatttt	ttagtagaga	95097
tggcgtttca	ccacattggt	caggctggtc	tcgacctgac	ctcaagtaat	ctgccatct	95157
tggcctccca	aaatactggg	attacaggcg	cgaacctgg	cgctggcct	tgggtgaaac	95217
cccttttaag	agaggttag	caaggaagag	ctgaaagata	aggggggttg	ttccaagtgt	95277
agcaaggtca	aggaaaggtt	ttttattttt	tttgataaag	aaaacttgcg	tctgttaata	95337
aactgggaga	ggagattggg	aagtacaatc	gtcggtggac	ttgatcccag	aggaagcgaa	95397
actgcattgt	tctgaaaggc	aggcggcagt	gtcccatgtt	tctcacagcc	ctcactgtgc	95457
tggtctcag	ttgccctgtc	ctgggactct	gaacaggcag	tgagtgtctg	attccagcct	95517

-continued

ctgtgcatgc	cttcacccga	cagcgtgcg	gagcagagtg	ttggataaaa	gtcggacaca	95577
ttagggttct	gcactactgt	gactgtggct	gtcacacctt	tctgggcctc	agtttcctca	95637
actgtaaaag	ccaatattac	cagataaaaag	tggggagcac	agtgcctaac	acatgacagg	95697
aacaggtaga	gtgtccctta	ttcctttatc	caaaatgctt	ggtagctggag	tgggtttttt	95757
gttggtgttt	ttgtttttgt	ttttgagatg	aagtcttact	ctgtcaccca	ggctggaatg	95817
cagtggcaca	atcttagttc	acggcaacct	ccacctccca	ggttcaagcg	attctcctac	95877
ctcagcctcc	cgagtagctg	ggattacaga	tgtgtgctac	cacacctggc	taatttttgt	95937
atttttagta	gagatggggg	ttcccatgt	tggccaggct	ggctcttaac	tcccgatctc	95997
aggtgatctg	cctgcctcgg	cctcccaaag	tgtgtggatt	acaggcatca	gccaatgagc	96057
aagaaataaa	ttctttatca	gatacatgtt	ttacaaagaa	tttctcccag	tcttgtcttt	96117
tcattccctt	aagagtcata	ctgtggccag	acacacctgt	aatccagca	attttggaag	96177
ctgaggtggt	ggattgcttg	ggcccagggt	tttaagacct	gtttggcaac	atggcaaaac	96237
cctgtctcta	ccaaaaaaa	atataaaaag	acaaaaacaa	aaaacaaaa	ttaccgggc	96297
atggtggcac	acgcctgtaa	tcccactac	tcgggaggct	gaggtggcag	aattgcttca	96357
gccttgagg	tataggttgc	agtgagtcac	gatcatgcc	ctgcactcca	aactgggcaa	96417
cagagtgaga	ccctgtttca	atttatttat	ttattttaaa	gaagagtgat	attgttttga	96477
atgcaggtta	atagtcctta	atcccctgag	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	96537
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	96597
nnnnnnnnnn	gtgaaacct	atctctaata	aaaatacaaa	agttagctgg	gcatggtggc	96657
ttgttcctgt	aatcccagct	actcgggagg	ctgaggcagg	agaatcgctt	gaaccagga	96717
ggtggagggt	gcagtgagcc	gagatcatgc	cactgcactc	tagcctgggc	cgtagagcaa	96777
aactctgctt	ccaaaaaaa	aaaaaaaatc	tattgggttt	taaattatac	aatcattcta	96837
gaaaatgtct	tacaatacaa	tgttgtataa	gctaagtata	aaaagtaaaa	agagtaaaaa	96897
tggccaggcg	tgggtgttca	cacctgtaac	ccaagcactt	tgggaggcca	acgtgggcgg	96957
atcacaaagt	caggagtctg	agaccaacct	ggccaatatg	gcgaaacct	gtctctacta	97017
aaatacaaaa	attagctggg	cgtggtggcg	cacacctgta	gtcccagcta	ctcaggagac	97077
tgaggcagaa	gaatcgcttg	aaccggggag	gcagaggttg	cagtgagctg	aggtcacacc	97137
actgcactcc	agcctcgggt	acagagttag	actgcactc	aaaaaaaaag	gaagcgtaaa	97197
aattttacaa	atccacttcc	ttccagcccc	aattctacaa	agcaaggcc	accactgctg	97257
ttgatatgta	tatataagct	tcatgagggt	ttgtctgttt	tctttaacat	tatatcccta	97317
atttttggca	gtgtctaagt	catagtaatc	attcaataaa	tattcattga	ttaaatgatt	97377
aaagtaatgt	tctgcatgta	tattttttac	tttagtatca	catttagtgt	gtatatataa	97437
gattacattg	tattctatat	aattaatata	ttatacatta	tttaaccaat	gcctgaactt	97497
ttaggctggt	tataattttt	cctatagcaa	acaatgctga	tacaatcaac	cttttatgca	97557
catctttgta	cttgtgtgat	tctttctgaa	gaacaatttt	tagaactgga	attacagtgt	97617
caatgtgcaa	acataattaa	cttttttttag	tatttctttc	ctctattttt	ctatttaggg	97677
ggcttttttt	ctaattacaa	aagtagtgca	tgtgtctctg	aacaagtcta	attataatgc	97737
taaaagttac	caaacattta	ttgtgtacca	gtcactatgc	caggattttt	tgtgtattac	97797
cttatgtact	ggctggctag	gccaaaggag	ggtagcccat	ggaaagcccc	aaagtaagga	97857
aaattaataa	aaaaattcct	ccgcatgaga	acagatgagg	aatattgtt	tcaatgacaa	97917

-continued

tacagcaaga	attacatggt	ctagaatgca	gccatttggg	tcggggatga	tgtgcctttc	97977
caaggatggg	tactttttac	aatagtaagt	ataattttgg	gagctgacct	tcttgaggat	98037
ataaaagacc	taaattctac	attgttgtga	ttctctcacc	aggcagacat	ctcattctat	98097
atctatgcta	acaactaatt	gttagcatct	ctgacctttg	gagacttttc	cataaaaaga	98157
caaaggaggc	aatgggaaac	cacatctacc	tacttgcatt	tttatcttac	atagaccttc	98217
aaggtaactt	agtttaagca	gacttaaaaca	gaatccagat	cattattctc	attcatcttt	98277
ttgtttttgt	ttttgttttt	gttttttttc	tgagatgtag	tctcgccctg	tgcccaggc	98337
tgagatgcag	tggcgcgac	tcggctcact	gcaagctccg	ccttcggggt	tcacgccatt	98397
ctctgcctc	agcctcccta	gtagctggga	tcacaggcgc	cggccatcac	gcccagctaa	98457
ttttttgtat	ttttagtaga	gacgggggtt	caccgtgtta	gccaggatgg	tctcaatctc	98517
ctgaccttgt	gatccgctcg	cctcggcctc	ccaaagtgct	gggattacag	gcgtgagcca	98577
ccgcgcccag	cctattctca	tccatcctta	agactggact	ctttggteat	tgtaactga	98637
ctttttcgta	taggataaat	tcttaaacat	gagatagtag	tcaattctgc	caacattcag	98697
ttgttgtttc	tgaatttccc	acattgctta	aggtaacctc	caccatgacg	ctataaaaac	98757
acttttctcc	attttttcat	atatttgtat	aggtttgttt	ttacatttaa	gtgaatttta	98817
aagataaaac	ttacctatct	atatggaatg	aggaaggaaa	cctcttactt	tcatatacat	98877
aaccaattat	gttacactat	ttattacata	aaccatactt	tatcaatgat	tgcaagtcca	98937
tctttgtcat	atattaagtc	ctaacaataa	cctaaatatg	ttcctacaat	ctctattcta	98997
ttacagatc	tacttgacag	ctgtcgaaac	aatacatgcc	attctgacca	taataccttt	99057
aagataagtt	tgaccattta	acataagaag	taataaccag	accgggctca	gtggctcacg	99117
cctgtaatcc	cagcactttg	ggagtcgag	gtgggtggat	cacctgaggt	cggaaagtca	99177
agaccagcct	gaccaacatg	gagaaacccc	atttctacta	aaaatacaaa	attagctggg	99237
cgtggtggca	catgcctgta	gtcccagcaa	ctcaggaggc	tgaggcagga	aaatcgcttg	99297
aaccggggag	ccggagggtta	cagtgcgctg	agatcgaccc	attgcactcc	agcctgggca	99357
acaagagtga	aattgtctca	aaaaaaaaaa	aaaaaaaaaa	aatgtgggga	aaaaatctt	99417
cctcagctga	agaaagaaaa	aaaaaacaaa	tctgacgtgg	tagacaaaat	agtctaaagg	99477
aattccctac	tacaaaaata	tgagatcctg	cacaaaacaa	aatgtttatt	gctgggcttc	99537
caggaaataa	ggtaaacctc	tgacagtagg	tccaaacctt	gaactgacac	cagaatagaa	99597
gtcctaagat	gcttaaaaaa	tcagcttgct	ctgcaggcat	atgtgatatc	agctctgcaa	99657
tgtagagttc	aaattttggg	tcaatagaaa	aaaaatagaa	gctgaagctg	agctttcctg	99717
attaagaaa	gggaacaaaa	gtgactccta	gcagaagcta	ttccgctcac	agtttcattc	99777
gacggatttt	ctacaagtta	agggttaatga	aatctgactg	ccaagcatac	gtgttaatga	99837
gtttcttctg	agtgagagcc	agctgaaatc	acaaacaaca	gatttgagca	cccttaatta	99897
ttttaattat	gtataagatg	ttttaataaa	ataggagatc	ttttttgtag	ttcataaatg	99957
cgatgattgg	gttttcatgt	ttatgtgtga	gatgtgcttc	cctcaaacct	tgttatgatg	100017
tcagtacggt	atccatctga	tgtggaagaa	aaagaaaaca	aacaagaaga	aataaatagg	100077
agtcataaag	caataaatta	cagaacacaa	aatatgagga	ataaaagatt	atccaaagtg	100137
gccagacttt	agaagaagcc	aaagtgaatt	tttagttttt	aaaaattggt	gaagtaaaaa	100197
tttgaatata	tggaataaaa	ttagatacac	cttaaaacag	aattagtaaa	ctggaagttg	100257
ggtagaataa	attatccaga	atacagccct	ctcactccca	aatggatagt	atgataagag	100317

-continued

atagaagtgt atatatctaa ttcaaatcca gaagtagaga acagataaga ctgagaagtg 100377
gcaatatttg aagctatttg ccaggcacgg tggctcacgc ctgtaatccc agcactttgg 100437
gaggctgagg tgggtggatc acatgggtcag aggttcgaga ccagcctgac caacatgggtg 100497
aaacctgtgc tgtactaaaa atacaaaaat tagctgggca tgggtggcagg cacctgtaat 100557
ccaagctact caggaggctg aggcaggaga attgcttgaa cctgggaggc ggagggtgca 100617
gtgagccgag atcgccccac tgcactccag cctgggtgac agagcgagac tctgtctcaa 100677
gaaaaaaaaa tttgaagcta ttatgggtga gaattttcca gaagcaatgt atgacattga 100737
tccacagata cagatggaaa atgaatacca aggaaaacaa atagaaagaa atctacactt 100797
aaacatattt ctgtgaata caaaacacca atgcccctcc ctaccactcc cctcacacac 100857
acagaatgca actactgaga taaaatagat taccaataat ggaatgacaa ttagagtgat 100917
aacagacttt ttcataatgt ggggaaggcag gagatagtgg aataatatct tcaaagtgtt 100977
gagaaaaaat tctgtcaatc ttaaattgta taccagaaa aactatctaa ttttaggaaa 101037
tgcattgtga agtatttaga ggtaaagtac ttaagagtac tataaatctg taacttaact 101097
tcaaacattt aagaaaaaaaa atacataaat aaatatatgt gtacacacat atatatttaa 101157
agagagagag aagcaataa gataaaatgt taacatttgg agaactctag tgaaggggat 101217
atttgggaat tctttatgct atttttacac ctttaggagt ataaaatgat ttcaaaattt 101277
caaaagataa aacttacaat agcagtaata aatataagta cctagaaata aaagatatga 101337
agaagactac aaaggagaaa cactatgcat tgatgagaga acacttagta ttatacaatg 101397
tatataatta tacaattaca cactacactt cacaacatcc ccacattta cctacagact 101457
caatgctttt cctataaaaa tcccaaaagg agtatttgag taacttaagc tgactctaaa 101517
atttatgtaa cagataaaag accccaaaat aattaaaata gccctgaaga acaacaacaa 101577
caaaaaacat gagtggaggac atgcccgtgc agatagcaag acttatcata gatgacatag 101637
tacttaacac agcttagtat cagttcagat agacaaagta atcatctgaa caaaattgaa 101697
agcctgaaaa aaaaggccca cacttacgtg gacacttgat ttatgacaaa aatgggtgaa 101757
tattcagtaa atgggtgttg gacaataggt tatgaaaaa acaaaagaaa atcatatact 101817
tatatatcat acacagaagc agtctctgct gtattatata caaaacttga attctcttag 101877
agaacgttat aggataatat ttttataacc ttaaggtagg gaagtatttc ttaacaaga 101937
ttgaaaggca cagataaatt cagctacatt aaaattaaga acttttagcc aggcacggtg 101997
gctcacgcct gtaatcccag cacttgtagg gcggagacgg gcggatcact tgaggccagg 102057
agtttgagat cagcctggcc aacatgggtga aaccccatct ctactaaaa atacaaaaac 102117
tgagtatggt ggtgcacgcc tgtaatccca gctactcagg aggctgaggc acaagaatca 102177
cttgaaccca ggagggtggag gttgcagtga gccaagatca cgccactgca ctgcaccctg 102237
ggtgacagag tgagactctg tctcaaaaaa agaaaaaaaa aaagaacttt tgttcttta 102297
aaggcaccat agagaataa agaagctatt tgctacactt ataactattg aagggttagt 102357
atccagaata tccaaagtcc aaaaaattag taatccataa aacagtaaat cagtaaaaca 102417
cacatgatgc aatatagttc tggacaggaa gtatgagcag gcatctcaca aaagagaaaa 102477
tatgaatggt gaaaagagat atgaaagttc ctcaaactca ctagtaatta gcaaaataag 102537
accataagga attatatattt acaccactg gattgccaaa agttaagaag cctgagtccta 102597
cagagttggt gaaattttag atcaactgta actcatatat acaattgttg gggctgggca 102657
tggtggctca cacctgtaat ccagcactc tgggaggctg aggcaggagg attgcttgag 102717

-continued

cctagacatt caagaccagc ttgggcaaca tagcaagacc ctgtctctac aaaacaaaat 102777
aataataatt taaaaagtaa ctgggcatgg tgggtgcttg ctgcattccc agctacttag 102837
gaggctgagg tggaagaatt gcttgagcct gggagattga ggctgcagtg agctgtgata 102897
atgectctat acctcagcct ggggtgacaga gtgagacctc atctcaaaaa caataaatta 102957
attaattaaa taaataaaac ctcatcttgg taagcttctt ctcaatacac aggtgactat 103017
atttcagat ttttaaaaa atgtggtttc ttggccaggt gtggtagctc acacctgtaa 103077
tctcagcacc ttgggaggct gaggcagggt gattgcttgg gctcagcagt tcaagaccag 103137
catgggcaac atggtaaaat gccgtcccta caaaaaatac aaaaaacaaa acaaaacaaa 103197
acaaaaaaat taccgatca tgttggcacg tgctgtagt ccagctact cagaagactg 103257
aggtagaaga atcgcttgag ccaggagct taaggctgaa gtgagccatg atcatgccac 103317
tgcaactcag cctgggggac acagtgagat cctgtctcaa aagaaaataa tatatatatg 103377
tttctttaa gatatctttg gattctttga ggtttttaca aataactaaca taatcttcat 103437
ctcttttagca aggtatcca cattgactct ggatatatat ccaggagtaa ttttttaaag 103497
tttacttaca atcataaaac tgtgtttgca ttgctcagta gccctgcata gtttactaaa 103557
acagttcaaa tcatttcgac atagtaaacac cagctaatta tcacaaacta atcacacttg 103617
gaagaattgt ttccttgact aacaattgcc atatctcaga accgttactt ctcaataata 103677
taagctcttg gtcattagga ttgaaaaag aggagatgag ctcatcatca tctttggaga 103737
gacaagcagg gggcaaaagc aacaagactg catgtcctgg ctattttccc cagaatagat 103797
tccagtttgc ctttctccta atatgctcag aatataaacc aacacttcac atttggtcta 103857
tttcttgctt cagtcattac gctttcatta gtggactttt tagttccttt aattctttat 103917
ctctcactag cactactttt taatatattca ttttatagtc tttattagct tattggttgt 103977
atctcttttt atttgttctc ttttgtctgg gtttgtggct ttggggtcta cagtgtacat 104037
tctcacttg tcttttttct tctttctttt ttacagacat gatctcactt ccatacccca 104097
gactgcagtg cagtggtgca atcgagctc actgcagcct ggaattccag agctcaagcg 104157
atcttccac ctacagcctc caagtagctg ggactatggg tacacacaac tacaccctgc 104217
aaagtctaca gtgtacctc ttaacttata agtctctttt caaataatat tagactacct 104277
ttttattgat ttatttttta atcgagacgg agtcttctc tcttgcccag gctggagtgc 104337
agtggtgcaa tcttggtcga ctgcaacctc tgccctccgg gttcaagtga ttctcctgcc 104397
tcagctccca agtagctggg attacaggtc tgtgccacca cgcccagcta atttttgat 104457
ttttagtaga gacaggggtt caccatgttg gccaggctga tctcgagctc ctgatctcaa 104517
atgatccacc caactcagcc tcccaaagt ctgggattac aagcgtgagc caccacacct 104577
ggcctagacc accttttgta gaagaatttg gcctattata taaaagcctt acaacagtgt 104637
gcttccattt ttctctccca gtttctgtgc tattgttgcc ttttacttta cttctgtata 104697
cactttattc tcattattta cagattctat atttgtaaag tcacctactt gctacaattt 104757
atttgtaact ccaaaatcta tatggtaatt ctgtaattat ttgtgaacat gctcagagca 104817
gcaaaatctt tgagtccctt gaggttcaca atccaatcag aagaaataag gcaatgcctg 104877
tcttctttgt ttcagctctt ctaatgtaaa taagtgtcct atttttggtc tagttattgc 104937
cacattgttt atatgttgtg ctttccatgt agatgatttc actgtttaaa gtggccccc 104997
aaaagacttg tatactgaaa actatgaaat gttgttgaaa gaaataagta aatggaaaga 105057
catctggtgt tcatggaaga cttggtattg ttaggatgtc aatattacc aaagtgatct 105117

-continued

acagatgcaa tgcaattcct atcaaaatcc caatgacatt tttttttgca aaaatagaaa 105177
agtccatcctt aaaattcatg tagaatctca aggaaccacc aaatagccaa aacaatcttg 105237
aaaaagaaga aagttagaag tctcatatct tctgatttaa aaattttctg caaagggtatg 105297
gtaatcaaaa tagactggta ctggcataaa gacagatata gagactagtg gaagaaaata 105357
gagaactcag aaataaaccc tctcatatgg tcaaatgatt ttcaacaagg cttccagcca 105417
tactcaatag ggaaaggaca gactccttaa caaatagtgt caagaaaact ggatgtcagg 105477
ccaggcgctg tggtctacgc ttgtaatccc agcaccttgg gaggccaaaga caggcggatc 105537
acctgaggtc aggagtttga gaccagcctg gccaacatgg tgaaccccg tctctaataa 105597
aaatacaaaa gttagccggg cgtggtggca catgctgta atcccagcta cataggaggc 105657
tgaggcagga gaatcacttg aaccaggag gtggagggtg cagtgaacct agatcatgcc 105717
actgcactcc agcctgggag acagagcgag actctgtcaa aaaaaaaaa cagaaaaaaa 105777
gaaagaaaga gaaaactaga tgtccacatg caaagaata aagttggacc tttatcttat 105837
accatataca aaaatggact caaggccggg cgcggtggct cagcctgtt atcccagcac 105897
tttgggaggc cgaggcgggt ggatcacgag gtcaggagat cgagaccatc ctggctaaca 105957
cagtgaacc cgtctctac taaaaatata aaaaattagc cgggcgtggt agcgggcgcc 106017
tgtagtccca gctactcggg aggcctgagg aggagaatgg cgtgaacccc ggggggcgga 106077
gccctgcagt gagccgagat cgccactg cactccagcc tgggtgacag agcaagactc 106137
cgtctcaaaa aaaaaaaaa atggactcaa aatggattaa agatctaaac 106197
atgaggccta gacctataaa actcctagaa gaaaacatag gggaaaagct tcatgatgtt 106257
ggatttggca atgatttagt ggatatcact ggataatgat aaatattaga taatgatttc 106317
ttcctttgga tatgacacca aaagcacgag caacaaaaga aaaaaagac aaatggaact 106377
acatcaaact caaaaacttt tgctcatcaa aggacacagt ccacagagtg aaaagggaac 106437
ctatggaatg ggagaaaata ttttgaaatc ctatatctga taagggatcc agaatatata 106497
aacaactaca actcaacaac aataaaaaaa tcaataaacc cattttaaaa gtgggtaaag 106557
gcatggaata ctgtgtggct ataaaaatga gtgagatcgc cgggtgcggt ggctcatgcc 106617
tgtaatcgca gcactttggc aggcagataa tgaggtcagg aattcaagac cagcctggcc 106677
aacatggtaa aaccctgtct ctactaaaaa taaaaaacag ctggctgtgg tggcaggtgc 106737
ctgtaatccc agctactcag gaggtgagg aaggagaatg acttgagcc gggagggtga 106797
gggtgcagt agccaagatc atgccactgc actccacct gggtgacaca gcgagactct 106857
gtctcaaaaa aaataaaaat aaataagatc atgtcctttg cagcaacatg gatggagcta 106917
gaggccatta tcctaagcaa atacagaaac agaaagccaa atactgcatg ttctcactta 106977
taagtgggag ctaaacatg agtgacatg aacacaaata aggaacaac agacaccagg 107037
acctactga gggtagaggg tgggaggagg gtgaggatgg ccaaaactacc tatctggtac 107097
tatgtctgatt atatgagtga caaaataatc cgtacaccaa actcctgtga gacacagctt 107157
acctatatca caaacctgca catgtagccc tgaccctaaa ataaaagtga aaaaaatgga 107217
taaaggatct gcttgagtga acatttctcc aatgataata cacaaatgac catcaagcat 107277
atgcaaagat gctcaacatg actaatcatc agagaaaagc aaatcaaac cacaatgaga 107337
tatcacttta cacctcttag aatatcaaaa acaacaaaca agcaaaacc cagaaaacag 107397
caagtattgg caggaatatg gagaggcctg gacccttgaa cactgttgggt atgactataa 107457
aatggtacaa ccacggtgga aacagtatg gtggttcttc aaaaagttaa aacagaacta 107517

-continued

ccgtatgggc tagcaatccc acttctgaat atatctccaa aagaactgaa atcagggttt 107577
tgaagagaga ttgcaaacc cctatatcta gcagcactat taacaatagc gaagagttgg 107637
gaacaaacta aatgtccatc catggatgaa tcaatagaca aaatgcaata tgtatgcaca 107697
atggaatact atgcagcctt aagaaggaaa gaaatcctgt cacatgcaac agcatagatt 107757
acccttgagg acattatgct aagtgaacaa agccagttac aaaagaacaa acaccgtgtg 107817
attcttccta tataaggtat ccaaaatagt cgaattcatt gatatagaaa gtagaatggc 107877
tgttaccagg ggatgagggg aagggaaaaa ggggagatgt tgtttaatgg atatagaatt 107937
tcagtctctg aagatgaaaa agtactgggtg atctatttca taacaatgta aatatgctta 107997
acactactga accgtatact taaaaaagggt taattatggg ctaggcgtgg tggttcatgc 108057
ctgtaatcct agcacttttg gaggcogagg tgggtggatc acctgaggtc aggagttgga 108117
gaggagcctg gccaacatgg tgaaacccca tctctaccaa aaatacaaaa attagctggg 108177
caagggtggt cgcacctgta atgccagcta ctggggaggc tgaagcagga gaattgcttg 108237
aacacggaag gtggagggtg cagtgaacca ggattacgcc actgtactct agcctgggag 108297
acagagctgg actcaatctc caaaaaaaaa aaatattggt aacatggtaa cttttatgat 108357
ttgtttttta accacaattt ttaaaatctt atttttagtg atatgtataa ctaagatata 108417
cagaatttcc tggctcagtg acccttcag atgctttgcc tttgggggag aaatcaagta 108477
gaagttcggg ggggctaata cagttacaca gatcataaaa tatgctgtga gagaaaagag 108537
gcagagttgt ttgtctattt tgtgttttgg gctcacattt gctcaagagc tttatgttta 108597
tcaatcagat aattaagaa tatttgctta aatatcactt tggtttctg aaatcaacac 108657
agcctaagga taaaaaccta gtttttctc aaattttgtc atgactgggt gaattaagt 108717
atccccctag attcacacat tgaagtcata cccccccagt cccttaaaat tgatacat 108777
tatgttgtgt tttttccccc caaatgaaaa tttttaaaac ttttttaaa aaataaataa 108837
actcaaaagg gatcaaaagg ccaactataa aactataaat ttttttaaa agaaaacata 108897
aaactgggag tgggtggtta tgcctgtaat ctgagcactt tgggaggcca agaagagtgg 108957
attgcttgag tccaggagtt tgagaccagc ccaggcaaca tggggagacc cccatctcta 109017
taaaaaatac aaaattagcc aggcgtatgt gcggacgcct gtagtccctc ctgttcagga 109077
ggctagggtg gaggatcact tgagcctggg aggtagaggc tgcagtgagc tgtggtcaca 109137
ccactgcact ccagcctggg tgacagagta aaacctgtc tcaaaaaaaaa aattagggaa 109197
gaagctttat gacattgggt ttgacaatga tttattggat atgacatcaa aagcataggc 109257
aacaaaaaga aaaattgata agatggactt cttcaagatt gaaaaacttt gtgcatcaaa 109317
gggcactatc aacagggtga aagggaatcc acgaaatggg agaaagtatt tgtaaatcat 109377
atatctgata agagattgat attcaagata tatagagaac tctcttaaaa tgcaacaacc 109437
aaaaaaaaacca acctgatttt aaaatgagca aaagattcaa ataaatgatt ttcaaaaaaa 109497
atacaaatgg ccaataagta catttaaaaa tgggtcaaat gaggccagggt gcagtggctc 109557
acctgtaatc ccagcacttt aggaggctga ggtgggaaga tcacttgagg ccaaaagtta 109617
agatcagcct ggtcaacatg gtgaaatccc atctctacta gaaatacaaa aaaaaaaaaa 109677
aaaaaaaaatt atctgggcat ggcagtacat gcctgtggtc ccagctactc atgaggtgta 109737
ggtaggagga tggcctgagg ccaggagggt gaggttgcaa tgagtcaaga ccatgccact 109797
gcaatccagc ctgggcgaca gagcaagacc ctgtctcaa aaaataaata aataaaaaat 109857
aacatcagta agcattagggt aaatgaataa caaaacacag taaaatacca cttcacatac 109917

-continued

accattaga atggctatta cttattattt taaaaaatga caacaacaaa taatgtgttg 109977
gtgaaaatgt ggagaaacag gaacccttgt gcattgtgta ggaaaaatgt aaaatggagc 110037
agctgctgtg aaaaacagta tggcaatttc tcaaacatt agacatagaa ttaccataag 110097
atccagcaat tccacttctg ggtgtatacc caaagaacta aaatcaaggt cttaaagaga 110157
catttgtaca cctgcgttca tatcacactg tgattatagc attattcata ataacaaaa 110217
gatagaagca acccagcgt tcatcaatga atgaatgaat aaacaaaatg tggcgatac 110277
atacaagga atattattca acctgtcac aaaaggacaa atattgtatg attccactta 110337
tatgagtgtg ggaacaagag tgacttctga ctaaccctga gtccaaaaat gcctccataa 110397
tgtctaggtg tcagtacttt ttgtgtagaa acagctagtc actgtaagtt tctccaaaa 110457
caacacttaa tgctgttaca aacatcatag gctaggattc ctgtagcacc tatacattcc 110517
ttccagagca catattttta tacttttccc caagacatca gcctccctaa ggatctggga 110577
ggttgtgtgt ctaagatcta cctgtcttgc agcccccag accatgcttc tgtccataaa 110637
ttccctgat aaataatctc ataccaacaa actggatttg tctgcttctc tctttgattt 110697
cttcacttct ttggtatttg gggatctctt tgcataaca gccctttcac agaacaatga 110757
ggtacctaga gtactcaaat tcatagagac aaaaagtaga atggtggttg tcagggcaga 110817
aggcacagga caggggagtt attgtttaat gggtaggag gtttcatttg agaagatgaa 110877
aacgttctag agatgggtaa tgggtggtgt ggtggttgca gaataatata aaaatgctta 110937
atggcactga attgtacact gaaaaataat taaaatagta aattttatgc catatatatt 110997
ttcaccata aaaaatggc tcccaggggc aattgtaaaa ttatatctgg tattcctagt 111057
acgagaagac atggatgtgc cttatgtgtg tgtagatga gctttgttca gacatgttg 111117
ctgtgagctc catgttaata aatcaatgat ttgtattaca taagctgact ttaagtagag 111177
acacacataa aacaaggta tgtgttgatt gcttgacaaa agtgttgcaa ccagaggttt 111237
acagaatcta actctgtatt tcccctgtga acaatgttca gtgttacta attcatcatt 111297
ttcaacaact ttacagagca taactatcat gactaaaaag aatcagctga gacagacaca 111357
gtggctcaca cctgtaatcc cagcattttg ggaggatgag gtgggatgac tgcctgagtc 111417
caggagtcca aaatcagcct gggcaacata gtgaacccc atctctaatt tttttttaa 111477
aagtaaaaaa aaaaaaacca aaaaaaaac tgtatgttat aaactccaca atatattact 111537
atttttgctt taaaatattc aattatcttt aaaagagatc ttttaaaaac atcttttata 111597
tttaccaca tattttttat ttgcaggcat gttcccatct acgtcttgc acttgtttct 111657
acctctgtct ggaattctct tgctccagca agccatgtga tcagttctcc acattctctt 111717
taggtctcta ttcaaaagt actttttcag ttagaccttc catggctact ttatctaaat 111777
agctatatat cttcacatct atttccttat ttaactatca atgtccttat ttaattctca 111837
actattaatt atccttattt tacaaatgag gcaagtggaa gtcagaggga tgaagtgaat 111897
tgcccgaggt cacactgcta gtaaatggta aagcacgtag attgtctcca gaaacttctc 111957
aatatattta ccttatgtac atgatattta gcctatataa acatttcat atatttatca 112017
tgtgtatata cacacctata gatatatccc atcttcaagc tatatttcat catagctgtt 112077
tctaagtcct ccatgattga tgcaactggt agagacttgg aagtaagatg atgcaactgac 112137
ccagctagca ttactgggc atctgctagt aggtgctagg cattgtgatg aatgctaagg 112197
atatagagat gaaagatgca gttgctgtca tcaatgtcct cacagttggg aatagggaga 112257
agacagacac ttagaagttc catggagaaa gaactaggta ggaccaatg gataaaaaat 112317

-continued

actgaatgaa gattctaate caacacaaga aagtttctaa tggtaaaagc tgtctgaaaa 112377
tgaaatgggt tagaggggtg agttcctctc acaggagttg tcccagcaaa agtatgggtga 112437
cagttgagct ggctgttata gaagggattg acttaaacat aacatggctg atcaggagcc 112497
aggtaaccaa tgtgagctag ggttttttaa gacacttttc aacaaagcga ctatttgtag 112557
agatgtgtgt agggctaatt gaactaacia gaattttgat gcaccagggt gactagcaga 112617
aactagaagg catttcact tcatgcctga aggcacagggt ggagtctgat taaaagccag 112677
agcctaggaa aataggtctc caaagagaaa aagaatttct agagaagcag caactgccag 112737
aactggaaca atataacatt cccagaaaaca atatacctgc agttctctat ccttaggttg 112797
ttcggttatt tgcagtgcga cttattcacc aaatgcaaat ggaagccaga ggcaagcgcc 112857
tgccagtgcg gcagttgata aaggaaacta tactgtccac aaaggtcagt gtcgagggc 112917
accagcagg gcagaagagg gcgaaatgga tccagatgga aaacgcagga taatcagcag 112977
agttgttttt aagggccctt tatatttca gaggcaaaat tttctttccc tttagactct 113037
acaaatgaac aatcggaag cgaacctca ctgtgggtg agtggcgctt ggagaaaatt 113097
ggagctgagt ggataatccg gctatgcctt tcccacgtct ctttcccacg cagcgtcacc 113157
gtcgtgctct ccagtgcaca ccaccagcca tccctgcctt ggcgcccgga cgaagctcac 113217
gggtgggga gcctcttttc tgcgcgggtg atcaaggcg tcccagccca ctgagggcca 113277
ggaggcgagg cttgggcaca cgtcccttcc cgcccgagc ctggtgcccg cgaggctctc 113337
ttggccctgc tgggagcgca ggggtcgcg caaccattca gaacccggc tggcagacaa 113397
gcgaggtttt ccacgtgggc agaggcgagc ttgttcaggt ggcaaggatc caaggctgag 113457
ccttctctcc tctgcgtcca cccacgccc cccccaccc cgcacctaga aaaggacacg 113517
cacacaaaaa actttcgcca cactattaat atattcgctt ttctccccc tttcccaatg 113577
ggctaccagc tgcagaactc ctgaatagaa agcttaattg tgctttgtca tgcagagtac 113637
ctcgattttc tatagaaggt tacaagggc catttgaagt atttctttct cgcctaatag 113697
tgaaccattt gcatacggca cctctgcgcc tgcagaccc aggtagctgt gccgaagctc 113757
cgggggcccc ggagtaacaa aaccagggc ggtttccaaa gggcgcccta ccccgctct 113817
cgccagcgt ttggactttt ctctccaatt cctcgggtc acggcccgcc ctaggcagct 113877
gatttgagg acgcgaata tggcctgcag gccgcgggtg cccagccggt cgtctgata 113937
tcttgaggc ctcgggccat ccaggccctt ctagectgga cccgagcctt ttttaggccg 113997
ggtctaccga acccagggtg tgtttttcat ctactatctg caggtccaga gaccaggcct 114057
ttgccacgc ggggtcctcc acccacttgc ttctcacgta aggcccaagt gaggcgctga 114117
agaactggaa ggtgattatg atttcgatac cacgtgttc gttctctctg gttgattgac 114177
agggctgcgt tcagaatato ttttctgtt gctgttttg acagttcaaa tccaggtctg 114237
tgtgacatat aaagctaata aaattctaata ttcattgtta atctatttcc attgcagtat 114297
aggtttttac cctcacacct gcatggcagg gtgtaattcc attataaaaa aaatcaaca 114357
tattcattgc atgtcttttc cctgatgata tattgtgagc agtgtgagtt gagaaagagc 114417
catttattcc caccgtgaat gagcctgcat ggggcgggag cttcacctgc cctcagtc 114477
attaggaatg tatcgaaaag tctagcagaa aacaggttaa attaacggtt ggctaatttc 114537
cttatgtccc tcctacataa tcccccttt tcagcttgcc ccagaaatta ccacatgttg 114597
caaggttcaa atagtgccta atgaacagc gactaaacgc ttctccctcc ggcgccaccg 114657
acgggggagc ctttctcgcc gccttcaaa cttgcaggat ttcgtggttc tggttcccg 114717

-continued

atccaagaaa aaaaaaaga aaaaaagaga agaaaagaaa gagaaagaaa tttttgacaa 114777
gcagaaaaaa gaaaatctaa gctgtcaata actctcgatc cagcgagtga aactacatta 114837
atgccccccc acttctctgc accgatgatg cagtgggatt ccgagatgcc tgtgcccgc 114897
gtagataccc aagtaggaat ggcagcttta gcctcctcct ctttccccgg agagctagga 114957
ggattgagcc atggccaggg gagactggat ggggaaaacg gccaggagaa caaagggtgg 115017
gggtgggggc ggatatcaag gcagaaggag atggagacaa gacagagaaa tgcagacaga 115077
gaaagatcac tggggaagca gatgcaaagg caaaaaaaaa aaaaaaagaca 115137
gagtgacagc aaacacacct ctaaagtctc aactccctta tccaagtta aaactacatg 115197
tatggcttaa gcaactcatc agcctctagc caaaggcatt ttgaagcctt gacattcaaa 115257
atcctaataa ttaatcatc ttattaatta attaaggagg aaaggaggaa ggtggctggc 115317
tgctgcttga ccccaacaa tctaaattag ggtttgtgaa ggaagtctcc aaaagcatgc 115377
actccctctc cttcgtatct tttcttttct acactctcaa aaatttccat tataatcctt 115437
caaggtctgg ggcaggcaga gcttctcacc ctgctccatc ccttcgcagc aaactgagac 115497
caagctggct tctgctcctt ggagccggct gccactcata ggcaggggagc tctttcccat 115557
cgggagcaac tcccacctgc ctttttttct ctgcacctgc tgtgggtggg ttctccttga 115617
acttcagaaa ccaagtagtt gcctagaatt actttcgcca cagtgtctac aggetaata 115677
ttactacatt ctctctctct ctctctctct ctctctctct ctctctctct ctctcttctg 115737
ttctctctcc tctctccctt tgcctccctc tcaactagaga cttgagtcct ctatttgaaa 115797
tggtgcagct aatacaaaag catcaaaagc ctatggttct tgtcttaaag tgacagcctg 115857
ctttatgaga ctgtttgaaa tactccctt gcttttcaat gtctctctat ccacttttgt 115917
ctgctcttca gaaaagggga caatataaag cccagcctgg cgagctcccc acgctcaggc 115977
ctgggcagtg ccaacctccg cctttaagca gattgaaatt gtcactgctt cattaatctg 116037
aaactagtta ctttctcaag cacacagcat acacttccga tctgttagga ttcactcagg 116097
ggagccctg gggccttctt gggtttgga tttagaaggc tcaacaaaga tacagcaagg 116157
gttcaggaaa acatagggct cagcttgaag aaaagcagtg tccagtaccg aaggcgaggc 116217
ttgacatcag tatattaaga gagcacaaaa cactatttct agagacaatg ggatgccag 116277
gattttggag ggtacacttg agaataagta gtctggctat ggcaacagac aagggtatct 116337
attgccacat ggagcagcac tagaggtctc acaggcctca gaattttttt ccccaaacag 116397
aagaaactgg aatccaaatt tctttgcaag ttggagtttt gctgacttct ttttttttta 116457
gttttttttt ttttttaatc tgagttctga ttcaagtctg attctaagag atgtcttaag 116517
ttctgtgctt ctttgcccc tcccttagtt ccagcctgtg ttgcccactc caagtgccag 116577
atgttggtg tagaagcctc gggctcctat agaatttcta tgagacaagt tgcccctttt 116637
cttcataccc ccaccattaa caaaagacaa tacaaggat tctattactt ttaatatctc 116697
tagctggctt agaatagcaa gtttttgggt tctattctat gtagtttagg gaagagatgt 116757
gggcattttt taagagaagc tcaattttca gtaatgtgag cctaaagatt tataaaatag 116817
atztatatta aattatgtta atagacgcct agtaaagca ccatttaatt gcatggaaaa 116877
aaatgttccc ttttaaaagg tctgtcacct taacaggtac attcaaagat ttctgtgaa 116937
taatgaaat aggaacaatt gctttgatgc actgaactgc attcatcgtc taggacagct 116997
ttgggctgtg tttggagaag atgggaggag ctcttttgaa aggagtgtt gctcctttaa 117057
acttgatttc ctctagcaaa taggttctat tggagtgtca ttctcctccc ctctctcaca 117117

-continued

cccgttaaggc tgggcttgag atcatgcccc agagctcttc tccatgtctc cctccatgt 117177
tcagactggt ttctctcccc acaacccaac actgagcacc tccccatctc cctcaaagaa 117237
atctctcaag gagtgcatt aaaagcgagt ggaacctgca ggaaaggtat aagtgggaaa 117297
caaaaagaaa aagaaaacct ggttaaaaaat tactcttttc cacctacatc accaccatca 117357
aaggaccctc tctgtctctt tcacacacac atgtgcctca tgcattgcaca cactacacac 117417
atgtacatac aaagcccctg ttgccctctg tgactgcttt tagttagaac caccaccttt 117477
ctggcaattg tctgaccaca gttagagtgt gccaaagaaa ctgcatttct aatcctgacc 117537
agatataact ggacagaact ggtggggcgt tgtgggtag cggggtggtg gttggcaatg 117597
aggagacgga ggcgagggtc agaaatcaaa gacttcacat cccaagtgt tttgtctctc 117657
ctaaaattat tagatattct ttaggggagt ggggaaggga ctgagctatg atgaccactt 117717
cagaataagg accctagagg aaaagaggtc tatgggcacc agtgtctcca tcatgcaggc 117777
ccactgacac cctaaggatg ggctactggg tcaacttttg ttttggccta gtttgcatac 117837
agtatcaggc ccttggcctt aggcatttgt tgggtgctga gtgggagagt gaaggggaaa 117897
agtctctgtt cctcctctat gctctgaatg tctgggctgg gccagggcac atgggtgaga 117957
ggtcatectt cctgctctcc actctgcctt ccaccccag ctcttttctt gtttaaaact 118017
aacatgagac ttgttctcaa aaagatggac tcaaccacac tcacagcggg tgctaccac 118077
tgattttctc ttgggtggagc aagttcctgt tttctaattc tcattctcat ttccattctc 118137
tttctttcca ttctttcttt ctttccatga cctctctaag aggtcatgct ctgggggaac 118197
atagtctgtt ttctgttttt caattggggc ataagtgaaa ctagtatcta gtgcttcca 118257
ggtagagaaa ttgtcaaggg tgaccccata catcttaaac tttcctctta aatgggtgtt 118317
tgatatcaag attatttagc tgagaatgtg agtttctgag ggttggettta aatgctctta 118377
aactaaagt aaactgttgg tctttagaat cagaccgact ccaaaatacc aaagcattat 118437
tccgatttga aaacttcaaa aacatcaact gatatttttt gaggagtggt gatagggaaa 118497
catgtaaaac ttattctagc atagtaggag acctcatact ccattttgaa agtgacccaa 118557
ggagtccact ttgcatcgga tgtcctagaa ggaagacctc cctgggaacc ctggagaacc 118617
ttttttttta tggagagtgt cccaacattt aaataggat cgctacgctt tttttttttt 118677
tttttttttt ttttttttgc ctctgggcag aaatactttg tttattctcc tttccctagg 118737
gaacttcccc aaagatcgaa gcaagagggg ctggggccat ccaagcagat ccaaaccatc 118797
taaacagggt tggcactgcg gctatctgcg gcatggcaga gctgggtcca ccgcgcgcgg 118857
tacctgggtg tccaagtgtt tggctccgca gggcctggga gccggggggc gggagaggct 118917
taagagactg tgatcggggc tagtcatgga cataggggag ggctaaacct aagcgtgag 118977
ccccagagg gcccggctgg gtagatggaa cggggaccag aggagtctcc ccacagccca 119037
aaggaaagctt aactttgggc aaaaacgcaa agagctgcag caggcgctct tttgtcttct 119097
tatttccctt ggtggaata gactgcttaa actcctgttc tttgcgctg caaactcccg 119157
tcctccacc tctgttctcg cgcgcggaga ggctgcttc ttgggaagaa gggagacaga 119217
atcttttga aaggcagcgg gcctgcgcct cctcccttcc gtggcgggca gggcgaagag 119277
cccgagctc tgcgctgtag agacaggagg aaagagatcc agaggcctga gcttcccagg 119337
ccaggcagta gtgagccggc tgtctgggac ctctgcgcag gacagagctc agcacattgc 119397
acaaagcgcc ggcagctccc ttttcagcct cacacagtgc gggccctcct cctatgtcc 119457
cttgacggaa cgaagaggga ttttccttct gagcctactg tgtgtgtgtg tgtgtgtgtg 119517

-continued

tgtgtgtgtg tgtgtgtgtg tgcgcgcgcg cgcgcgcgcg aaagacaaca ctcaggga aa 119577
accgtgtcca gttttagaac ccagccgta cctggtagg ttcagtccga ccggcctcta 119637
gtaactcaga cctaaagccc ttgtgtatgt gtgttgcat taactcctgt ggcttgaacc 119697
tattgggtgg cgtctttata gaacctaate agaaatcaca ccggttgagg attagtgggg 119757
ctcagcttgc agggaatgag atctcttcgt tttcctgttt ccagtttctt cacttctctc 119817
cctaagataa caagcccagg ccgcaactgag gagagagcca gttgccctgc tgagggaaga 119877
gctagaaata agtcttctct gggaccaggc ttaaaggaag tgattctgct aggetatggg 119937
aaggggggtg ggctggaagg gactagaagg gagccaaatt aactgaatat tagggtgacc 119997
gggaaaaaaa gccccaaaac tcaaagctct aaaggcatct ctgggctgct ttgaaaaagt 120057
gagattataa atctttgaac agaatacttc ctgtccctga ctttttgttt tcttaacatt 120117
gagggaaacc cgctaattct gcttgtagca tcgttattaa gttccactg tttgcttctg 120177
acctgtttga tggattgttg ctcttcttaa aactattctg actctacaaa ttccttcaca 120237
taattcaagt tttcgtactg agagaaatga ggaagtagaa agaagaaaac aaaaactaga 120297
tgggggattt ttacccttcc ttgctaaata aagggttacc tgcgttaat ggtcagtgtc 120357
attccaaatg gagtgatttg tcctatcaac tgtgaggagg ttgcctatth taaggatgga 120417
gaggcactgc ctggttagatg ccactcatgac taaagggtgc tccttgccga aagtctctgt 120477
acatagaaaa cccattgagc cacaactcc ctcagtcaag agaccacat taccaagttc 120537
ttactcaaca ttttctcaga attcctcaga cagcttttcc ctgcataatgc ctttctctag 120597
acattggagg agggggcagg agaagatagg gagagcaaac accacagatt taaaattctg 120657
gtttttgttt cattttatta aataaatata aatataaatt ttatataaac ctattcacat 120717
acaaagggac ttccagcgac ttagatttta aattctcccc aggcgaaatt tcagaaagca 120777
agacctacaa ggtctaattt tctaaattat tttcaacttg ggtgtttttg tttgaaaacg 120837
acaacagaaa ataataata aatcctgtgt tcttatcgag ttctgaaaga gagtagggat 120897
ggggaactga catgtgcttt caaaaacccc atacagtgtt aaacttaaac caaccctgtt 120957
tttctctgtt tatacgacaa gaatgagttg aattataggt tatttacatt ttttaaaaaa 121017
atctgtaact tcaagttgga gtcctagata aacagggtcaa gaaggagacg cgaagggtca 121077
gggcccggtt tgtccattcc agaacttcca gggtcgtttc ttctccagat gggaccactg 121137
caatgagcaa ggattctggc ccctgggtgc ccacgcctt ggcgttgctt ggtctgccag 121197
gagcggggga tgtgaggagg gagggcctcc ctcataaggg ggaaatctcc ttgtcatcgt 121257
tggttgaggc cggcgacagg gagtcccat cctcgagcgc cgcgtagtgc acctggctcc 121317
cgacgcactt gcagcccgcg tgactgttcc tctgcgtgcc cttccctcc ttctgtgtct 121377
tcactcggcg gttctgaaac cagattttca cctgcttctc cgacaggttc aggttaagtgg 121437
cgatttcaat cctccggagt cgagacaggt acatgttgga agagaattct ctctccagct 121497
ccaggagttg cgtgctagt aacgcgcgtc tcatcctctt gccattgggt acctggctgg 121557
cgtcagagcc tcctcgggac cggcgaagag agggtagaga ggttaaggctc gggcaagggtg 121617
ctcccacccc atgtgctaac caggacgcat ttcagggacc caccggggga agcccagccg 121677
aacatctgta tccctttccc atttcaaggc acgtgggtgc ttagcgggga agaaaagaga 121737
cgtgcaaagc aaataaaggc cttcgatgag caggatgcga agtcacagga ttaaagaggg 121797
atgggggctt gcactatctg atcgccctcc tttgagccaa gcggagaagc gcgcaggctt 121857
agccaaaaac gtcaagacgc tttagccgcc ccgacgcggg gatgccacac aggttcaaac 121917

-continued

acaccacccc caaatcccaa gcagttaacc tctggtttat ccgccgtgac gttegaggtc 121977
cctaaggccc cagtattaat aaggcaatac tcgagcacct actactagga gtaaaacgca 122037
ccaggctgag tggagaagct ggcaaaactaa cttccacttt cgtggaactt ctgtggctga 122097
ctctacggtt aactaaaaag ccgcctctct ctcttcaccc tgtccccggg cttccacttc 122157
ctccactgga ggtggaagt ttgctccagg agcgcgaaag gcgcggagcg cagggtgcccc 122217
aagacccccc cctaccatg gtgaggcagt ggaatctccg cgggtccgcc acgttgtagg 122277
tggtggcggt gcagacaggt gcgtgggtgt cggggtgccc caaggccgcc gcggccgccg 122337
ccgcgcgtgc tgcgtgtgcc gccgcgcgg cgcagccagg ctgctggggc tgatgatggt 122397
gatggtggtg ctgcggcggtg tgggtggtgat gatgcgcagt gttcaccgcc gggcaaaaact 122457
gcgcgtcccc aggagccgaa gagaactggc ccttaagcag aggcagtgcc cctgcggccc 122517
ctgccacccc actgcctccg gcccgggtaa ccccggtccc tgcgcccccg ctgcgcggcg 122577
ccacagaccc ccgagaggag tgcaggtgcg aagtgcacga gagagggcac acgcagaacg 122637
cgccgctctt gggggacggg cagccggggc cggacacgga catcaccaat gggggcgcca 122697
tgccaagcgg gatgaagaaa tccggcccgg ggtgcggttc aggcagcgag ggcgcaggcc 122757
gtgaggtgtc cttgatgatg agcagtcga catagaagga gcgcgacatg tcgagagggg 122817
tggttggtgt gaagccccg cagttcgcgg cgaccctct cctctagtgt tctaagctct 122877
gccctgggag ccgcgcagac acgggcagtc aagcccttgg ggacgcagag gtgttggtgt 122937
ctgggctggg aacaaagggg tccccggaga gggctggtcc tcacgtcccc cgcccggcg 122997
cccggtcgg gtattttata gccccccacc ctggcacgtg atgctgcgga gtaccgctcg 123057
gctcaggctc ctgcgcagct ccgcaccctc gggataggct gcccgagtca caacagaagc 123117
cgcgaggagg ggcgggcgcg cggcggggaa gaactcgggg gaggggatg ggggagactt 123177
tgcaaagtgt aggttttgtt aatttcccg ggaggccggc ctctctcccc tctttctcca 123237
cgctttactg agaaatcaca gcgtgcac cctccatcca cccctctcg ctaccctggc 123297
cgagcccaa ctcttcccca cgccccaccg caaagcgtac caggtgggga cttggaggct 123357
tatttaatat gaatgtcag tgtttccagc tcctctgtgg taggggtggc tgcggcgcg 123417
tgaagtgtga ggcctgcggt ttggagcagg attgtgcggg cgacggactg gcagtcgtcc 123477
agtccttgag cgcagctctg gccacgggta cacctacccc tgtccacagc ttttgactt 123537
ggcagaggtc attcaggtg ttagttcagg actgtccggc gcagaactgt gaggcctccc 123597
agctaagaaa ccgtcaagct tttcatgtg atgttcgaca aggtctgaag tgtctttgta 123657
cttggggccc tcctggggcc actcagacca acgacccttc cttgtttccc tttctgatcg 123717
gcacctccca cttccgcaga gagagagaga tgttgaagag taccctttt ctttctccaa 123777
gtagtaacac catggcatc cagggcaatc ctacaaactc catcctgaag attttggagg 123837
gaggacctca aacaccaagc cctcctaaag acgcagcagg gattagatag accttcgctc 123897
tggtgtctgag gatttctgt cctctatttt taccaatcat gggcagctta gcaaggctaa 123957
ccaggaagca ctctttcctc tgcattctaa gaacctaaaa aggatgaaga ggattcagcc 124017
atccagggaa tcttgccctc gattggcaga agtggctttg taagggaact ctctctggtc 124077
catggaagtc ttgcacaccc cttactgccc gagagagggt ggctgccaaa ctattgggac 124137
tatttatctt cggagaaggc aaggcagcag aggtggccat tttctctctt catttcccc 124197
tgcagaaaag cgggctgggg ccatgtggtt gggcaatagt tagaagtctg atcctttttc 124257
cagagcagct aacttcaatc ctgagttcat gatggtgcta agaaacttag agacaggact 124317

-continued

ccctccacct gagagaacaa ggtgccccaa tccaggagag cactagctag aggcacggct 124377
ctatctttcc atcctctgtc ttccctctc catctctgtg acagtctctc ttgcctgcta 124437
gagaagtgtg attgggttgt agggatgccc ggctctgggg agcccaggat ttatggatgg 124497
caattaaagt tttatgaatt gcagctgagg ctggttattg agctatttga atgtgattag 124557
aattcaatta gaaagcgggt agtggacggt gggctctctgg agtgtaaaca gacagctatt 124617
ccagaaatgt gctaatacaa catcttgtga caacaattaa ggagtctcag ggcttaacat 124677
ggggcagctc agctgtaaact acttttgtac cacaaggtct gcagacgctc aggetcacc 124737
cagccccccc ttgttcatga ctggaggatc taggcaatcc ccgaaatcat ttcagcccca 124797
agaagaaggc ttggagccac tgatggagaa tggcaataaa aaacataccc tgcgtaagg 124857
caggatattt ttacagtc taaactgtcc aaatagatga ctcgattccc cccattcact 124917
ttgcaactat acaagcatat atagatatag atacagatac tctttaagaa taatagcttt 124977
ctctcttttc ctctctggg ttaggtecca gggtatccac agtctgtttt gggctgatgg 125037
tttgagtcac aatgttccca gcagtttggg atgtgttcag aggaagagct cctatgctaa 125097
agtcctagaa atcgcaccca tgtgcagacc attttacctt agagaatctt aactatgcaa 125157
gaggcttgtg catcttattc aatttgtgtc tgactgtgga aactttcatt tttcagtgcc 125217
aaggagtttt gagaaatgtg aggggtctcat ggggtttcct aaagacttca aggggagcag 125277
tgggttcaga ccagctgag gctgaaagca agaccatgtc tgaaaaactt gacccttagg 125337
gtacttggtt aattccttca gcccaccaag agcaagtata ctggaatccc atttcttgca 125397
cagtttctgt ccactctgac tcactctctc agttctcttt ggatctctca gtgtctgcca 125457
gtctctctcc ctctctctc tctgagtcca gccctatct ggccctacct gcctatcccc 125517
tctcaaagg aagcctaccc tccatgcccc cggggcagca ctgcccaccc cccaccccag 125577
ccctgcccag ccctactgtt ccccagagt cagtgccctg aaccagcagg agaccccaag 125637
ttcagctttc ttttctgag agggaaacaga cagaccattg gcgtgtgccc atgggtgtctg 125697
agccgccaca caattttatt tctcagtgat tctgtccgat aaaatttcat cgtccattaa 125757
gtaatcccca aatgagagc tcttatgagc ctataatgag ctctaattgc cacaactcca 125817
ggagccacgt ggaaggattt attctgtatt aagcagtcgg gtacagagta caggctgtta 125877
cctaagccat tactttcata attcaaggag aaaattagtt cttttaaagg aaaggggaaa 125937
tctttttatt atctccctct tgcttgggac aatagagtat ggttttgtct tccttgagtg 125997
caagacagtg tcacatatgt gatggttaaca aaattgttct ttgtacctc tcctggccaa 126057
ggcactccac ccttaccctc aacttacaaa aaaaaaatca aagcttttct agaaagaaca 126117
gcagaggcat ggccttcttg tctctogatt ctccaagttg agcctgggtg agcagtttcc 126177
tttcagccca accctgagat ttggattctc agttctagct tccaaaaggt ctccagtact 126237
tcttccagc tctggaatgg cacctgacct gaaccccaaca ttctgtctc acttctcttt 126297
cttctgtttt gctttcatgg gcaaagtcag gacaagtaaa gggcagggac ttagcattgc 126357
ttattcaaca ggccccagag ttctgaccg ttctgtgct tagctgtttt tttcaggctg 126417
taactccac tttgcccctc cctctgtgtc ctccaaacct cccacctcc cccaccacca 126477
ctttcatccc cagtcttttt ttctcttagt ttcagcattt gccacatgg ttctccagct 126537
ccaaatggag gctgcaggca gggcgggaca gccggggagt tggcggggcc gcctcggatt 126597
tatattgctc tcttacattg atttcatatt agtttccaaa gcgatgaatg atctcaaagc 126657
tgggttttgt tagccgaaca caaacaggag acaggactta cttgccccca gctcccttta 126717

-continued

atgaggtcat tatcaaagcg tgaacaagtc tatgaatggt ttattgaaag tgcacgtta 126777
acttgatatcc atccttttct ccgagtgga ttgtgatatt gctgtctgtg gcacatctta 126837
cccgatatag ccgagattt cccattctc tgtaaccagg caacccttc tgaataccca 126897
aaaattgaaa agaaccgctt agtcttcaag aaagtcctca ataatagtgg aaaagaacaa 126957
agatccagga gacaacaaaa tgccacagg gtgacttttc atgagcaatt atctctcatt 127017
aatcagaaga acagctgcaa tattaatttt ctctctttct tctctctttt tcacagtccc 127077
caacatttga ataatacata attttgattt tatgaaggag tcacattttc aggggctgga 127137
ggaaagcagc tacctagggtg aagacaagaa gaaaatgctc tcattttatt ttattttttg 127197
tttgggtaaa gctgccaaca agcaaaaatg gaaaaataa aaataagaaa tgccagagaa 127257
aatgcccccc ccccttttct ctcttagatg gctgttgaga ataaggactc tcttctcccc 127317
cacctctgc tcacaactac cctccttctc tttctctccc ccgccagac ccattcccca 127377
gttttgcctc gagcagggcg gagggaaaacg tccctggcgt ctggcgtggg agtttcagcc 127437
gggtttctgc ccgtttaact tgcaaacgtg aagccaagcg ttgtcgatct gaccaaagag 127497
acactctttg ggcgttaact gcattgtggc catcaaaagc ccgccagcct tggatgaact 127557
gagaagtgtg ttcagcagaa atggggcgct cgctctcctt tcaggctctg gagaggcaat 127617
tgttcacagg atgtgtagcc agggtggaac acgtgggtcc ccagataagg ctataacctg 127677
caaacgagct tgggggagtt aaaagaatct cattaagcc ccggctgcaa ttagcaaata 127737
cacactcata gagaactcaa gctcctcttg aaaagctgtg ggtcaagatg aaagagggca 127797
gttgggagct agtccccaca ttctgttact gcttgagtga tggggggctc aggagccagg 127857
ctattccttc agctgcccc atattgttag ttttaatgca aggccaggga aggcctttct 127917
agagggaggg caggctgttg gccctgtgtt catgcaccac caaaaataat cttgcttctc 127977
cctgggtgtt attcagaacg gatgggctt tgagaaacct gaattcgctt ttgtgctcac 128037
cacagttgca agagttaaat tcggccctct gagaagaagc agcggggaga ggggggtggg 128097
gggtggtagt ggaggtcttc tgagaaataa gtgaggggtt tggcttagaa tttcagggaac 128157
ggcccagttg gaaaaagtt gtgatggcac tgaatgcctg ccacacagcc cctctgctcc 128217
ccacttcaat ttaattaata ttcgcccacc cccaaatcct caagccgaac aaggcatccc 128277
tctccacccc tcagagctct cctctgtcat cagaataaaa tttatcgagc gcctactctg 128337
tgcccagcgt gtgctaggca ctgacgggag caggcctgaa aaggccaaga cagtatccaa 128397
tagaatattg tttcatttca gtaacaatgg cctgaggtgg ggaacaatta tccggataat 128457
tgaagcaaat gcttcacctc cctccctccc tctccagttc tctgggcaact tactattttt 128517
tactacccta ttcagagatg tgggttttgt attggagggc gggcggggga ggcaggagt 128577
tgtaagagga gggttgaatt attcacatgc ataccaatc ccacttccc ttggcctaaa 128637
ttttctgaaa gcttggagcc aaaatagctg cttagttagg ggagcaaaga cttaaaaaaa 128697
aaaaagtcac taaaataaga gcaattcttt ataattttta gcagcccagc ccttctgggt 128757
tttgatcttg gtcacttaca aaaatcacct ggagagcttt ataaaaatac tgattacct 128817
agggatttct atttaatatg gtgaggtgg aacacggcgg ggtgtagatg gagggggaga 128877
cagaagtcaa ccagaattct gcatgcggtt ctgatgtagt tgagaaataa ctgataaatc 128937
ctgcccccta cggcctccta ccatggaatc tgaagagagc aacgtaactt ttttgagcct 128997
tatctggtea tttgatagtt ggaaagtgtg tattgagcgc ctattatacc ccaggctgcg 129057
cgcaagggaa ttcagtagca caagaccgc cccgggggag tttccaggtt aagcgaatca 129117

-continued

acaaattaac tcggagctgg tgagttaaaa aggtcgtgtg aatatgaaag aaaagctcaa 129177
ggggctctgg gtgatgataa aaccgaagct tgaagtgaca tttaacgga gacctgcaag 129237
atgtgcgggt gttggcctgg gaaagaggga tggggaatgc gttcccggcc acctaaaggt 129297
gctcacggga gcctccgaga gtttctcttg gttaattgca aaaactgaaa ggaggcctag 129357
gaaagtggag aaagaatttc agtttctgca tctgtaaaat agagaaaatg ccacgtctct 129417
cgagtttttg tgaggaattc aggactgcct aacaccgggc ctggtgcctg gtaaggctcg 129477
tggtcttctct tgttggtttt attattatct gagacctgca gctccatagg ctcttgaagc 129537
ttgtaaatga ggatcagag tccctgggct tggcaactag gagccaggaa gccgctgcac 129597
aatcatctct ccgtccccc gcgccttttc ccggccgagt gttgccctct aaggctcttc 129657
cacagcctgg cgctcgacc ctgaaggcgc ccagtgtggg gcctttctat cctcggttt 129717
ccgggcataat gtttggttcag cagttacatt aacctcgcca cccccaccc ccgtcaaagg 129777
ctctggcgtc ctggcgtcc ctacttggga ctgcgccta aatttcaaaa cgttcctatg 129837
atattagaaa cctcccagct ttgctgcaca cccacctgct ttgcatagga ggaaaacagt 129897
cgcttttga gtatatgaca atactcgtag gtacattttc tgagctctca ctgtgtggca 129957
gttcttgaac caagagcctt gcctgcata cctcattaat ccgcacaaca gccctcccag 130017
ataaaatgcc attattttct cctcattatg tttgaggaga accctatttg aactactgaa 130077
gttcaaaagc tgaaccaagg tcacacagct agtgatggca gagcctttta ggcaactaagc 130137
aatactaacc acctgataac acctagcatt tattgaacac ctactatatg cctggcagtg 130197
gctgaagact ttaatgcctc ctttattttc cacagcaacc ctgtgaggta ggtgctttta 130257
ttacttcctt atttggtggc tgtccatttg ttggttagtg tggttggtt tccacatat 130317
taaaggttct gagggccagt ccaatgtacg gactgaaatt agaagtagga cagggaacat 130377
gattgttttt attcacctgt gccagaaca cagtaagcgc tgaaaaacat ttggagtggga 130437
tgaaagcaat attttattat ttaattcaaa agccctcttc ataataatc cgtatgcttg 130497
ttgactgcaa actgctcctg ggcagaaact gggctctgtt tatgtattca ccagtgtatg 130557
ccaaatgtcc agaccagagg tgacatatat taggatggca attaatattt gttgaatgaa 130617
tgattcctta tttcagatag gaaacggagg ctccgagaca acggtaaact ggccaaggcc 130677
acatagcaag tggcaggggg agaattccaa ccatagtttc taacgctgag tccctttttc 130737
agcctcctgc cctgtgtccc cggggcatag ggacagggcg cgggaaccct gtgctgcgcg 130797
gccgaggacg gttgtaagtc tgtcctcact cgcccgctc ccacacctgg gcgagggcaa 130857
gggaggcaga agaaatgaga cgctggagaa gccgctccga ggaagagggt aaacaaacag 130917
gctctggggc tgcgcgaggt gctctctgcg cgacagctcc taccggcgct tcttgcctcc 130977
acggctctaa aacctcaacc tactcccttc ctccagtctc ggtctccctg ggtctccgcc 131037
tctctctctt cctggctaac ttatttttca ctgggaaacc aaggaaatct aaacgatcgc 131097
actgacccca cagcctcaaa acaagcccat ccgcaaaggc caccaaacac ccgctccac 131157
accaggcaca aagtctcttc cgcgacggat gcgcatgcac gagcgcgagt gaggaggcag 131217
agttagcgtg tgcgcctgtg cgcagcgtg agtgtaagt ggtagggagt ccttgagtgt 131277
gtctgcgcgc aagctcgtgt aaagagcgaa ggcgaggtgg gggcgagtgt gcatgagcgc 131337
gagcataagt gtactgtcaa cagtgcatt aaggtacgtg ggcgtgatgg tgtgtgaaga 131397
ggtgaaaagt gaattagaat gagggtaggg aatgagattg ctttctctt tttattttta 131457
aattatttca atagtttttt gaggaacagg tgggtgttag ttacatggat aggttcttta 131517

-continued

gtggtgattt ctgagatttt ggtgcaccca tcaccaagc agtgtacact gtaccaatg 131577
tggtctttga tccctgtgcg cggagctgtg tgagtgaagc gtgtttggga gcatgggtgt 131637
gtgtgaatat atgagtgtat gaatgtgtga atgtgaggaa tacgagaaac tggggatgtg 131697
cacaggggtga gtgcggtgtg aatgagagtgt tgagaacgtg cgtagagaga gcaggagtgt 131757
gtctgcgtgt gcccggcccc tggagccccg cctccccact aggcacgcct tcctcttggt 131817
ggggtgcgct acgggcgcag cccagtgcct ctgtccgcgc agaccgcgc tctgtgtcct 131877
ggagcctggc gtgggctgag gcttgaaact ggcgtcactc agcgagccag aaaggagtgg 131937
gcgggagtgt ctgggggggtg cgctgtctcc ccatgtagaa gcctggacac tctaagcagg 131997
aggggtctgt gcagtattgc ctgcagggtcc tccctttcac ctgccccag tattgttcac 132057
ccacctgtgg atcatcttta tgttcatgta ctacgggagc acccatggtg tgcctatagt 132117
atgccaggct ctacttgggc ttgggaaacc gtgagaacaa gatagcttag atctcatttg 132177
ttttggaact tccactgggc cttttattaa tgtgtaacca gcttgcaaaa tgccagtcac 132237
acacaagttt tgtcgctctc gtcctcaagc agaggggcat ggagattatg agacaaacac 132297
tgatcgtaat aagacgatgc attgaaatca gtgcaaatcc atttcctctc caaccaaac 132357
tcacccttc actgcaccac tgagtttggg attgggttta ggaggtcctg gatgtgaatc 132417
cacctctct ctgaccatgg aaataataat gaccctcttc tcacaggatg gttgtgagca 132477
ttaagtgagt taagcctgac atcccttggc acaacgcctt gcacatactt agcactcagt 132537
atacaaaacta tgacgacgtt gatgtgtgat gacgttcctt gagtctgatg gaatgttgtg 132597
gggaaagagg gaggatgcgt ttgtgagcta caaaatttaa gggattatct ctggatttag 132657
gttaaatag gccggttgtg gtggctcatg tcaataatcc tagcactttg gcaggccgag 132717
gcaggcagat tacttgaggc tagaagttcg agaccagcct ggccaatata gtgaaacccc 132777
atctctacta aaaatacaaa aattagccag cgtggttgta cagcctgta gccgcagcta 132837
cttgggaggc tgagacagga gaattctga acctgagagg tggaggttgc agtgagccga 132897
gattgcacca ctgcacttca gcctgggcca tagagcaaaa cttcatctaa aaaatatata 132957
tatataaaat aaaataatta aattgtgtat aatttataca gattgagtat ccttcattag 133017
aaatgcttgg gaccagatgt gtctgaagat tttggatttt ttatggtttt ggaacatttg 133077
catgtatata atgagatata ttggaagagg acctagtctt aaacacaaaa ttcatttata 133137
ttcacatac agcttattca gtgtacatag cctaaaagt ttttatacaa tattttaaat 133197
gattttttgc atgaagcaat atgttttaag tacttctgtg tggaattttc cacttgtgat 133257
gtcatgttgg tgctcaataa gttgcaaatt ttcaatatc agcctgtatt acattctcct 133317
ctagcatcag gctagtgtta tagtatcaga tactccatct tcacccctta ctatgacttc 133377
ttttcttcca ccaatgttat caaaagtact gttaccaagg gaaataaaaa tgcagcaaga 133437
acctatagga gctgaatatt cttttaggca gctttggaag catttttagt cctgttaaaa 133497
tggaagggaa tattttcaca gtggcacaaa atgaatgctg taatttaacc ttgtgagcaa 133557
aatttctgat taaatacaac ataggaaata tgttccctga ttagccatgt acctccctgg 133617
aacaaggat tgtataaaca attgcaagac atacttattt ttattttaga gaagctgact 133677
tattaaaaac attttttgat attttgatca aatattttga tcactatata tgtgtgtgta 133737
tatatatata tatatatata tggaatgtgg tgggtgggac atagctcact gtagccttga 133797
actcctaggg tcaagctgat cacaatataa ttttgtttaa aaccaaaaat tttaaagatt 133857
ggatttcatt attgagatgt tttcccaagg aaaaaaatc aaaaagaagg cttgaaagat 133917

-continued

tggagaaccg attgcagatc taggttcttg aatttaacag caagaaagga attctgtcct 133977
tatgtaactg acctatctca tgttataagt agggagactg aggtotcaag ggatgaaatg 134037
gtcttagtgg tcagtctctc ctacagtcac caaataggac catatcagct ttgttcctct 134097
acctacagtt ttatacactt gcaggaagat gccctggaaa ctaggagaag agaaggtaca 134157
ggagttccag gtctctgcat taccctcagg tctctgttgc tggcacctcc atcttctggt 134217
ggctcttgcc caaatccttt gaatcttctg tgactcctct cttgctcttt ctetaatcct 134277
gtacatttaa cccatcatga agtctgaag gctttaactt caaatgtaac tggaaactga 134337
ccacttctta acactccaac tactatcgca cgggtccaag ccataccac tgcataggga 134397
tgactgggtt cattcttctc atacttgct ctacaatctg ttctcaacag agcagccaga 134457
aggatcgttt tgaatagaa gtctgatcag gtcagaccaa gaacaaaagg cctccatga 134517
tgccaccatg gctgtctctg accactccaa ccactggcct acttgctccc tctgttttcc 134577
ttgctggtct ggccctctct agccttcccc tctgttgaga actcttcccc tacaagetca 134637
cacgtcttac ttctcactt ttaggtcttt cctccaaaga cactttctta ctgtcttttt 134697
tcttttttgc tttgaaattt agaaacaaat tttatttaag atctgaaatg taattcctaa 134757
aatatcaact ttttcagaaa actgtggctt acacaataat gcattgcctc tatcacgtta 134817
caacatgcat tagactcaaa tgcaaaaacc atgaacaaa cgaccacct tcaacaattt 134877
gcgcaaagac agaatgccta aggaacaaca tagacggatt tgcagaggat gggctgtttt 134937
acttcaagca tcattaaaaa aaagagaaca aatgcatggg tttttgggta tatatatcaa 134997
attgaatggt tggcactagg agtcagggca ttttgtcatg tagcattaac acatattaga 135057
aaattgtgta gtgtcaaagg ggtagaacca ccagcattca agcaatgttg tcaactaggc 135117
aataaaatgt tccactgaat atttcttctt tgttctaatt actgcatacc ctggtagcaa 135177
ctttgaaatg agaaaaggag cttacactcc ttttatttct tgtttaaaac agaacagaaa 135237
acaaactgaa acataagccc tgttttacat taacaatggt aaagaatctc cattttacaa 135297
gaaaaagact aagaacaaaa agtgtttcca gatctcaggg aaataacagt gaatggtctg 135357
tagaccagca cagggtcttg tgggtgtact tagcagaagc tactttgtaa tcaccgccag 135417
taaaaagaga tgcagaatcc tttgccagat attttaggaa atcatgcaa tggcccaaca 135477
ataacgcaag gctcttctca tcaagggata tataggccaa catttctcct attcttacia 135537
ataacctcag taggtgtgtg ccccttaaac ctgggacaca ggagcatcag ggtgagccaa 135597
gaggatttct gcatacaggg gcctctcaaa tttgtagagc agctgagtgc ctaacatcac 135657
gtcgaaatat tcttttatcc ttgtcacaat ttcattaact gcctatgcct tattatcgac 135717
gtttccctgc gatgttttac aatttgcata ctcccttaga attgcatcta cattttgctt 135777
agcaggaggat taaaacagct gcttctgctt ggtaactaag ttccagtccc cagcaagcca 135837
tggtttcgat tcttcaggca tcttcacttt aacttccatt ctgttcttaa atcgctcctc 135897
gctttcaaca gtgaggtctg cccaggctct ttccttcctt ggggtctgag gtgctttgct 135957
ggtagtgcct ccatactctg ttccaggagt cctctgtttg ttctttctgg tcttctcac 136017
ggatcctgaa gctaagaagt tctctgcaga gcgacccac atcttctga gagagggtgt 136077
tcaagatttt tctgtgtgg accagctgcc ttctttctg aggaggcccc tctcatctct 136137
gcatgttgct tctagttggt tttttgaagt tgtcttcttc tgcagattgt tgtccatgag 136197
attgagaacc cggctttctg gaactcattc aacccttttt attccaacca acaatcttct 136257
ttctttccaa gaactcctag ggatttccca aaaggactct tatagatctt gcaggatggt 136317

-continued

ctaggaggat acagtgggag atacaatcca agattctgta atcagagggt tctacaatca 136377
 ggatcagatc tcctgagcct tactgtacag caaacttagc ttttotgaat ggtgacctga 136437
 aatgagaatc cagatctttc tagctgccgc tttctcactc tttttaaaat atcaaagctg 136497
 ctactgtgcc ttctgcactc ccaatccctt ttccatgctc tatttttttc tcccatagca 136557
 gtcatcactt tccaactata tgctacataa tatcttctgt ttatgtttat cgtctgaatc 136617
 tccctgctag aatggaagct cctgcaggat atttatgtct actgggttca ttgagaacaa 136677
 ccacctatg agaagagggc cattattatt tcaaagagag ggtgaattta catccaggac 136737
 ctctaaacc aaaccccaaa ctcaatggtg cagtaaaagg gtgagggttg gatggagatg 136797
 aaatggattt gcaactgatt caatgcacat tcttattact atcatcatct gtctcataat 136857
 cttctccatg cccctctgct tgagggcaga gcccaaaact tgtgtatgac cagcattttg 136917
 caagctgggt gcacatgaat caaaggccta gtggaagctt caaaatgaat gagatctaag 136977
 ctatctgtt tacatgcttt cctaagcata taaagcagaa cctggcagag gagatgctca 137037
 ataatttatg aaggattgaa agaagaatgt cagtgttcta ggtggatgct tcctcaccat 137097
 tctattttac ctgtatacag gactgcagtt tataaagact ctaaccagtt atgtccttgg 137157
 gttagcacia ttatttaagc tagataggac tttttgtttt ttttttaact gttatttcca 137217
 caataagata ttgagagggt aaacgacttg ccaaaatcag atcctggatt tagacttgca 137277
 atcaaagtat cttttgtttt ttgggtggag acaagttccc tttccagacc tcctggctaa 137337
 atgaggaaaa ctaataagtt actggattta ctgtggatgc ttctaaatcc agtggccctg 137397
 agattagggc taaggttctc cctccactgt cggcctgtgg aattcttttag ctgctcacat 137457
 cacagctaca tgaacagttt ttgggaaaca caccataatg gccacatcct cttgttttta 137517
 taatttacac aggggtgaaa acaagagata ttgtcttgtt gttagctaga gctcatttgg 137577
 agtctgccct gagtctctgg acttggtctg atgcccttcc tcacttgact gctctgggca 137637
 aaccaactac tgtcttagtc attgtattac totgtttgga ttctctgtca gtccatcaga 137697
 tttagctgat gagctcattg actgaaaatt gattgagcaa gacagtgtcc ctaattctgt 137757
 atgcatacac agcaccattg tcttccacag atacttcgta ataattggca tccccctacg 137817
 agatcattgg tatctcaata attaaaatca atagctgttg ttaaggcaag aatttatcat 137877
 agtaacctac aaaagtggta aaaaggtaat ataattcaga agatagatgt aaatataaaa 137937
 ttaccaatc tgaacagggt tttaaagata atacttgttc ctaaggaca ttcatattta 137997
 ataaaataaa tgagttattt cttttatcatt tgaatgacat aaattgttac ttttttatgt 138057
 gagtggggaa aatatagcac tttaacattt tgagataagg agtagaacac tttatttata 138117
 tcaattcagt gtttagcttt tcacagattt tgtctctatg ctacctgttt gatttttttt 138177
 tttttttttt tttttgagac agagcaaggc tgtgtctccc aggctggagt ttagtgggtga 138237
 aaccttggct cattgcaacc ttcgcctcct gagttcaagt ggttctcatg tgtcagcctc 138297
 ccgagtagct gagattgcag gtatacacca ccacgcctga ctaatttttt atactttttt 138357
 gagtatactc taattttttg ctttctgggg ttttaccatg ttggccagggt tggctcctaaa 138417
 ctctgggct caagtgcact gtctgccctg gctcccaac gtactgggat tacagggtga 138477
 agccactgtg cttagcctgt tagaatttaa taggtctcag ttatacacta ttctactatt 138537
 ctgggtgctc taaagcatca gtgacaataa ttatgaatgt agaagggtga ttggtagcca 138597
 aagttaacta tgctattgct gtccttgaga ggggttttta cctgtgtttt cttttttttt 138657
 tgtaattttt ctgagatcag acaagttagt tagattccaa acaatatggg ctaatatata 138717

-continued

tcacaattcc atttaaatg gccaaagaat gacccttata cagacaggac tcttagtgta 138777
cttagctgtc aacaaaatat aaaacttata agaataatgg ctacttttaa atataaggcc 138837
tgcatcatat tgtagagga acttctggaa ataggagaca gttgctatta aaattcaatt 138897
tagtttaatt caccattatt tactgagtgc ctacatatgt taggtactag ggctacaaag 138957
atgactagac cccgggctgg gcacagtggc tcacctaacc atagccatca atgaattcaa 139017
gtaagtgtgt gatagtggca tgcaacaact gtggaacat ggaggagaga tctgttcttt 139077
cttctgctg gcacatgga ctctgagact gaggttgaa ctatttctag gagatgctca 139137
gagtaaaac aacagcagga gaagagactt ctaggccaaa gtttcaagag tgagcacagg 139197
cccagaggat ggatagcat taagtgcac gcaggagaca gaagcaggaa gggctgctta 139257
gtggcagaaa gcaaagatg tgagtggcag gtgaagaagt atgaaggcct ctgtagtaag 139317
atgaatggtc tttgaaggat gctaagcaga aaattgaaat gattatattg taatcattgt 139377
aaaggatggg attggaagag agagaaacca gagacagtta gtgtccagta ccaaagtcca 139437
gacttgaaat gataagtgc acattaatca gtagtggcag gaatggagag gagagaataa 139497
attcaagagt aatttgaag gtagcaccia tgagccttgg ttactaatta gataggacag 139557
gggtacagaa agacaaatgg gtcagtgggg acttgggttt ctagctcagg tgtctgtatt 139617
gaatatgatt gtgttaacaa atatagtggc tacagatgaa agataagcag tttttgttg 139677
tttcagatga gactgtgat agagtgaatg gaacagaaaa aagataaatt ggttgtaaac 139737
attttgagtt ttaagtgcac taagaatagc caagaggaag tttttgatgt agagtgcag 139797
ttggaatat ggatctgaat ttaacagaaa ttgagattgg agttgggcgt ggtggctcat 139857
gcctgtaac ccagcacttt gggaggctga ggtgggtgga tcacctgagg tcaggagtcc 139917
gagaccagcc tgaccaacat agtgaacccc cgtctctact aaaaatacaa aattagctgg 139977
gtgaggtggc acatccctgt aatcccagct acttggctgg ctgaggcagg agaatcgctt 140037
aaacccggga ggcagagggt gcagtgcac gagatcactc cagcctgggc aatagagcaa 140097
gactcagctt caaaaaaaaa aaaaaaaaa aaaaaagaaa gaaagaaaa agaaagtgcag 140157
agtagaata aaatggcat cagcctatat tatttaaagc atatataata tttgaagcaa 140217
tatgatgaga tgaaattacc cagggttggc gtcattggtta ggtggtggc caggaaagtc 140277
attgttttgg ttagtactt agagtgttt gaatatatta tgtatatat ttgttggtg 140337
ctgagtctct tctacagtct cacttccctc ctctaaggac ttgtataatc ttttggtgag 140397
tctatctagg gataatccag tacttactat ttgacagtgg aactggaata cacctgggaa 140457
accaaattaa ggttgtaaga cagggttggc taaatatggg attggattta gaaacgactg 140517
gtatgaatat gagattagag ttacaaatag cctgaccac cagatgactt gaaaagggtg 140577
ctgagtactt tttcctcat cctctcatc aatagaaata gagggtgta gggaaatcct 140637
gatggagggt tcagacaccc tgccttcttt tctttccaaa agactttctt ttccatgtag 140697
accgtagatg ttttctgact gactcaactt tatatccaca aggtctgttg acatttaaca 140757
tgccaaagat ccatacagt gagcagccag atgtttaggc cctggctctg gcttattgcc 140817
atgagcattg ctcagattcc cagtctgagt cagaatcctg agtgacagat cacaggatgt 140877
ttgtgtttcc tgaaggactt aaagggcttg caaaatgttc tgtcttatcc acctccagag 140937
agaagattgc tcatttttga gatccatgta gatggaaaa gaaaggaaaa atgggtatct 140997
aatgcacaaa atcatatata gtatcccat tcatcatcag ctatcactct tgattttcca 141057
tcagtcactt ccttacctat ctaatgcct catccatta tgttcgggat caacctttt 141117

-continued

gcttcgacca ggctagcctg tttgtggtcc atggcacaca tagttatctt accatatgtg 141177
gggtttccca ttgacacctt tctccacctc tatcatctat ttttcactct taaattgcta 141237
ttcaaaacta tggcttctcc acaaaacatt tgcttcccaa tggtaaaaac ttaggctggg 141297
tgctatggct cacacctata atcccagcac tttgggaggg caaggcagga ggctcactta 141357
agaccaggag ttcgagacca tcttgggcaa catagtgaga cctcatctct aaaaacaaca 141417
acaacaacaa caacagcaac aagcaacca aaacaagcac atcaaatcat cccaaattca 141477
ccagtgggtt cctatatggc aattaaagt ttatctcccc atagaaatta taccagaggt 141537
aaaaattata ctcatctggg cataaagtac ttatttatac atgtctaggg cagattcctg 141597
atctttccat agcagtatgt tacagagtag cctcactta gagaggtaga taagtagaat 141657
agaatatctg actacatcaa attgaagtat cttagatgat gagaataata gcgataataa 141717
gtatcattca tcaagtgtct gccatgccag acactctact aagcattttg taatgttatt 141777
acatttaact atcacataa agattaagaa gggtatcatg cccatcttat agactagaaa 141837
acaagattc aaagaagtaa tttgaagcca ggcacagtgg tgtgtgcctg tagtcctagc 141897
tacttgggag gctaaggcag gaggatccct tcagctcagg agttcaaggc cagcctgggt 141957
aacatagtga gaccctgtct ctgaaaaaag aaaagaaaca aataaaggac taatttgccc 142017
aaggctctaa tttataggca gtggaatctg gattcagacc taagtctttt ttttcccag 142077
cttttgaga tattaatcaa ataaaatttg tatatatata attgacaaat aaaaattgta 142137
tatatttaag gtatatgtgt gatgatttta tatatatata tatatatata tatatatata 142197
tatatatata tacacacaca cattgtgaaa tgattaccac aatcaagcta attagcacat 142257
ccattatctg acatagttac catgtgtggt gagaatactt aagatctact ctcacagtaa 142317
atttcaagta tacaatgcag tattaacat tgctaccatg ctgtacatta gagaccccag 142377
tacttttttt tttttttttg agacagagtc tcaactctgta gcccaagctg gagtccagt 142437
gtgcatctc ggccctccacc tcctgggttc aagcaattct catacctcag cttcccaagt 142497
agctgagact acaggtgtgt gccaccacgc ccagctaatt tttgtattt tagtagagat 142557
gggttttcac catgttgctc aggttggtct tgaactcttg atttcagatg atccacctgc 142617
ctcagccttc caaagtctg ggattatagg catgagccac tgcaccacgc cgagacccca 142677
gtgctcttta atctttcaac agaaagtgtg tacccttaac caacatcttc ccatctcttc 142737
cccttacct gcaccccaaa cccctgcctc agctcctgga aaccactatt ctactttctg 142797
cctctgtgag ttcaattttt ttagattcca cctataagtg agattatata gcatttgtct 142857
ttctttgtct gtcttatttc acttagcata atgtcctcat tgtcacaat ggtagaattt 142917
tctttttttt aatggctgaa tatatatata tatacacata tatatacaca tatatatata 142977
catatatata tacacataca tatacacata tatacacata tatatatgta tatatatata 143037
ccaaattttc tttatccatt aactgtggat gaatacttaa gttgatatca taacatgcaa 143097
taaacatgag aatgcagata tctctttgag ataccgattt cattttgttt gactacatac 143157
ccagaagtgg gattgctgga tcatatagga gttctatttt taattttttg aggaactgcc 143217
gtactgtttt tcataatggc tataccaagt tacatttcct ccaacagtgt ataagggttc 143277
cctttctcca tacccttgca gacactcctc ttttatcttt tggataatag ccattctatt 143337
ttaaaaaatt tttatttttt aatttgtttt tttttatttc tgagacctct cagggatgaa 143397
aatattaata attgccattc taacaggtgt gaagtgatat cccattgtgg ttttgatttg 143457
cacttacctg atgattagta atgctgagga ccttttatat acctgctgga cattggtaca 143517

-continued

tcttctttga aaaaatgtct attctgggcc tttgcctatc tttaaatcag gttttttgtc 143577
tttactattt gagggtgatg acttcttttt ctatattaaa tactaaccctt ttctctgata 143637
cgtgggtttct aaatattttt ttctattctg tgggtttttt tttcatttgt tgcttggttt 143697
cttgctgtg cagaagcttt ttgatttgat gcagtgtact acttctttat tttgttttct 143757
attgctgtga cttttggtat cacatccaaa aaaaatcatt gccaaataca acgtcaagga 143817
aattttccctt ttttttttgt tctaggaggt ttgtgggttc agacttttagc ttaagtctga 143877
aaggataaaa gttttctgga aggggaagtt ttgttggtgt tgtgttttct ttgtttgctt 143937
taaatggagt ctctgtcacc taggctcgag tgtgcagtgg cgcaatctca gctcactgca 143997
acctctgctt tccaggttca agcaattctc ctgcctcagc ctctgagta gctgggatta 144057
caggcaccct ccaccatgcc tgcctaattt ttatattttt agtagaggcg gggtttcacc 144117
atgttggtga ggctgggtct gaactcctga cctcaagtga tctgcctgcc tcagcctccc 144177
aaattgctag gattacagcc atgagccacc gcacccggct ctgtaagggg aagttttaac 144237
actaacatgg aaaagaaagt atatagtaaa atttcaaaga ttgtataatt taatgtcatg 144297
taggaaaaca taaagataat agttaacaaa tcataagaga ggccgggaac ggtgggtcac 144357
ttatgtaatc ccagcacttt gggaggccaa ggtgggcaga tcacttgagg tcaggagatc 144417
gagaccagtc gtgaccaaca tggcgaaacc ccactctctac taaaaatata aaattaacgg 144477
gggtgggtag tgcctgcctg taatccagc tacttgggag gctgaggcca gataatcgct 144537
tgaaccagcagg agggcgagggt tgcagtaagc caagatctgt tcaactgcact ccagccctgg 144597
ggacagagac agactctgtc tcaaaacaat aaataaataa ataatcatg agagatcttt 144657
taagggtgta tgacagaaaa atgaaaggcc agctcaatac agacaaacta attcaagctt 144717
tattaataag gttgttctta tattatttta attatgatcc agaaacaaaa gaggaattag 144777
aaaagattgt ggaactgttc tctaattgga tgatcctaata atgactggat taaatctgac 144837
tggactgctc tgttcaacac aaccatcaaa atgttgattt tgaccatcct agcaacgaga 144897
ataaaaaagca acatctgacc ctttgacagt ggcatttata aaaatgaaat ctacatata 144957
catgagggta gggctctgag ctacctaag tttgtaaact catttcagta actgaagaa 145017
acctctatta gtaagcacta attatagaat ccacatgtg agacacatta cattcatggg 145077
ttgattggca tcattctcag ttgatctgag attatcatca aaaaaatttt gacttaggat 145137
ttctttgcca agttacatca ttctaaagc atctaaaatc aggcagggca gaatagaacc 145197
acatgctgat gtcacagggt gtaggtgggt ttgaatggc tctgatttag tcaacattca 145257
tgctgtaatt gtgaatgata gctgctctgt gataactaata agaattgctc cctgctcaag 145317
tgatacggcc ttgaacaaca ggtcctcaca gttggcagcc ggggtggcagg agggctgcta 145377
tagaaatgaa gttatagaga cctaacagaa ccactggcag agtgggatct ttgagccaaa 145437
gtgggatcat gtctaagggt agtagtagcc tcaacagcct tgcaagtaca ttttgaggaa 145497
gcatattctt gtggagaaac ctcttacagg ctagtgacta tgctcatcct cagcaaaata 145557
acctgtctgt tctttagatg ataggtgcat agatagtggt aactattcat ttgattctca 145617
gaaaacaata aaatcatgct ggctgttctt tccagttcag ccattgaaact cttaaattgc 145677
cagacagcca tgtaagtctg aatgaatgac cattcatata ccttttcac tgcactgcaa 145737
tatggctctg ctcaaatgg caaggagaaa gactggaaga gaaaaatggg tgcaggatct 145797
tcttggttt ctacaaggct ttgacgggtg tgagaacata atccattctg gtgaattttt 145857
tctgtgaagg aggcaactag aaaggaatat tgtcttcatt ctctagaaaa aaagaactga 145917

-continued

aggaagagaa tttatagttg gctgattata acagcatgaa aacgcataac ttctactctt 145977
tatctagaat ttgtgccatc ctgattaaaa taacaacacc ctcaataaca actaacgttg 146037
agtactgtgc atatattgta tcattttaat cctcccaaca actttatgaa tgagtactat 146097
aattagctgc attacacaga tgataacaag gatgacaatt gttgagttaa cccagtttcc 146157
tcagtttctt tttttaaatt ttaattgtt tatttatcag taaaaatgat tccttagccc 146217
acataattcat gtttcatagt tcaggaacat aggtcagtga caaactcttg aggaactcaa 146277
tcccaaaaca ttcttaacat tccaaaatca ctttgcactc tgaagggtac cagccctctt 146337
cacctcctca aaatctttca tggaatcata gtttctgtag aaatctacat atatctgctt 146397
tcttggttca gcaatgtaaa ctttaagaga gctgcaaccc ccagcattac aagaaatgct 146457
ctgacaatat gaaatcacag acacctggcc aaaaggctat gcatctgaaa tttcttcaaa 146517
acactggaag ccgtggtagt tattgtctc aacaccaatg tccttcctgg ctgatggaga 146577
aatgccagct ttcttaataa tcactcatggg attgtaaaat ctttggggaa gcatatagac 146637
ttttaaaata accactcaac aattgctaata tatactgagt aaaaccagtt agctttatctt 146697
tctcattgct tatatttttt ccttcttatt tatcttttct cccttgcaatg agaacattt 146757
acctacagca gaagtcttag accttagttg tatttcagct tttaggggcc atctgagctg 146817
agtaagtcat ttttaaaat taatttaatt aattaattaa ttttttttt gagacagatt 146877
ttcactctat tgcccaggct ggactacagt ggcatgatca tggctcactg tagtcttggc 146937
tttctggtc caagcaatc tgcctgagcc ccccaataa ctgggactac agctgtgcct 146997
taccacgct acctaattta tttgaatttt tagtagagac aagatctcgc tatgttgcat 147057
aggctgttct tgaactcctg agctcaagca aacctcctgc ctgagctgcc caaagtgcct 147117
ggattacagg tgtgagccac catgcccagc ctgagtaagt catttaactt aagttttctc 147177
tgaagtttat agaatgggat gaatatctct ctgtttacag cactggggta tggtaggggt 147237
cagatgtgac attgcaaatg aacatgtttt ataaaatatt aagcagtatg taaatactga 147297
tataaatatg gccggcacag tggctcacat ctgtaatccc agcatttttg gaggccgagg 147357
cgggccttga ggtcaggagt tcaagaacag cctatgcaac atagcgagat cttgtctcta 147417
ctaaaaatac aaataaatta gggcggtggg ggtaagtcca tgaatggcg gctagtcagg 147477
agctgatgca agagaattct tgaacccaaa aggacacggt gcaatgaact gaaaagaacc 147537
cactgcattc catttgcgca ctagatgaca ctgagccccc aacaacaata aactcacaaa 147597
aatcctcccc cccattacaa acccaaaaaca tcccactac tctctgcaca aaaactgcac 147657
ctcctcacca cacaaatnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 147717
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnntgc 147777
tcagacaagg ttgattttca gggtttttta gcaaaagtga tctaattttt tgatgggctg 147837
ccttgccaac cccaacataa ttcattgata ataaagtccc atattcctgt gataattgaa 147897
atagttaagg ttatatattg tttacattgg ggcataattt ttttttaata aaagtaaagt 147957
tttttttag aaagctattt tttttgaaa gggaggttct tttgtaggta atacctatgt 148017
tgagaatgtg atatgatgat atttatagac tcaacgttca gccagattg acatttcctg 148077
cttctgatat tttttttttt ggatatatga tgaatatttt tttttttttt ttagaaaacc 148137
ccgagttttg gtgaaatatt gttttttttt tatatgctac cagacgcaa aatttacgga 148197
tttaaaagt gatttacttt ttattaattt ttcccagggt ggaccttaac tgtaagggga 148257
attttttttt tttttttttt tttttttttt tttttttttt ttttagttta 148317

-continued

gggtctcttt gttttttcca acataatgtt tctgcattca tctattctta aaatgaaaac 148377
cacataatth acttcttata aagtctttaa tgggaaacca agaaatttaa tcgagcagta 148437
aaaacattct caaaatgtag accatgatct cagtttcttc catttttctc ccgagtagaa 148497
aatagacttc tgcataagaa agctaaaatg tgtaaatatt ttaagttaa aggtttaata 148557
ttatcagaat acaatccaaa gagtaaatca aattacataa ttacattttt atttattaaa 148617
tatggaatca tctactgaat tgcaatacat taaatatact gtttctctt aaataaaact 148677
gcttgacagt taaaaaatta tgggcttgcc atacttgacg gtctcttatg tttttagatc 148737
ttatttactt atttatattt ttacagttaa atagtaattt aaaaagagga tgggaaaatt 148797
ctgtagtac ttgagtttcc tctagccaca ttttattgca aaccagttcc tcttttgaa 148857
atctttataa ttaagtctt taaaaatgct ttcatttcaa aactaaata tttctatatt 148917
agaaaagtth ttacagtata ttaaattatt tttccacat gccccacccc ttacagtat 148977
attttaata ctatctttgg atttcatttc tttctgtttt gtaagatgga tactataatt 149037
cacctggta aactcagttt ttctttcagt attatgtgta caataacat tgtactgtac 149097
aatgtacatt aatgaaaaac acataatata cattcagtg acattttctt tcagtactat 149157
gtgtttttca ttaatgtaca cttcataatg tatattgaaa ctgaacatgt tgaagctcaa 149217
caagagttth cgattaatth tgtttatatt ctgaacgatt agaagtctta agtgaaggc 149277
agagtacgag ctttgaggtt gggcatctgg cttggtcact tacttgcaa actctttttg 149337
tcttgatgaa cttccatath tctgtgcaca aaatgggaaa acaaaaaatc tcataaattt 149397
tggattaatt taattctcac aaaatgtcta tgaagcaaat tctaattgta tcttcagaga 149457
aaaaaatggc caagctgaat agcaccatgt gtaagcacgt tctgcagaac tggcagagct 149517
tccagcataa aagaaagggg gagaggaat gttctagagt caaagagact taagagacct 149577
cacttgatc ctcacttgaa aaaacaactg taaaaggta ttttgagac aattggggaa 149637
atgtgaataa aattcattaa atgtcaagga gctattattt ttgtttgta tgataatgt 149697
tattatgggt agattttctt aatcccata atttacagat atatgtataa gtgaaatcac 149757
ataagggata agatttacct tgacatact tagaagaaaa cccacaact gattaaatga 149817
agcaagtga gcttaattgt tgcagacttt tggatagttg tggaaatctg gtgatggtta 149877
tgtttgaat gtttcagaat taaaaaaga gaaaaattat gcagtggact cagatatgaa 149937
ataactggga tactagtac acagatacag agactatgca aacatagtt cccagtgcc 149997
tggagaactc tcttgcatgc cagtgtatga caaaaatact ttcaccaag cactttcata 150057
ttcactttgt aattattgtg aatgtgtaga tatgctagtt tgccctaata tggtttatta 150117
agttggcctc cccatctaaa ctgtaatttt ctctgagact gagaagatcg gtttgatath 150177
tttatcttt tccattgccc cttgcatgat tactattcaa tcattgctga attaaacaac 150237
actttcttt gtttaggaag atgctggatg ctaaacacct gtcttactca ggcttcttat 150297
tgacatagca aattctaaac gtgttacata tacatgtgtt ccttttctgc tttaaataa 150357
actgatgggt atttatttct cccattgtgt aatgtagtct tgggaaatag tagccagtg 150417
aggatgcctc agatatatcc agctctgcag gccaaagctc agcttttaaa gtggcgattc 150477
ccagttattt tgtaaatgg atgttaaagt catccctggg ttggagtta gacttttatt 150537
gaaaagctth tctactaat accagttaat ggatgaataa aattcacact tttggtctct 150597
tcattgtttt attgtcaaca cattctttct caaggagag aattaatttg gaagttggag 150657
gtcttcaaat taggaaagtc tgacaaatag gccaaactca atattcatat ttacagtgga 150717

-continued

gattttcaaa gaagtttgac ataatacacc tcacaaaggg atgccaataa gtcagtttta 150777
ggcattatatt ttgaatacaa ggagactggt catttcttct tttctagtat aaacacacca 150837
tatgtttaag tgtttgtaag gcatgttgct atcttaaata atatttataa aaatcaaagt 150897
ggtacagaca caagctcctg gaaatgtgct ggtatctttt tttttttttt tgattgttga 150957
gtaatcctga aatgaatttc ttccaaataa agggatgtag ctttgtatta aattttgtaa 151017
taaaagtctt caaatgatag attcaaaatt ctaaacattt ttaaggatta taaaaagata 151077
tgctgaaat cttgcatggt ttaaaacgta gtacaaagta agctttttat atgtaggcat 151137
ttgtaattta aaaaaaagt ttatttgtgt tttcagaata aacgagctaa cataaattgt 151197
acatatttac agcaataaac tacatttcag aagctgcaca acaactttta taagtacagc 151257
tgatgatttt tgacaccagc tttcaaatgt gttttcattc tttcatttgc tgcaacattt 151317
aaaaatctgt agtaccaaag caaaggaaac accaagttat tttatagcaa agccacatta 151377
ttaacaaaaa atactgagtg aactacagtc ccgtgactgt tatggatatc gtgagtcctg 151437
aaatcgagag cacaagcatt tcttgtgtcc atacctgatt gcatgtaaat tgattttgca 151497
ttttacaaga acacacaatt actcaaggaa taattaagaa tagaaaaaag gccatgaagg 151557
gtaaaagggc caggaatcag aggccactga acagtttctt attcactgat tcaactgctta 151617
ggaggaaatt ggtttttttc tttcacgtgt ataaatcaca gtcaacaggc ttcattggatt 151677
ttgtccacag atagcttttg agataacaaa gccataaatg tcacatacat taagcacata 151737
aaaaggaatt aatgaacgg ttagagtatt ttaatcaaat ccctaacaga aggggtacag 151797
ttaagcacac acagtatgaa agtttgcttt caaatgtaaa aagcaactac agaaaatcac 151857
aagtttcatt agacagaaca gcaatttcaa tcagaaaatg cagcatatat tgatacaaaa 151917
tagaaaaact gaaatataaa agtaaggagt ccaccttttc ctttcttggc atttttttaa 151977
acctgtccca tttcattaaa attttacag gttttactga aatactcact cttgacattt 152037
agcttcttta gtgtctggta ggtatacaaa agtattacct gcttaggtaa gaaagcaa 152097
gcttatgtca aagagcctta aaatattgta atttatgttt atttgcaatg aaagaagtct 152157
acttggtaaa aataaaggag gagaaaagga ttcttttatt tacaagaatt gtaataccaa 152217
tcaggatatg agttggttaa ataatgtttg taggaggat agatagcaaa ttggtaactg 152277
gagatctaaa aacacaagga atgaacatt taacatgtaa cgtatttggg gagtttagca 152337
taacggattt tgagaggcaa cagaaggat gtatttcttt ctgtatatac gtagcacctg 152397
cttttgaaag ccccgctat ttagtacagg atgctatgaa ttaaaattgc aggagactgg 152457
tgtggaaagt tcagctaatt ttctgattca atgaagtttt aggtgagggt gtagccaaag 152517
aggtgtccca ttgctggcag gatagtagtt tctaatttt tagtctcatg agtcctgctt 152577
tctcaaacct cctgaatcac tgtaggatta ggcccttgta gtaaagtaa gaggagcaaa 152637
ataatgttca gagatgatag acaggagaag ttttcaagca agccacgctc aacacagatg 152697
cctttctttc aaaaacaatt ttatttgtat taaacaatat taaacttccc aattttcatg 152757
tctgttaacc ttttaaatga catgccaa caattttcaca ttagccatca ggcttccatc 152817
atgatggcac agcatgctgc atggtgggta aaaaggataa agcttatttt aaaatatcaa 152877
aaagtttttg gtccttgtaa acatgtaagt catttggaat tttcaaaaat gttgtgaaat 152937
cttggttttg tataatgcca cgtggtagtt tttttttttt tttttttttt cctttattta 152997
ggcagtgtct cactctgtca cccaggctgg agtacagtgg cacgatctca gctcaactgca 153057
gcctcagcca cccgggctca agtgatctc ccacctcagc cctccgagta gctgagacta 153117

-continued

caggcacgcg ccaccatgcc tggctaattt ttgtatttta agtagaaaac gggettccacc 153177
acgttgtcct ggctgggtcct gagctcatgg gctcaagaaa tcagcccacc tcagcctccc 153237
aaagtgcctg gattacaggt gtgaaccacc gtgcttggt gacatggtag tttttatcaa 153297
gaaaaagagt tactgactct ccttgagata agaagctgag caacacagtc aataaatata 153357
tgtgtatata atcatgaaca ttccttctt ggaagagtac tggatgttct gaatatgaaa 153417
gaacacttgg atataataat ctgttttcca tgacactgaa gttaagttag aataatcaaa 153477
ggacttccct aaaattgtct caggggcatt gttgtaaaat ttcaagcttt atccagttag 153537
tattttaaaa agatctaaca aacagatcaa caatgaatta attagcttaa aaaaagaaaa 153597
agcagatata ctgcaattca atttatttga ggagtatcag gtagaaaaat acgttatcta 153657
gtaaactggg atggctgggt gccactctga ggtaaggctt gcaaattata tatttctttt 153717
atgcaaatga gtaattatt taacaggaca actggaaaagt taataattga aaaaaggggg 153777
tggaggcaga aaatgcattt ccttgtacat ctattatatt ttatgcactc ttgagaagca 153837
gtggtgaatg tcaagaactg tccatccctc ttatatagtt ctaaatcttc tatttatatc 153897
ttggcagaaa taggatttgt tgtgcagtac cttctgggag tattagaatt cacatgggaa 153957
tgttccatca ataatacagt gtagcccccag cttcaagaat aaataccctg tagaacctag 154017
atttaaaagg ccattaataa ggcaaacat gataaacagg gaaaaaaact ataaaagaaa 154077
actttccttt ttccataaag gaaaagcagc ggtaattagc aaggaatatt caattcttct 154137
agaactggta gaatctagat tgggtggtatt atcaggattc agtctgcttg gaaaatccca 154197
gtagaaaaaa atcttaataa ccactttgca agacacaaac ctggattcaa ctgtaccttt 154257
gactgcattt ttattcttt gagaggttgt agatagaggc tctatgggac taaaaaatt 154317
tgagagagga ggtcatctgt cccacaagggt attatctata atcctgaaat attgcctgtt 154377
atgaaaaagt gtttgtcttt tgctgccttt cccactgtag gtgatctaata cagcatttat 154437
agacctgcc atgggcagaa caatagtgc tttggacaat acaaaagaat tagaaaatgg 154497
ggtgtttgct ttaaggacc tcacaaaggg aggcagaata tctctttgca aaactagaaa 154557
tgtgcaaata aactgtctat tattattgaa taaagtgacc acaagaattg agggagtgtt 154617
aacaggagag tgaacagaat gaggcagggt gctcatggac agcatttttg aggatgttgg 154677
cctgattcat aaaccacgat tgagatgggg ctaggaagaa aaatatctaa tcagtggaaa 154737
taaaatgtaa aacttcaagc acagcagtga ggacattttg ggatgatgtg tggatgttgg 154797
agtggaagga taaggaagac ctgaggatga gcttgcttgc agctaattaa ggaactcatg 154857
gagaaataag gtgagtatga acgagtgggt gagaagactg ggccagactt aaatgatttg 154917
tagggagcca agacatgttt tctgtagtgt gttaatgtta catttattaa tatttcccca 154977
cccttcagggt ggctgagatc ccataattat ggtggtcgta tcatattata ttcacatgga 155037
caattttgag agtgaaaagg agttttatta ataattacac actgagactg tctgaggcaa 155097
attgggtcat atggctctaa caataatgtt aaccaaaaag aactggagca catttcaggc 155157
tattttgctg ctgtgcaaac tttccttcta tataattttct caagagacta aggaaaggct 155217
tttatgtatg ggtaagcaag tgggtggaac agatggaaaa agcagaaaaac aaaactggac 155277
acagagtgtc tactgagcat gatatttato tgttgggagt gggaaatagt ctcttccccc 155337
ttactctcta ctcattttg aactgcccac aatctggatc atcaaggtaa aatggataaa 155397
atctagacag cttagtagag tggaaaaagc ttgaatggcc aggaaatact caggaaaatc 155457
atgaaagttt agagttggaa ggtatctttc aacaagaag aaaaagttaa gaacatctgt 155517

-continued

ttacagaagt tgtattgagg acaatgttca gagaccggaa ttcttcatgc atgettgaag 155577
aacatgaata gctagaatgc taatcacaaa ttaataaact gtcagttttg tcatggctgt 155637
gcctaacacc agtggattta actaggttaag tagttaacta ggtaagtagt taactaggta 155697
agccgggggtg gaaggacttg agcaaggaga gtggataaca gatgttctaa agaccttga 155757
tctttccaac tattatagat ggaaagtgc ttcttgctg agagctcaaa aatatctgct 155817
actctacttt caggaaacaa gacagtgtgg ggtccaagac tgaggagggc actgcaacaa 155877
catttgggct tagatgctgc ctagagattg gcttttctac ccatgatggg gtgttgcatg 155937
gctgttcctt aattgaatta cagagaatgg ttaagaaca tctttatctt ccagggatct 155997
aaaaataaag gatttgtatt atctgagact ctctcttaaa gggaaatatt gtagttatag 156057
aaaattacaa aaatagtaac atttttccac ttggcttgca aatgtaactg tatgtcctat 156117
atatttttaa aggaacatga ataggattg aattcaattc acttgatacc agatggctta 156177
ctctcaaaga catgatatca agaattatta ccaaattagt tgggttatgt tagcagaggc 156237
catggctctc ctgtatcttt ctgctaacct ccatacaaa tgaacttctc taaaattacc 156297
tttgaattt agttttggaa gagaacttgg aggtcatctg gtggcatgtt caaagtcatt 156357
ctctaggca gtggcagaga cagcaccaag accaggtccc caatcatatt aataattcca 156417
aggtgtcttc catccactgt gaattccctc tctccatcat gatgtcact tattgttaac 156477
ttttcgaggt taggctgcat actctttggt atatgtttag agaactctct tccaaatcta 156537
tataaatgct gtctagagga aacagatgtt ctacatattt ttatgggaga aatttagaca 156597
gtttgcaggc tgtctgcaag gctgagggga agtgggtagg gtgttatata gaagtagaaa 156657
tttgaatgg gggtaataa caaaaaagat gaaatggatc aaggatagtc tgtaactagt 156717
gggtgtctat ttgaatgata agcccttcta ggaggaataa taataaattg taaaatgggc 156777
ctactggaga ctgaaaaagc taatgaataa acaagtttga taaaggattg atacacttta 156837
agttcactat attacaatta tagtgtaagg agatggcctt atcttcaaac tctggggtag 156897
ataatataaa tttctgtaag attgagctaa agatttttat ttccacttta ttttgaata 156957
ggccgggaca gagaaggttt atgtaaatc atgtactctt tacataagtg acagaaaagc 157017
agaaaagaaa aacaactcaa ggcagttcag aggaggctat tatgattata caacctgcct 157077
ctaaaggact tttaaaggca atgggaataa gaatttgaa aaaaattatt aaaattcatt 157137
gttttagtga attcnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 157197
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 157257
acttcccagg aggtcccagc tcttctcagg ccactcctct accttgccct cccaaagcac 157317
tgggattaca gatatgaacc accacgcctg gccactggtg gtttaattct ttttttaaaa 157377
aaattattat gttaaaaact ttgtgggtac atagtaactg tatatattta tggggtacat 157437
gacataggca tgcgataagc aataatcaca tcatggaaaa tgaggatatcc atcccctcaa 157497
gcatttatcc tttgtattac agacaatcca attacactct tagatatttt taaatgtaca 157557
gttaaatatc attgactata atcactcttt tgtgctatca aatactaggc cttactcatt 157617
ctttctaact gtatacactt tttgttccca ctaaccatcc gcaggctggg cggagtggct 157677
cactcctgta atcccagcac tttgggaggc ccaggcaggc agatcacttg aggccaaagaa 157737
ttcaagacca gcctggccaa catggcgaaa tcttatctct gctaaaaata caaaaattag 157797
cagggtgtagt ggtgggtgcc tgtaacccca gctacttggg aactgaggc atgagaactg 157857
ctcgaagctg ggagggtggag gctgcagtga gccaaagatc tgccactgca ctccagcctg 157917

-continued

tgacagtgtg tgactctgtc tcaaaacaaa aacaaaaacc atctccgctt accccaacc 157977
cctcactacc cttccagacc tctggtaact atccttctac tctctatctc cacaagttca 158037
attgtactga tttttaccac ccacaaataa gtaagaacat gtgaagtttg tctttctgtg 158097
tctgacttat ttcacttaag ataatgaccc ccagttccac acatgttggt acaaatgaca 158157
gaatctcatt cttttcatgg ctgcatagta ctccattgta catatgtatc atattttctt 158217
tatccagtga tatgttgatg aacatttagg ttccctccaa atcttggtta ttgtgaacaa 158277
tgctgcaaca aacatggagg tgatagtgta catactgatt tcctttcttt tgggtatata 158337
cccagcagtg ggattgctgg atcgcatgat agctctatct ttaggttttt ttgaggaac 158397
ctccaaactg ttgtctataa tggctatact aatttatatt ctccaccaac gtgtatgagg 158457
gttccttttc ctccacatcc tcaccagcat ttgttattgc ctgtcttttg gagataagcc 158517
attttaactg gagtgaatg atatctcact gtagttttga ttgcatcttc tctgatgatc 158577
aatgatgttg agcacatttt tatatgcttg tttgccattt gcatggcttc tttggagaaa 158637
tgactattca aatcttttgc ccatttttaa atcagattat taaatttttc ctacagagag 158697
gtttgagctc cttatatatt ctcgttatta atctcttgtc agatgagtag ttgcaaata 158757
tttttttccc attctgtggg ttgtctcttg attttggtga ttgtttcctt ggctgtgcag 158817
aagcttttta acttgatgtg atcccatttg tccatttttg tttggttgcc tatgcttggtg 158877
gggtattact caagaatttt ttgccagac caatgtcctg gagagtcttc tcagtgtttt 158937
cctgtagtaa tttcatagtt tgaggtctta agatcaagtc tttaatccat ttttaattga 158997
tttttgata tgatgagtcg taggggtcta gttttatttt tctgtatatg gatatccagt 159057
ttcccagca ccatttatct aagagactgt ccttgctcca atgtatatc ttggcacctt 159117
tgtcaaaaat gagttaactg taggtgtata gatttggttc tggtctcttt attctgttca 159177
attggtctat gtgtctgttt ttatgccagt accatgctgt tttgattact atagctttgt 159237
aatataattt gaagtccagt aatgtgattt ttccagtttc attctttttg ctccagatag 159297
ctttggtgag tctgggtctt tgtggttcca tataaatttt agcgttggtt tttctattcc 159357
tgtgaagaat gtcattggta ttttgatagg gattgtattt aatctgtaga ccgccttggg 159417
tagaatggac attttaacaa taatgattct tccaatacat gaatatggaa tatatttcta 159477
tttttaagtg tcctcttcca ttcccttcat cagtgtttta tagtttttat tgtagagatc 159537
ttcacatct ttggttaact cctgggcatt taattttatt tgtggctatt gtaaatggga 159597
ttccattttt gattcttttt cagattgttc actgttgga tatagaaatg ctacaaattt 159657
ttctatgttg attttgtaac ctgtaacttt actgaatttg tttattagtt ctaatagttt 159717
tttggtgag tcttttaggt tttttttaa tataagatca tatcatctac atacaaggat 159777
aatttgactt ctttctttcc aatttgagg ccctttatct ttctctgtt taatttttcc 159837
atthaggaact tccagtaact tccattgttg aaagtggaca tacttgtgct ccagatctta 159897
gagaaaggct tccagttttt ccccatgcag tatgatacta gctgtgagtc tgcatatat 159957
ggcttttatt atgttgagg atgttcctc tatttccagt ttttgaggg tttttatcat 160017
gaagagatgt tgaattctat ctaatgcttt ctccagcatcg attgaaatga tcacatgggt 160077
ttgtctttc attctgttga tatgatgtg tatatcacat tgattgggtt gcgtatgttt 160137
gaccattctt gcatccctgg gataaatctt acttcatcat gatgaatgaa taatcttttt 160197
agtgtattgc tgaattagct tgctcatatt ttgttgagga tttttgcaa aatattcttt 160257
agaggtattg gcctgtagtt ttcttttttt gatgtgtctt tgtctgggtt tggatatcagg 160317

-continued

atgatactgg ccttgtagaa tgagtttgga agtattttccc tctcctctat tttttcagtt 160377
cattttgagc aggattggta ttattttcttc tttaaatggt tgctagaatt cagcagagaa 160437
gctattaggt tctgggcttc tctttgctgg gagacctttt aattacggct ttgatctcat 160497
tatttgttat tggctctgtc aggttttgga tttcctcatg gttcaatctt ggtaggtagg 160557
ttgtatgtgt ctaggaattt atccatttcc tctagacttt ccaatgtgtt ggcatacagt 160617
tgctcatagt agccactaat gatccgttga atttctgtga tatcagttgt aatgcctcct 160677
ttttcatctc tgattttatt tattttgtct tctttctttt tatcttttag tctggataat 160737
gatttgccga ttttatattt tcaaaaaacc aactttttgt tctgtcaatt ttttgattt 160797
ttcgttcatt ttaaattcat tcatttctgc tctgattttt tttttttttt tttttttttt 160857
ttttttttt taaaaaaa cctggctggg tcaactcagga ggcacaaagg ggtgattttg 160917
gctcaaggca acccccacct ccgggggttaa acctttctc ctgcctaacc cttttgggta 160977
gctgggatta caagggcccg tcaccatacc cagttaattt ttgtttttt agaaaaacg 161037
gggtttcacc atgttgccca ggctggctct gaactcctac ctgggattac aggggggagc 161097
caccaagccc ggccataca ttacatttta aaaaaacggc atctgaattt ctgctctata 161157
ctctacattt tattgaaagg ccctctgac aaaaagtcc caaatttatt aaaaatccct 161217
taaaaattat atttttttac actatcttc tcaaaattgg gcaaatata acaaaccttc 161277
acaaattttt gaaagtaaac tgtttctcaa caattgaaat gggtagccct ttagctaca 161337
cattttgact atgcccttca tatgataaaa attccctttg cacaatttct taaaggttg 161397
aaaatttctc attaaaaata aaaaaacca caagtcctct acccattgaa aaaattttt 161457
gaaaaatgct atcaggtnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn 161517
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnctt 161577
ggaaactttc tcttttttct tgattagtct agcttttgtt aaggtttgtc agttttgcta 161637
atcttataaa aaacaacac ttagtttcat tgttcttta tattgttta tgagtccctg 161697
tttcatttat ttctgctctg atttttatta tttatttctt tttgctaaca ttaggcttac 161757
ttgtacttc cttttctatt tccttgaggc atagcactaa gttgtttatc tgcaatctt 161817
cttctctttt gacgtaggca tttattgctt taaattttt tcttagaact gcttttgcta 161877
aaccataag ttttggtatg ttgtgtttct attttcattt gtctcaagat aattttaaat 161937
ttccatttta atttctttat tgacctattg gttattcagg agcatgtgt ttaatttcca 161997
tgtatttgtg aattttctaa aatttctct gctattgatt tctagtttca taccattgtg 162057
gtcaaaaaag tacttgatat gacttcagtc ttcttaagtt tactaagact tgtcttggtg 162117
cctaacatat gatctattct ggagaatgtt ttatgtactt gagaagaatg tgtattctgt 162177
tgatgttaga tggaatgctc tatatatgtc tgtagatcc atttgttctt gaatgctgtt 162237
taagtccgat gtttacttgt ttattttctc tctgcatgat ttgtccatta ccaaaagtgg 162297
tatattgaag tcccctacac tattattcta ttgcagtcta tatctcttc agatttttaa 162357
atatgtgctt tatatattta ggtgtgcat tattgcatgc atatatatat atatatatat 162417
atatatattt tttttttttt ttttgagatg ggggctcact ctgtcaccga gaatggagtg 162477
cagtggcttg atcttggtc actgcaacct ctgcctcttg ggctcaagtg aatctctgag 162537
tatctgggac cacacatgcg ccaccataca cgtgtttgta ttttggttag aggtgggggt 162597
ttgccatgtt gccagctgg tctcaaacct ctgacctcag cttaagcgat ttgcctacct 162657
cggcctccca aagtgtggg attacaggca tgagccactg caccagcca tcatgcatat 162717

-continued

atatttgcaa tcattttatc ctggtgatga attgaccctt ttaccattat aaaatgtcct 162777
tcttggtctc gtttttacag tttttgactt aaaatctatt ttgtttaatt taactattgc 162837
tatccctgct cttttttggt ttcatttata taaaacattt ttctattcct ttactttcag 162897
acaatgtgtg tccttaaaat tgaagtgagt ctctatagg cagcatagag ttgggttttg 162957
tttttaaatc ccattcatc actctatgct tttttttaa aaaaaattaa gacaacattc 163017
atggcacatt taatcaggaa ttccaaatta gtgctacaaa cactaaaagt ataatgtttt 163077
attaatataa atatcaccct tcaactgacat aagcaaaaaa aagctcaatt atgtggaaag 163137
aaatgtttac ccaaagaggt gccttcgct tataaacaca gactatatca catagcatat 163197
cagttctcaa aaggaagtaa ttctagatct aaagcttctt ctgtaagtaa catcaggttt 163257
atggacctgt atggaagaaa agtggctaca aaaaaaggac atgactatct ttctaatac 163317
gttgctgcgt gcaaacatta gcataagttt tacacattct tcaaaatata catacatgca 163377
tagaaaagtc acatttgctt taggctttct aagattgtgc tacactaagt tatggataaa 163437
agactatgtg ttgcttcacc tttaaaataa aaagattttc agtacaaaga agaaaatgac 163497
acactgactc tgcactgga ttcagtgtaa taagtagtaa ttgtatctca ttacaggcag 163557
atttctccca accatttaaa aagttacttc ctatcataat tcaatttttt aattccaaac 163617
ttagaacta catataacct caggatttag ctgaaattgt actatctgat tattttgtaa 163677
attagcaaag ctaaaaatc tagcttgaat aatttcttca tagtataagg gatagtattt 163737
tatagtaata aaattattct taaagtcaat agttatcatt tattgaacac tttttatgtg 163797
tgctctacaa actcatttac acccaacctc atcctcagaa atagatacta ttgtcatttt 163857
aggaaaaaca gattcgaaat ttaaataact tgcttaaggt cagagacagc agacgtagga 163917
ttcaaacctt agcctttccc actccaaagt caaggctcct aattctcctt gaggacacta 163977
agatttgtaa aagaaatctt caggggtcaaa gtggtaaaag ggtgtcctgt tggtaaatgc 164037
agtgtgaga tctgttttag agaagtgacc agtaccaaaa ataaaaaaat ggtagtaac 164097
atcaaagaaa tcctgccaga gagtttatgt gcagcacata tgttgggttc tgtaaacttg 164157
aatgaaattt gaagtataat gttactagag gccttccaaa cttcatttct ttttattgaa 164217
taacttaacc catttacaat caaggttaatt attgacaggt aaggacttgc tactgccatt 164277
ttgttaatta ttttctgatt gttttgtaga gactgtttct ttcttcatct tttgctgtct 164337
ttttttgtgg ttgatagtt ttcttttagt atgtcttatg aatctttttc attttgtatt 164397
gtgtttctta taaatgttga ttttggttac catgaggctt acatagaata tcttatactt 164457
aacattgtat ttcaagctga taacaactta actttgattg tataaaataa cgtacattt 164517
tactatcccc tccaacattt tatgtttttg atgtctgaat ttacattatg ttataatatg 164577
tatcccttga ccatttatct taggtaacat tggtattaat aattttgtcc ttatactaga 164637
gataaaatta cactagagat aaacacttat actagagata aaattacttt acacactact 164697
atgataatcc tagagtatc tgactatttc tctatactac ttataccatt aagttttgta 164757
ctttcataag ttttatgtta ttaattagca gattttcgtt tccattaata aaaatttttag 164817
caatacctat aaagaaggcc tagtggtgat gaactctctt agcttctgtt tgtgtgggaa 164877
agtttttatt tctcatttct gaaagacagt tttgtgggg aaagtactct tggttggcag 164937
tttttttctt tcaacatttt gaatgtacca tcccactctc tcctggcctg tagggtttct 164997
gctgaaaagt atactgataa ttatattggg actcctttgt atgtgttaca tttattgtct 165057
ctaacttctc tcagaatttt ttctttgttt ttgatgcttg ataggttgat tattatgtgt 165117

-continued

```

cttggagaac tcttcttttg gatgaatttg atgggagact tctgcactct ctgtacttgg 165177
atatttggtt ctttctctag attaagaaaa ttgcatcaa ttattccttt aaatatgttt 165237
tcnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 165297
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnaaggacaa tcaaatgggc 165357
acatactata ttatgcaca tacatacaca cacacacaca cacacacaca cacacaacca 165417
gatgtcattt ataatccatg taaaatattt ttggggaagt ttctctttaa taaagtattg 165477
agagacatat attttttttt ttgaagagg catatttttt ctaacttttt tttttttttt 165537
tgagatggag tcttgctctg tcaccaggc tggagtgcag cggtagcatc acggctcact 165597
gcaacctccg cctctgggt tcaagcgatt cttcagcttc agcctcctga gtagctggga 165657
ttacaggcat gtgccaccat gcctggctaa tttttttttt ttgtatttt tagtagagat 165717
gggggtttca ccatgtttgt gaggtgtgtc tcgaactcct gacctcaagt gattcaccta 165777
ccttgacctc ccaaagtgtt gggattacag gtgtgagtca tcacaccag cctataactt 165837
ttttttaata ggtgatagaa tcccgtgtt gaaaaataat caaacaaaaa gagaatgcat 165897
tgtaagaagc ctactgtac tctgtctccc agctgcccag ttctccctc ctcctcacag 165957
ggaaacatct tcattagttt cattaggttc ttatgaaacc ttccagagtt tctttaagca 166017
aaatacaagc aagtaggact gtcatatcct gcagaccgct acatacaaat acatagaaag 166077
tgctctcatt ctatctcca gtgatattcc attttttggc tgaaccacct aaatgatgga 166137
tatttagggg aagcaagtat tttttaaaaa aggtaaaaat caaaggtttt tattttttat 166197
ttttttaaag aaaagtgtt aggctgtgtt tattcattca gaagtcaggc cgtggctgaa 166257
ctgatagctc ttggagatgg ccattgtcga tctctgaatg tctggttttc tcttgtaaga 166317
attgtgtgta tgatccagac cttcagtggtg tgcactatat attgagaatt ccagaagaga 166377
tgataggac aagaaaaaaa gatgacttta ctttttacag taaaaataaa acttaaatg 166437
aagagtacaa ttgtttaaac aattggaact tacttagcta ctgctgtgtg aaacaaaatc 166497

ctttttttaa aag g tat cga agc aaa tta aag ctg atc cgt gct aag gaa 166547
          Tyr Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu
          375              380              385

gaa gac agt ggc cat tat act att gta gct caa aat gaa gat gct gtg 166595
Glu Asp Ser Gly His Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val
          390              395              400

aag agc tat act ttt gaa ctg tta act caa g gtatgtaaag ggagtataaa 166646
Lys Ser Tyr Thr Phe Glu Leu Thr Gln
          405              410

gataatgcta gctctgtaga tgagtgtctt ccaaggaaag cctggcactt ttctccccgg 166706
tcattggaaga aaagcagcac ttaggggaga agcagtgctt gcatatgtca catatcgga 166766
atacctctgc tggactcatg aattcaggtt tttctgggag gttctgggtt actctagagt 166826
aggcgaggaa tccctaggct ccaccagcta gctttatttt tgtagagatg gagtcttgcc 166886
atgttgctca ggtgtgtctc ctgggttcaa gctatcttcc caccttggcc tctcaaagta 166946
ctgggattac aggtgtgagc cactgcacct ggctccacc agcttactta gcacctgctt 167006
ctcaatctga gaagagagaa gcagatgacc ttagattgtt ctggagagtt ttgctacaag 167066
ttttccttat agacattgta cagtggtctt taccagaagg gtagtgcctaa gtctgtttac 167126
attcaggctc agcacctatc cagagtccta gccatgagcc aggtgctgtc tgagggtgcg 167186
tcatgtgac ctcacagtaa aacctgtgat acaagcaaca ccgtatatct aatttatttg 167246
accacagatt tagaaaagaa tctttaaaac ctaataacat accacagatg catttttgta 167306

```


-continued

```

aatgctgctt tagattatac tttagctgaa tccattagtt gaatcctaag ctataatata 167366
atTTtaagaa cctccttgcc tttcaagcca aataaccaag ggactttctc tctctcttTc 167426
cctccctccc ttcccttccT ccttccttct tctctccctc ccttggtatc tcttttccTt 167486
tcctttctct ccttccttcc ctcttccctt tttcctttct ctcccttccT ccttccttgc 167546
ttccttcttc cctccctccT ttgttctctc ttttcccttc ctttctcttt ttctttccTt 167606
ccttccttcc tcaactcactc ttttcttttc ctttctctcc ttccctccTt ccttcctccc 167666
tccctcactc tctcttttct ttgcctttct ctcccttccT ccttcctttt cctccctccc 167726
tccctccctt gttctccctt ttccttccTt ccttctttcc tttcttccTt ccttcctctc 167786
tccctcactc tctcttttcc tttctctccT tccttccctc cttcattctc cctccctcc 167846
ccccctccc tccccctccc ctccccctc cccccctccc ctccccctcc cttcccttcc 167906
catttttctt ctcccatgt tgcccaggt tgcctcaaac tctgggctc aagtgttct 167966
cttcacctc agctcccaa gtagctggg ctacatgtgt gaggcacac aaccatggac 168026
ttttcacttt cttcactcca ggttaaaaa atcacaggga taaatctcaa aacacaaaa 168086
ctgtgaaaa gctgctaacc atgtgggtct gtctaaactg gagtggtact tgtacaactg 168146
gtttcagccc ctccggagt ttttgaatgc catgtagatg agttgtgaac tcatattcca 168206
ctttgtagtc tcatatgttc tgggacacga gctattccat tctgacttct ttctgcctct 168266
tgcag tt cct tca tcc att ctg gac ttg gtc gat gat cac cat ggc tca 168315
Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp His His Gly Ser
415 420 425
act ggg gga cag acg gtg agg tgc aca gct gaa ggc acg ccg ctt cct 168363
Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly Thr Pro Leu Pro
430 435 440
gat att gag tgg atg ata tgc aaa gat att aag aa gtatggaaaa 168408
Asp Ile Glu Trp Met Ile Cys Lys Asp Ile Lys Lys
445 450
cagatgtgtc ttcttcttcc gtggtcagaa tatttctccc ttgacacaaa tgatgtcaaa 168468
tacattttac ttattgacta taagataggg ttttgggtgt gatagcttca ggggtgtgat 168528
cttttgtcat gaatagctgt gagaagaagg tccagggctc tcattagacc ttcaaatgt 168588
ctccaatcta aaaacaagag tgaattttaa gaaccactgt tctaagaaga tttttactac 168648
cctggctcac atatcttatt tgggtgaactt tgtttggtag tcggactgca tgtaaacata 168708
aatgtgactg cttagtcctt tatctgccca cctgctgttt ggtgggttaa ttccgcatc 168768
cctccctccc cccccagtc ctccgcttc ttaaattggc acatgagcaa tgtgtttaca 168828
cttcatecat ggtaactggt tgtgttcaga agcctcagtt gtttcttccT ctgacagag 168888
actcctcctc ttaacttcta gggctaagaa cagacttggg tgttgactgg ggtttctagt 168948
agattccagt gtggagcagg attctaggtc ttataactca atctgaggat catcgcaacc 169008
ctagtgcac cctaggggct cttcccagtg tgagtgttga gaaggagggt ctcaggcct 169068
ttttgaagggt ggggagatt gagatcatta aatatggttg aagtgaact gttcagtttg 169128
ctcataggtt caagattggg gaatgtagt catattttat taaacttgat tatctctgcc 169188
tgctatgtaa acacttagct ttcagttggt catgtgtgag ttattccctc ttcagcacat 169248
gcagacaagt ttaattgttc atctgcatgt aaaataaatc agtggtgatt gccccgaaat 169308
gcagacaagg tcccaactcc ttgccatctt agagtgttcc cgtgggtcca ctcatgcca 169368
tgactctcag gaattggccc tatacttagg cctttttct ctctag a tgt aat aat 169424
Cys Asn Asn

```

-continued

gaa act tcc tgg act att ttg gcc aac aat gtc tca aac atc atc acg	169472
Glu Thr Ser Trp Thr Ile Leu Ala Asn Asn Val Ser Asn Ile Ile Thr	
460 465 470	
gag atc cac tcc cga gac agg agt acc gtg gag ggc cgt gtg act ttc	169520
Glu Ile His Ser Arg Asp Arg Ser Thr Val Glu Gly Arg Val Thr Phe	
475 480 485 490	
gcc aaa gtg gag gag acc atc gcc gtg cga tgc ctg gct aag aat ctc	169568
Ala Lys Val Glu Glu Thr Ile Ala Val Arg Cys Leu Ala Lys Asn Leu	
495 500 505	
ctt gga gct gag aac cga gag ctg aag ctg gtg gct ccc a gtgagttcct	169618
Leu Gly Ala Glu Asn Arg Glu Leu Lys Leu Val Ala Pro	
510 515	
caacagtcag gacaactcat cagctgagcc gcactctgccc caggcggaac ttgtaatccc	169678
agataggggt tatatagaaa tgaaggtccc aaggcagaaa ttcagttatg aatgctctta	169738
aagtcattgtg ggactttgtt ttattttgtt ttgttttttg agacagagtt ttgctctgtg	169798
gcccaggctg gagtgcattg gcacaatatt ggctcactgc aacctctacc taggacgttg	169858
ttttagattc agatccaaaa ctgcattttt gcagaggccc ctcaacattt tgcttgtcta	169918
ataatatagc tacagtctct actttgaatg tctgtgtatg tggatggagt gtggggaagg	169978
atcttctgtc tcattgtctc ttaaaagata gatgaagcca aaagcaatat aagcaaaatg	170038
caacttacaa aataagcttt ataataaagc atatgaagta gaggtgtctg cccatatagt	170098
agctgtcaat tgcatttate ctattcaaat tctgtccaca aggttactgt tggagcaact	170158
ttggagaaaa tactgagttc tcctgattga attttgtccc cttcttgtat aaggaaagag	170218
ttgatgtagt ttctgtgggt tagatgggtt gagagatggt actgcctatc cctaaaatga	170278
accaggcagc cctcacactt ccccaccagc agtgagagat tcctgggtca gacacagcca	170338
cactaccttg ctgccctgt gcattgtctg caggaaactt ttcattgtgc ctctctctct	170398
tgtcacgtag cc ctg cgt tct gaa ctc acg gtg gct gct gca gtc ctg	170446
Thr Leu Arg Ser Glu Leu Thr Val Ala Ala Ala Val Leu	
525 530	
gtg ctg ttg gtg att gtg atc atc tca ctt att gtc ctg gtt gtc att	170494
Val Leu Leu Val Ile Val Ile Ile Ser Leu Ile Val Leu Val Val Ile	
535 540 545	
tgg aaa cag gtagatattt tctcataaaa ctaaagatct ttgaagccaa	170543
Trp Lys Gln	
550	
tgagaacaag catagcaacc tagttcagtg cttggcacag agaaggagct cagcaattac	170603
atgtggagtg aacgttggtg gactctactg tgtccagtea ctgtgctgct tcagtgaagc	170663
tcctgggtcac tgggactttg gtaattcacc agttacctgt cctgggtcatt tatag aaa	170721
Lys	
ccg agg tat gaa att cgc tgg agg gtc att gaa tca atc agc cca gat	170769
Pro Arg Tyr Glu Ile Arg Trp Arg Val Ile Glu Ser Ile Ser Pro Asp	
555 560 565	
gga cat gaa tat att tat gtg gac ccg atg cag ctg cct tat gac tca	170817
Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp Ser	
570 575 580	
aga tgg gag ttt cca aga gat gga cta gtg ctt g gtaagtcca	170861
Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu	
585 590 595	
tggggtaacc tcccaagact cccttttccc ttgcacacaa ctttacaatt tataggcctt	170921
ggcagaatag agatctgagc ttgtgcttag taagaactag gcaatggaaa tttgctttca	170981
gaaatacatt tctgtcttga cagtaagtta attggatcat tgcaatgatt tttttaaatc	171041
tcctttccata acaaattata gttaaggaaa attttataaaa gggagaagag aatatgaaga	171101

-continued

```

gggetggcaa agataccac caaattgct tttctttaga atgacacaa attgaaaatg 171161
aatttctgtg actaaaaatg agcagatgag aatgaatga ggacaaccac aaaatgtatt 171221
ttgattcagt acattctgaa gatgcattag atactccttt ttacatatatt ggaatatgga 171281
atataaaaat ataggtacat tttgaggcaa aatatgtaaa aataagcaag ccaacttatt 171341
acaagcattt caagtatttc aatcctgggc tgagaccaag tatatgaagc tttagtccaa 171401
gggagtattt cttttttaa tccattcct aatgaatgaa agcaagacaa aggcacaaatga 171461
aagtagagggt agaggtgtg ttatgatgaa tgatctaaca gtatatatgt taaagaatgc 171521
caaatgcagg ttttaattat ccaccggtct cattgcaaaa tacagaagag tttaatgtctt 171581
cttagagagt taggtaaact gaaatcaagc aaggcaccag agtgaaatca cctttgcaaa 171641
aattgtaact gaggaatta tgacagtgaa tgagatatga cctaaccaac tccattttgc 171701
tttagcctcc aagttgtcct tgttccttcc tgggcatagg ccgaactaac tttgagagga 171761
acttagttta tagtttgact ttgaaaaaaa gacaataata gccctttgcc aaaacaaacc 171821
ctctttttcc ctgggaacta gactgccttt gcgggactaa cgaattagct acaagattag 171881
aaagtatggt ttaggggtca ctggtgtaaa acctgaggtc agtgcttgag atattttgga 171941
gacctgtat ttcatgacac cagctgacac caccaggtc aataaactgg ctcatctgat 172001
cttggggccc ctacctagga actgactcag tgcaagagga cagcatcagc tccctataat 172061
ttcatctttg acccaaccaa tcagcactcc ccttttcacc ccctaccac caaatcatcc 172121
ttaaaacccc cattccccca gtttcagaga cactgatttg agtaatagca gaatagtaga 172181
aattccccca gtttcagaga cactgattcg agtaatagta gtaatagtag aataggcttc 172241
ccgtacagct ggctctgtgt gaattaaacc ctttttctat tgcaattccc ctgtcttggt 172301
aaatcggtc tgtctaggca gcggacaagg agaatccatg gggcggttat aagagctgcc 172361
cccaatttc aaatatatt atctaagctt tctttatttt cctgcctatt tcccaacaag 172421
ggatgaggag cttaggaggt taaaaagtag taaaatatgg ggaaaagggc ataattccca 172481
ttataccaag aggcattgct ggtgaagcaa tacctttcca ggtacgattt tcagtaacac 172541
agacgtgcag taagaggcag tgttggctgt tagtgtcttt tatgagccaa gtcttttcct 172601
ggcttggtca tccgtggtga gactgacacc ccgggaaatg tttctctcag ggtgagctct 172661
ttcaggggtg gacaacagct tcagtgtctt tacgtatgtc tcctcccaac atgaagctaa 172721
ttgtgtgtct ctgggcatg tttagctctt ggtagagtgg ctttcctaac aaataggag 172781
cagtgagccc agcctgaagt ttttatttag tcaactccta gaatcagtga tattttgaat 172841
actgaagtat ttccagtggc tagtaattta ctaagacaaa agatgcccct gtttgcata 172901
ggaaaacaga aggggagaga gccaggaggt gtgggtgaga gcccgaagg caagaggatc 172961
ccaggggctg gccagcacg gagctggtag acagcgcgct cacaccaggg agggctgcac 173021
cctcctttct cccgtctgtg ttttctttcc cttgcaagtg ttattcgaca aaagcaatta 173081
tgctaatttc cttccctgtg ggctcaattc cttttttgac acgatgactt ggaggagtca 173141
ttatgattac tccaaacagg aaagacactc gccagctgt cggccgcag agagctggct 173201
acggtgcaga aagctgagga ggcgtctgga gtttttgggt gttaatgatt ctgctgccc 173261
acag gt cgg gtc ttg ggg tct gga gcg ttt ggg aag gtg gtt gaa gga 173309
      Gly Arg Val Leu Gly Ser Gly Ala Phe Gly Lys Val Val Glu Gly
        600                                605                                610
aca gcc tat gga tta agc cgg tcc caa cct gtc atg aaa gtt gca gtg 173357
Thr Ala Tyr Gly Leu Ser Arg Ser Gln Pro Val Met Lys Val Ala Val
        615                                620                                625

```

-continued

```

aag atg cta aaa c gtaagtgtc ctctctgggg attttttgag cacggggatt 173410
Lys Met Leu Lys
630

ttttgagcat ggggatatta agggaatttc tcaaaatcat gcagctagta aataagacat 173470

ttaggactag gtcttgatta ttttgactcc aggttttatg tgtatttaga ttaggtttat 173530

ttagattgct ctgtctgcct gtatgttgga aaattaagag ctgtttattt ccagtgcactt 173590

ctttttacta gaaagaccag gaattagtta ttagcactga ggccaagtag ctatctgcctt 173650

cttttagact tctggtaaat agaatgatat ccaatcacag gattagtcatt attcttggtt 173710

tttttctgag aacaggaagt tggtagctca gctggactga tatgtgattt attctttcaa 173770

cag cc acg gcc aga tcc agt gaa aaa caa gct ctc atg tct gaa ctg 173817
Pro Thr Ala Arg Ser Ser Glu Lys Gln Ala Leu Met Ser Glu Leu
635 640 645

aag ata atg act cac ctg ggg cca cat ttg aac att gta aac ttg ctg 173865
Lys Ile Met Thr His Leu Gly Pro His Leu Asn Ile Val Asn Leu Leu
650 655 660

gga gcc tgc acc aag tca g gtgggctcac tgacctggag tgaggatttt 173914
Gly Ala Cys Thr Lys Ser
665

cactggacac atgtggttgt gaaaactggt caatcaggct taaatcctcc actctccatc 173974

cccacacatg gcaggaata gaagtcctt gaattggagct gactgggtccc ttgaattgat 174034

ggaagctcat tggtttttga gcaaaatctg ttgccagtcc agtcatagcc attcatggct 174094

ctttattaaa aaaaaaaaaa aaaaaaaaaa aaaaaaactt ttttgggtatc ttattttttt 174154

ctgtgccata tggctctgcag gacaattcat ggcttttctg ttcttcattt tcatacccat 174214

ctcctaacgg cttttgtccc catag gc ccc att tac atc atc aca gag tat 174265
Gly Pro Ile Tyr Ile Ile Thr Glu Tyr
670 675

tgc ttc tat gga gat ttg gtc aac tat ttg cat aag aat agg gat agc 174313
Cys Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser
680 685 690

ttc ctg agc cac cac cca gag aag cca aag aaa gag ctg gat atc ttt 174361
Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe
695 700 705

gga ttg aac cct gct gat gaa agc aca cgg ag gtgggtgcaa agagagatgt 174413
Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser
710 715

tgctgtctat cattatctta caggcatcac aaatggaaag acccatgtcc tgatagatat 174473

catgtctgca gattcagtgc ccaaggtagc aagacttaga gtcaaaccac cctgtccagt 174533

ctttccatgg tcatgcagag agatgcata tgtctaaagg tgttttggac tggggtgtca 174593

catgggaagg ccttgcctgat aggtttgaat gagagtgagt tagaatgact ctgggagctc 174653

ttctgctatt tacatgtgat ccacttagac ctataaaatg cagctctggc cagggatgct 174713

tgagttctgg aaccttgcaa gaactgtctg tggatctcca agctcgaggt ccttgcctgaa 174773

cctggacctt taaatgacgt caatgatagt gatccctact gcagaaatct acaagtggct 174833

ataaagaact ctgtaggtaa gaaattctgt aagatcagaa agtacaatga attcacttca 174893

taataaatta cttggtggac accaaatggg tgctaaattg attgggtaga aggaattgta 174953

tgcccaagcc acatggccac acggctcaag ttccaaccaa ggcttgtgag ttgaaaaact 175013

gagaaagaat aatgacagac ttaacgtagt gaattcttca aactttaagt gtaatggact 175073

tacaggtcca tgggagcaca gccccactgt cttagatgtg gctcttcagg atgtgcgggc 175133

tcctgctaag gatgtgcagg gaactggctc tgaaaacaag tgaacagtag tcatcatggc 175193

```

-continued

```

agctgacatt tgtggagtcc tttgtatgtg ccaggtgccca tgacaaatat tccgctagtc 175253
tttcccatct ttgtcagtg gattccattct acgtcttctg aaaagtgtt ccttgacccc 175313
cagatcaagt cattttcctt acaagctatt gaaacctttc ttccttcaca acacagctga 175373
gtttgagttg atctgtgtat ttattttgtt ttttacattt ctttttttcc ctatttaaaa 175433
aattttttta tttccatagg tttttgggga acaagtggta tttggttaca tgagtaaatt 175493
cttcagtggt gatattgtgag atttttggtgc acccatcact ggagcagtat acaactgaacc 175553
cagttttag tag tcttttatcc ctcacctgcc tctcaatttt tccccgagtc cccaagtcca 175613
ttgtgtcatt cttatgcctt tgcctcctca tagcttagct ctcacttatg agtgagaacg 175673
tacgatgttt gggttccatt tctgagttac ttcacttaga ataatagtct ctaatcccat 175733
ccaggttgct gcaaaagcca ttaattcatt cttttttata gctgagttac atatatatat 175793
atatatatgc acacctacac atacatatgt atagatacac tgcagtttct ttatccactc 175853
cttgattgat gggcatttgg gggttggtcc acattttttc aatatgtgaa ttgtgctgct 175913
ataaacatgt gtgtgcaagt atcttttttag tatgacttcc tttcctctgg tagataccca 175973
gtagtggaat tgctgtgatg catgtatttg tgcgactatt tgattaatgc tcatttcctt 176033
gactagatca cctcatgtga aaggtatgga ttggttttgc ttttaccag ttagctccca 176093
tgcctacctc agtacctggc acataatcat catctactga aagtggaatg accacttcag 176153
aagggcaccc tgggtaagat ttctctttct gtttttacag c tat gtt att tta tct 176209
                                Tyr Val Ile Leu Ser
                                720

ttt gaa aac aat ggt gac tac atg gac atg aag cag gct gat act aca 176257
Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr
725                                730                                735                                740

cag tat gtc ccc atg cta gaa agg aaa gag gtt tct aaa tat tcc gac 176305
Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp
                                745                                750                                755

atc cag aga tca ctc tat gat cgt cca gcc tca tat aag aag aaa tct 176353
Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser
                                760                                765                                770

atg tta g gtaaaagtgt ctatactcac tctgggtgtt gggactttcc agtgggttaa 176410
Met Leu

tatgatactt aaagtattta gaggaagtg tatagggatg gtaagtgaac ctggcagccc 176470

acgtggtctc taaatgcagg tctgcacaac cagttctgtg acatgtttcc aggtttgttg 176530

cctgtaaatt gaaaagaata aaagctgaca atgtaacaaa ttttttaaac tttaaattta 176590

atagttttaa agaattttct tgggtgtgtc ctgcagtaaa cattttttta aaaaaataat 176650

tattttattct gatataatga acttcctttt ttattgctgt ctttttcttt tttaatgaaa 176710

atatggtgat tgattttttt taatgccctt acttggcaga attacaagtt ggtgtcttta 176770

tgttggttcc tcacctgtct ttttttccct taagtttttag aagtctctga tgtctatgag 176830

ttcagtaacc cttgctttta cttttcctaa cattcaattt gtgataggaa ctctagagta 176890

gataatttgc agttatatat tctggaccag tgtttctgtt gaatgtattt tgaaggtggg 176950

tctatctgtt tttcaagtac atgaatatgt ggcagggtta aattgattta taaactccag 177010

ggagtccagc tgatgccag accagatgga tcacttcaca tctgctcagg gtgggttctc 177070

cagagccctg aactggtcac agacatgaag ctggaagtct gacattggct tgtcctgtga 177130

gcttgccctt ttgggtctga gccttcccat tagtcaatgc aaaaaagtgt tgagctgccc 177190

tggacattgt tttggaatt attgatgtgc totgaatgtt ttcaggttct taagtgaag 177250

```

-continued

gtacaatcca tttaaaaaag aatgtgtttg ttttgcaaag ctcagtacac aatattttcc 177310
atctctgagg ttccaagttc cattcacttc tcattgcaa atgggtgaac ttccaagcgc 177370
ttttaaaga ttagccagtg agagtatcg gaaccagtac ttctctccc ctcccatatt 177430
gttaaaaata gtttacattg cttcccaggc tgggctggg gagttggcac gagatgtcag 177490
aggaacctga gtcattgctca ggcccaagcc ctggtggcag gcagaccact gctttctggc 177550
cttcogtgac tatctgaaaa aaatcgtgaa tggctagagc tactcttcac ttgctgaaca 177610
ttttcaaaa gaattgagaa cttctggatt aaattgcctt cttctcgaa aacctggga 177670
cccttcaga tgggactaac tggggaaagt ggacaagtta caaacaaga aactcaaagg 177730
aaagtcattg gactgatct ctaagatgct atcacatgtg attggtggtt gattttatta 177790
acaaattata agcaaagtac tacaaagggt gctttaaaaa gaaaataaag caattcacag 177850
aaactacttt ttcattgtagc ttgtatgtg gctccatgta tttcatcatg gaagatttta 177910
gtgtgtgttt atgtgtatgt gtgttttaa ggtagctgag atgatttctt aattatggtt 177970
gaaaaaaga aatttaggag gtaacaaaa taattatgtg taagattggt ccttgggct 178030
gtgtgtgtgt tttgtgtgtg cgtgtatgtc tctgtgtgtt ttaggtgtt cttttattgc 178090
tataataaaa tacttgagac tgggtaattt ataagggaag gaggtttaat tagttcatga 178150
ttctgcaggc ttacaggaa tcaagatact ggtagatctg ctcagttttt ggagaggcct 178210
catgaagcca tgaagtcatg gcagaaggca aagcagtgcg ggcacatcac atggccagag 178270
caagagcaag cgagagagag aaagagagag gtgccacaca cttctaaca gtcagatctt 178330
acaagaagtc acttactatt gcgaggacag caccagaagg atggtgctaa attgttcgta 178390
agaaatctgt ccccatgac cattcatctg ccaccagtcc ccacctcaa tactggagat 178450
tacaattcaa catgagattt ggggtgggac acatattcaa actatatcat actgacctg 178510
gacctccca aatctcatgt cttctcaca tttcaaaa caatcatccc tccacaatag 178570
tcccccaag ccttaactca ttccagcatc aactcaaagt ccaaagtctt atctgacaca 178630
aggcaggtcc cttccaccta tgagcctgta aaataagaa caagtattt actttcaaga 178690
tacaatggg ttataggcat tgggtcaaca tccccattcc caaagggaga aatcggccaa 178750
aagaaaggg ctacaagccc cacagaagtt cagaaccag cagggtgaa aactccaaat 178810
aaactccatt gactccatat cccatgtcca gagcacactg atgcaagggt tggagctctt 178870
gggagggatg gaacaccctg tggctttgca gggtttagcc cctgcagctg ctctcagggg 178930
ctgttgtcga gtgctgtgg tttttcctgg tgcagagtgc aggtgttgg tggatatatt 178990
attcatggag gatggtggcc ctcccctcgt agcttcacga ggcagtgcc cagtggagac 179050
tctgtgtggg gacttcaacc ccacatttc cctctgcagt gcctagtag aggttctctg 179110
tgagggtcc aatcctgcag catgcttctg tctggacacc ctggtttttt aatatacct 179170
ccgaaatcta ggcagaggct cccaagctc aactctaac actctgtgca cccacaggct 179230
aacaccacat ggaagcggcc aaggtttatg gctgtcaca gctgaagcag cagcccaagc 179290
tgcacctgaa ctcccttgag ccacagctgg agctggagtc atagggatgc agggagcagt 179350
gtctcgaggc tgcacaggcc agtggacctt ggggctggcc catgagacca ttcttccctc 179410
ctaggcctct gggcctgtga tgggaggggc tgccatgaag gtgtctgaaa tgccttaaag 179470
gcctttttcc cattgttttg gcaatcagcc tttgctcct ttttagttat gcaaatttct 179530
ctagcaagtg gttgccagc agccctctt aattctctcc caaaaagct tttactttct 179590
ctgtcacatg gccaaagctac aaattttcca accttttatg ctctgcttcc cttttacttt 179650

-continued

```

ttttttat tt taaagagatg ggggtctcact atgttggtcca ggctagtttg aactcttgga 179710
ctcaagcaat cctctcactc atcctcccaa agtggtggga ttataggtgt gagccactgc 179770
gcccagcctc tgcttctctt ttaaataaa gtttcaactt caagtcattt ctttgcttct 179830
gcatctgact gtaggtattt ggaagcagcc aggccatata gtgaacactt tgctgcttag 179890
aaatttcttc caccagatat cctaggtcat cactctcaag ttcaaacttc cacatatctc 179950
tagggcatgg acataatgtg gccaaagtctt ttgctgaagc ttaacaaggg tgacctttac 180010
tccagttccc aataagttct tcatcttcat ccgagacctt ggagcctgg atttcattgt 180070
ccatctcatt atcagcattt tgggtcacaag catttaacca gtctctaaga agttccaaac 180130
ttctcttcat ctctctgtct tctctgagc cctccaaact cttcttatct ctgctgttta 180190
cccagttatc ttacagcaa ttccccctc cttgatacca atttctctc ttaggctggt 180250
tttgcatgct tataaagaaa tacctgagac tgagtaattt ataaagaaaa gaggtttcat 180310
tggcacatgg attctgcagg ctatacagcc atttgcttct ggagaggcct caggaagctt 180370
ccaatcatgg tggaaggtaa agggggagca ggcatatcac atggccagag caggagcaag 180430
tgagagagag acagagagag agagagagag agagagagag agagaggtgc catacagttt 180490
taaacaggca gatcttgtaa gaagtcactc acttttgcaa ggatagcacc aaggggatgg 180550
tgctaaacca ttgtgagaa attcaccctc atgatccagt cacctccac caggcccccac 180610
ctccaatact ggggattaca cttaacatg agatttgggt ggggacacat atccaaacta 180670
tatcattgct tgtgtgtgtg tgtgtataat ttttaacca gatatatgtt tctgcatatc 180730
tctttctctt ctttcattct ttctatctt ttttttttt ttttttttg agacagagtc 180790
tcactctgtc acccaggctg cagtgcagtg gtgtgatctt ggctcactgc aactcattgc 180850
aacctcctcc tcctgatctc aagcaattcc cctgctcag cctcctgagt agctgggatt 180910
acaggcacat gccaccatgc ctggctaatt ttttgtatt attagtagag atagggtttt 180970
accatgttgg ccagactggt ctcaaacttc tgacctcagg caatccaccc acctcggcct 181030
cccaaagtgc tgggattata ggcataagcc accatgcctg gcctatatat ctattttcta 181090
agatagaatc ttgcatagt gatattcatc tgtgagatct aaacattcta caaaaaaatt 181150
aagaaaaat ttttgatgt gttctttggg catgcctctg caacctgatg atttctgct 181210
gcctgccagc accaatatc ttaatttctt ttctgcag ac tca gaa gtc aaa aac 181265
                                Asp Ser Glu Val Lys Asn
                                780

ctc ctt tca gat gat aac tca gaa ggc ctt act tta ttg gat ttg ttg 181313
Leu Leu Ser Asp Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu
                                785                                790                                795

agc ttc acc tat caa gtt gcc cga gga atg gag ttt ttg gct tca aaa 181361
Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys
                                800                                805                                810

aat gtaagtcaa ggaacacaga cttttttaga ccagatttc agtgagtgga 181414
Asn

gtgtggacgg agatgctagg agatagatgt tggaaaggcc attaataaca ggggcctctt 181474
acttacctgt ctctctcctt catccccac gcaggtcagg gagtctgaaa tcatcaggca 181534
tctactcttc tctagagctt tctctctgtt gggagtgggt ggagtggaaa cctgggagaa 181594
ggccagccct ttatatccag gcagacagct ccaagtgcc ccatggatca gccagtcttg 181654
caggggtgat gctattcagc tacagatggc ttgacctga gtcatttctt ccttttccat 181714
gcag tgt gtc cac cgt gat ctg gct gct cgc aac gtc ctc ctg gca caa 181763
Cys Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln
                                815                                820                                825

```

-continued

```

gga aaa att gtg aag atc tgt gac ttt ggc ctg gcc aga gac atc atg 181811
Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met
830 835 840

cat gat tcg aac tat gtg tcg aaa ggc agt gtacgtcctc acttccctca 181861
His Asp Ser Asn Tyr Val Ser Lys Gly Ser
845 850

ctggtcaggc tcatcctcct tcaactttaat ctctaaagtc aggtgttgct tctagagatt 181921

cggtgccctgt tttttaaaac atcaatagat ttcaaggggt cagtacactg ccttggcagc 181981

agattgccca ggtttgatgt ccagctccac cacttactta atttgattt ggggctagat 182041

acttgactgt tctgcccctc tgtctccctg attgtagtgg gaggtgataa tagtacctat 182101

ttgctgagtt gctatgggga ttaaatcaat gaattcatgt aaagtgtta ggacagtgcc 182161

tggcatatag aaacagcact caataatgtt agctatttta tttatttatt tatttattta 182221

tttatttatt tatttatttt cttttttttt gagacagagt ctactctgt caccaggct 182281

ggagtgcagt ggcgcaatct tggtcactg caaacttctg cctcccagggt tgaagcaatt 182341

ctcctgcctt agcctcccgta gtaggtggga ttacaggcat gcaccacat gtacagctaa 182401

ttttgtatt ttagtagag acagggttct accatgttgc ccagactggt ctggaactcc 182461

tggcctcaag tgatctacct gcctcagcct cccaaagtgc tgggatgaca ggtgtgagcc 182521

actgcatctg gcaagtgtta gctattaata tgtcaattgc gtgtatgcat ggacaagcat 182581

gcattcccaa ggatggtgtc tttacatttt aagcttttat cagattttca aaagccatct 182641

gtgaccoccta aaatagattg gaaccatttg ggtttatgta tcttgagggc acagtttcct 182701

taaagatact cattttgttg tctacttgaa ccattcttcc catcccttcc acttctcagc 182761

agatgacata gctccctgtg gggatataat tgctccctgt aggtacaatt ccaaaccacc 182821

tcaactgcact ggatgtgaga cagcttatgg cagctgctgc ttccacctag agaaagacat 182881

gggcctgcat ccagtctgtg tgtgattcat gtactcatgt ggccgtgata gctgtaatcg 182941

gctcatagat cattggatct gttcttagtt ttgttccag gaatatctaa aaataggaaa 183001

ctgggccatt cagggettac accttttggg tgaaaattca ggattaatgt ttttgatat 183061

tattcctttg gaggacataa aaggcaatat tgaccattca tcattcatct agtatttatt 183121

gagcacctac tatgtgccag ggactgagag ttcagtaatg aacaaaacac atgtaaaaga 183181

cactcaaatg ggacaagata attagcacia gttattaaga gcccagggg aacccttttc 183241

tatttccact gctgtggatc atcagtgagt agacatgggt ttaactgtct cctccttcc 183301

ttgcag acc ttt ctg ccc gtg aag tgg atg gct cct gag agc atc ttt 183349
Thr Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe
855 860 865

gac aac ctg tac acc aca ctg agt gat gtc tgg tct tat ggc att ctg 183397
Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu
870 875 880

ctc tgg gag atc ttt tcc ctt g gtaggggcct gacattgctg cttatttggg 183449
Leu Trp Glu Ile Phe Ser Leu
885 890

ctgttctgaa acaccactgg aaggaaaatg tgttctttca agccccagga tgtagacagt 183509

gttaagataa cctggtgtga ggccagtatg ctgcagccac ctcaaaccac atgttgtgcc 183569

ttattgtgtc tgagataggc ccagtgcagg ggagatgggg gtttttgttg ggggttgctg 183629

cttactcctg gcctctgccc ctccctcctt ttgggctatg ccagagtgcac ttccctccac 183689

tggaagtggc cccaatgaca ttgcacccc agctgctttt tcattttggg ctttgggtca 183749

catgggttca cccatggaga gtgggcccct cctcacctgg tggcgattga tgctcagggt 183809

```


-continued

```

aaaaggggta cgtggcggga agggcagggc tctcattcct ggttgtcatt ggccagtctt 183869
gacaacccag gtgctgaaca acccaggtgc cctgggctat ccggtgaggt ccctaagaga 183929
aggatgagcc ataacccctga catctggatg gttcatctgg ggagatgaga cttacacact 183989
tagggataaa cagtgtgctg ctgatttaaa attgtaattt gagtcttgag taaagagaaa 184049
ggagtccctgg aatagtgtgg gaaggcttca gagagggaaac ttaacttgac ctggccttgg 184109
ctttgaaagt gtgaaatgtt tcatgaattt atctgtgac aggatgtaat agtaaagtgt 184169
gtcttctcgc cccgtctcct ttttcactct agttctccct ccatggatga tcacaatgga 184229
tcaccccca gtggcttaat ggagtccctg actcccttaa aagcagagag gccacaactt 184289
tgatttttgc tttagctatt tgaacatacc tggtgaaaaa gactctctgg gttttaatga 184349
ttcagaattt ctctctgctt ttctagtcca ttttgtctgt gttgatccag tagtcataca 184409
cattgaaaaa cacttgaacg cttatttcta aagatgtaga atttttgtga tggtaacttg 184469
acttgacca cctggagtcc taattaaact taaggtttga gctgggtctct gaagtcaagg 184529
agatgatgac actgaatttt cttgaaaaaa ccagtgcctc aaggctatag gatctgaaag 184589
gttttctaac agtgttctat catgccaaat gtttcagcaa tgcactgagc gtttgtagt 184649
cctgggtgtt tattgtttgg cttttg gt ggc acc cct tac ccc ggc atg atg 184702
                                Gly Gly Thr Pro Tyr Pro Gly Met Met
                                895                                900

gtg gat tct act ttc tac aat aag atc aag agt ggg tac cgg atg gcc 184750
Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala
                                905                                910                                915

aag cct gac cac gct acc agt gaa gt gtgagctcct tccccatccc 184796
Lys Pro Asp His Ala Thr Ser Glu Val
                                920

gggggcctgt gttcacagtc tgtgggtcta gggggagggga ggggccctga gaattccccc 184856
tgtgcccact cttgagttct gtccccacag c tac gag atc atg gtg aaa tgc 184908
                                Tyr Glu Ile Met Val Lys Cys
                                930

tgg aac agt gag ccg gag aag aga ccc tcc ttt tac cac ctg agt gag 184956
Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu
                                935                                940                                945

att gtg gag aat ctg ctg cct gga caa tat aaa aag gtgtgtttgg 185002
Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys
                                950                                955                                960

atctgtgggt ggaaggtct ggataaagct ggaagttata ccagtgaact gtgctgttcc 185062
gcagttctag aggagcattt tcaaaagagg caaaagactg tgtgatccag tggctgggct 185122
tcatggcgggt gctccacgag accctagtag caatgatgaa tgaaaacct ccccttcccg 185182
tggggctttc ctttcatctt atatgtacag tacctgtaag cactattctc cagatgtttg 185242
agtatcagaa gttagtgtgc agttagaaga ctacgggcat ccatggccat tacatcacta 185302
atttgagtgc acttaaatcc atgcgaaatt ggcttttacc agcggactgg aaggaacaac 185362
ctcagctggt atctgtggca ccagctggtt ttttgtggaa tgggaagcat tgttcaaagg 185422
aacaatatga atttcttgga accaggcagg atatgtaaat gaatgaaaca actttctgct 185482
gaggtgttga gaggaaaact cagacataac ctgagtttct tagattgaga ttagtccctg 185542
tgtagacttt ttatacttat catttttctt ccttcttctc aaggaggaat agtgtagga 185602
gattgtgtgc cgaactggaa gttaaatgct tctgtctggt aattatctca ctgccacta 185662
caactttcac aggtgaggca gtgaggaggc agaaggaaat taaccctcag ttggtcaaag 185722
atgctctgac tgggtgaaat gtgttggtgg gaagagattg aagttattgt tgaaaatagg 185782

```

-continued

```

gtcttttcac atccaatgtt agacctctcc aatgtttaag gatcatgaag gctttgggta 185842
ttatccacccc aatagaaggc ctactgcct ctctatggga cccatccaag ccttggaag 185902
gcaacgtgat ggggaccaga aggattctca gttgtagcta ctgacttgga gaaggggcta 185962
ctggtatctt agcacctaag ggcagaagct ctttaccatt ggtggccct tcttcatgtt 186022
ctatgtctct ggggatagtt gacatgactc tccttcaact aagtcaccaca tcttcaggt 186082
agtttgagaga tatgtacagt taaataatag taagttctga gtgtctctat tcatttttga 186142
ggtttgggtt ttaacacttg attaaatatg ttcaatgaat gtttatag agt tat gaa 186199
                               Ser Tyr Glu

aaa att cac ctg gac ttc ctg aag agt gac cat cct gct gtg gca cgc 186247
Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg
965                               970                               975

atg cgt gtg gac tca gac aat gca tac att ggt gtc acc tac aaa aac 186295
Met Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn
980                               985                               990                               995

gag gaa gac aag ctg aag gac tgg gag ggt ggt ctg gat gag cag 186340
Glu Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln
1000                               1005                               1010

aga ctg agc gct gac agt ggc tac atc att cct ctg cct gac att 186385
Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile
1015                               1020                               1025

gac cct gtc cct gag gag gag gac ctg ggc aag agg aac aga cac 186430
Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His
1030                               1035                               1040

ag gtagctgtgg gggcagcctc ggtgtctcac ctttccctc cctataggc 186482
Ser

cctgaaggag aggaccatt ttcccgataa tgggtgcactc ccggttggtta aatatgtact 186542
cagggacaag ttgcagaatc ctacggaggt ccacgtggtt ttgaaaatgc ttcccagatg 186602
attctaatat gttccccctg gggctgggag agggatgtgc atgttgtggg gagagggaca 186662
tgcttcctg gtggagaatc tttgagctaa attctcaggt aatttgatca aattgataca 186722
gaactgtgat tactgagatc atataagcct ctctgcat tgtcttaaat agtcattgaa 186782
ctggggaaaa agtgaagaga ggcgggactg ggtcctttga cgctataccc tacctgtgaa 186842
ttggaatcac ctgcagagat ttaaaaaactg ctgatctaca agcctcacc aaaacaacaa 186902
attagaatcc ctgggggtgg tggccaactg ctccctggct gatttgtttc ttctttcttt 186962
taaatTTTgt attatggaag atttctaag tgtgcacaat tcacatagta tagtgagctg 187022
ttcagtattc gtcaccagc ttcaatgact atgcctctg ccagcctgga tgcacacatg 187082
gccatgtctg tctctctca gctcctctg gattgtttgg aagcaaatcc tagacacctt 187142
atcatttcac ccaataatat tccagtgtgt gtctcttaaa gataagggt ctatttttaa 187202
gaagaacaac agttattaaa aataactaca atgccgttat ctcacccaaa acagggacaa 187262
taaatcgtaa aggcacagg cagccagtta aagttcaaat tatctcacia atattatcat 187322
actccattaa aaagtgggca gaggacataa gcagacactt ttcaaagaa gacatactg 187382
cagccaacaa gcatatgaaa aaatgctcaa catcactgat cactagagaa atgcaaatca 187442
gaaccgtgat gagataccat ctacaccag acagaatggt tattattaaa aagtcaaaaa 187502
ataacagatg ctggtgaggt tgtggagaaa aggggaagcg tatacactgc ttgttgaggt 187562
gcaaattagt tcagctattg tggaaagcag tgtggtgatt tctcaaagaa cttttaacag 187622
aattaccatt ggatccagca atccattac tgggtatata accaaaggaa tataaatcat 187682
tctaccataa agacatgcat acgtatgttc actgcagcac tattcacgat agcaaagaca 187742

```

-continued

tggaatcatc ctaaattgcc attgacagta gactggataa agaacatctg gcacatatatc 187802
accatggaat actatgtgtt gataaaaaag aacaagatct gagataccat ctcccaccag 187862
tcagaatggc tattatttaa aagtcaaaaa gcaacagatt gtggcgaggt tgtggagaaa 187922
aagaacact tttaaatgt tggttggagt gtaaattagt tcaaccattg tgaagacag 187982
tgtggcgatt ccccaagac cttagaggcag aaatactgtt tgacctatca atccattac 188042
tgagtatata ccagagtga tgtaaatcat tctattataa aggcacatga atgtgtatgt 188102
tactgtctgc actgttcaca atagcaaaat catggaatca acctaaatgc ccatcaatga 188162
tagactggat aaagaaaatg tgatacatat acaccatgga atacgatgca gccgtaaaaa 188222
ggaatgagat catgtccttt gcaggagcat ggatggagct ggaagccgtt accgtcagca 188282
aactaacaca ggaacagaaa accaaacacc acatgttctc acttataagt gggagctgaa 188342
cgatgaggac acatggacac atggagggaa acaacacaca ctggagcctt tcaggggttg 188402
gggattgggt ggaacatcag gaagaatagc taatggatac tgggcataat acctgggtga 188462
tgggatgatc tgtgcggcaa accaccatga cgcattgtta cccatgtaac aaacctgcac 188522
atctgcata tgtaccctg aacttaaaaa gtggaaaata caaaaatgaa attaaaaaaa 188582
gaacaagatc atgtcctttg cagcaacgtg gatggagccg gaggtcacta tccttagcaa 188642
actaatcgg gaacagaaga ccagataccg catgttctca cttataagt ggagctaaaa 188702
ctacgagaac acatggacac aaagagggga acaacagaca ccagggcata gttgagggtg 188762
cagggtgga gaaggaagag gatcagaaaa aatacctatc ggatactgtg cttattatct 188822
gggtgatgaa ataactgtga catcaaacg coactgacatg tgatttatcc atgtaacctg 188882
cacacgtgcc cttgaacata aaataaaagt taaaaaaaaa ttatcatata cttgttttgt 188942
tctgtctgag atccagataa gagtcacaca ttgcacttgg ttgtatgtc tctgtaagtt 189002
cactatgtct ctattttttg ccctcttaca tattatttgt gaagaaacca tagtgtttgc 189062
ctgtggagtt ccacaaatcg gcattttgt gattacatcc ttgaagtgc cttctcaggt 189122
gcttctgtct tctctatgtg ttgtaaacgt gtagttagtc taggaactta acctgactca 189182
ggttagatct ttggcaaaaca tgcttcatag atggttctgt gtgcttctgt caagaggat 189242
gcactgtcca gttgtctgcc ttttgtaaca ttatcagtc ttgggtgatc attacctaga 189302
atttcttttt tttttttttt ttttgagatg gagtctcgct ctgtcaccca ggtggagtg 189362
cagtgggtgt atctcagctt actgtaacct ccacctctg agttcaagcc attctcatal 189422
ctccgcctcc tgagttagct ggattacagg cacatgccac catgccagc taatttttgt 189482
atttttagta gaaatggggt ttcagcatgt tggccaggct ggttttgaa tctgacctc 189542
aagtgatctg ccggtctcgg cctccaaga tgctgggatt ataggcatga accacctcac 189602
ccggcctaga ttctttaact cagcaccaag gtggagctaa tgcccaggca ggactgagaa 189662
tactggctg acgtggtcag atggaggaga ccatgcccc gttctccgct gtctttgcat 189722
ggccttgga cagaggtagg agaaggtgat gatagtgcc cctagttaa ggtccaagtt 189782
gcttggtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtt tcctctctt tccatcaga 189842
acattatctt ggaggcttat gactgtgacc tttgttaacc aatttaggta taatatgtag 189902
acagcccttg tttatttgta tggactgggt aattttgaaa gtatggcttt tctattttgt 189962
tttagaatat gttatgtgat ttgaagatgg gacacagtgg cccatcagtc ttcggttttt 190022
tattatgctt tgctcaggcc agtttttata acgtgtttat atctcttgag catacggtgt 190082
tcctccaagt tttgggggtc tgcgatgaa cttcacgggg gtcggggaag gctgggcagt 190142

-continued

```

gaatctaggg ctctctgtct cagatccttt ctcaatttgg ttactttgtg tttgtgggct 190202
ctgaataata tttgagttgt aagaggggttc tgcttttata taaagttaga aagtcacatt 190262
ggaataaata acatgagaaa ggtgcccaga agttttctag ggctacaaca ggctgagctg 190322
cagaatttga cagccagga attgaacttt ctcaagttgaa gttcacgttc aagttaagta 190382
acttgtgtgg catcacacag ctagtaagtg gggggacat tccagaccta aggcctttctg 190442
actccagaac tcccccttca gccactttctc tagtacgtaa ggagccgtca cctgggacct 190502
caagttgggg gttgtggggg gggcatttga tgtcaagaga gaggggaaga gggcattcca 190562
ggcaagtggc aggagatcct gagaacacag tttggatgct caggaggctt ccgggagagc 190622
acctgatggg cctgggtgca gcttgacccc tgatgggacct gacttcaccc cctgctctgc 190682
cttcccaggc ctttggatca ggcattgctt atgttctctt ccactaggat tgagtaggga 190742
aagtagaaat tcttgacgt tgtcagtaac tttgatgaaa gaccagcag aaaagcagga 190802
aagctgaaga gtaaaaaatga tgggtggacc ttggttttcc acgtggccta ccacagcatg 190862
tcaggcctgg gggcagaatc ttgccatact gtgcagccca aatttgaatg ccaaaggctt 190922
tcgtttgtct ctggggggcc acagtctagg tctagtctctg tgcaggagtt gtaatatattg 190982
ctcttctctc cctctccag c tgc cag acc tct gaa gag agt gcc att gag 191033
                Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu
                1045                        1050

acg ggt tcc agc agt tcc acc ttc atc aag aga gag gac gag acc 191078
Thr Gly Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr
                1055                        1060                        1065

att gaa gac atc gac atg atg gat gac atc ggc ata gac tct tca 191123
Ile Glu Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser
                1070                        1075                        1080

gac ctg gtg gaa gac agc ttc ctg taa 191150
Asp Leu Val Glu Asp Ser Phe Leu
                1085

```

```

<210> SEQ ID NO 20
<211> LENGTH: 6633
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (395)..(3664)

```

```

<400> SEQUENCE: 20

```

```

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc cctgattgc 60
gtaagagcaa aaagcgaagg cgcaatctgg aactgggag attcggagcg cagggaagttt 120
gagagaaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa 240
aacgcggttt ttgagcccat tactgttgga gctacaggga gagaaacagg aggagactgc 300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360
cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg 415
                Met Gly Thr Ser His Pro Ala
                1                        5

ttc ctg gtc tta ggc tgt ctt ctg aca ggg ctg agc cta atc ctg tgc 463
Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys
                10                        15                        20

cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg 511
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val
                25                        30                        35

```

-continued

cag	ctg	aat	tca	tcc	ttt	tct	ctg	aga	tgc	ttt	ggg	gag	agt	gaa	gtg	559
Gln	Leu	Asn	Ser	Ser	Phe	Ser	Leu	Arg	Cys	Phe	Gly	Glu	Ser	Glu	Val	
40					45					50					55	
agc	tgg	cag	tac	ccc	atg	tct	gaa	gaa	gag	agc	tcc	gat	gtg	gaa	atc	607
Ser	Trp	Gln	Tyr	Pro	Met	Ser	Glu	Glu	Glu	Ser	Ser	Asp	Val	Glu	Ile	
				60					65					70		
aga	aat	gaa	gaa	aac	aac	agc	ggc	ctt	ttt	gtg	acg	gtc	ttg	gaa	gtg	655
Arg	Asn	Glu	Glu	Asn	Asn	Ser	Gly	Leu	Phe	Val	Thr	Val	Leu	Glu	Val	
			75					80					85			
agc	agt	gcc	tgc	gcg	gcc	cac	aca	ggg	ttg	tac	act	tgc	tat	tac	aac	703
Ser	Ser	Ala	Ser	Ala	Ala	His	Thr	Gly	Leu	Tyr	Thr	Cys	Tyr	Tyr	Asn	
		90				95						100				
cac	act	cag	aca	gaa	gag	aat	gag	ctt	gaa	ggc	agg	cac	att	tac	atc	751
His	Thr	Gln	Thr	Glu	Glu	Asn	Glu	Leu	Glu	Gly	Arg	His	Ile	Tyr	Ile	
	105					110					115					
tat	gtg	cca	gac	cca	gat	gta	gcc	ttt	gta	cct	cta	gga	atg	acg	gat	799
Tyr	Val	Pro	Asp	Pro	Asp	Val	Ala	Phe	Val	Pro	Leu	Gly	Met	Thr	Asp	
120					125					130					135	
tat	tta	gtc	atc	gtg	gag	gat	gat	gat	tct	gcc	att	ata	cct	tgt	cgc	847
Tyr	Leu	Val	Ile	Val	Glu	Asp	Asp	Asp	Ser	Ala	Ile	Ile	Pro	Cys	Arg	
				140					145					150		
aca	act	gat	ccc	gag	act	cct	gta	acc	tta	cac	aac	agt	gag	ggg	gtg	895
Thr	Thr	Asp	Pro	Glu	Thr	Pro	Val	Thr	Leu	His	Asn	Ser	Glu	Gly	Val	
			155				160						165			
gta	cct	gcc	tcc	tac	gac	agc	aga	cag	ggc	ttt	aat	ggg	acc	ttc	act	943
Val	Pro	Ala	Ser	Tyr	Asp	Ser	Arg	Gln	Gly	Phe	Asn	Gly	Thr	Phe	Thr	
		170					175					180				
gta	ggg	ccc	tat	atc	tgt	gag	gcc	acc	gtc	aaa	gga	aag	aag	ttc	cag	991
Val	Gly	Pro	Tyr	Ile	Cys	Glu	Ala	Thr	Val	Lys	Gly	Lys	Lys	Phe	Gln	
	185				190						195					
acc	atc	cca	ttt	aat	gtt	tat	gct	tta	aaa	gca	aca	tca	gag	ctg	gat	1039
Thr	Ile	Pro	Phe	Asn	Val	Tyr	Ala	Leu	Lys	Ala	Thr	Ser	Glu	Leu	Asp	
200					205					210					215	
cta	gaa	atg	gaa	gct	ctt	aaa	acc	gtg	tat	aag	tca	ggg	gaa	acg	att	1087
Leu	Glu	Met	Glu	Ala	Leu	Lys	Thr	Val	Tyr	Lys	Ser	Gly	Glu	Thr	Ile	
				220					225					230		
gtg	gtc	acc	tgt	gct	gtt	ttt	aac	aat	gag	gtg	gtt	gac	ctt	caa	tgg	1135
Val	Val	Thr	Cys	Ala	Val	Phe	Asn	Asn	Glu	Val	Val	Asp	Leu	Gln	Trp	
			235					240					245			
act	tac	cct	gga	gaa	gtg	aaa	ggc	aaa	ggc	atc	aca	atg	ctg	gaa	gaa	1183
Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys	Gly	Ile	Thr	Met	Leu	Glu	Glu	
		250				255						260				
atc	aaa	gtc	cca	tcc	atc	aaa	ttg	gtg	tac	act	ttg	acg	gtc	ccc	gag	1231
Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val	Tyr	Thr	Leu	Thr	Val	Pro	Glu	
	265					270					275					
gcc	acg	gtg	aaa	gac	agt	gga	gat	tac	gaa	tgt	gct	gcc	cgc	cag	gct	1279
Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr	Glu	Cys	Ala	Ala	Arg	Gln	Ala	
280				285						290				295		
acc	agg	gag	gtc	aaa	gaa	atg	aag	aaa	gtc	act	att	tct	gtc	cat	gag	1327
Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys	Val	Thr	Ile	Ser	Val	His	Glu	
			300						305					310		
aaa	ggt	ttc	att	gaa	atc	aaa	ccc	acc	ttc	agc	cag	ttg	gaa	gct	gtc	1375
Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr	Phe	Ser	Gln	Leu	Glu	Ala	Val	
		315						320					325			
aac	ctg	cat	gaa	gtc	aaa	cat	ttt	gtt	gta	gag	gtg	cgg	gcc	tac	cca	1423
Asn	Leu	His	Glu	Val	Lys	His	Phe	Val	Val	Glu	Val	Arg	Ala	Tyr	Pro	
		330				335						340				
cct	ccc	agg	ata	tcc	tgg	ctg	aaa	aac	aat	ctg	act	ctg	att	gaa	aat	1471
Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn	Asn	Leu	Thr	Leu	Ile	Glu	Asn	
	345					350					355					

-continued

ctc act gag atc acc act gat gtg gaa aag att cag gaa ata agg tat	1519
Leu Thr Glu Ile Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg Tyr	
360 365 370 375	
cga agc aaa tta aag ctg atc cgt gct aag gaa gaa gac agt ggc cat	1567
Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu Glu Asp Ser Gly His	
380 385 390	
tat act att gta gct caa aat gaa gat gct gtg aag agc tat act ttt	1615
Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val Lys Ser Tyr Thr Phe	
395 400 405	
gaa ctg tta act caa gtt cct tca tcc att ctg gac ttg gtc gat gat	1663
Glu Leu Leu Thr Gln Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp	
410 415 420	
cac cat ggc tca act ggg gga cag acg gtg agg tgc aca gct gaa ggc	1711
His His Gly Ser Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly	
425 430 435	
acg ccg ctt cct gat att gag tgg atg ata tgc aaa gat att aag aaa	1759
Thr Pro Leu Pro Asp Ile Glu Trp Met Ile Cys Lys Asp Ile Lys Lys	
440 445 450 455	
tgt aat aat gaa act tcc tgg act att ttg gcc aac aat gtc tca aac	1807
Cys Asn Asn Glu Thr Ser Trp Thr Ile Leu Ala Asn Asn Val Ser Asn	
460 465 470	
atc atc acg gag atc cac tcc cga gac agg agt acc gtg gag ggc cgt	1855
Ile Ile Thr Glu Ile His Ser Arg Asp Arg Ser Thr Val Glu Gly Arg	
475 480 485	
gtg act ttc gcc aaa gtg gag gag acc atc gcc gtg cga tgc ctg gct	1903
Val Thr Phe Ala Lys Val Glu Glu Thr Ile Ala Val Arg Cys Leu Ala	
490 495 500	
aag aat ctc ctt gga gct gag aac cga gag ctg aag ctg gtg gct ccc	1951
Lys Asn Leu Leu Gly Ala Glu Asn Arg Glu Leu Lys Leu Val Ala Pro	
505 510 515	
acc ctg cgt tct gaa ctc acg gtg gct gct gca gtc ctg gtg ctg ttg	1999
Thr Leu Arg Ser Glu Leu Thr Val Ala Ala Val Leu Val Leu Leu	
520 525 530 535	
gtg att gtg atc atc tca ctt att gtc ctg gtt gtc att tgg aaa cag	2047
Val Ile Val Ile Ser Leu Ile Val Leu Val Val Ile Trp Lys Gln	
540 545 550	
aaa ccg agg tat gaa att cgc tgg agg gac att gaa tca atc agc ccg	2095
Lys Pro Arg Tyr Glu Ile Arg Trp Arg Asp Ile Glu Ser Ile Ser Pro	
555 560 565	
gat gga cat gaa tat att tat gtg gac ccg atg cag ctg cct tat gac	2143
Asp Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp	
570 575 580	
tca aga tgg gag ttt cca aga gat gga cta gtg ctt ggt cgg gtc ttg	2191
Ser Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu Gly Arg Val Leu	
585 590 595	
ggg tct gga gcg ttt ggg aag gtg gtt gaa gga aca gcc tat gga tta	2239
Gly Ser Gly Ala Phe Gly Lys Val Val Glu Gly Thr Ala Tyr Gly Leu	
600 605 610 615	
agc ccg tcc caa cct gtc atg aaa gtt gca gtg aag atg cta aaa ccc	2287
Ser Arg Ser Gln Pro Val Met Lys Val Ala Val Lys Met Leu Lys Pro	
620 625 630	
acg gcc aga tcc agt gaa aaa caa gct ctc atg tct gaa ctg aag ata	2335
Thr Ala Arg Ser Ser Glu Lys Gln Ala Leu Met Ser Glu Leu Lys Ile	
635 640 645	
atg act cac ctg ggg cca cat ttg aac att gta aac ttg ctg gga gcc	2383
Met Thr His Leu Gly Pro His Leu Asn Ile Val Asn Leu Leu Gly Ala	
650 655 660	
tgc acc aag tca ggc ccc att tac atc atc aca gag tat tgc ttc tat	2431
Cys Thr Lys Ser Gly Pro Ile Tyr Ile Ile Thr Glu Tyr Cys Phe Tyr	
665 670 675	

-continued

gga gat ttg gtc aac tat ttg cat aag aat agg gat agc ttc ctg agc Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser Phe Leu Ser 680 685 690 695	2479
cac cac cca gag aag cca aag aaa gag ctg gat atc ttt gga ttg aac His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe Gly Leu Asn 700 705 710	2527
cct gct gat gaa agc aca cgg agc tat gtt att tta tct ttt gaa aac Pro Ala Asp Glu Ser Thr Arg Ser Tyr Val Ile Leu Ser Phe Glu Asn 715 720 725	2575
aat ggt gac tac atg gac atg aag cag gct gat act aca cag tat gtc Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln Tyr Val 730 735 740	2623
ccc atg cta gaa agg aaa gag gtt tct aaa tat tcc gac atc cag aga Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile Gln Arg 745 750 755	2671
tca ctc tat gat cgt cca gcc tca tat aag aag aaa tct atg tta gac Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met Leu Asp 760 765 770 775	2719
tca gaa gtc aaa aac ctc ctt tca gat gat aac tca gaa ggc ctt act Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly Leu Thr 780 785 790	2767
tta ttg gat ttg ttg agc ttc acc tat caa gtt gcc cga gga atg gag Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu 795 800 805	2815
ttt ttg gct tca aaa aat tgt gtc cac cgt gat ctg gct gct cgc aac Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn 810 815 820	2863
gtc ctc ctg gca caa gga aaa att gtg aag atc tgt gac ttt ggc ctg Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu 825 830 835	2911
gcc aga gac atc atg cat gat tcg aac tat gtg tcg aaa ggc agt acc Ala Arg Asp Ile Met His Asp Ser Asn Tyr Val Ser Lys Gly Ser Thr 840 845 850 855	2959
ttt ctg ccc gtg aag tgg atg gct cct gag agc atc ttt gac aac ctc Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu 860 865 870	3007
tac acc aca ctg agt gat gtc tgg tct tat ggc att ctg ctc tgg gag Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu 875 880 885	3055
atc ttt tcc ctt ggt ggc acc cct tac ccc ggc atg atg gtg gat tct Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser 890 895 900	3103
act ttc tac aat aag atc aag agt ggg tac cgg atg gcc aag cct gac Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp 905 910 915	3151
cac gct acc agt gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser 920 925 930 935	3199
gag ccg gag aag aga ccc tcc ttt tac cac ctg agt gag att gtg gag Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu 940 945 950	3247
aat ctg ctg cct gga caa tat aaa aag agt tat gaa aaa att cac ctg Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu 955 960 965	3295
gac ttc ctg aag agt gac cat cct gct gtg gca cgc atg cgt gtg gac Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met Arg Val Asp 970 975 980	3343
tca gac aat gca tac att ggt gtc acc tac aaa aac gag gaa gac aag Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys 985 990 995	3391

ctg	aag	gac	tgg	gag	ggt	ggt	ctg	gat	gag	cag	aga	ctg	agc	gct		3436
Leu	Lys	Asp	Trp	Glu	Gly	Gly	Leu	Asp	Glu	Gln	Arg	Leu	Ser	Ala		
1000					1005					1010						
gac	agt	ggc	tac	atc	att	cct	ctg	cct	gac	att	gac	cct	gtc	cct		3481
Asp	Ser	Gly	Tyr	Ile	Ile	Pro	Leu	Pro	Asp	Ile	Asp	Pro	Val	Pro		
1015					1020					1025						
gag	gag	gag	gac	ctg	ggc	aag	agg	aac	aga	cac	agc	tcg	cag	acc		3526
Glu	Glu	Glu	Asp	Leu	Gly	Lys	Arg	Asn	Arg	His	Ser	Ser	Gln	Thr		
1030					1035					1040						
tct	gaa	gag	agt	gcc	att	gag	acg	ggg	tcc	agc	agt	tcc	acc	ttc		3571
Ser	Glu	Glu	Ser	Ala	Ile	Glu	Thr	Gly	Ser	Ser	Ser	Ser	Thr	Phe		
1045					1050					1055						
atc	aag	aga	gag	gac	gag	acc	att	gaa	gac	atc	gac	atg	atg	gac		3616
Ile	Lys	Arg	Glu	Asp	Glu	Thr	Ile	Glu	Asp	Ile	Asp	Met	Met	Asp		
1060					1065					1070						
gac	atc	ggc	ata	gac	tct	tca	gac	ctg	gtg	gaa	gac	agc	ttc	ctg		3661
Asp	Ile	Gly	Ile	Asp	Ser	Ser	Asp	Leu	Val	Glu	Asp	Ser	Phe	Leu		
1075					1080					1085						
t	a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	3714
g	t	t	c	a	g	a	a	a	a	a	a	a	a	a	a	3774
a	g	a	a	a	a	a	a	a	a	a	a	a	a	a	a	3834
t	g	a	a	a	a	a	a	a	a	a	a	a	a	a	a	3894
g	a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	3954
a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	4014
a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	4074
c	t	t	c	t	a	a	a	a	a	a	a	a	a	a	a	4134
c	t	g	t	t	a	a	a	a	a	a	a	a	a	a	a	4194
a	c	t	a	t	a	g	a	t	a	a	a	a	a	a	a	4254
t	g	t	t	a	a	a	a	a	a	a	a	a	a	a	a	4314
g	t	t	t	a	a	a	a	a	a	a	a	a	a	a	a	4374
c	c	t	c	a	g	a	a	a	a	a	a	a	a	a	a	4434
t	t	g	a	c	a	t	t	a	a	a	a	a	a	a	a	4494
t	a	a	t	t	a	a	a	a	a	a	a	a	a	a	a	4554
t	t	a	a	c	t	a	a	a	a	a	a	a	a	a	a	4614
a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	a	4674
a	t	a	a	a	c	t	a	a	a	a	a	a	a	a	a	4734
g	c	a	a	a	a	a	a	a	a	a	a	a	a	a	a	4794
g	g	c	a	a	c	c	c	c	c	a	a	a	a	a	a	4854
c	a	g	a	c	a	t	c	a	g	a	a	a	a	a	a	4914
c	c	a	t	a	a	a	a	a	a	a	a	a	a	a	a	4974
a	t	g	t	g	t	g	g	a	c	a	a	a	a	a	a	5034
g	a	a	g	t	c	t	g	a	t	a	a	a	a	a		

-continued

```

ctacttccca ctgtatgggg gagattgaac tttccccgtc tcccgctcttc tgcctccac 5394
tccatacccc gccaggaaa ggcattgtaca aaaattatgc aattcagtgt tccaagtctc 5454
tgtgtaacca gctcagtgtt ttggtggaaa aaacatttta agttttactg ataatttgag 5514
gttagatggg aggatgaatt gtcacatcta tccacactgt caaacagggt ggtgtgggtt 5574
cattggcatt ctttgcata ctgcttaatt gctgatacca tatgaatgaa acatgggctg 5634
tgattactgc aatcactgtg ctatcgccag atgatgcttt ggaagatgca gaagcaataa 5694
taaagtactt gactacctac tgggtgaato tcaatgcaag ccccaacttt cttatccaac 5754
tttttcatag taagtgcgaa gactgagcca gattggccaa ttaaaaacga aaacctgact 5814
aggttctgta gagccaatta gacttgaaat acgttttgtt ttctagaatc acagctcaag 5874
cattctgttt atcgctcact ctcccttgta cagccttatt ttgttggtgc ttgcatcttt 5934
gatattgctg tgagccttgc atgacatcat gaggccggat gaaacttctc agtccagcag 5994
tttccagtcc taacaaatgc tcccactga atttgatat gactgcattt gtgggtgtgt 6054
gtgtgttttc agcaaattcc agatttgctt ccttttgccc tcctgcaaag tctccagaag 6114
aaaaattgcc aatctttcct actttctatt tttatgatga caatcaaagc cggcctgaga 6174
aacactattt gtgacttttt aaacgattag tgatgtcctt aaaatgtggt ctgccaatct 6234
gtacaaaatg gtcctatttt tgtgaagagg gacataagat aaaatgatgt tatacatcaa 6294
tatgtatata tgtattttcta tatagacttg gagaatactg ccaaaacatt tatgacaagc 6354
tgtatcactg ccttcgttta tattttttta actgtgataa tccccacagg cacattaact 6414
gttgcacttt tgaatgtcca aaatttatat tttagaaata ataaaaagaa agatacttac 6474
atgttcccaa aacaatgggt tgggtgaatgt gtgagaaaaa ctaacttgat aggggtctacc 6534
aatacaaaat gtattacgaa tgcccctgtt catgtttttg ttttaaaacg tgtaaatgaa 6594
gatctttata tttcaataaa tgatatataa tttaaagtt 6633

```

<210> SEQ ID NO 21

<211> LENGTH: 1089

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1           5           10           15

Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20          25          30

Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35          40          45

Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50          55          60

Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65          70          75          80

Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85          90          95

Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
100         105         110

Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
115         120         125

Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
130         135         140

Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr

```

-continued

145	150	155	160
Leu His Asn Ser	Glu Gly Val Val	Pro Ala Ser Tyr Asp Ser Arg Gln	
	165	170	175
Gly Phe Asn Gly	Thr Phe Thr Val	Gly Pro Tyr Ile Cys Glu Ala Thr	
	180	185	190
Val Lys Gly Lys	Lys Phe Gln Thr	Ile Pro Phe Asn Val Tyr Ala Leu	
	195	200	205
Lys Ala Thr Ser	Glu Leu Asp Leu	Glu Met Glu Ala Leu Lys Thr Val	
	210	215	220
Tyr Lys Ser Gly	Glu Thr Ile Val Val	Thr Cys Ala Val Phe Asn Asn	
	225	230	235
Glu Val Val Asp	Leu Gln Trp Thr	Tyr Pro Gly Glu Val Lys Gly Lys	
	245	250	255
Gly Ile Thr Met	Leu Glu Glu Ile	Lys Val Pro Ser Ile Lys Leu Val	
	260	265	270
Tyr Thr Leu Thr	Val Pro Glu Ala	Thr Val Lys Asp Ser Gly Asp Tyr	
	275	280	285
Glu Cys Ala Ala	Arg Gln Ala Thr	Arg Glu Val Lys Glu Met Lys Lys	
	290	295	300
Val Thr Ile Ser	Val His Glu Lys	Gly Phe Ile Glu Ile Lys Pro Thr	
	305	310	315
Phe Ser Gln Leu	Glu Ala Val Asn	Leu His Glu Val Lys His Phe Val	
	325	330	335
Val Glu Val Arg	Ala Tyr Pro Pro	Pro Arg Ile Ser Trp Leu Lys Asn	
	340	345	350
Asn Leu Thr Leu	Ile Glu Asn Leu	Thr Glu Ile Thr Thr Asp Val Glu	
	355	360	365
Lys Ile Gln Glu	Ile Arg Tyr Arg	Ser Lys Leu Lys Leu Ile Arg Ala	
	370	375	380
Lys Glu Glu Asp	Ser Gly His Tyr	Thr Ile Val Ala Gln Asn Glu Asp	
	385	390	395
Ala Val Lys Ser	Tyr Thr Phe Glu	Leu Leu Thr Gln Val Pro Ser Ser	
	405	410	415
Ile Leu Asp Leu	Val Asp Asp His	His Gly Ser Thr Gly Gly Gln Thr	
	420	425	430
Val Arg Cys Thr	Ala Glu Gly Thr	Pro Leu Pro Asp Ile Glu Trp Met	
	435	440	445
Ile Cys Lys Asp	Ile Lys Lys Cys	Asn Asn Glu Thr Ser Trp Thr Ile	
	450	455	460
Leu Ala Asn Asn	Val Ser Asn Ile	Ile Thr Glu Ile His Ser Arg Asp	
	465	470	475
Arg Ser Thr Val	Glu Gly Arg Val	Thr Phe Ala Lys Val Glu Glu Thr	
	485	490	495
Ile Ala Val Arg	Cys Leu Ala Lys	Asn Leu Leu Gly Ala Glu Asn Arg	
	500	505	510
Glu Leu Lys Leu	Val Ala Pro Thr	Leu Arg Ser Glu Leu Thr Val Ala	
	515	520	525
Ala Ala Val Leu	Val Leu Leu Val	Ile Val Ile Ile Ser Leu Ile Val	
	530	535	540
Leu Val Val Ile	Trp Lys Gln Lys	Pro Arg Tyr Glu Ile Arg Trp Arg	
	545	550	555
Asp Ile Glu Ser	Ile Ser Pro Asp	Gly His Glu Tyr Ile Tyr Val Asp	
	565	570	575

Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly
			580					585					590		
Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val
		595					600					605			
Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val
	610				615						620				
Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala
	625				630					635					640
Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn
			645						650					655	
Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile
		660						665					670		
Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys
	675						680					685			
Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu
	690					695					700				
Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr
	705				710					715					720
Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln
				725					730					735	
Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser
			740					745					750		
Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr
		755					760					765			
Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp
	770					775					780				
Asp	Asn	Ser	Glu	Gly	Leu	Thr	Leu	Leu	Asp	Leu	Leu	Ser	Phe	Thr	Tyr
	785				790					795					800
Gln	Val	Ala	Arg	Gly	Met	Glu	Phe	Leu	Ala	Ser	Lys	Asn	Cys	Val	His
			805						810					815	
Arg	Asp	Leu	Ala	Ala	Arg	Asn	Val	Leu	Leu	Ala	Gln	Gly	Lys	Ile	Val
		820						825					830		
Lys	Ile	Cys	Asp	Phe	Gly	Leu	Ala	Arg	Asp	Ile	Met	His	Asp	Ser	Asn
		835					840					845			
Tyr	Val	Ser	Lys	Gly	Ser	Thr	Phe	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro
	850					855					860				
Glu	Ser	Ile	Phe	Asp	Asn	Leu	Tyr	Thr	Thr	Leu	Ser	Asp	Val	Trp	Ser
	865				870					875					880
Tyr	Gly	Ile	Leu	Leu	Trp	Glu	Ile	Phe	Ser	Leu	Gly	Gly	Thr	Pro	Tyr
			885						890					895	
Pro	Gly	Met	Met	Val	Asp	Ser	Thr	Phe	Tyr	Asn	Lys	Ile	Lys	Ser	Gly
		900						905					910		
Tyr	Arg	Met	Ala	Lys	Pro	Asp	His	Ala	Thr	Ser	Glu	Val	Tyr	Glu	Ile
		915					920					925			
Met	Val	Lys													

-continued

Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro
 1010 1015 1020
 Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn
 1025 1030 1035
 Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly
 1040 1045 1050
 Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu
 1055 1060 1065
 Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu
 1070 1075 1080
 Val Glu Asp Ser Phe Leu
 1085

<210> SEQ ID NO 22
 <211> LENGTH: 6618
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395)..(3649)

<400> SEQUENCE: 22

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccttgattgc 60
 gtaagagcaa aaagcgaagg cgcaatctgg aactgggag attcggagcg caggagattt 120
 gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180
 tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa 240
 aacgcggttt ttgagcccat tactgttggg gctacagggg gagaaacagg aggagactgc 300
 aagagatcat ttgggaaggg cgtgggcacg ctctttactc catgtgtggg acattcattg 360
 cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg 415
 Met Gly Thr Ser His Pro Ala
 1 5
 ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc 463
 Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys
 10 15 20
 cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg 511
 Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val
 25 30 35
 cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg 559
 Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val
 40 45 50 55
 agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc 607
 Ser Trp Gln Tyr Pro Met Ser Glu Glu Glu Ser Ser Asp Val Glu Ile
 60 65 70
 aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg 655
 Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val
 75 80 85
 agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac 703
 Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn
 90 95 100
 cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc 751
 His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile
 105 110 115
 tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat 799
 Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp
 120 125 130 135
 tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc 847
 Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg

																140																	145																	150																
aca Thr	act Thr	gat Asp	ccc Pro 155	gag Glu	act Thr	cct Pro	gta Val	acc Leu 160	tta Leu	cac His	aac Asn	agt Ser	gag Glu 165	ggg Gly	gtg Val	895																																																		
gta Val	cct Pro	gcc Ala 170	tcc Ser	tac Tyr	gac Asp	agc Ser	aga Arg 175	cag Gln	ggc Gly	ttt Phe	aat Asn	ggg Gly 180	acc Thr	ttc Phe	act Thr	943																																																		
gta Val	ggg Gly 185	ccc Pro	tat Tyr	atc Ile	tgt Cys 190	gag Glu 190	gcc Ala	acc Thr	gtc Val	aaa Lys	gga Gly 195	aag Lys	aag Lys	ttc Phe	cag Gln	991																																																		
acc Thr 200	atc Ile	cca Pro	ttt Phe	aat Asn	gtt Val 205	tat Tyr	gct Ala	tta Leu	aaa Lys	gca Ala 210	aca Thr	tca Ser	gag Glu	ctg Leu 215	gat Asp	1039																																																		
cta Leu	gaa Glu	atg Met	gaa Glu 220	gct Ala	ctt Leu	aaa Lys	acc Thr	gtg Val 225	tat Tyr	aag Lys	tca Ser	ggg Gly	gaa Glu	acg Thr 230	att Ile	1087																																																		
gtg Val	gtc Val	acc Thr 235	tgt Cys	gct Ala	gtt Val	ttt Phe	aac Asn	aat Asn 240	gag Glu	gtg Val	gtt Val	gac Asp 245	ctt Leu	caa Gln	tgg Trp	1135																																																		
act Thr	tac Tyr 250	cct Pro	gga Gly	gaa Glu	gtg Val	aaa Lys	ggc Gly 255	aaa Lys	ggc Gly	atc Ile	aca Thr	atg Met 260	ctg Leu	gaa Glu	gaa Glu	1183																																																		
atc Ile 265	aaa Lys	gtc Val	cca Pro	tcc Ser	atc Ile	aaa Lys 270	ttg Leu	gtg Val	tac Tyr	act Thr	ttg Leu 275	acg Thr	gtc Val	ccc Pro	gag Glu	1231																																																		
gcc Ala 280	acg Thr	gtg Val	aaa Lys	gac Asp	agt Ser 285	gga Gly	gat Asp	tac Tyr	gaa Glu	tgt Cys 290	gct Ala	gcc Ala	cgc Arg	cag Gln	gct Ala 295	1279																																																		
acc Thr	agg Arg	gag Glu	gtc Val 300	aaa Lys	gaa Glu	atg Met	aag Lys	aaa Lys 305	gtc Val	act Thr	att Ile	tct Ser	gtc Val	cat His 310	gag Glu	1327																																																		
aaa Lys	ggc Gly	ttc Phe 315	att Ile	gaa Glu	atc Ile	aaa Lys	ccc Pro	acc Thr 320	ttc Phe	agc Ser	cag Gln	ttg Leu 325	gaa Glu	gct Ala	gtc Val	1375																																																		
aac Asn	ctg Leu 330	cat His	gaa Glu	gtc Val	aaa Lys	cat His	ttt Phe 335	gtt Val	gta Val	gag Glu	gtg Val	cgg Arg 340	gcc Ala	tac Tyr	cca Pro	1423																																																		
cct Pro 345	ccc Pro	agg Arg	ata Ile	tcc Ser	tgg Trp 350	ctg Leu	aaa Lys	aac Asn	aat Asn	ctg Leu	act Thr 355	ctg Leu	att Ile	gaa Glu	aat Asn	1471																																																		
ctc Leu 360	act Thr	gag Glu	atc Ile	acc Thr	act Thr 365	gat Asp	gtg Val	gaa Glu	aag Lys	att Ile 370	cag Gln	gaa Glu	ata Ile	agg Arg	tat Tyr 375	1519																																																		
cga Arg	agc Ser	aaa Lys	tta Leu 380	aag Lys	ctg Leu	atc Ile	cgt Arg	gct Ala 385	aag Lys	gaa Glu	gaa Glu	gac Asp	agt Ser	ggc Gly 390	cat His	1567																																																		
tat Tyr	act Thr	att Ile 395	gta Val	gct Ala	caa Gln	aat Asn	gaa Glu	gat Asp 400	gct Ala	gtg Val	aag Lys	agc Ser	tat Tyr 405	act Thr	ttt Phe	1615																																																		
gaa Glu	ctg Leu	tta Leu 410	act Thr	caa Gln	gtt Val	cct Pro	tca Ser 415	tcc Ser	att Ile	ctg Leu	gac Asp 420	ttg Leu	gtc Val	gat Asp	gat Asp	1663																																																		
cac His 425	cat His	ggc Gly	tca Ser	act Thr	ggg Gly 430	gga Gly	cag Gln	acg Thr	gtg Val	agg Arg	tgc Cys 435	aca Thr	gct Ala	gaa Glu	ggc Gly	1711																																																		
acg Thr 440	ccg Pro	ctt Leu	cct Pro	gat Asp	att Ile 445	gag Glu	tgg Trp	atg Met	ata Ile	tgc Cys 450	aaa Lys	gat Asp	att Ile	aag Lys	aaa Lys 455	1759																																																		
tgt Cys	aat Asn	aat Asn	gaa Glu	act Thr	tcc Ser 460	tgg Trp	act Thr	att Ile	ttg Leu	gcc Ala	aac Asn	aat Asn	gtc Val	tca Ser	aac Asn	1807																																																		

-continued

460						465						470						
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855		
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg			
			475					480					485					
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903		
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala			
			490				495					500						
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951		
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro			
			505				510					515						
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999		
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Ala	Val	Leu	Val	Leu	Leu			
							525			530					535			
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047		
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln			
							540			545					550			
aaa	ccg	agg	tat	gaa	att	cgc	tgg	atc	agc	ccg	gat	gga	cat	gaa	tat	2095		
Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Ile	Ser	Pro	Asp	Gly	His	Glu	Tyr			
			555					560							565			
att	tat	gtg	gac	ccg	atg	cag	ctg	cct	tat	gac	tca	aga	tgg	gag	ttt	2143		
Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe			
			570				575						580					
cca	aga	gat	gga	cta	gtg	ctt	ggt	cgg	gtc	ttg	ggg	tct	gga	gcg	ttt	2191		
Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe			
			585				590						595					
ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	gga	tta	agc	cgg	tcc	caa	cct	2239		
Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro			
							605			610					615			
gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	aaa	ccc	acg	gcc	aga	tcc	agt	2287		
Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser			
							620			625					630			
gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	aag	ata	atg	act	cac	ctg	ggg	2335		
Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly			
			635					640							645			
cca	cat	ttg	aac	att	gta	aac	ttg	ctg	gga	gcc	tgc	acc	aag	tca	ggc	2383		
Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly			
			650				655					660						
ccc	att	tac	atc	atc	aca	gag	tat	tgc	ttc	tat	gga	gat	ttg	gtc	aac	2431		
Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn			
			665				670					675						
tat	ttg	cat	aag	aat	agg	gat	agc	ttc	ctg	agc	cac	cac	cca	gag	aag	2479		
Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys			
							685			690					695			
cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	ttg	aac	cct	gct	gat	gaa	agc	2527		
Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser			
							700			705					710			
aca	cgg	agc	tat	gtt	att	tta	tct	ttt	gaa	aac	aat	ggt	gac	tac	atg	2575		
Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met			
							715			720					725			
gac	atg	aag	cag	gct	gat	act	aca	cag	tat	gtc	ccc	atg	cta	gaa	agg	2623		
Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg			
							730			735					740			
aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	cag	aga	tca	ctc	tat	gat	cgt	2671		
Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg			
							745					750			755			
cca	gcc	tca	tat	aag	aag	aaa	tct	atg	tta	gac	tca	gaa	gtc	aaa	aac	2719		
Pro	Ala	Ser	Tyr	Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn			
							760			765					770			
ctc	ctt	tca	gat	gat	aac	tca	gaa	ggc	ctt	act	tta	ttg	gat	ttg	ttg	2767		
Leu	Leu	Ser	Asp	Asp	Asn	Ser	Glu	Gly	Leu	Thr	Leu	Leu	Asp	Leu	Leu			

-continued

780										785										790											
agc ttc acc tat caa gtt gcc cga gga atg gag ttt ttg gct tca aaa																															2815
Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys																															
795										800										805											
aat tgt gtc cac cgt gat ctg gct gct cgc aac gtc ctc ctg gca caa																															2863
Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln																															
810										815										820											
gga aaa att gtg aag atc tgt gac ttt ggc ctg gcc aga gac atc atg																															2911
Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met																															
825										830										835											
cat gat tcg aac tat gtg tcg aaa ggc agt acc ttt ctg ccc gtg aag																															2959
His Asp Ser Asn Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val Lys																															
840										845										850										855	
tgg atg gct cct gag agc atc ttt gac aac ctc tac acc aca ctg agt																															3007
Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser																															
860										865										870											
gat gtc tgg tct tat ggc att ctg ctc tgg gag atc ttt tcc ctt ggt																															3055
Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu Gly																															
875										880										885											
ggc acc cct tac ccc ggc atg atg gtg gat tct act ttc tac aat aag																															3103
Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn Lys																															
890										895										900											
atc aag agt ggg tac cgg atg gcc aag cct gac cac gct acc agt gaa																															3151
Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser Glu																															
905										910										915											
gtc tac gag atc atg gtg aaa tgc tgg aac agt gag ccg gag aag aga																															3199
Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys Arg																															
920										925										930										935	
ccc tcc ttt tac cac ctg agt gag att gtg gag aat ctg ctg cct gga																															3247
Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly																															
940										945										950											
caa tat aaa aag agt tat gaa aaa att cac ctg gac ttc ctg aag agt																															3295
Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser																															
955										960										965											
gac cat cct gct gtg gca cgc atg cgt gtg gac tca gac aat gca tac																															3343
Asp His Pro Ala Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala Tyr																															
970										975										980											
att ggt gtc acc tac aaa aac gag gaa gac aag ctg aag gac tgg gag																															3391
Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp Glu																															
985										990										995											
ggt ggt ctg gat gag cag aga ctg agc gct gac agt ggc tac atc																															3436
Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile																															
1000										1005										1010											
att cct ctg cct gac att gac cct gtc cct gag gag gag gac ctg																															3481
Ile Pro Leu Pro Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu																															
1015										1020										1025											
ggc aag agg aac aga cac agc tcg cag acc tct gaa gag agt gcc																															3526
Gly Lys Arg Asn Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala																															
1030										1035										1040											
att gag acg ggt tcc agc agt tcc acc ttc atc aag aga gag gac																															3571
Ile Glu Thr Gly Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp																															
1045										1050										1055											
gag acc att gaa gac atc gac atg atg gac gac atc ggc ata gac																															3616
Glu Thr Ile Glu Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp																															
1060										1065										1070											
tct tca gac ctg gtg gaa gac agc ttc ctg taa ctggcggatt																															3659
Ser Ser Asp Leu Val Glu Asp Ser Phe Leu																															
1075										1080																					
cgaggggttc ctccacttc tggggccacc tctggatccc gttcagaaaa ccactttatt																															3719

-continued

gcaatgcgga	ggttgagagg	aggacttggt	tgatgtttaa	agagaagttc	ccagccaagg	3779
gcctcgggga	gcgttctaaa	tatgaatgaa	tgggatatth	tgaatgaac	ttgtgcagt	3839
ttgcctctcg	caatgcctca	gtagcatctc	agtggtgtgt	gaagtttga	gatagatgga	3899
taagggaaata	ataggccaca	gaaggtgaac	tttgtgcttc	aaggacattg	gtgagagtcc	3959
aacagacaca	atttatactg	cgacagaact	tcagcattgt	aattatgtaa	ataactctaa	4019
ccaaggtgt	gtttagattg	tattaactat	cttctttgga	cttctgaaga	gaccactcaa	4079
tccatccatg	tacttccctc	ttgaaacctg	atgtcagctg	ctgttgaact	ttttaaagaa	4139
gtgcataaaa	aaccattttt	gaaccttaaa	aggtactggg	actatagcat	ttgtctatct	4199
tttttagtgt	taagagataa	agaataataa	ttaaccaacc	ttgtttaata	gatttgggtc	4259
atttagaagc	ctgacaactc	attttcatat	tgtaacttat	gtttataata	ctactactgt	4319
tatcagtaat	gctaaatgtg	taataatgta	acatgatttc	cctccagaga	aagcacaatt	4379
taaaacaatc	cttactaagt	aggtgatgag	tttgacagtt	tttgacattt	atattaaata	4439
acatgtttct	ctataaagta	tggtaatagc	tttagtgaat	taaatttagt	tgagcataga	4499
gaacaaaagta	aaagtagtgt	tgtccaggaa	gtcagaattt	ttaactgtac	tgaatagggt	4559
cccaaatcca	tcgtattaaa	aaacaattaa	ctgcctctcg	aaataatggg	attagaacaa	4619
aacaaaactc	ttaagtccta	aaagttctca	atgtagaggc	ataaacctgt	gctgaacata	4679
actttctcatg	tatattaccc	aatggaaaat	ataatgatca	gcaaaaagac	tggatttgca	4739
gaagtttttt	ttttttttct	tcatgcctga	tgaagctttt	ggcaacccca	atatatgtat	4799
tttttgaatc	tatgaacctg	aaaaggggtc	gaaggatgcc	cagacatcag	cctccttctt	4859
tcaccctcta	cccaaaagag	aaagagtttg	aaactcgaga	ccataaagat	attctttagt	4919
ggaggctgga	tgtgcattag	cctggatcct	cagttctcaa	atgtgtgtgg	cagccaggat	4979
gactagatcc	tgggtttcca	tccttgagat	tctgaagtat	gaagtctgag	ggaaaccaga	5039
gtctgtatth	ttctaaaactc	cctggctgtt	ctgatcggcc	agttttcgga	aacactgact	5099
taggtttcag	gaagttgcc	tgggaacaa	ataatttgaa	ctttggaaca	gggttggaat	5159
tcaaccacgc	aggaagccta	ctattttaat	ccttggtctc	aggttagtga	cattttaatgc	5219
catctagcta	gcaattgcga	cotttaattta	actttccagt	cttagctgag	gctgagaaaag	5279
ctaaagtthg	gttttgacag	gttttccaaa	agtaaagatg	ctacttccca	ctgtatgggg	5339
gagattgaac	tttccccctg	tcccgtcttc	tgcctcccac	tccatacccc	gccaaaggaaa	5399
ggcatgtaca	aaaattatgc	aattcagtgt	tccaagtctc	tgtgtaacca	gctcagtggt	5459
ttggtggaaa	aaacattthta	agttttactg	ataatttgag	gttagatggg	aggatgaatt	5519
gtcacatcta	tccacactgt	caaacagggt	gggtgtgggt	cattggcatt	ctttgcaata	5579
ctgcttaatt	gctgatacca	tatgaatgaa	acatgggctg	tgattactgc	aatcactgtg	5639
ctatcggcag	atgatgctth	ggaagatgca	gaagcaataa	taaagtactt	gactacctac	5699
tgggtgaatc	tcaatgcaag	ccccaaactt	cttatccaac	tttttcatag	taagtgcgaa	5759
gactgagcca	gattggccaa	ttaaaaacga	aaacctgact	aggttctgta	gagccaatta	5819
gacttgaaat	acgttttgtgt	ttctagaatc	acagctcaag	cattctgtth	atcgctcact	5879
ctcccttgta	cagccttatt	ttgttggtgc	tttgcattht	gatattgctg	tgagccttgc	5939
atgacatcat	gaggccggat	gaaactttctc	agtccagcag	tttccagttc	taacaaatgc	5999
tcccactcta	atttgtatat	gactgcattt	gtgggtgtgt	gtgtgttttc	agcaaatcc	6059
agatttgtth	ccttttggcc	tcctgcaaaag	tctccagaag	aaaatttgcc	aatctttcct	6119

-continued

```

actttctatt tttatgatga caatcaaagc cggcctgaga aacactatgt gtgacttttt 6179
aaacgattag tgatgtcctt aaaatgtggt ctgccaatct gtacaaaatg gtcctatgtt 6239
tgtgaagagg gacataagat aaaatgatgt tatacatcaa tatgtatata tgtattttcta 6299
tatagacttg gagaatactg ccaaaacatt tatgacaagc tgtatcactg ccttcgttta 6359
tattttttta actgtgataa tccccacagg cacattaact gttgcacttt tgaatgtcca 6419
aaatttatat tttagaata ataaaaagaa agatacttac atgttcccaa aacaatggtg 6479
tggtgaatgt gtgagaaaaa ctaacttgat aggggtctacc aatacaaaat gtattacgaa 6539
tgccctgtt catgtttttg ttttaaaacg tgtaaatgaa gatctttata tttcaataaa 6599
tgatatataa tttaaagt 6618

```

<210> SEQ ID NO 23

<211> LENGTH: 1084

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1           5           10           15
Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
20          25          30
Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
35          40          45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
50          55          60
Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
65          70          75          80
Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
85          90          95
Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
100         105         110
Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
115         120         125
Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
130         135         140
Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
145         150         155         160
Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
165         170         175
Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
180         185         190
Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
195         200         205
Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
210         215         220
Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
225         230         235         240
Glu Val Val Asp Leu Gln Trp Thr Tyr Pro Gly Glu Val Lys Gly Lys
245         250         255
Gly Ile Thr Met Leu Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val
260         265         270
Tyr Thr Leu Thr Val Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr
275         280         285

```

Glu 290	Cys	Ala	Ala	Arg	Gln	Ala	Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys
Val 305	Thr	Ile	Ser	Val	His 310	Glu	Lys	Gly	Phe	Ile 315	Glu	Ile	Lys	Pro	Thr 320
Phe	Ser	Gln	Leu	Glu 325	Ala	Val	Asn	Leu	His 330	Glu	Val	Lys	His	Phe	Val
Val	Glu	Val	Arg	Ala 340	Tyr	Pro	Pro	Pro	Arg 345	Ile	Ser	Trp	Leu	Lys	Asn
Asn	Leu	Thr	Leu	Ile 355	Glu	Asn	Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu
Lys	Ile 370	Gln	Glu	Ile	Arg 375	Tyr	Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala
Lys 385	Glu	Glu	Asp	Ser	Gly 390	His	Tyr	Thr	Ile	Val 395	Ala	Gln	Asn	Glu	Asp 400
Ala	Val	Lys	Ser	Tyr 405	Thr	Phe	Glu	Leu	Leu 410	Thr	Gln	Val	Pro	Ser	Ser
Ile	Leu	Asp	Leu	Val 420	Asp	Asp	His	His 425	Gly	Ser	Thr	Gly	Gly	Gln	Thr
Val	Arg	Cys 435	Thr	Ala	Glu	Gly	Thr 440	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met
Ile	Cys 450	Lys	Asp	Ile	Lys 455	Lys	Cys	Asn	Asn	Glu	Thr 460	Ser	Trp	Thr	Ile
Leu 465	Ala	Asn	Asn	Val	Ser 470	Asn	Ile	Ile	Thr	Glu 475	Ile	His	Ser	Arg	Asp 480
Arg	Ser	Thr	Val 485	Glu	Gly	Arg	Val	Thr	Phe 490	Ala	Lys	Val	Glu	Glu	Thr 495
Ile	Ala	Val	Arg 500	Cys	Leu	Ala	Lys	Asn 505	Leu	Leu	Gly	Ala	Glu	Asn	Arg
Glu	Leu	Lys 515	Leu	Val	Ala	Pro	Thr 520	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala
Ala 530	Ala	Val	Leu	Val	Leu 535	Leu	Val	Ile	Val	Ile 540	Ile	Ser	Leu	Ile	Val
Leu 545	Val	Val	Ile	Trp	Lys 550	Gln	Lys	Pro	Arg	Tyr 555	Glu	Ile	Arg	Trp	Ile 560
Ser	Pro	Asp	Gly 565	His	Glu	Tyr	Ile	Tyr 570	Val	Asp	Pro	Met	Gln	Leu	Pro 575
Tyr	Asp	Ser	Arg 580	Trp	Glu	Phe	Pro	Arg 585	Asp	Gly	Leu	Val	Leu	Gly	Arg
Val	Leu	Gly 595	Ser	Gly	Ala	Phe	Gly 600	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr
Gly 610	Leu	Ser	Arg	Ser	Gln 615	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu
Lys 625	Pro	Thr	Ala	Arg 630	Ser	Glu	Lys	Gln	Ala 635	Leu	Met	Ser	Glu	Leu	640
Lys	Ile	Met	Thr 645	His	Leu	Gly	Pro	His 650	Leu	Asn	Ile	Val	Asn	Leu	Leu
Gly	Ala	Cys 660	Thr	Lys	Ser	Gly	Pro	Ile 665	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys
Phe	Tyr	Gly 675	Asp	Leu	Val	Asn	Tyr 680	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe
Leu 690	Ser	His	His	Pro	Glu 695	Lys	Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly
Leu 705	Asn	Pro	Ala	Asp 710	Glu	Ser	Thr	Arg	Ser	Tyr 715	Val	Ile	Leu	Ser	Phe 720

-continued

Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln
 725 730 735
 Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile
 740 745 750
 Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met
 755 760 765
 Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly
 770 775 780
 Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly
 785 790 795 800
 Met Glu Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala
 805 810 815
 Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe
 820 825 830
 Gly Leu Ala Arg Asp Ile Met His Asp Ser Asn Tyr Val Ser Lys Gly
 835 840 845
 Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp
 850 855 860
 Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu
 865 870 875 880
 Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val
 885 890 895
 Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys
 900 905 910
 Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp
 915 920 925
 Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile
 930 935 940
 Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile
 945 950 955 960
 His Leu Asp Phe Leu Lys Ser Asp His Pro Ala Val Ala Arg Met Arg
 965 970 975
 Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu
 980 985 990
 Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser
 995 1000 1005
 Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val
 1010 1015 1020
 Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln
 1025 1030 1035
 Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr
 1040 1045 1050
 Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met
 1055 1060 1065
 Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe
 1070 1075 1080
 Leu

<210> SEQ ID NO 24
 <211> LENGTH: 6633
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395)..(3664)

-continued

<400> SEQUENCE: 24

ttctccccgc cccccagttg ttgtcgaagt ctggggggttg ggactggacc cccgtattgc	60
gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt	120
gagagaaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta	180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa	240
aacgcgggttt ttgagcccat tactgttgga gctacagggg gagaaacagg aggagactgc	300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg	360
cggaataaca tcggaggaga agtttcccag agct atg ggg act tcc cat ccg gcg	415
Met Gly Thr Ser His Pro Ala	
1 5	
ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc	463
Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys	
10 15 20	
cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg	511
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val	
25 30 35	
cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg	559
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val	
40 45 50 55	
agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc	607
Ser Trp Gln Tyr Pro Met Ser Glu Glu Ser Ser Asp Val Glu Ile	
60 65 70	
aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg	655
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val	
75 80 85	
agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac	703
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn	
90 95 100	
cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc	751
His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile	
105 110 115	
tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat	799
Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp	
120 125 130 135	
tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc	847
Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg	
140 145 150	
aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg	895
Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val	
155 160 165	
gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act	943
Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr	
170 175 180	
gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag	991
Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln	
185 190 195	
acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat	1039
Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp	
200 205 210 215	
cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att	1087
Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile	
220 225 230	
gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg	1135
Val Val Thr Cys Ala Val Phe Asn Asn Glu Val Val Asp Leu Gln Trp	
235 240 245	
act tac cct gga gaa gtg aaa ggc aaa ggc atc aca atg ctg gaa gaa	1183

-continued

Thr	Tyr	Pro	Gly	Glu	Val	Lys	Gly	Lys	Gly	Ile	Thr	Met	Leu	Glu	Glu	
		250					255					260				
atc	aaa	gtc	cca	tcc	atc	aaa	ttg	gtg	tac	act	ttg	acg	gtc	ccc	gag	1231
Ile	Lys	Val	Pro	Ser	Ile	Lys	Leu	Val	Tyr	Thr	Leu	Thr	Val	Pro	Glu	
	265					270				275						
gcc	acg	gtg	aaa	gac	agt	gga	gat	tac	gaa	tgt	gct	gcc	cgc	cag	gct	1279
Ala	Thr	Val	Lys	Asp	Ser	Gly	Asp	Tyr	Glu	Cys	Ala	Ala	Arg	Gln	Ala	
	280				285				290					295		
acc	agg	gag	gtc	aaa	gaa	atg	aag	aaa	gtc	act	att	tct	gtc	cat	gag	1327
Thr	Arg	Glu	Val	Lys	Glu	Met	Lys	Lys	Val	Thr	Ile	Ser	Val	His	Glu	
			300						305					310		
aaa	ggt	ttc	att	gaa	atc	aaa	ccc	acc	ttc	agc	cag	ttg	gaa	gct	gtc	1375
Lys	Gly	Phe	Ile	Glu	Ile	Lys	Pro	Thr	Phe	Ser	Gln	Leu	Glu	Ala	Val	
		315						320						325		
aac	ctg	cat	gaa	gtc	aaa	cat	ttt	gtt	gta	gag	gtg	cgg	gcc	tac	cca	1423
Asn	Leu	His	Glu	Val	Lys	His	Phe	Val	Val	Glu	Val	Arg	Ala	Tyr	Pro	
		330					335					340				
cct	ccc	agg	ata	tcc	tgg	ctg	aaa	aac	aat	ctg	act	ctg	att	gaa	aat	1471
Pro	Pro	Arg	Ile	Ser	Trp	Leu	Lys	Asn	Asn	Leu	Thr	Leu	Ile	Glu	Asn	
		345				350				355						
ctc	act	gag	atc	acc	act	gat	gtg	gaa	aag	att	cag	gaa	ata	agg	tat	1519
Leu	Thr	Glu	Ile	Thr	Thr	Asp	Val	Glu	Lys	Ile	Gln	Glu	Ile	Arg	Tyr	
	360				365					370					375	
cga	agc	aaa	tta	aag	ctg	atc	cgt	gct	aag	gaa	gaa	gac	agt	ggc	cat	1567
Arg	Ser	Lys	Leu	Lys	Leu	Ile	Arg	Ala	Lys	Glu	Glu	Asp	Ser	Gly	His	
			380					385						390		
tat	act	att	gta	gct	caa	aat	gaa	gat	gct	gtg	aag	agc	tat	act	ttt	1615
Tyr	Thr	Ile	Val	Ala	Gln	Asn	Glu	Asp	Ala	Val	Lys	Ser	Tyr	Thr	Phe	
		395					400						405			
gaa	ctg	tta	act	caa	gtt	cct	tca	tcc	att	ctg	gac	ttg	gtc	gat	gat	1663
Glu	Leu	Leu	Thr	Gln	Val	Pro	Ser	Ser	Ile	Leu	Asp	Leu	Val	Asp	Asp	
		410				415						420				
cac	cat	ggc	tca	act	ggg	gga	cag	acg	gtg	agg	tgc	aca	gct	gaa	ggc	1711
His	His	Gly	Ser	Thr	Gly	Gly	Gln	Thr	Val	Arg	Cys	Thr	Ala	Glu	Gly	
	425				430					435						
acg	ccg	ctt	cct	gat	att	gag	tgg	atg	ata	tgc	aaa	gat	att	aag	aaa	1759
Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met	Ile	Cys	Lys	Asp	Ile	Lys	Lys	
	440				445				450					455		
tgt	aat	aat	gaa	act	tcc	tgg	act	att	ttg	gcc	aac	aat	gtc	tca	aac	1807
Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	Leu	Ala	Asn	Asn	Val	Ser	Asn	
			460					465						470		
atc	atc	acg	gag	atc	cac	tcc	cga	gac	agg	agt	acc	gtg	gag	ggc	cgt	1855
Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp	Arg	Ser	Thr	Val	Glu	Gly	Arg	
		475					480						485			
gtg	act	ttc	gcc	aaa	gtg	gag	gag	acc	atc	gcc	gtg	cga	tgc	ctg	gct	1903
Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr	Ile	Ala	Val	Arg	Cys	Leu	Ala	
		490				495						500				
aag	aat	ctc	ctt	gga	gct	gag	aac	cga	gag	ctg	aag	ctg	gtg	gct	ccc	1951
Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg	Glu	Leu	Lys	Leu	Val	Ala	Pro	
		505				510						515				
acc	ctg	cgt	tct	gaa	ctc	acg	gtg	gct	gct	gca	gtc	ctg	gtg	ctg	ttg	1999
Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	Ala	Ala	Val	Leu	Val	Leu	Leu	
		520			525				530					535		
gtg	att	gtg	atc	atc	tca	ctt	att	gtc	ctg	gtt	gtc	att	tgg	aaa	cag	2047
Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	Leu	Val	Val	Ile	Trp	Lys	Gln	
				540				545						550		
aaa	ccg	agg	tat	gaa	att	cgc	tgg	agg	gtc	att	gaa	tca	atc	agc	ccg	2095
Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg	Val	Ile	Glu	Ser	Ile	Ser	Pro	
		555					560						565			
gat	gga	cat	gaa	tat	att	tat	gtg	gac	ccg	atg	cag	ctg	cct	tat	gac	2143

-continued

Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp	Pro	Met	Gln	Leu	Pro	Tyr	Asp	
		570					575					580				
tca	aga	tg	gag	ttt	cca	aga	gat	gga	cta	gtg	ctt	ggt	cgg	gtc	ttg	2191
Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly	Leu	Val	Leu	Gly	Arg	Val	Leu	
	585						590				595					
ggg	tct	gga	gcg	ttt	ggg	aag	gtg	gtt	gaa	gga	aca	gcc	tat	gga	tta	2239
Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	Glu	Gly	Thr	Ala	Tyr	Gly	Leu	
	600					605				610					615	
agc	cgg	tcc	caa	cct	gtc	atg	aaa	gtt	gca	gtg	aag	atg	cta	aaa	ccc	2287
Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	Ala	Val	Lys	Met	Leu	Lys	Pro	
				620						625				630		
acg	gcc	aga	tcc	agt	gaa	aaa	caa	gct	ctc	atg	tct	gaa	ctg	aag	ata	2335
Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala	Leu	Met	Ser	Glu	Leu	Lys	Ile	
				635				640						645		
atg	act	cac	ctg	ggg	cca	cat	ttg	aac	att	gta	aac	ttg	ctg	gga	gcc	2383
Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn	Ile	Val	Asn	Leu	Leu	Gly	Ala	
		650					655					660				
tgc	acc	aag	tca	ggc	ccc	att	tac	atc	atc	aca	gag	tat	tgc	ttc	tat	2431
Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile	Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	
		665					670					675				
gga	gat	ttg	gtc	aac	tat	ttg	cat	aag	aat	agg	gat	agc	ttc	ctg	agc	2479
Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys	Asn	Arg	Asp	Ser	Phe	Leu	Ser	
	680					685				690					695	
cac	cac	cca	gag	aag	cca	aag	aaa	gag	ctg	gat	atc	ttt	gga	ttg	aac	2527
His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu	Leu	Asp	Ile	Phe	Gly	Leu	Asn	
				700						705				710		
cct	gct	gat	gaa	agc	aca	cgg	agc	tat	gtt	att	tta	tct	ttt	gaa	aac	2575
Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr	Val	Ile	Leu	Ser	Phe	Glu	Asn	
				715						720				725		
aat	ggt	gac	tac	atg	gac	atg	aag	cag	gct	gat	act	aca	cag	tat	gtc	2623
Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln	Ala	Asp	Thr	Thr	Gln	Tyr	Val	
		730					735						740			
ccc	atg	cta	gaa	agg	aaa	gag	gtt	tct	aaa	tat	tcc	gac	atc	cag	aga	2671
Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser	Lys	Tyr	Ser	Asp	Ile	Gln	Arg	
		745					750					755				
tca	ctc	tat	gat	cgt	cca	gcc	tca	tat	aag	aag	aaa	tct	atg	tta	gac	2719
Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr	Lys	Lys	Lys	Ser	Met	Leu	Asp	
						765				770					775	
tca	gaa	gtc	aaa	aac	ctc	ctt	tca	gat	gat	aac	tca	gaa	ggc	ctt	act	2767
Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp	Asp	Asn	Ser	Glu	Gly	Leu	Thr	
				780						785					790	
tta	ttg	gat	ttg	ttg	agc	ttc	acc	tat	caa	gtt	gcc	cga	gga	atg	gag	2815
Leu	Leu	Asp	Leu	Leu	Ser	Phe	Thr	Tyr	Gln	Val	Ala	Arg	Gly	Met	Glu	
				795						800				805		
ttt	ttg	gct	tca	aaa	aat	tgt	gtc	cac	cgt	gat	ctg	gct	gct	cgc	aac	2863
Phe	Leu	Ala	Ser	Lys	Asn	Cys	Val	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	
		810					815						820			
gtc	ctc	ctg	gca	caa	gga	aaa	att	gtg	aag	atc	tgt	gac	ttt	ggc	ctg	2911
Val	Leu	Leu	Ala	Gln	Gly	Lys	Ile	Val	Lys	Ile	Cys	Asp	Phe	Gly	Leu	
						825						835				
gcc	aaa	atc	atc	atg	cat	gat	tcg	aac	tat	gtg	tcg	aaa	ggc	agt	acc	2959
Ala	Lys	Ile	Ile	Met	His	Asp	Ser	Asn	Tyr	Val	Ser	Lys	Gly	Ser	Thr	
						845					850				855	
ttt	ctg	ccc	gtg	aag	tg	atg	gct	cct	gag	agc	atc	ttt	gac	aac	ctc	3007
Phe	Leu	Pro	Val	Lys	Trp	Met	Ala	Pro	Glu	Ser	Ile	Phe	Asp	Asn	Leu	
						860				865					870	
tac	acc	aca	ctg	agt	gat	gtc	tg	tct	tat	ggc	att	ctg	ctc	tg	gag	3055
Tyr	Thr	Thr	Leu	Ser	Asp	Val	Trp	Ser	Tyr	Gly	Ile	Leu	Leu	Trp	Glu	
						875				880					885	
atc	ttt	tcc	ctt	ggt	ggc	acc	cct	tac	ccc	ggc	atg	atg	gtg	gat	tct	3103

Ile	Phe	Ser	Leu	Gly	Gly	Thr	Pro	Tyr	Pro	Gly	Met	Met	Val	Asp	Ser	
	890						895					900				
act	ttc	tac	aat	aag	atc	aag	agt	ggg	tac	cgg	atg	gcc	aag	cct	gac	3151
Thr	Phe	Tyr	Asn	Lys	Ile	Lys	Ser	Gly	Tyr	Arg	Met	Ala	Lys	Pro	Asp	
	905					910					915					
cac	gct	acc	agt	gaa	gtc	tac	gag	atc	atg	gtg	aaa	tgc	tgg	aac	agt	3199
His	Ala	Thr	Ser	Glu	Val	Tyr	Glu	Ile	Met	Val	Lys	Cys	Trp	Asn	Ser	
	920				925					930				935		
gag	ccg	gag	aag	aga	ccc	tcc	ttt	tac	cac	ctg	agt	gag	att	gtg	gag	3247
Glu	Pro	Glu	Lys	Arg	Pro	Ser	Phe	Tyr	His	Leu	Ser	Glu	Ile	Val	Glu	
				940					945					950		
aat	ctg	ctg	cct	gga	caa	tat	aaa	aag	agt	tat	gaa	aaa	att	cac	ctg	3295
Asn	Leu	Leu	Pro	Gly	Gln	Tyr	Lys	Lys	Ser	Tyr	Glu	Lys	Ile	His	Leu	
			955				960						965			
gac	ttc	ctg	aag	agt	gac	cat	cct	gct	gtg	gca	cgc	atg	cgt	gtg	gac	3343
Asp	Phe	Leu	Lys	Ser	Asp	His	Pro	Ala	Val	Ala	Arg	Met	Arg	Val	Asp	
		970					975					980				
tca	gac	aat	gca	tac	att	ggc	gtc	acc	tac	aaa	aac	gag	gaa	gac	aag	3391
Ser	Asp	Asn	Ala	Tyr	Ile	Gly	Val	Thr	Tyr	Lys	Asn	Glu	Glu	Asp	Lys	
						990					995					
ctg	aag	gac	tgg	gag	ggc		ctg	gat	gag	cag	aga	ctg	agc	gct		3436
Leu	Lys	Asp	Trp	Glu	Gly		Gly	Leu	Asp	Glu	Gln	Arg	Leu	Ser	Ala	
	1000				1005						1010					
gac	agt	ggc	tac	atc	att	cct	ctg	cct	gac	att		gac	cct	gtc	cct	3481
Asp	Ser	Gly	Tyr	Ile	Ile	Pro	Leu	Pro	Asp	Ile		Asp	Pro	Val	Pro	
					1020					1025						
gag	gag	gag	gac	ctg	ggc	aag	agg	aac	aga	cac	agc	tcg	cag	acc		3526
Glu	Glu	Glu	Asp	Leu	Gly	Lys	Arg	Asn	Arg	His	Ser	Ser	Gln	Thr		
					1035					1040						
tct	gaa	gag	agt	gcc	att	gag	acg	ggc	tcc	agc	agt	tcc	acc	ttc		3571
Ser	Glu	Glu	Ser	Ala	Ile	Glu	Thr	Gly	Ser	Ser	Ser	Ser	Thr	Phe		
					1050					1055						
atc	aag	aga	gag	gac	gag	acc	att	gaa	gac	atc	gac	atg	atg	gac		3616
Ile	Lys	Arg	Glu	Asp	Glu	Thr	Ile	Glu	Asp	Ile	Asp	Met	Met	Asp		
					1065					1070						
gac	atc	ggc	ata	gac	tct	tca	gac	ctg	gtg	gaa	gac	agc	ttc	ctg		3661
Asp	Ile	Gly	Ile	Asp	Ser	Ser	Asp	Leu	Val	Glu	Asp	Ser	Phe	Leu		
					1080					1085						
taa	ctggcgggatt	cgagggggttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	cttcacttc	3714
gttcagaaaa	ccactttatt	gcaatgcgga	gggttagagagg	aggacttggt	tgatgtttaa											

-continued

```

ttaactgtac tgaatagggt ccccaatcca tcgtattaaa aaacaattaa ctgccctctg 4614
aaataatggg attagaacaa aacaaaactc ttaagtccta aaagttctca atgtagaggc 4674
ataaacctgt gctgaacata acttctcatg tatattaccc aatggaaaat ataatgatca 4734
gcaaaaagac tggatttgca gaagtttttt ttttttttct tcatgcctga tgaaagcttt 4794
ggcaacccca atatatgtat tttttgaatc tatgaacctg aaaaggggtc gaaggatgcc 4854
cagacatcag cctccttctt tcaccoccta ccccaaagag aaagagtttg aaactcgaga 4914
ccataaagat attcttttagt ggaggttgga tgtgcattag cctggatcct cagttctcaa 4974
atgtgtgtgg cagccaggat gactagatcc tgggtttcca tccttgagat tctgaagtat 5034
gaagtctgag ggaaaccaga gtctgtattt ttctaaactc cctggctgtt ctgacgggcc 5094
agttttcgga aacactgact taggtttcag gaagttgcca tgggaaacaa ataatttgaa 5154
ctttggaaca gggttggaat tcaaccacgc aggaagccta ctattttaat ccttggtctt 5214
aggttagtga catttaatgc catctagcta gcaattgcga ccttaattta actttccagt 5274
cttagctgag gctgagaaag ctaaagttag gttttgacag gttttccaaa agtaaagatg 5334
ctacttccca ctgtatgggg gagattgaac tttccccgtc tcccgctctc tgccctccac 5394
tccatacccc gccaaaggaaa ggcattgtaca aaaattatgc aattcagtgt tccaagtctc 5454
tgtgtaacca gctcagtgtt ttggtggaaa aaacatttta agttttactg ataatttgag 5514
gttagatggg aggatgaatt gtcacatcta tccacactgt caaacagggt ggtgtgggtt 5574
cattggcatt ctttgcaata ctgcttaatt gctgatacca tatgaatgaa acatgggctg 5634
tgattactgc aatcactgtg ctatcggcag atgatgcttt ggaagatgca gaagcaataa 5694
taaagtactt gactacctac tgggtgaatc tcaatgcaag ccccaacttt cttatccaac 5754
tttttcatag taagtgcgaa gactgagcca gattggccaa ttaaaaacga aaacctgact 5814
aggttctgta gagccaatta gacttgaaat acgttttgtt ttctagaatc acagctcaag 5874
cattctgttt atcgctcact ctcccttgta cagccttatt ttgttggtgc tttgcatttt 5934
gatattgctg tgagccttgc atgacatcat gaggcggat gaaacttctc agtccagcag 5994
tttcagtc taacaaatgc tcccactga atttgtatat gactgcattt gtgggtgtgt 6054
gtgtgttttc agcaaattcc agatttggtt ccttttggtc tcctgcaaag tctccagaag 6114
aaaatttgcc aatctttcct actttctatt tttatgatga caatcaaagc cggcctgaga 6174
aacactatgt gtgacttttt aaacgattag tgatgtcctt aaaatgtggt ctgccaatct 6234
gtacaaaatg gtcctatttt tgtgaagagg gacataagat aaaatgatgt tatacatcaa 6294
tatgtatata tgtattttta tatagacttg gagaatactg ccaaaacatt tatgacaagc 6354
tgtatcactg ccttcgttta ttttttttta actgtgataa tccccacagg cacattaact 6414
gttgactttt tgaatgtcca aaatttatat tttagaaata ataaaaagaa agatacttac 6474
atgttcccaa aacaatgggt tgggtgaatgt gtgagaaaaa ctaacttgat aggggtctacc 6534
aatacaaaat gtattacgaa tgcccctgtt catgtttttg ttttaaaacg tgtaaatgaa 6594
gatctttata tttcaataaa tgatatataa tttaaagtt 6633

```

<210> SEQ ID NO 25

<211> LENGTH: 1089

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr

-continued

1	5	10	15
Gly Leu Ser	Leu Ile Leu Cys Gln	Leu Ser Leu Pro Ser	Ile Leu Pro
	20	25	30
Asn Glu Asn	Glu Lys Val Val Gln	Leu Asn Ser Ser Phe	Ser Leu Arg
	35	40	45
Cys Phe Gly	Glu Ser Glu Val Ser Trp	Gln Tyr Pro Met Ser	Glu Glu
	50	55	60
Glu Ser Ser	Asp Val Glu Ile Arg Asn	Glu Glu Asn Asn Ser	Gly Leu
	65	70	80
Phe Val Thr	Val Leu Glu Val Ser Ser	Ala Ser Ala Ala His	Thr Gly
	85	90	95
Leu Tyr Thr	Cys Tyr Tyr Asn His Thr	Gln Thr Glu Glu Asn	Glu Leu
	100	105	110
Glu Gly Arg	His Ile Tyr Ile Tyr Val	Pro Asp Pro Asp Val	Ala Phe
	115	120	125
Val Pro Leu	Gly Met Thr Asp Tyr Leu	Val Ile Val Glu Asp	Asp Asp
	130	135	140
Ser Ala Ile	Ile Pro Cys Arg Thr Thr	Asp Pro Glu Thr Pro	Val Thr
	145	150	160
Leu His Asn	Ser Glu Gly Val Val Pro	Ala Ser Tyr Asp Ser	Arg Gln
	165	170	175
Gly Phe Asn	Gly Thr Phe Thr Val Gly	Pro Tyr Ile Cys Glu	Ala Thr
	180	185	190
Val Lys Gly	Lys Lys Phe Gln Thr Ile	Pro Phe Asn Val Tyr	Ala Leu
	195	200	205
Lys Ala Thr	Ser Glu Leu Asp Leu Glu	Met Glu Ala Leu Lys	Thr Val
	210	215	220
Tyr Lys Ser	Gly Glu Thr Ile Val Val Thr	Cys Ala Val Phe Asn	Asn
	225	230	240
Glu Val Val	Asp Leu Gln Trp Thr Tyr	Pro Gly Glu Val Lys	Gly Lys
	245	250	255
Gly Ile Thr	Met Leu Glu Glu Ile Lys	Val Pro Ser Ile Lys	Leu Val
	260	265	270
Tyr Thr Leu	Thr Val Pro Glu Ala Thr	Val Lys Asp Ser Gly	Asp Tyr
	275	280	285
Glu Cys Ala	Ala Arg Gln Ala Thr Arg	Glu Val Lys Glu Met	Lys Lys
	290	295	300
Val Thr Ile	Ser Val His Glu Lys Gly	Phe Ile Glu Ile Lys	Pro Thr
	305	310	320
Phe Ser Gln	Leu Glu Ala Val Asn Leu	His Glu Val Lys His	Phe Val
	325	330	335
Val Glu Val	Arg Ala Tyr Pro Pro	Pro Arg Ile Ser Trp	Leu Lys Asn
	340	345	350
Asn Leu Thr	Leu Ile Glu Asn Leu Thr	Glu Ile Thr Thr Asp	Val Glu
	355	360	365
Lys Ile Gln	Glu Ile Arg Tyr Arg Ser	Lys Leu Lys Leu Ile	Arg Ala
	370	375	380
Lys Glu Glu	Asp Ser Gly His Tyr Thr	Ile Val Ala Gln Asn	Glu Asp
	385	390	400
Ala Val Lys	Ser Tyr Thr Phe Glu Leu	Leu Thr Gln Val Pro	Ser Ser
	405	410	415
Ile Leu Asp	Leu Val Asp Asp His His	Gly Ser Thr Gly Gly	Gln Thr
	420	425	430

Val	Arg	Cys	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met
		435					440					445			
Ile	Cys	Lys	Asp	Ile	Lys	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile
	450					455					460				
Leu	Ala	Asn	Asn	Val	Ser	Asn	Ile	Ile	Thr	Glu	Ile	His	Ser	Arg	Asp
465					470					475				480	
Arg	Ser	Thr	Val	Glu	Gly	Arg	Val	Thr	Phe	Ala	Lys	Val	Glu	Glu	Thr
			485						490					495	
Ile	Ala	Val	Arg	Cys	Leu	Ala	Lys	Asn	Leu	Leu	Gly	Ala	Glu	Asn	Arg
			500					505					510		
Glu	Leu	Lys	Leu	Val	Ala	Pro	Thr	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala
		515					520					525			
Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val
	530					535					540				
Leu	Val	Val	Ile	Trp	Lys	Gln	Lys	Pro	Arg	Tyr	Glu	Ile	Arg	Trp	Arg
545					550					555					560
Val	Ile	Glu	Ser	Ile	Ser	Pro	Asp	Gly	His	Glu	Tyr	Ile	Tyr	Val	Asp
			565						570					575	
Pro	Met	Gln	Leu	Pro	Tyr	Asp	Ser	Arg	Trp	Glu	Phe	Pro	Arg	Asp	Gly
			580					585					590		
Leu	Val	Leu	Gly	Arg	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val
		595					600					605			
Glu	Gly	Thr	Ala	Tyr	Gly	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val
	610					615					620				
Ala	Val	Lys	Met	Leu	Lys	Pro	Thr	Ala	Arg	Ser	Ser	Glu	Lys	Gln	Ala
625					630					635					640
Leu	Met	Ser	Glu	Leu	Lys	Ile	Met	Thr	His	Leu	Gly	Pro	His	Leu	Asn
			645						650					655	
Ile	Val	Asn	Leu	Leu	Gly	Ala	Cys	Thr	Lys	Ser	Gly	Pro	Ile	Tyr	Ile
		660						665					670		
Ile	Thr	Glu	Tyr	Cys	Phe	Tyr	Gly	Asp	Leu	Val	Asn	Tyr	Leu	His	Lys
	675						680					685			
Asn	Arg	Asp	Ser	Phe	Leu	Ser	His	His	Pro	Glu	Lys	Pro	Lys	Lys	Glu
	690					695					700				
Leu	Asp	Ile	Phe	Gly	Leu	Asn	Pro	Ala	Asp	Glu	Ser	Thr	Arg	Ser	Tyr
705					710					715					720
Val	Ile	Leu	Ser	Phe	Glu	Asn	Asn	Gly	Asp	Tyr	Met	Asp	Met	Lys	Gln
				725					730					735	
Ala	Asp	Thr	Thr	Gln	Tyr	Val	Pro	Met	Leu	Glu	Arg	Lys	Glu	Val	Ser
			740					745					750		
Lys	Tyr	Ser	Asp	Ile	Gln	Arg	Ser	Leu	Tyr	Asp	Arg	Pro	Ala	Ser	Tyr
	755						760					765			
Lys	Lys	Lys	Ser	Met	Leu	Asp	Ser	Glu	Val	Lys	Asn	Leu	Leu	Ser	Asp
	770					775					780				
Asp	Asn	Ser	G												

-continued

Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser
 865 870 875 880
 Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr
 885 890 895
 Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly
 900 905 910
 Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile
 915 920 925
 Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr
 930 935 940
 His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys
 945 950 955 960
 Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala
 965 970 975
 Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr
 980 985 990
 Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp
 995 1000 1005
 Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro
 1010 1015 1020
 Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn
 1025 1030 1035
 Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly
 1040 1045 1050
 Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu
 1055 1060 1065
 Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu
 1070 1075 1080
 Val Glu Asp Ser Phe Leu
 1085

<210> SEQ ID NO 26
 <211> LENGTH: 6633
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (395)..(3664)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2072)..(2086)
 <223> OTHER INFORMATION: Any N may equal either no nucleotide (i.e., a
 deletion) or any nucleotide (i.e., a, t, g, or c)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2074)..(2075)
 <223> OTHER INFORMATION: Insertion of the sequence "GAGAGG" in PDGFRA
 insertion ER561-562
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2090)..(2107)
 <223> OTHER INFORMATION: Any N may equal either no nucleotide (i.e., a
 deletion) or any nucleotide (i.e., a, t, g, or c)
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <222> LOCATION: (2916)..(2937)
 <223> OTHER INFORMATION: Any N may equal either no nucleotide (i.e., a
 deletion) or any nucleotide (i.e., a, t, g, or c)
 <400> SEQUENCE: 26

ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccttgattgc 60
 gtaagagcaa aaagcgaagg cgcaatctgg aactggggag attcgagcgc caggagattt 120

-continued

gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc ctgacagcta	180
tttacttaga gcaaatgatt agtttttagaa ggatggacta taacattgaa tcaattacaa	240
aacgcgggttt ttgagcccat tactgttgga gctacagggg gagaaacagg aggagactgc	300
aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg	360
cggaataaca tcggaggaga agtttccag agct atg ggg act tcc cat ccg gcg	415
Met Gly Thr Ser His Pro Ala	
1 5	
ttc ctg gtc tta ggc tgt ctt ctc aca ggg ctg agc cta atc ctc tgc	463
Phe Leu Val Leu Gly Cys Leu Thr Gly Leu Ser Leu Ile Leu Cys	
10 15 20	
cag ctt tca tta ccc tct atc ctt cca aat gaa aat gaa aag gtt gtg	511
Gln Leu Ser Leu Pro Ser Ile Leu Pro Asn Glu Asn Glu Lys Val Val	
25 30 35	
cag ctg aat tca tcc ttt tct ctg aga tgc ttt ggg gag agt gaa gtg	559
Gln Leu Asn Ser Ser Phe Ser Leu Arg Cys Phe Gly Glu Ser Glu Val	
40 45 50 55	
agc tgg cag tac ccc atg tct gaa gaa gag agc tcc gat gtg gaa atc	607
Ser Trp Gln Tyr Pro Met Ser Glu Glu Gly Ser Ser Asp Val Glu Ile	
60 65 70	
aga aat gaa gaa aac aac agc ggc ctt ttt gtg acg gtc ttg gaa gtg	655
Arg Asn Glu Glu Asn Asn Ser Gly Leu Phe Val Thr Val Leu Glu Val	
75 80 85	
agc agt gcc tcg gcg gcc cac aca ggg ttg tac act tgc tat tac aac	703
Ser Ser Ala Ser Ala Ala His Thr Gly Leu Tyr Thr Cys Tyr Tyr Asn	
90 95 100	
cac act cag aca gaa gag aat gag ctt gaa ggc agg cac att tac atc	751
His Thr Gln Thr Glu Glu Asn Glu Leu Glu Gly Arg His Ile Tyr Ile	
105 110 115	
tat gtg cca gac cca gat gta gcc ttt gta cct cta gga atg acg gat	799
Tyr Val Pro Asp Pro Asp Val Ala Phe Val Pro Leu Gly Met Thr Asp	
120 125 130 135	
tat tta gtc atc gtg gag gat gat gat tct gcc att ata cct tgt cgc	847
Tyr Leu Val Ile Val Glu Asp Asp Asp Ser Ala Ile Ile Pro Cys Arg	
140 145 150	
aca act gat ccc gag act cct gta acc tta cac aac agt gag ggg gtg	895
Thr Thr Asp Pro Glu Thr Pro Val Thr Leu His Asn Ser Glu Gly Val	
155 160 165	
gta cct gcc tcc tac gac agc aga cag ggc ttt aat ggg acc ttc act	943
Val Pro Ala Ser Tyr Asp Ser Arg Gln Gly Phe Asn Gly Thr Phe Thr	
170 175 180	
gta ggg ccc tat atc tgt gag gcc acc gtc aaa gga aag aag ttc cag	991
Val Gly Pro Tyr Ile Cys Glu Ala Thr Val Lys Gly Lys Lys Phe Gln	
185 190 195	
acc atc cca ttt aat gtt tat gct tta aaa gca aca tca gag ctg gat	1039
Thr Ile Pro Phe Asn Val Tyr Ala Leu Lys Ala Thr Ser Glu Leu Asp	
200 205 210 215	
cta gaa atg gaa gct ctt aaa acc gtg tat aag tca ggg gaa acg att	1087
Leu Glu Met Glu Ala Leu Lys Thr Val Tyr Lys Ser Gly Glu Thr Ile	
220 225 230	
gtg gtc acc tgt gct gtt ttt aac aat gag gtg gtt gac ctt caa tgg	1135
Val Val Thr Cys Ala Val Phe Asn Asn Glu Val Val Asp Leu Gln Trp	
235 240 245	
act tac cct gga gaa gtg aaa ggc aaa ggc atc aca atg ctg gaa gaa	1183
Thr Tyr Pro Gly Glu Val Lys Gly Lys Gly Ile Thr Met Leu Glu Glu	
250 255 260	
atc aaa gtc cca tcc atc aaa ttg gtg tac act ttg acg gtc ccc gag	1231
Ile Lys Val Pro Ser Ile Lys Leu Val Tyr Thr Leu Thr Val Pro Glu	
265 270 275	

-continued

gcc acg gtg aaa gac agt gga gat tac gaa tgt gct gcc cgc cag gct Ala Thr Val Lys Asp Ser Gly Asp Tyr Glu Cys Ala Ala Arg Gln Ala 280 285 290 295	1279
acc agg gag gtc aaa gaa atg aag aaa gtc act att tct gtc cat gag Thr Arg Glu Val Lys Glu Met Lys Lys Val Thr Ile Ser Val His Glu 300 305 310	1327
aaa ggt ttc att gaa atc aaa ccc acc ttc agc cag ttg gaa gct gtc Lys Gly Phe Ile Glu Ile Lys Pro Thr Phe Ser Gln Leu Glu Ala Val 315 320 325	1375
aac ctg cat gaa gtc aaa cat ttt gtt gta gag gtg cgg gcc tac cca Asn Leu His Glu Val Lys His Phe Val Val Glu Val Arg Ala Tyr Pro 330 335 340	1423
cct ccc agg ata tcc tgg ctg aaa aac aat ctg act ctg att gaa aat Pro Pro Arg Ile Ser Trp Leu Lys Asn Asn Leu Thr Leu Ile Glu Asn 345 350 355	1471
ctc act gag atc acc act gat gtg gaa aag att cag gaa ata agg tat Leu Thr Glu Ile Thr Thr Asp Val Glu Lys Ile Gln Glu Ile Arg Tyr 360 365 370 375	1519
cga agc aaa tta aag ctg atc cgt gct aag gaa gaa gac agt ggc cat Arg Ser Lys Leu Lys Leu Ile Arg Ala Lys Glu Glu Asp Ser Gly His 380 385 390	1567
tat act att gta gct caa aat gaa gat gct gtg aag agc tat act ttt Tyr Thr Ile Val Ala Gln Asn Glu Asp Ala Val Lys Ser Tyr Thr Phe 395 400 405	1615
gaa ctg tta act caa gtt cct tca tcc att ctg gac ttg gtc gat gat Glu Leu Leu Thr Gln Val Pro Ser Ser Ile Leu Asp Leu Val Asp Asp 410 415 420	1663
cac cat ggc tca act ggg gga cag acg gtg agg tgc aca gct gaa ggc His His Gly Ser Thr Gly Gly Gln Thr Val Arg Cys Thr Ala Glu Gly 425 430 435	1711
acg ccg ctt cct gat att gag tgg atg ata tgc aaa gat att aag aaa Thr Pro Leu Pro Asp Ile Glu Trp Met Ile Cys Lys Asp Ile Lys Lys 440 445 450 455	1759
tgt aat aat gaa act tcc tgg act att ttg gcc aac aat gtc tca aac Cys Asn Asn Glu Thr Ser Trp Thr Ile Leu Ala Asn Asn Val Ser Asn 460 465 470	1807
atc atc acg gag atc cac tcc cga gac agg agt acc gtg gag ggc cgt Ile Ile Thr Glu Ile His Ser Arg Asp Arg Ser Thr Val Glu Gly Arg 475 480 485	1855
gtg act ttc gcc aaa gtg gag gag acc atc gcc gtg cga tgc ctg gct Val Thr Phe Ala Lys Val Glu Glu Thr Ile Ala Val Arg Cys Leu Ala 490 495 500	1903
aag aat ctc ctt gga gct gag aac cga gag ctg aag ctg gtg gct ccc Lys Asn Leu Leu Gly Ala Glu Asn Arg Glu Leu Lys Leu Val Ala Pro 505 510 515	1951
acc ctg cgt tct gaa ctc acg gtg gct gct gca gtc ctg gtg ctg ttg Thr Leu Arg Ser Glu Leu Thr Val Ala Ala Val Leu Val Leu Leu 520 525 530 535	1999
gtg att gtg atc atc tca ctt att gtc ctg gtt gtc att tgg aaa cag Val Ile Val Ile Ile Ser Leu Ile Val Leu Val Val Ile Trp Lys Gln 540 545 550	2047
aaa ccg agg tat gaa att cgc tgg nnn nnn nnn nnn atc nnn nnn Lys Pro Arg Tyr Glu Ile Arg Trp Xaa Xaa Xaa Xaa Xaa Ile Xaa Xaa 555 560 565	2095
nnn nnn nnn nnn tat att tat gtg gac ccg atg cag ctg cct tat gac Xaa Xaa Xaa Xaa Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp 570 575 580	2143
tca aga tgg gag ttt cca aga gat gga cta gtg ctt ggt cgg gtc ttg Ser Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu Gly Arg Val Leu 585 590 595	2191

-continued

ggg tct gga gcg ttt ggg aag gtg gtt gaa gga aca gcc tat gga tta Gly Ser Gly Ala Phe Gly Lys Val Val Glu Gly Thr Ala Tyr Gly Leu 600 605 610 615	2239
agc cgg tcc caa cct gtc atg aaa gtt gca gtg aag atg cta aaa ccc Ser Arg Ser Gln Pro Val Met Lys Val Ala Val Lys Met Leu Lys Pro 620 625 630	2287
acg gcc aga tcc agt gaa aaa caa gct ctc atg tct gaa ctg aag ata Thr Ala Arg Ser Ser Glu Lys Gln Ala Leu Met Ser Glu Leu Lys Ile 635 640 645	2335
atg act cac ctg ggg cca cat ttg aac att gta aac ttg ctg gga gcc Met Thr His Leu Gly Pro His Leu Asn Ile Val Asn Leu Leu Gly Ala 650 655 660	2383
tgc acc aag tca ggc ccc att tac atc atc aca gag tat tgc ttc tat Cys Thr Lys Ser Gly Pro Ile Tyr Ile Thr Glu Tyr Cys Phe Tyr 665 670 675	2431
gga gat ttg gtc aac tat ttg cat aag aat agg gat agc ttc ctg agc Gly Asp Leu Val Asn Tyr Leu His Lys Asn Arg Asp Ser Phe Leu Ser 680 685 690 695	2479
cac cac cca gag aag cca aag aaa gag ctg gat atc ttt gga ttg aac His His Pro Glu Lys Pro Lys Lys Glu Leu Asp Ile Phe Gly Leu Asn 700 705 710	2527
cct gct gat gaa agc aca cgg agc tat gtt att tta tct ttt gaa aac Pro Ala Asp Glu Ser Thr Arg Ser Tyr Val Ile Leu Ser Phe Glu Asn 715 720 725	2575
aat ggt gac tac atg gac atg aag cag gct gat act aca cag tat gtc Asn Gly Asp Tyr Met Asp Met Lys Gln Ala Asp Thr Thr Gln Tyr Val 730 735 740	2623
ccc atg cta gaa agg aaa gag gtt tct aaa tat tcc gac atc cag aga Pro Met Leu Glu Arg Lys Glu Val Ser Lys Tyr Ser Asp Ile Gln Arg 745 750 755	2671
tca ctc tat gat cgt cca gcc tca tat aag aag aaa tct atg tta gac Ser Leu Tyr Asp Arg Pro Ala Ser Tyr Lys Lys Lys Ser Met Leu Asp 760 765 770 775	2719
tca gaa gtc aaa aac ctc ctt tca gat gat aac tca gaa ggc ctt act Ser Glu Val Lys Asn Leu Leu Ser Asp Asp Asn Ser Glu Gly Leu Thr 780 785 790	2767
tta ttg gat ttg ttg agc ttc acc tat caa gtt gcc cga gga atg gag Leu Leu Asp Leu Leu Ser Phe Thr Tyr Gln Val Ala Arg Gly Met Glu 795 800 805	2815
ttt ttg gct tca aaa aat tgt gtc cac cgt gat ctg gct gct cgc aac Phe Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala Ala Arg Asn 810 815 820	2863
gtc ctc ctg gca caa gga aaa att gtg aag atc tgt gac ttt ggc ctg Val Leu Leu Ala Gln Gly Lys Ile Val Lys Ile Cys Asp Phe Gly Leu 825 830 835	2911
gcc ana nnn nnn nnn nnn nnn nnc tat gtg tcg aaa ggc agt acc Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Val Ser Lys Gly Ser Thr 840 845 850 855	2959
ttt ctg ccc gtg aag tgg atg gct cct gag agc atc ttt gac aac ctc Phe Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Asn Leu 860 865 870	3007
tac acc aca ctg agt gat gtc tgg tct tat ggc att ctg ctc tgg gag Tyr Thr Thr Leu Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu 875 880 885	3055
atc ttt tcc ctt ggt ggc acc cct tac ccc ggc atg atg gtg gat tct Ile Phe Ser Leu Gly Gly Thr Pro Tyr Pro Gly Met Met Val Asp Ser 890 895 900	3103
act ttc tac aat aag atc aag agt ggg tac cgg atg gcc aag cct gac Thr Phe Tyr Asn Lys Ile Lys Ser Gly Tyr Arg Met Ala Lys Pro Asp 905 910 915	3151

-continued

cac gct acc agt gaa gtc tac gag atc atg gtg aaa tgc tgg aac agt His Ala Thr Ser Glu Val Tyr Glu Ile Met Val Lys Cys Trp Asn Ser 920 925 930 935	3199
gag ccg gag aag aga ccc tcc ttt tac cac ctg agt gag att gtg gag Glu Pro Glu Lys Arg Pro Ser Phe Tyr His Leu Ser Glu Ile Val Glu 940 945 950	3247
aat ctg ctg cct gga caa tat aaa aag agt tat gaa aaa att cac ctg Asn Leu Leu Pro Gly Gln Tyr Lys Lys Ser Tyr Glu Lys Ile His Leu 955 960 965	3295
gac ttc ctg aag agt gac cat cct gct gtg gca cgc atg cgt gtg gac Asp Phe Leu Lys Ser Asp His Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys 970 975 980	3343
tca gac aat gca tac att ggt gtc acc tac aaa aac gag gaa gac aag Ser Asp Asn Ala Tyr Ile Gly Val Thr Tyr Lys Asn Glu Glu Asp Lys 985 990 995	3391
ctg aag gac tgg gag ggt ggt ctg gat gag cag aga ctg agc gct Leu Lys Asp Trp Glu Gly Gly Leu Asp Glu Gln Arg Leu Ser Ala 1000 1005 1010	3436
gac agt ggc tac atc att cct ctg cct gac att gac cct gtc cct Asp Ser Gly Tyr Ile Ile Pro Leu Pro Asp Ile Asp Pro Val Pro 1015 1020 1025	3481
gag gag gag gac ctg ggc aag agg aac aga cac agc tcg cag acc Glu Glu Glu Asp Leu Gly Lys Arg Asn Arg His Ser Ser Gln Thr 1030 1035 1040	3526
tct gaa gag agt gcc att gag acg ggt tcc agc agt tcc acc ttc Ser Glu Glu Ser Ala Ile Glu Thr Gly Ser Ser Ser Ser Thr Phe 1045 1050 1055	3571
atc aag aga gag gac gag acc att gaa gac atc gac atg atg gac Ile Lys Arg Glu Asp Glu Thr Ile Glu Asp Ile Asp Met Met Asp 1060 1065 1070	3616
gac atc ggc ata gac tct tca gac ctg gtg gaa gac agc ttc ctg Asp Ile Gly Ile Asp Ser Ser Asp Leu Val Glu Asp Ser Phe Leu 1075 1080 1085	3661
taa ctggcggatt cgaggggttc cttccacttc tggggccacc tctggatccc	3714
gttcagaaaa ccactttatt gcaatgcgga gggtgagagg aggacttggg tgaagttaa	3774
agagaagttc ccagccaagg gcctcgggga gcgttctaaa tatgaatgaa tgggatattt	3834
tgaatgaac tttgtcagtg ttgcctctcg caatgcctca gtagcatctc agtgggtgtg	3894
gaagtttga gatagatgga taagggaata ataggccaca gaagggtgaac tttgtgcttc	3954
aaggacattg gtgagagtcc aacagacaca atttatactg cgacagaact tcagcattgt	4014
aattatgtaa ataactctaa ccaaggctgt gtttagattg tattaactat cttctttgga	4074
cttctgaaga gaccactcaa tccatccatg tacttccttc ttgaaacctg atgtcagctg	4134
ctgttgaaact ttttaaagaa gtgcatgaaa aaccattttt gaaccttaaa aggtactggg	4194
actatagcat tttgctatct tttttagtgt taagagataa agaataataa ttaaccaacc	4254
ttgtttaata gatttgggtc atttagaagc ctgacaactc attttcatat tgtaatctat	4314
gtttataata ctactactgt tatcagtaat gctaaatgtg taataatgta acatgatttc	4374
cctccagaga aagcacaatt taaaacaatc cttactaagt aggtgatgag tttgacagtt	4434
tttgacattt atattaaata acatgtttct ctataaagta tggtaatagc tttagtgaat	4494
taaaatttagt tgagcataga gaacaaagta aaagttagtgt tgtccaggaa gtcagaattt	4554
ttaactgtac tgaatagggt ccccaatcca tcgtattaaa aaacaattaa ctgccctctg	4614
aaataatggg attagaacaa aacaaaactc ttaagtccta aaagttctca atgtagaggc	4674
ataaacctgt gctgaacata acttctcatg tatattaccc aatggaaaat ataatgatca	4734

-continued

```

gcaaaaagac tggatttgca gaagtttttt ttttttttct tcatgcctga tgaaagcttt 4794
ggcaacccca atatatgtat tttttgaatc tatgaacctg aaaaggggtca gaaggatgcc 4854
cagacatcag cctccttctt tcacccctta ccccaaagag aaagagtttg aaactcgaga 4914
ccataaagat attcttttagt ggaggttgga tgtgcattag cctggatcct cagttctcaa 4974
atgtgtgtgg cagccaggat gactagatcc tgggtttcca tccttgagat tctgaagtat 5034
gaagtctgag ggaaaccaga gtctgtatct ttctaaactc cctggctgtt ctgatcggcc 5094
agttttcgga aacactgact taggtttcag gaagttgcca tgggaaacaa ataatttgaa 5154
ctttggaaca gggttggaat tcaaccacgc aggaagccta ctattttaat ccttggtctt 5214
aggttagtga catttaatgc catctagcta gcaattgcga ccttaattta actttccagt 5274
cttagctgag gctgagaaag ctaaagtttg gttttgacag gttttccaaa agtaaagatg 5334
ctacttccca ctgtatgggg gagattgaac tttccccgtc tcccgctctt tgccctccac 5394
tccatacccc gccaaaggaaa ggcatgtaca aaaattatgc aattcagtgt tccaagtctc 5454
tgtgtaacca gctcagtgtt ttggtggaaa aaacatttta agttttactg ataatttgag 5514
gttagatggg aggatgaatt gtcacatcta tccacactgt caaacagggt ggtgtgggtt 5574
cattggcatt ctttgcata ctgcttaatt gctgatacca tatgaatgaa acatgggctg 5634
tgattactgc aatcactgtg ctatcggcag atgatgcttt ggaagatgca gaagcaataa 5694
taaagtactt gactacctac tgggtgaatc tcaatgcaag ccccaacttt cttatccaac 5754
tttttcatag taagtgcgaa gactgagcca gattggccaa ttaaaaacga aaacctgact 5814
aggttctgta gagccaatta gacttgaaat acgttttgtt ttctagaatc acagctcaag 5874
cattctgttt atcgctcact ctcccttgta cagccttatt ttgttggtgc tttgcatttt 5934
gatattgctg tgagccttgc atgacatcat gaggccggat gaaacttctc agtccagcag 5994
tttccagtcc taacaaatgc tcccactga atttgatat gactgcattt gtgggtgtgt 6054
gtgtgttttc agcaaattcc agatttgttt ccttttgccc tctgcaaaag tctccagaag 6114
aaaaattgcc aatctttctt actttctatt tttatgatga caatcaaagc cggcctgaga 6174
aacactatct gtgacttttt aaacgattag tgatgtcctt aaaatgtggg ctgccaatct 6234
gtacaaaatg gtcctatctt tgtgaagagg gacataagat aaaatgatgt tatacatcaa 6294
tatgtatata tgtattttcta tatagacttg gagaatactg ccaaaacatt tatgacaagc 6354
tgtatcactg ccttcgttta tattttttta actgtgataa tccccacagg cacattaact 6414
gttgcacttt tgaatgtcca aaatttatat tttagaaata ataaaaagaa agatacttac 6474
atgttcccaa aacaatgggt tggatgaatgt gtgagaaaaa ctaacttgat aggggtctacc 6534
aatacaaaat gtattacgaa tgccctgtt catgtttttg ttttaaacg tgtaaatgaa 6594
gatctttata tttcaataaa tgatatataa tttaaagtt 6633

```

<210> SEQ ID NO 27

<211> LENGTH: 1089

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (560)..(560)

<223> OTHER INFORMATION: The 'Xaa' at location 560 stands for Lys, Asn, Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro, Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (561)..(561)

<223> OTHER INFORMATION: The 'Xaa' at location 561 stands for Lys, Asn,

-continued

Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (562)..(562)
<223> OTHER INFORMATION: The 'Xaa' at location 562 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (563)..(563)
<223> OTHER INFORMATION: The 'Xaa' at location 563 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (564)..(564)
<223> OTHER INFORMATION: The 'Xaa' at location 564 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (566)..(566)
<223> OTHER INFORMATION: The 'Xaa' at location 566 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (567)..(567)
<223> OTHER INFORMATION: The 'Xaa' at location 567 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (568)..(568)
<223> OTHER INFORMATION: The 'Xaa' at location 568 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (569)..(569)
<223> OTHER INFORMATION: The 'Xaa' at location 569 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (570)..(570)
<223> OTHER INFORMATION: The 'Xaa' at location 570 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (571)..(571)
<223> OTHER INFORMATION: The 'Xaa' at location 571 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (841)..(841)
<223> OTHER INFORMATION: The 'Xaa' at location 841 stands for Lys, Arg,
Thr, or Ile.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (842)..(842)
<223> OTHER INFORMATION: The 'Xaa' at location 842 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (843)..(843)
<223> OTHER INFORMATION: The 'Xaa' at location 843 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (844)..(844)
<223> OTHER INFORMATION: The 'Xaa' at location 844 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.

<220> FEATURE:

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (845)..(845)
<223> OTHER INFORMATION: The 'Xaa' at location 845 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (846)..(846)
<223> OTHER INFORMATION: The 'Xaa' at location 846 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (847)..(847)
<223> OTHER INFORMATION: The 'Xaa' at location 847 stands for Lys, Asn,
Arg, Ser, Thr, Ile, Met, Glu, Asp, Gly, Ala, Val, Gln, His, Pro,
Leu, Tyr, Trp, Cys, or Phe.
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (848)..(848)
<223> OTHER INFORMATION: The 'Xaa' at location 848 stands for Asn, Ser,
Thr, Ile, Asp, Gly, Ala, Val, His, Arg, Pro, Leu, Tyr, Cys, or
Phe.

```

```

<400> SEQUENCE: 27

```

```

Met Gly Thr Ser His Pro Ala Phe Leu Val Leu Gly Cys Leu Leu Thr
1          5          10          15

Gly Leu Ser Leu Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro
          20          25          30

Asn Glu Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg
          35          40          45

Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu
          50          55          60

Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly Leu
          65          70          75          80

Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala His Thr Gly
          85          90          95

Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr Glu Glu Asn Glu Leu
          100         105         110

Glu Gly Arg His Ile Tyr Ile Tyr Val Pro Asp Pro Asp Val Ala Phe
          115         120         125

Val Pro Leu Gly Met Thr Asp Tyr Leu Val Ile Val Glu Asp Asp Asp
          130         135         140

Ser Ala Ile Ile Pro Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr
          145         150         155         160

Leu His Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln
          165         170         175

Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr
          180         185         190

Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala Leu
          195         200         205

Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu Lys Thr Val
          210         215         220

Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys Ala Val Phe Asn Asn
          225         230         235         240

Glu Val Val Asp Leu Gln Trp Thr Tyr Pro Gly Glu Val Lys Gly Lys
          245         250         255

Gly Ile Thr Met Leu Glu Glu Ile Lys Val Pro Ser Ile Lys Leu Val
          260         265         270

Tyr Thr Leu Thr Val Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr
          275         280         285

```

Glu 290	Cys	Ala	Ala	Arg		Gln 295	Ala	Thr	Arg	Glu	Val	Lys 300	Glu	Met	Lys	Lys
Val 305	Thr	Ile	Ser	Val	His 310	Glu	Lys	Gly	Phe	Ile 315	Glu	Ile	Lys	Pro	Thr	320
Phe	Ser	Gln	Leu	Glu 325	Ala	Val	Asn	Leu	His 330	Glu	Val	Lys	His	Phe	Val	335
Val	Glu	Val	Arg	Ala 340	Tyr	Pro	Pro	Pro	Arg 345	Ile	Ser	Trp	Leu	Lys	Asn	350
Asn	Leu	Thr	Leu	Ile 355	Glu	Asn	Leu	Thr	Glu 360	Ile	Thr	Thr	Asp	Val	Glu	365
Lys	Ile	Gln	Glu	Ile 370	Arg	Tyr	Arg	Ser	Lys 375	Leu	Lys	Leu	Ile	Arg	Ala	380
Lys 385	Glu	Glu	Asp	Ser	Gly 390	His	Tyr	Thr	Ile	Val 395	Ala	Gln	Asn	Glu	Asp	400
Ala	Val	Lys	Ser	Tyr 405	Thr	Phe	Glu	Leu	Leu 410	Thr	Gln	Val	Pro	Ser	Ser	415
Ile	Leu	Asp	Leu	Val 420	Asp	Asp	His	His	Gly 425	Ser	Thr	Gly	Gly	Gln	Thr	430
Val	Arg	Cys 435	Thr	Ala	Glu	Gly	Thr	Pro	Leu	Pro	Asp	Ile	Glu	Trp	Met	445
Ile	Cys 450	Lys	Asp	Ile	Lys 455	Lys	Cys	Asn	Asn	Glu	Thr	Ser	Trp	Thr	Ile	460
Leu 465	Ala	Asn	Asn	Val	Ser 470	Asn	Ile	Ile	Thr	Glu 475	Ile	His	Ser	Arg	Asp	480
Arg	Ser	Thr	Val 485	Glu	Gly	Arg	Val	Thr	Phe 490	Ala	Lys	Val	Glu	Glu	Thr	495
Ile	Ala	Val	Arg 500	Cys	Leu	Ala	Lys	Asn 505	Leu	Leu	Gly	Ala	Glu	Asn	Arg	510
Glu	Leu	Lys 515	Leu	Val	Ala	Pro	Thr 520	Leu	Arg	Ser	Glu	Leu	Thr	Val	Ala	525
Ala 530	Ala	Val	Leu	Val	Leu 535	Leu	Val	Ile	Val	Ile	Ile	Ser	Leu	Ile	Val	540
Leu 545	Val	Val	Ile	Trp	Lys 550	Gln	Lys	Pro	Arg	Tyr 555	Glu	Ile	Arg	Trp	Xaa	560
Xaa	Xaa	Xaa	Xaa 565	Ile	Xaa	Xaa	Xaa	Xaa	Xaa 570	Xaa	Tyr	Ile	Tyr	Val	Asp	575
Pro	Met	Gln	Leu 580	Pro	Tyr	Asp	Ser	Arg 585	Trp	Glu	Phe	Pro	Arg	Asp	Gly	590
Leu	Val	Leu 595	Gly	Arg	Val	Leu	Gly 600	Ser	Gly	Ala	Phe	Gly	Lys	Val	Val	605
Glu	Gly 610	Thr	Ala	Tyr	Gly 615	Leu	Ser	Arg	Ser	Gln	Pro	Val	Met	Lys	Val	620
Ala 625	Val	Lys	Met	Leu	Lys 630	Pro	Thr	Ala	Arg	Ser 635	Ser	Glu	Lys	Gln	Ala	640
Leu	Met	Ser	Glu 645	Leu	Lys	Ile	Met	Thr	His 650	Leu	Gly	Pro	His	Leu	Asn	655
Ile	Val	Asn 660	Leu	Gly	Ala	Cys	Thr 665	Lys	Ser	Gly	Pro	Ile	Tyr	Ile		670
Ile	Thr 675	Glu	Tyr	Cys	Phe	Tyr	Gly 680	Asp	Leu	Val	Asn	Tyr 685	Leu	His	Lys	685
Asn 690	Arg	Asp	Ser	Phe	Leu 695	Ser	His	His	Pro	Glu	Lys 700	Pro	Lys	Lys	Glu	700
Leu 705	Asp	Ile	Phe	Gly	Leu 710	Asn	Pro	Ala	Asp	Glu 715	Ser	Thr	Arg	Ser	Tyr	720

-continued

Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met Lys Gln
 725 730 735
 Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg Lys Glu Val Ser
 740 745 750
 Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr Asp Arg Pro Ala Ser Tyr
 755 760 765
 Lys Lys Lys Ser Met Leu Asp Ser Glu Val Lys Asn Leu Leu Ser Asp
 770 775 780
 Asp Asn Ser Glu Gly Leu Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr
 785 790 795 800
 Gln Val Ala Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His
 805 810 815
 Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val
 820 825 830
 Lys Ile Cys Asp Phe Gly Leu Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 835 840 845
 Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val Lys Trp Met Ala Pro
 850 855 860
 Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser Asp Val Trp Ser
 865 870 875 880
 Tyr Gly Ile Leu Leu Trp Glu Ile Phe Ser Leu Gly Gly Thr Pro Tyr
 885 890 895
 Pro Gly Met Met Val Asp Ser Thr Phe Tyr Asn Lys Ile Lys Ser Gly
 900 905 910
 Tyr Arg Met Ala Lys Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile
 915 920 925
 Met Val Lys Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr
 930 935 940
 His Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys
 945 950 955 960
 Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro Ala
 965 970 975
 Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala Tyr Ile Gly Val Thr
 980 985 990
 Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp Glu Gly Gly Leu Asp
 995 1000 1005
 Glu Gln Arg Leu Ser Ala Asp Ser Gly Tyr Ile Ile Pro Leu Pro
 1010 1015 1020
 Asp Ile Asp Pro Val Pro Glu Glu Glu Asp Leu Gly Lys Arg Asn
 1025 1030 1035
 Arg His Ser Ser Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly
 1040 1045 1050
 Ser Ser Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu
 1055 1060 1065
 Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu
 1070 1075 1080
 Val Glu Asp Ser Phe Leu
 1085

<210> SEQ ID NO 28

<211> LENGTH: 400

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: Intron

-continued

```

<222> LOCATION: (1)..(168)
<223> OTHER INFORMATION: Intron sequence
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (169)..(291)
<223> OTHER INFORMATION: Exon
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (169)..(291)
<223> OTHER INFORMATION: intron
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (292)..(400)
<223> OTHER INFORMATION: intron

<400> SEQUENCE: 28

gctttctctc tgttgggagt ggggtggagtg agaacctggg agaaggccag ccttttatat      60
ccaggcagac agctccaagt gccaccatgg atcagccagt cttgcagggg tgaagtctatt      120
cagctacaga tggcttgatc ctgagtcatt tcttcctttt ccatgcag tgt gtc cac      177
                                   Cys Val His
                                   1

cgt gat ctg gct gct cgc aac gtc ctc ctg gca caa gga aaa att gtg      225
Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val
   5              10              15

aag atc tgt gac ttt ggc ctg gcc aga gac atc atg cat gat tcg aac      273
Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met His Asp Ser Asn
  20              25              30              35

tat gtg tcg aaa ggc agt gtacgtctc acttccctca ctggtcaggc      321
Tyr Val Ser Lys Gly Ser
              40

tcatcctcct tcactttaat ctctaaagtc aggtgttgct tctagagatt cggtgcctgt      381

tttttaaaac atcaataga      400

<210> SEQ ID NO 29
<211> LENGTH: 41
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Cys Val His Arg Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly
 1              5              10              15

Lys Ile Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met His
 20              25              30

Asp Ser Asn Tyr Val Ser Lys Gly Ser
 35              40

<210> SEQ ID NO 30
<211> LENGTH: 400
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (1)..(168)
<220> FEATURE:
<221> NAME/KEY: exon
<222> LOCATION: (169)..(300)
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (169)..(300)
<220> FEATURE:
<221> NAME/KEY: Intron
<222> LOCATION: (301)..(400)

<400> SEQUENCE: 30

aagcatagca acctagtcca gtgcttgcca cagagaagga gctcagcaat tacatgtgga      60

```

-continued

```

gtgaacgttg ttggactcta ctgtgtccag tcaactgtgct gcttcagtga agctctggtg    120
cactgggact ttggtaattc accagttacc tgtcctggtc atttatag aaa ccg agg    177
                                Lys Pro Arg
                                1
tat gaa att cgc tgg agg gtc att gaa tcc atc agc cca gat gga cat    225
Tyr Glu Ile Arg Trp Arg Val Ile Glu Ser Ile Ser Pro Asp Gly His
    5                                10                                15
gaa tat att tat gtg gac ccg atg cag ctg cct tat gac tca aga tgg    273
Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp Ser Arg Trp
20                                25                                30                                35
gag ttt cca aga gat gga cta gtg ctt ggtaggttcc atggggtaac    320
Glu Phe Pro Arg Asp Gly Leu Val Leu
                                40
ctcccaagac tccctttttcc ctgtcacaca acctttacaat ttataggcct tggcagaata    380
gagatctgag cttgtgctta    400

```

<210> SEQ ID NO 31
 <211> LENGTH: 44
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

```

Lys Pro Arg Tyr Glu Ile Arg Trp Arg Val Ile Glu Ser Ile Ser Pro
1                                5                                10                                15
Asp Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro Tyr Asp
                                20                                25                                30
Ser Arg Trp Glu Phe Pro Arg Asp Gly Leu Val Leu
                                35                                40

```

We claim:

1. An isolated constitutively active variant platelet derived growth factor receptor alpha (PDGFRA) polypeptide comprising:

the amino acid sequence set forth in SEQ ID NO: 27, wherein the sequence comprises a variant amino acid shown in one or more of positions 560 through 571 or 841 through 848 of SEQ ID NO: 27; or

a fragment of said constitutively active PDGFRA comprising at least 10 contiguous amino acids including at least one variant amino acid site as set forth in one or more of positions 560 through 571 or 841 through 848 of SEQ ID NO: 27.

2. An isolated constitutively active variant platelet derived growth factor receptor alpha (PDGFRA) polypeptide comprising:

the amino acid sequence set forth in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25; or

a fragment of said constitutively active PDGFRA comprising at least 10 contiguous amino acids including one or more of the following amino acid variants: substitution D842V (shown in SEQ ID NO: 4); deletion of DIMH842-845 (shown in SEQ ID NO: 6); deletion of HDSN845-848P (shown in SEQ ID NO: 8); insertion ER561-562 (shown in SEQ ID NO: 10); deletion of SPDGHE566-571R (shown in SEQ ID NO: 12); substitution V561D (shown in SEQ ID NO: 21); deletion of RVIES560-564 (shown in SEQ ID NO: 23); and substitution of RD841-842KI (shown in SEQ ID NO: 25).

3. The isolated variant PDGFRA polypeptide of claim 2, which comprises one or more of the following amino acid variants: substitution D842V (shown in SEQ ID NO: 4);

deletion of DIMH842-845 (shown in SEQ ID NO: 6); deletion of HDSN845-848P (shown in SEQ ID NO: 8); insertion ER561-562 (shown in SEQ ID NO: 10); deletion of SPDGHE566-571R (shown in SEQ ID NO: 12); substitution V561D (shown in SEQ ID NO: 21); deletion of RVIES560-564 (shown in SEQ ID NO: 23); and substitution of RD841-842KI (shown in SEQ ID NO: 25).

4. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 4.

5. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 6.

6. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 8.

7. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 10.

8. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 12.

9. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 21.

10. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 23.

11. The isolated variant PDGFRA polypeptide of claim 2, comprising the amino acid sequence as set forth in SEQ ID NO: 25.

387

12. A kit for determining whether or not a subject has a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation, the kit comprising:

an antibody specific for a variant PDGFRA polypeptide of claim 1, wherein said specific antibody binds to an epitope in said variant PDGFRA not found in the wild-type PDGFRA of SEQ ID NO: 2;

a negative control sample; and

instructions for using the kit, the instructions indicating steps for:

performing a test assay to detect a quantity of PDGFRA activating mutant protein in a test sample of tissue and/or bodily fluid from the subject,

performing a negative control assay to detect a quantity of PDGFRA activating mutant protein in the negative control sample; and

comparing data generated by the test assay and negative control assay, wherein the instructions indicate that a

388

quantity of PDGFRA activating mutant protein in the test sample more than the quantity of PDGFRA activating mutant protein in the negative control sample indicates that the subject has the neoplasia.

13. The kit of claim 12 further comprising a detectable antibody that binds to said specific antibody.

14. The kit of claim 12, wherein the neoplasia associated with an activating PDGFRA mutation comprises gastrointestinal stromal tumor (GIST).

15. A composition comprising at least one antigenic fragment of the isolated constitutively active variant PDGFRA polypeptide of claim 1, where the at least one antigenic fragment is at least seven amino acids long and includes the amino acid(s) as shown at position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25.

* * * * *